---
document_datetime: 2023-09-21 21:46:46
document_pages: 147
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/nubeqa-h-c-4790-ii-0009-epar-assessment-report-variation_en.pdf
document_name: nubeqa-h-c-4790-ii-0009-epar-assessment-report-variation_en.pdf
version: success
processing_time: 270.6548865
conversion_datetime: 2025-12-28 13:46:26.227328
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
26 January 2023 EMA/80060/2023

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## NUBEQA

International non-proprietary name: darolutamide

Procedure No. EMEA/H/C/004790/II/0009

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................9                                                         |
|-------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                  | ................................................................................................ 9      |
| 1.2. Steps taken for the assessment of the product                                                                      | ..................................................... 10                                                |
| 2. Scientific discussion                                                                                                | ..............................................................................11                        |
| 2.1. Introduction                                                                                                       | .................................................................................................... 11 |
| 2.1.1. Problem statement                                                                                                | ........................................................................................ 11             |
| 2.1.2. About the product .........................................................................................      | 12                                                                                                      |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                        | ..... 12                                                                                                |
| 2.1.4. General comments on compliance with GCP                                                                          | ...................................................... 13                                               |
| 2.2. Non-clinical aspects..........................................................................................     | 13                                                                                                      |
| 2.2.1. Introduction .................................................................................................   | 13                                                                                                      |
| 2.2.2. Pharmacology...............................................................................................      | 13                                                                                                      |
| 2.2.3. Toxicology....................................................................................................   | 13                                                                                                      |
| 2.2.4. Ecotoxicity/environmental risk assessment........................................................                | 13                                                                                                      |
| 2.2.5. Discussion on non-clinical aspects....................................................................           | 15                                                                                                      |
| 2.2.6. Conclusion on the non-clinical aspects..............................................................             | 15                                                                                                      |
| 2.3. Clinical aspects ................................................................................................  | 15                                                                                                      |
| 2.3.1. Introduction                                                                                                     | ................................................................................................. 15    |
| 2.3.2. Pharmacokinetics ..........................................................................................      | 16                                                                                                      |
| 2.3.3. PK/PD modelling............................................................................................      | 33                                                                                                      |
| 2.3.4. Discussion on clinical pharmacology                                                                              | ................................................................. 47                                    |
| 2.3.5. Conclusions on clinical pharmacology                                                                             | ............................................................... 49                                      |
| 2.4. Clinical efficacy                                                                                                  | ................................................................................................ 49     |
| 2.4.1. Dose response study(ies) ...............................................................................         | 49                                                                                                      |
| 2.4.2. Main study(ies) .............................................................................................    | 49                                                                                                      |
| 2.4.3. Discussion on clinical efficacy ..........................................................................       | 92                                                                                                      |
| Design and conduct of clinical studies........................................................................          | 92                                                                                                      |
| 2.4.4. Conclusions on the clinical efficacy...................................................................          | 97                                                                                                      |
| 2.5. Clinical safety .................................................................................................. | 97                                                                                                      |
| 2.5.1. Discussion on clinical safety                                                                                    | ...........................................................................130                          |
| 2.5.2. Conclusions on clinical safety                                                                                   | .........................................................................136                            |
| 2.5.3. PSUR cycle                                                                                                       | ..................................................................................................137   |
| 2.6. Risk management plan.....................................................................................137       |                                                                                                         |
| 2.7. Update of the Product information                                                                                  | .....................................................................140                                |
| 2.7.1. User consultation..........................................................................................140   |                                                                                                         |
| 3. Benefit-Risk Balance............................................................................141                  |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                | ........................................................................................141             |
| 3.1.1. Disease or condition......................................................................................141    |                                                                                                         |
| 3.1.2. Available therapies and unmet medical need                                                                       | ....................................................141                                                 |
| 3.1.3. Main clinical studies                                                                                            | ......................................................................................141               |
| 3.1.4. Favourable effects                                                                                               | ........................................................................................141             |
| 3.2. Uncertainties and limitations about favourable effects                                                             | ..........................................142                                                           |
| 3.3. Unfavourable effects........................................................................................142    |                                                                                                         |

<div style=\"page-break-after: always\"></div>

3.4. Uncertainties and limitations about unfavourable effects .......................................  143

3.5. Effects Table ..................................................................................................  144

3.6. Benefit-risk assessment and discussion ..............................................................  145

3.6.1. Importance of favourable and unfavourable effects ...........................................  145

3.6.2. Balance of benefits and risks  ..........................................................................  145

3.6.3. Additional considerations on the benefit-risk balance .........................................  145

3.7. Conclusions  ....................................................................................................  145

4. Recommendations ...............................................................................  145

5. EPAR changes  ......................................................................................  147

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| A      | Value cannot be estimated                             |
|--------|-------------------------------------------------------|
| ADR    | Adverse drug reaction                                 |
| ADT    | Androgen deprivation therapy                          |
| AE     | Adverse event                                         |
| ALP    | Alkaline phosphatase                                  |
| ALT    | Alanine aminotransferase                              |
| AR     | Androgen receptor                                     |
| ARI    | Androgen receptor inhibitor                           |
| AST    | Aspartate aminotransferase                            |
| ATC    | Anatomical Therapeutic Chemical classification system |
| AUC    | Area under the curve                                  |
| BCRP   | Breast cancer resistance protein                      |
| BID    | Twice daily                                           |
| BM     | Biomarker(s)                                          |
| BPI-SF | Brief pain inventory - short form                     |
| BS     | Bone scan                                             |
| CBF    | Cerebral blood flow                                   |
| CHMP   | Committee for Medicinal Products for Human Use        |
| CI     | Confidence interval                                   |
| CMH    | Cochran - Mantel - Haenszel                           |
| CO     | Cross-over                                            |
| CRF    | Case report form                                      |
| CRPC   | Castration-resistant prostate cancer                  |
| CSR    | Clinical study report                                 |
| CT     | Computed tomography                                   |
| CTCAE  | Common Terminology Criteria for Adverse Events        |
| CYTOC  | Cytotoxic chemotherapy                                |
| CYP    | Cytochrome P450                                       |
| Daro   | Darolutamide                                          |
| DDI    | Drug-drug interaction                                 |
| DMC    | Data Monitoring Committee                             |
| DLT    | Dose-limiting toxicity                                |

<div style=\"page-break-after: always\"></div>

| DRS-E                                                                                                 | Disease-related emotional symptoms                                                                    |
|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| DRS-P                                                                                                 | Disease-related physical symptoms                                                                     |
| EAIR                                                                                                  | Exposure-adjusted incidence rates                                                                     |
| EBRT                                                                                                  | External beam radiation therapy                                                                       |
| ECG                                                                                                   | Electrocardiogram                                                                                     |
| ECOG (PS) Eastern Cooperative Oncology Group (performance status)                                     | ECOG (PS) Eastern Cooperative Oncology Group (performance status)                                     |
| eGFR                                                                                                  | Estimated glomerular filtration rate                                                                  |
| EMA                                                                                                   | European Medicines Agency (EU)                                                                        |
| EPAR                                                                                                  | European Public Assessment Report                                                                     |
| ePRO                                                                                                  | Electronic patient reported outcome                                                                   |
| EOT                                                                                                   | End of treatment                                                                                      |
| ESMO                                                                                                  | European Society for Medical Oncology                                                                 |
| EudraCT European Clinical Trials Database                                                             | EudraCT European Clinical Trials Database                                                             |
| FACT- Functional assessment of cancer therapy                                                         | FACT- Functional assessment of cancer therapy                                                         |
| FPSI-17 Functional assessment of cancer therapy / Prostate cancer symptom index 17 item questionnaire | FPSI-17 Functional assessment of cancer therapy / Prostate cancer symptom index 17 item questionnaire |
| FACT-P Functional assessment of cancer therapy / Prostate                                             | FACT-P Functional assessment of cancer therapy / Prostate                                             |
| FAS                                                                                                   | Full analysis set                                                                                     |
| FDA                                                                                                   | Food and Drug Administration (US)                                                                     |
| DRS-P                                                                                                 | FPSI - 17 disease-related symptoms - physical                                                         |
| FWB                                                                                                   | Function and well-being                                                                               |
| GCP                                                                                                   | Good Clinical Practice                                                                                |
| GI                                                                                                    | Gastrointestinal                                                                                      |
| GLP                                                                                                   | Good Laboratory Practices                                                                             |
| GnRH                                                                                                  | Gonadotropin-releasing hormone                                                                        |
| HIV                                                                                                   | Human immunodeficiency virus                                                                          |
| HLGT                                                                                                  | High level group term                                                                                 |
| HLT                                                                                                   | High level term                                                                                       |
| HR                                                                                                    | Hazard ratio                                                                                          |
| HRQoL                                                                                                 | Health-related Quality of life                                                                        |
| HSPC                                                                                                  | Hormone-sensitive prostate cancer                                                                     |
| ICH                                                                                                   | International Council for Harmonization                                                               |
| INR                                                                                                   | International normalized ratio                                                                        |

<div style=\"page-break-after: always\"></div>

| ITT                                                                                                            | Intent-to-treat                                                                                                |
|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| IV                                                                                                             | Intravenous                                                                                                    |
| IxRS                                                                                                           | Interactive voice/web response system                                                                          |
| LHRH                                                                                                           | Luteinizing hormone-releasing hormone                                                                          |
| LPLV                                                                                                           | Last patient last visit                                                                                        |
| KM                                                                                                             | Kaplan-Meier                                                                                                   |
| Max                                                                                                            | Maximum                                                                                                        |
| MedDRA Medical Dictionary for Regulatory Activities                                                            | MedDRA Medical Dictionary for Regulatory Activities                                                            |
| mCRPC Metastatic castration-resistant prostate cancer                                                          | mCRPC Metastatic castration-resistant prostate cancer                                                          |
| mCSPC Metastatic castration-sensitive prostate cancer                                                          | mCSPC Metastatic castration-sensitive prostate cancer                                                          |
| MFS                                                                                                            | Metastasis-free survival                                                                                       |
| mHSPC Metastatic hormone-sensitive prostate cancer                                                             | mHSPC Metastatic hormone-sensitive prostate cancer                                                             |
| MID                                                                                                            | Minimally important difference                                                                                 |
| Min                                                                                                            | Minimum                                                                                                        |
| MLG                                                                                                            | MedDRA labeling grouping                                                                                       |
| MTD                                                                                                            | Maximum tolerated dose                                                                                         |
| MRI                                                                                                            | Magnetic resonance imaging                                                                                     |
| n                                                                                                              | Number of patients with event                                                                                  |
| N                                                                                                              | Total number of patients                                                                                       |
| NA                                                                                                             | Not applicable / Not available                                                                                 |
| NCA                                                                                                            | Non-compartmental analysis                                                                                     |
| NCCN                                                                                                           | National Comprehensive Cancer Network                                                                          |
| NCI                                                                                                            | National Cancer Institute                                                                                      |
| FPSI-17 National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Prostate Symptom Index | FPSI-17 National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Prostate Symptom Index |
| NCI-ODWG National Cancer Institute Organ Dysfunction Working Group                                             | NCI-ODWG National Cancer Institute Organ Dysfunction Working Group                                             |
| NE Not evaluable                                                                                               | NE Not evaluable                                                                                               |
| nmCRPC Non-metastatic castration-resistant prostate cancer                                                     | nmCRPC Non-metastatic castration-resistant prostate cancer                                                     |
| NYHA                                                                                                           | New York Heart Association                                                                                     |
| OL                                                                                                             | Open-label                                                                                                     |
| OS                                                                                                             | Overall survival                                                                                               |
| PBRER                                                                                                          | Periodic Benefit-Risk Evaluation Report                                                                        |
| PC                                                                                                             | Prostate cancer                                                                                                |

<div style=\"page-break-after: always\"></div>

| PCWG3 Prostate Cancer Clinical Trials Working Group 3                                                                                                               | PCWG3 Prostate Cancer Clinical Trials Working Group 3                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PD                                                                                                                                                                  | Pharmacodynamics                                                                                                                                                    |
| PFS                                                                                                                                                                 | Progression-free survival                                                                                                                                           |
| PK                                                                                                                                                                  | Pharmacokinetic(s)                                                                                                                                                  |
| Pla                                                                                                                                                                 | Placebo                                                                                                                                                             |
| PMDA                                                                                                                                                                | Pharmaceuticals and Medical Devices Agency (Japan)                                                                                                                  |
| popPD                                                                                                                                                               | Population pharmacodynamics                                                                                                                                         |
| PP                                                                                                                                                                  | Pain progression                                                                                                                                                    |
| PRO                                                                                                                                                                 | Patient reported outcome                                                                                                                                            |
| PS                                                                                                                                                                  | Performance status                                                                                                                                                  |
| PSA                                                                                                                                                                 | Prostate-specific antigen                                                                                                                                           |
| PSADT                                                                                                                                                               | Prostate-specific antigen doubling time                                                                                                                             |
| PT                                                                                                                                                                  | Preferred term                                                                                                                                                      |
| PY                                                                                                                                                                  | Patient year                                                                                                                                                        |
| QoL                                                                                                                                                                 | Quality of life                                                                                                                                                     |
| QRS (complex) The series of deflections in an ECG that represent electrical activity generated by ventricular depolarization prior to contraction of the ventricles | QRS (complex) The series of deflections in an ECG that represent electrical activity generated by ventricular depolarization prior to contraction of the ventricles |
| QT                                                                                                                                                                  | Interval on the ECG from the beginning of the QRS complex to the end of the T wave                                                                                  |
| QTc                                                                                                                                                                 | QT interval corrected for heart rate                                                                                                                                |
| QTcF                                                                                                                                                                | QT interval corrected for heart rate using the Fridericia's formula                                                                                                 |
| RECIST v1.1 Response Evaluation Criteria in Solid Tumors version 1.1                                                                                                | RECIST v1.1 Response Evaluation Criteria in Solid Tumors version 1.1                                                                                                |
| ROW                                                                                                                                                                 | Rest of the world                                                                                                                                                   |
| rPFS                                                                                                                                                                | Radiographic progression-free survival                                                                                                                              |
| SAE                                                                                                                                                                 | Serious adverse event                                                                                                                                               |
| SAF                                                                                                                                                                 | Safety population                                                                                                                                                   |
| SAP                                                                                                                                                                 | Statistical analysis plan                                                                                                                                           |
| SCE                                                                                                                                                                 | Summary of Clinical Efficacy                                                                                                                                        |
| SOC                                                                                                                                                                 | Standard of care                                                                                                                                                    |
| SSE                                                                                                                                                                 | Symptomatic skeletal event                                                                                                                                          |
| SSE-FS Symptomatic skeletal event-free survival                                                                                                                     | SSE-FS Symptomatic skeletal event-free survival                                                                                                                     |
| StD                                                                                                                                                                 | Standard deviation                                                                                                                                                  |
| TEAE                                                                                                                                                                | Treatment-emergent adverse event                                                                                                                                    |
| TSE                                                                                                                                                                 | Treatment side effects                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| TURP                                             | Transurethral resection of the prostate          |
|--------------------------------------------------|--------------------------------------------------|
| UK                                               | United Kingdom                                   |
| ULN                                              | Upper limit of normal                            |
| US(A)                                            | United States of America                         |
| USPI                                             | United States Prescribing Information            |
| WBC                                              | White blood cell                                 |
| WHO-DD World Health Organization Drug Dictionary | WHO-DD World Health Organization Drug Dictionary |
| WPS                                              | Worst pain subscale                              |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bayer AG submitted to the European Medicines Agency on 4 March 2022 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel, based on final results from Study 17777 (ARASENS); this is a randomized, double-blind, placebo-controlled Phase 3 study designed to demonstrate the superiority of darolutamide in combination with docetaxel over placebo in combination with docetaxel in OS in patients with mHSPC. As a consequence, sections 4.1, 4.2, 4.5, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. As part of the application, the MAH is also requesting one additional year of market protection.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) CW/0001/2015 on the granting of a class waiver.

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## MAH request for additional market protection

Initially the Market Authorization Holder (MAH) requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication. The request was withdrawn during the procedure.

## Scientific advice

The MAH received Scientific advice (SA) from the CHMP on 24 September 2015 (EMEA/H/SA/2639/2/2015/II). The Scientific advice pertained to clinical aspects of the dossier. SA was provided on the use of androgen deprivation therapy (ADT) (i.e. orchiectomy, luteinizing hormone-

<div style=\"page-break-after: always\"></div>

releasing hormone (LHRH) agonists or antagonists) based on investigator's choice, which was considered acceptable by the CHMP; the use of docetaxel as backbone treatment; the proposed stratification factors (i.e. extent of disease and the level of alkaline phosphatase) as well as the primary endpoint (overall survival) and the statistical design and secondary endpoints. Some other questions were raised to the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur:                                          | Alexandre Moreau                                     | Co-Rapporteur:                                       | Blanca Garcia-Ochoa   |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|-----------------------|
| Timetable                                            | Timetable                                            | Timetable                                            | Actual dates          |
| Submission date                                      | Submission date                                      | Submission date                                      | 4 March 2022          |
| Start of procedure:                                  | Start of procedure:                                  | Start of procedure:                                  | 26 March 2022         |
| CHMP Rapporteur Assessment Report                    | CHMP Rapporteur Assessment Report                    | CHMP Rapporteur Assessment Report                    | 25 May 2022           |
| PRAC Rapporteur Assessment Report                    | PRAC Rapporteur Assessment Report                    | PRAC Rapporteur Assessment Report                    | 31 May 2022           |
| PRAC members comments                                | PRAC members comments                                | PRAC members comments                                | 1 June 2022           |
| CHMP Co-Rapporteur Critique                          | CHMP Co-Rapporteur Critique                          | CHMP Co-Rapporteur Critique                          | 8 June 2022           |
| Updated PRAC Rapporteur Assessment Report            | Updated PRAC Rapporteur Assessment Report            | Updated PRAC Rapporteur Assessment Report            | 2 June 2022           |
| PRAC Outcome                                         | PRAC Outcome                                         | PRAC Outcome                                         | 10 June 2022          |
| CHMP members comments                                | CHMP members comments                                | CHMP members comments                                | 13 June 2022          |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | Updated CHMP Rapporteur(s) (Joint) Assessment Report | Updated CHMP Rapporteur(s) (Joint) Assessment Report | 17 June 2022          |
| Request for supplementary information (RSI)          | Request for supplementary information (RSI)          | Request for supplementary information (RSI)          | 23 June 2022          |
| CHMP Rapporteur Assessment Report                    | CHMP Rapporteur Assessment Report                    | CHMP Rapporteur Assessment Report                    | 17 August 2022        |
| PRAC members comments                                | PRAC members comments                                | PRAC members comments                                | 24 August 2022        |
| PRAC Outcome                                         | PRAC Outcome                                         | PRAC Outcome                                         | 1 September 2022      |
| CHMP members comments                                | CHMP members comments                                | CHMP members comments                                | 5 September 2022      |
| Updated CHMP Rapporteur Assessment Report            | Updated CHMP Rapporteur Assessment Report            | Updated CHMP Rapporteur Assessment Report            | 9 September 2022      |
| Request for supplementary information (RSI)          | Request for supplementary information (RSI)          | Request for supplementary information (RSI)          | 15 September 2022     |
| CHMP Rapporteur Assessment Report                    | CHMP Rapporteur Assessment Report                    | CHMP Rapporteur Assessment Report                    | 15 November 2022      |
| PRAC Rapporteur Assessment Report                    | PRAC Rapporteur Assessment Report                    | PRAC Rapporteur Assessment Report                    | 18 November 2022      |
| PRAC members comments                                | PRAC members comments                                | PRAC members comments                                | 23 November 2022      |
| Updated PRAC Rapporteur Assessment Report            | Updated PRAC Rapporteur Assessment Report            | Updated PRAC Rapporteur Assessment Report            | 24 November 2022      |
| PRAC Outcome                                         | PRAC Outcome                                         | PRAC Outcome                                         | 01 December 2022      |
| CHMP members comments                                | CHMP members comments                                | CHMP members comments                                | 05 December 2022      |
| Updated CHMP Rapporteur Assessment Report            | Updated CHMP Rapporteur Assessment Report            | Updated CHMP Rapporteur Assessment Report            | 08 December 2022      |
| Request for Supplementary Information                | Request for Supplementary Information                | Request for Supplementary Information                | 15 December 2022      |
| PRAC Rapporteur Assessment Report                    | PRAC Rapporteur Assessment Report                    | PRAC Rapporteur Assessment Report                    | 03 January 2023       |
| PRAC members comments                                | PRAC members comments                                | PRAC members comments                                | 04 January 2023       |

<div style=\"page-break-after: always\"></div>

| Timetable                                 | Actual dates    |
|-------------------------------------------|-----------------|
| Updated PRAC Rapporteur Assessment Report | 05 January 2023 |
| CHMP Rapporteur Assessment Report         | 11 January 2023 |
| PRAC Outcome                              | 12 January 2023 |
| CHMP members comments                     | 16 January 2023 |
| Updated CHMP Rapporteur Assessment Report | 19 January 2023 |
| CHMP opinion                              | 26 January 2023 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Claimed the therapeutic indication

The applied indication for Nubeqa was for the treatment of adult men with metastatic hormonesensitive prostate cancer (mHSPC) in combination with docetaxel.

The recommended indication is: NUBEQA is indicated for the treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).

## Epidemiology

Prostate cancer is the second most frequent cancer diagnosed in men, and the fifth leading cause of death in the world. Based on Global Cancer Observatory (GLOBOCAN) 2020 estimates, 1,414,259 new cases of prostate cancer were reported worldwide, with higher prevalence in developed countries (Sung et al. 2021). In Europe, the estimated number in 2020 of new prostate cancer cases was approximately 473,344, and the number of deaths was approximately 108,088 (Sung et al. 2021).

## Clinical presentation, diagnosis and stage/prognosis

Metastatic HSPC is defined as metastatic prostate cancer in patients who have not yet received or are continuing  to  respond  to  anti-hormonal  therapy.  Depriving  prostate  cancer  cells  of  androgen  is  the primary form of therapy since prostate cancer depends on androgen for growth and survival. Androgen deprivation therapy (ADT) is defined as surgical castration by bilateral orchiectomy or medical castration with LHRH agonist/antagonists. Metastatic HSPC can occur due to recurrence after initial local treatment with surgery and/or radiotherapy, or as de novo disease in patients whose first diagnosis of prostate cancer is metastatic disease (Lowrance et al. 2021).

Metastatic  castration  resistant  prostate  cancer  is  associated  with  a  range  of  symptoms  but  is predominantly characterised by bone pain, fatigue, and urinary dysfunction. Metastasis is predominantly

<div style=\"page-break-after: always\"></div>

localized  in  bones  (90%  of  patients  with  metastatic  castration-resistant  prostate  cancer),  causing significant morbidity which requires medical interventions.

Although almost all men with mHSPC initially respond to ADT, most will progress to mCRPC within 1 to 3 years of their initial diagnosis (Wenzel et al. 2021).

## Management

The treatment and management of patients with mHSPC has evolved over recent years with several new treatment options. Historically, for decades ADT, achieved by surgical or medical castration, was the standard of care (SOC) for mHSPC. Nowadays, ADT in combination with one of the following is currently approved in the EU for the treatment of mHSPC: abiraterone, a CYP17 inhibitor (with prednisone or prednisolone), apalutamide, an androgen receptor inhibitor (ARI), or enzalutamide, another ARI. In the EU, docetaxel in combination with ADT, with or without prednisone or prednisolone, is also approved for the treatment of mHSPC. (C Parker et al. Ann Oncol 2020)

## 2.1.2. About the product

Darolutamide is a structurally distinct non-steroidal ARI that binds with a high affinity and selectivity to the AR, thus inhibiting androgen binding, AR nuclear translocation and AR mediated transcription, thus preventing transcription of oncologic genes necessary for cancer growth and survival.

## Chemical structure of darolutamide

<!-- image -->

Darolutamide (Nubeqa) was first approved in the EU on 27 March 2020 for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.

The recommended dose is 600 mg darolutamide (two tablets of 300 mg) taken twice daily, equivalent to a total daily dose of 1200 mg. The proposed dose for the current indication is the same. Darolutamide should be continued until disease progression or unacceptable toxicity. mHSPC patients should start darolutamide in combination with docetaxel.The first of 6 cycles of docetaxel should be administered within 6 weeks after the start of darolutamide treatment. Treatment with darolutamide should be continued until disease progression or unaccepatble toxicity even if a cycle of docetaxel is delayed, interrupted, or discontinued.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The  pivotal  study  to  support  efficacy  and  safety  of  darolutamide  for  the  treatment  in  the  mHSPC population is the randomized, double-blind, placebo-controlled Phase 3 Study 17777 (ARASENS). Study 17777 was designed to demonstrate the superiority of darolutamide in combination with docetaxel over placebo in combination with docetaxel in overall survival (OS). The study randomized 1306 patients in

<div style=\"page-break-after: always\"></div>

a 1:1 ratio to receive 6 cycles of docetaxel and either darolutamide + docetaxel + ADT or matching placebo+docetaxel concurrently with ADT until disease progression.

The MAH sought Scientific Advice at the CHMP on the design of study 17777, the pivotal trial for this application (EMEA/H/SA/2639/2/2015/II) (See section 1). The MAH mostly followed the recommendations of the CHMP scientific advice.

## 2.1.4. General comments on compliance with GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH. The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

New non-clinical studies as well as environmental studies have been submitted in support to this procedure. The non-clinical studies are oncology studies conducted in transgenic mice submitted and discussed under Variation EMEA/H/C/004790/II/0012. The submitted study on the environmental risk was an update of the study submitted in 2019.

## 2.2.2. Pharmacology

## 2.2.3. Toxicology

## Carcinogenicity

The carcinogenic potential of darolutamide was evaluated in a 6-month study in TgRAS transgenic mice. Seven -day and 4-week studies were also conducted to select the appropriate dosing regimen for the 6month study.

The chosen maximum tolerated dose was 500 mg/kg twice daily.

## 2.2.4. Ecotoxicity/environmental risk assessment

| Substance: darolutamide             | Substance: darolutamide        | Substance: darolutamide   | Substance: darolutamide   |
|-------------------------------------|--------------------------------|---------------------------|---------------------------|
| CAS-number: 1297538-32-9            | CAS-number: 1297538-32-9       | CAS-number: 1297538-32-9  | CAS-number: 1297538-32-9  |
| PBT screening                       |                                | Result                    | Conclusion                |
| Bioaccumulation potential- log K ow | OECD107                        | 2.41                      | Not potential PBT         |
| PBT assessment                      | PBT assessment                 | PBT assessment            | PBT assessment            |
| Parameter                           | Result relevant for conclusion |                           | Conclusion                |
| Bioaccumulation                     | Log K ow                       | 2.41                      | Not B                     |

<div style=\"page-break-after: always\"></div>

| Persistence                                                      | DT50                                            | Darolutamide: up to 542.37d (total system,12C) M-1 (keto-darolutamide):                                                                                   | Darolutamide: up to 542.37d (total system,12C) M-1 (keto-darolutamide):                                                                                   | Darolutamide: up to 542.37d (total system,12C) M-1 (keto-darolutamide):                                                                                   | vP                                                                                                         |
|------------------------------------------------------------------|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| Toxicity                                                         | NOEC (fish)                                     | NOEC = 28 g/L                                                                                                                                             | NOEC = 28 g/L                                                                                                                                             | NOEC = 28 g/L                                                                                                                                             | Not T                                                                                                      |
| PBT-statement                                                    | The compound is not considered as PBT nor vPvB. | The compound is not considered as PBT nor vPvB.                                                                                                            | The compound is not considered as PBT nor vPvB.                                                                                                            | The compound is not considered as PBT nor vPvB.                                                                                                            | The compound is not considered as PBT nor vPvB.                                                            |
| Phase I                                                          |                                                 |                                                                                                                                                            |                                                                                                                                                            |                                                                                                                                                            |                                                                                                            |
| Calculation                                                      | Value                                           | Unit                                                                                                                                                       | Unit                                                                                                                                                       | Unit                                                                                                                                                       | Conclusion                                                                                                 |
| PEC surfacewater                                                 | 1.74                                            | mg/L                                                                                                                                                       | mg/L                                                                                                                                                       | mg/L                                                                                                                                                       | >0.01 threshold: Yes                                                                                       |
| Other concerns                                                   | Endocrine active substance                      | Endocrine active substance                                                                                                                                 | Endocrine active substance                                                                                                                                 | Endocrine active substance                                                                                                                                 | Yes                                                                                                        |
| Phase II Physical-chemical properties and fate                   | Phase II Physical-chemical properties and fate  | Phase II Physical-chemical properties and fate                                                                                                             | Phase II Physical-chemical properties and fate                                                                                                             | Phase II Physical-chemical properties and fate                                                                                                             |                                                                                                            |
| Study type                                                       | Test protocol                                   | Results                                                                                                                                                    | Results                                                                                                                                                    | Results                                                                                                                                                    | Remarks                                                                                                    |
| Adsorption-Desorption                                            | OECD 106                                        | Kf oc soil = 186; 910; 1877 Kf oc sludge = 244; 452                                                                                                        | Kf oc soil = 186; 910; 1877 Kf oc sludge = 244; 452                                                                                                        | Kf oc soil = 186; 910; 1877 Kf oc sludge = 244; 452                                                                                                        |                                                                                                            |
| Water solubility                                                 | OECD 105                                        | 12.9 mg/L (25C, pH 6)                                                                                                                                     | 12.9 mg/L (25C, pH 6)                                                                                                                                     | 12.9 mg/L (25C, pH 6)                                                                                                                                     |                                                                                                            |
| Dissociation constant                                            | OECD 112                                        | Neutral                                                                                                                                                    | Neutral                                                                                                                                                    | Neutral                                                                                                                                                    |                                                                                                            |
| Hydrolysis                                                       | OECD 111                                        | Stable at pH 4, 7, and 9                                                                                                                                   | Stable at pH 4, 7, and 9                                                                                                                                   | Stable at pH 4, 7, and 9                                                                                                                                   |                                                                                                            |
| Vapour Pressure                                                  | OECD 104                                        | 2.61 x 10 -5 Pa (20C)                                                                                                                                     | 2.61 x 10 -5 Pa (20C)                                                                                                                                     | 2.61 x 10 -5 Pa (20C)                                                                                                                                     |                                                                                                            |
| Ready Biodegradability Test                                      | OECD 301                                        | Not degraded on day 29                                                                                                                                     | Not degraded on day 29                                                                                                                                     | Not degraded on day 29                                                                                                                                     | Not readily biodegradable                                                                                  |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD 308                                        | DT 50, water = < 1 d DT 50, sediment = 129.55 d - 289.76 d DT 50, total system = 129.55 d - 289.76d Transformation product > 10%: M-1 (keto- darolutamide) | DT 50, water = < 1 d DT 50, sediment = 129.55 d - 289.76 d DT 50, total system = 129.55 d - 289.76d Transformation product > 10%: M-1 (keto- darolutamide) | DT 50, water = < 1 d DT 50, sediment = 129.55 d - 289.76 d DT 50, total system = 129.55 d - 289.76d Transformation product > 10%: M-1 (keto- darolutamide) | sandy clay and sand, 12C sediment 1 and total system: SFO kinetic; sediment 2 and total system HS kinetic |
| Phase IIa Effect studies                                         | Phase IIa Effect studies                        | Phase IIa Effect studies                                                                                                                                   | Phase IIa Effect studies                                                                                                                                   | Phase IIa Effect studies                                                                                                                                   | Phase IIa Effect studies                                                                                   |
| Study type                                                       | Test protocol                                   | Endpoint                                                                                                                                                   | value                                                                                                                                                      | Unit                                                                                                                                                       | Remarks                                                                                                    |
| Algae, Growth Inhibition Test                                    | OECD 201                                        | NOEC                                                                                                                                                       |  8037                                                                                                                                                     | g/L                                                                                                                                                       | Desmodesmus subspicatus                                                                                    |
| Daphnia sp . Reproduction Test                                   | OECD 211                                        | NOEC                                                                                                                                                       |  1137                                                                                                                                                     | g/L                                                                                                                                                       | Daphnia magna                                                                                              |
| Fish, Short Term Reproduction Screen                             | OECD 229                                        | NOEC                                                                                                                                                       |  119                                                                                                                                                      | g/L                                                                                                                                                       | Pimephales promelas                                                                                        |
| Fish, Full Life-Cycle Toxicity Test                              | OECD 240 adapted                                | NOEC                                                                                                                                                       | 28                                                                                                                                                         | g/L                                                                                                                                                       | Pimephales promelas                                                                                        |
| Activated Sludge, Respiration Inhibition Test                    | OECD 209                                        | NOEC                                                                                                                                                       |  12900                                                                                                                                                    | g/L                                                                                                                                                       | Maximum water solubility                                                                                   |
| Phase IIb Studies                                                |                                                 |                                                                                                                                                            |                                                                                                                                                            |                                                                                                                                                            |                                                                                                            |
| Sediment dwelling organism, Chironomus riparius                  | OECD 218                                        | NOEC                                                                                                                                                       | 128.16                                                                                                                                                     | mg/k g                                                                                                                                                     | Sediment dry weight, 10% Corg                                                                              |

Regarding the environmental risk, the data submitted provide the results of 2 new studies which aim to assess the endocrine disrupting (ED) potential of darolutamide.

On the basis of these study results, it appears that darolutamide poses a risk to aquatic organisms in surface waters. This result leads the manufacturer to calculate a Refined PECsw (based on a refined Fpen) which no longer showed any risk for aquatic organisms in surface waters.

<div style=\"page-break-after: always\"></div>

## 2.2.5. Discussion on non-clinical aspects

The carcinogenic potential of darolutamide was evaluated in a 6-month study in TgRAS transgenic mice presented in Variation  EMEA/H/C/004790/II/0012. The study was well constructed about number of mice, positive and negative controls. The chosen maximum tolerated dose was 1000 mg/kg/day. This is a dose which did not show any toxicity in transgenic mice. Beyond this dose, the appearance of an exposure plateau justified the choice of this maximum dose. The results of this study did not demonstrate an increase in tumor development in mice treated with darolutamide versus untreated mice. However, studies in transgenic mice alone and the maximum dose used do not offer sufficient safety margins to rule out the risk of second primary cancers in humans.

Since darolutamide unlike other second-generation anti-androgens did not produce pre-neoplastic lesion in repeated toxicity studies and in order to reduce the use of animals, the need for 2-year studies in rats, was waived.

## 2.2.6. Conclusion on the non-clinical aspects

The 6-month study in transgenic mice did not show significantly higher tumor occurrence in treated mice compared to negative controls. However, this study alone does not rule out the risk of a second primary cancer in humans, especially since the safety margins are low. The non-discarded risk of development of a second primary cancer in humans has been added to the SmPC.

Darolutamide was found to be very persistent and not readily biodegradable but without toxicity to aquatic organisms.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

## Tabular overview of clinical studies

| Bayer study no Study name (Orion study no) Study report no/ Region   | Study design                                        | Treatment and dose                                                                                                                                                                                               | Main objectives                                                          | Study population                                    | Treated patients as of 25 OCT 2021                                                                                                                                    |
|----------------------------------------------------------------------|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase 3 pivotal study in mHSPC - PRIMARY COMPLETION                  | Phase 3 pivotal study in mHSPC - PRIMARY COMPLETION | Phase 3 pivotal study in mHSPC - PRIMARY COMPLETION                                                                                                                                                              | Phase 3 pivotal study in mHSPC - PRIMARY COMPLETION                      | Phase 3 pivotal study in mHSPC - PRIMARY COMPLETION | Phase 3 pivotal study in mHSPC - PRIMARY COMPLETION                                                                                                                   |
| 17777 ARASENS Primary completion                                     | Randomized 1:1, double-blind placebo-controlled     | Darolutamide 600 mg (2 tablets of 300 mg) BID with food, equal to a daily dose of 1200 mg, or placebo. In combination with 6 cycles of docetaxel 75 mg/m 2 as an IV infusion every 21 days Concurrently with ADT | Efficacy and safety compared with placebo, in combination with docetaxel | Patients with mHSPC                                 | darolutamide+ docetaxel 652 placebo+docetaxel 650 424 patients ongoing with treatment (299 darolutamide+ docetaxel arm; 125 placebo+ docetaxel arm) as of 25 OCT 2021 |
| North America, Asia Pacific, ROW                                     |                                                     | at                                                                                                                                                                                                               |                                                                          |                                                     |                                                                                                                                                                       |

## 2.3.2. Pharmacokinetics

Darolutamide pharmacokinetic (PK) in mHSPC patients has been investigated in Study 17777 ARASENS using non-compartmental analysis (NCA) and population PK modelling and simulation techniques (study number CPMX50017 / report R-13408, report date 10 January 2022). This pivotal study was a randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of 600 mg (bis in die) BID oral darolutamide in combination with docetaxel (75 mg/m 2  Day 1 as 1 h intravenous [IV] infusion every 21 days) in mHSPC patients for six treatment cycles.

In addition, the PK has been investigated in a subgroup of Chinese patients who were randomized to the darolutamide+docetaxel arm.  Moreover, exposure-response analysis was provided.

Clinical pharmacology data in mHSPC patients were compared, where applicable, with the previously submitted data in nmCRPC patients from a Phase 3 Study 17712 (ARAMIS).

## 2.3.2.1. Methods

## 2.3.2.1.1. Bioanalytical methods

##  Darolutamide

In study 17777, bioanalysis of darolutamide, the two diastereomers, (S,R)-darolutamide and (S,S)darolutamide, and its metabolite keto-darolutamide in human plasma (K2EDTA) was performed utilizing quantitative high performance LC-MS/MS assay. All Samples were stored at nominal temperature of -20C and analysed within at most 728 days after sampling. The stability data indicated that the analyte(s) were stable for this time period. A summary of the calibration range, precision and accuracy is provided in Table 1 . The lower limit of quantification (LLOQ) values for (S,R)-darolutamide, (S,S)-darolutamide, ketodarolutamide and docetaxel were 4.87 g/L, 5.13 g/L, 10 g/L and 1 g/L respectively.

<div style=\"page-break-after: always\"></div>

Table 1: Brief summary of working range and precision and accuracy of the bioanalytical method darolutamide in human plasma

|                                                                                                                                                                                                | (S,R)- darolutamide (BAY 1896951)   | (S,S)- darolutamide (BAY 1896952)   | Keto- darolutamide (BAY 1896953)   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------|------------------------------------|
| Calibrationrange(ng/mL)ofruns1to10a                                                                                                                                                            | 4.94 to 4940 4.87 to 4870           | 5.06 to5060 5.13to5130              | 10.0to10000 10.0 to10000           |
| Calibration range(ng/mL)of runs 11 to52                                                                                                                                                        |                                     | 96.8to101.2                         | 97.2to102.2                        |
| Meaninter-assayaccuracyrange(%)of back-calculated concentrationsofruns1to10(exceptLLoQ)incalibrators Meaninter-assayaccuracyrange(%)ofback-calculated concentrationsofruns11to52exceptLLOQ)in | 95.5to 102.3 98.4 to 101.5          | 98.9to101.0                         | n.a.b                              |
| calibrators Mean inter-assay precision range (%) of runs 1 to 10 of back-calculatedconcentrations(exceptLLOQ)in                                                                                | 2.4 to6.6 1.8 to5.3 103.0           | 1.8to3.5                            | 1.7to3.5                           |
| calibrators Meaninter-assay precisionrange(%)of runs11to52of back-calculatedconcentrations(exceptLLoQ)in calibrators                                                                           |                                     | 1.9to4.1                            | n.ab 102.0                         |
| Accuracy (%) of runs 1 to 10 (LLOQ) Accuracy(%)of runs 11to52(LLOQ)                                                                                                                            | 100.6                               | 101.0 100.4                         | n.a.b                              |
| Precision(%)of runs 1 to10 (LLOQ)                                                                                                                                                              | 3.0 2.6                             | 1.8 1.9                             | 1.6 n.a.b                          |
| Precision(%)of runs11to52(LLOQ)                                                                                                                                                                |                                     |                                     |                                    |
| Qualitycontrolrange(ng/mL)of runs1to10                                                                                                                                                         | 14.8 to19800                        | 15.2to20200                         | 30.0 to40000                       |
| Qualitycontrol range(ng/mL)ofruns11to52                                                                                                                                                        | 14.6 to 19480                       | 15.4 to 20520                       | 30.0 to40000                       |
| Accuracy(%)ofruns 1to10                                                                                                                                                                        | 100.2to103.7                        | 100.0to103.3                        | 100.6to102.1                       |
| Accuracy(%) of runs 11 to 52                                                                                                                                                                   | 99.9to 101.8                        | 100.3to 102.0                       | n.ab                               |
|                                                                                                                                                                                                |                                     | 3.7 to 6.8                          |                                    |
| Precision(%)of runs 1to 10                                                                                                                                                                     | 5.7 to 6.6                          |                                     | 3.1to5.9                           |
| Precision(%)ofruns11to52                                                                                                                                                                       | 4.6to5.7                            | 2.8to5.8                            | n.a.b                              |

Thecalibrationrangeisbasedonthediastereomericratioshowninthisstudy

Abbreviations:LLoQ=Lowerlimitofquantification

forruns1-10:49.4%BAY1896951,Rfom),50.6%(BAY1896952,S-form)

IdenticalrangeforBAY1896953throughoutstudy,dataforruns1to52forBAY1896953summarizedandonlyshownonce

forruns11-52:48.7%BAY1896951,Rfom),51.3%BAY1896952,S-fom).

##  Docetaxel

In study 17777, quantitative analysis of docetaxel in plasma was performed utilizing liquid phase extraction followed by quantitative high performance LC-MS/MS detection, with quantitation being achieved by weighted linear regression using paclitaxel as the internal standard. All samples were stored at -20C and -80C and analysed within 1158 days after sampling. The stability data indicated that docetaxel was stable for this time period. A summary of the calibration range, precision and accuracy is provided in Table 2 .

Table 2: Brief summary of working range and precision and accuracy of the bioanalytical method docetaxel in human plasma

| Docetaxel                                                                         | Docetaxel       |
|-----------------------------------------------------------------------------------|-----------------|
| Calibration standards mean inter-assay accuracy of back-calculated concentrations | 97.00%to103.00% |
| Calibration standards precision                                                   | 6.13%          |
| Accuracy at the lowest calibration standard (LLOQ)                                | 99.40%          |
| Precision at the lowest calibration standard (LLOQ)                               | 5.29%           |
| Concentration range of Quality control (QC) samples (g/L)                        | 15.0 to 3750    |
| QC accuracy                                                                       | 91.20%to98.00%  |
| QC precision                                                                      | 5.81% to 7.22%  |

<div style=\"page-break-after: always\"></div>

## 2.3.2.1.2. Pharmacokinetic analyses

The PK of darolutamide (i.e. the sum of the two diastereomers (S,S), and (S,R)-darolutamide), (S,S)darolutamide, (S,R)-darolutamide, keto-darolutamide, and docetaxel were evaluated in study 17777 ARASENS.

PK data were analysed using NCA and population PK modelling. NCA evaluation was performed using WinNonlin Phoenix (Certara). Population PK modelling and simulation was performed using the nonlinear-mixed effects modelling approach with NONMEM software (ICON Development Solutions, version 7.4).

In the first 25 patients (safety/PK lead-in) PK samples were taken on day 1 pre-dose, and after 20 min, 1h, 1.5 h, 2 h, 3 h, 4 h, 6 h, and 8 h post-dose, as well as two additional samples at two later visits (one per visit). For those who received at least 1 cycle of docetaxel, AUC(0 -12) (using the predose plasma sample also as 12 hour sample), AUC(0 -8), AUC(0 -tlast), Cmax, tmax, tlast were estimated for darolutamide, (S,S)-darolutamide, (S,R)-darolutamide, keto-darolutamide, and docetaxel. For docetaxel, AUC(0 -t last), Cmax, tmax, and tlast were estimated.

For all other patients, sparse PK sampling was done.

China PK substudy: At sites in China additional blood samples at visit 1 (days 1, 2 and 3), and day 15 for assessment of pharmacokinetics were drawn. Differences in study drug administration compared to the main study were (i) single dosing of study drug on day 1, (ii) study treatment holiday on day 2, and (iii) tart of regular twice-a-day dosing of study drug on day 3.

## Absorption

The population PK analysis using data from Study 17777 ARASENS in patients with mHSPC showed that peak plasma concentrations (Cmax) of darolutamide following oral administration of 600 mg (2 tablets of 300 mg), were about 20 % lower compared to those observed in study 17712 ARAMIS in patients with nmCRPC (i.e. 3.84 mg/L [35.6 %CV] versus 4.79 mg/L [30.9 %CV]).

In study 17712 ARAMIS in patients with nmCRPC Cmax were usually reached around 4 hours after administration.

## Distribution

The apparent volume of distribution of darolutamide after intravenous administration is 119 L. The population PK analysis using data from Study 17777 ARASENS in patients with mHSPC reveal an overall volume of distribution of 32.7 L (117 %CV) after oral administration of 600 mg BID of darolutamide.

## Elimination

The clearance of darolutamide following intravenous administration was 116 mL/min (CV: 39.7%).

In study 17712 ARAMIS in patients with nmCRPC the effective half-life of darolutamide and keto-darolutamide in plasma of patients was approximately 20 hours. Of the two diastereomers comprising darolutamide, (S,R)-darolutamide had a shorter effective half-life of 9 hours compared to (S,S)-darolutamide with an effective half-life of 22 hours.

The population PK analysis using data from Study 17777 ARASENS in patients with mHSPC revealed that the effective half-life of darolutamide, (S,R)-darolutamide, (S,S)-darolutamide, and

<div style=\"page-break-after: always\"></div>

keto-darolutamide in plasma of patients were approximately 18.4 h (62 %CV), 10.9 h (76.2 %CV), 20.5 h (58.8 %CV), and 19 h (63.2 %CV), respectively.

## Dose proportionality and time dependencies

No new information submitted.

## 2.3.2.2. Intra- and inter-individual variability

Variability was reported to be higher in study 17777 ARASENS in patients with mHSPC ( Table 8 ) compared to study 17712 ARAMIS in patients with nmCRPC ( Table 11 ).

## 2.3.2.3. Pharmacokinetics in target population

The PK in the pivotal study 17777 ARASENS was analysed using NCA and population PK modelling methods.

The PK parameters from NCA analysis and population PK analysis are listed in Table 3 .

Table 3 Geometric mean (%CV) of darolutamide PK parameters from Study 17712 (population PK approach) and from Study 17777 (NCA approach and population PK approach)

|                     | Study 17777 Pop PK (n=652)   | Study 17777 NCA (n=11-12)   | Study 17712 Pop PK (n=388)   |
|---------------------|------------------------------|-----------------------------|------------------------------|
| C max , mg/L        | 3.84 (35.6%)                 | 4.33 (50%)                  | 4.79 (30.9%)                 |
| tmax, h             | 3.33 (18.4%,1.35 - 4.59)     | 3.83 [0.00 - 8.13]          | 3.64 (4.4%, 2.72 - 3.92)     |
| AUC(0 - 12), mgh/L | 38.2 (39.1%)                 | 35.5 (75%)                  | 52.8 (33.9%)                 |
| Effective t 1/2 , h | 18.4 (62.0%)                 | NA                          | 19.6 (29.7%)                 |

Abbreviations: AUC(0 -12)=Area under the plasma concentration-time curve from time 0 to 12 hours post dose; Cmax=Maximum observed drug concentration; CV=Coefficient of variation; PK=Pharmacokinetic; tmax=Time to maximum observed drug concentration; t1/2=Half-life, NA=not available

## Study 17777 ARASENS

Overall,  1305  patients  were  randomly  assigned  to  receive  darolutamide  +  docetaxel  +  Androgen deprivation therapy (ADT); (n = 651 patients) or placebo + docetaxel + ADT (n = 654 patients). At the time of the primary completion, 45.9% of the randomized patients in the darolutamide + docetaxel + ADT arm and 19.1% in the placebo + docetaxel + ADT arm were ongoing with study treatment.

All patients were required to receive treatment with ADT of the investigator's c hoice (luteinizing hormone Patients were randomly assigned in a 1:1 ratio to receive darolutamide or placebo at 600 mg (2 tablets of 300 mg) BID with food, equal to a daily dose of 1200 mg. Randomization was stratified by extent of disease and alkaline phosphatase (ALP) levels. Docetaxel was administered after randomization, at a dose of 75 mg/m 2  as an IV infusion every 21 days for 6 cycles, and the first cycle was to be administered within  6  weeks  after  the  start  of  study  drug.  Docetaxel  could  be  administered  in  combination  with prednisone/prednisolone at the discretion of the investigator. All patients were required to receive ADT of  the  investigator's  choice  (luteinizing  hormone -releasing  hormone  [LHRH]  agonist/antagonists  or orchiectomy) as standard ther apy starting 12 weeks before randomization.

<div style=\"page-break-after: always\"></div>

## NCA results for study 17777 ARASENS

## Safety/PK lead-in phase

In total, PK data from 25 patients were evaluated during the safety/PK lead-in phase. Among those, 12 patients were randomized into the darolutamide + docetaxel arm.

The results from NCA evaluation showed a slight increase in exposure in the darolutamide + docetaxel arm compared with the placebo + docetaxel arm ( Table 4 ) with the AUC(0 -tlast) being 6% higher (2.10 vs. 1.98 mg * h/L) and Cmax being 15% higher (1.93 vs. 1.68 mg/L) in the darolutamide + docetaxel arm (23 -54 %CV docetaxel).

Table 4: Geometric mean (%CV) PK parameters of docetaxel after repeated administration of 600 mg darolutamide BID on the first day of docetaxel administration of 75 mg/m 2  (PKS -Safety/PK lead-in)

| Parameter    | Unit    | Darolutamide+ docetaxel arm (n=12)   | Placebo+ docetaxel arm (n=13) a   |
|--------------|---------|--------------------------------------|-----------------------------------|
| AUC(0-tiast) | g-h/mL | 2.10 (30%) b                         | 1.99 (33%)                        |
| Cmax         | g/mL   | 1.93 (23%)b                          | 1.68 (54%) c                      |
| Lmax         | h       | 1.00 [0.33 - 1.50]b                  | 0.967 [0.167 - 2.25]             |
| tlast        | h       | 7.85 [5.83 - 8.00]                   | 7.92 [6.00 - 8.15]                |

Abbreviations: AUC=Area under the plasma concentration-time curve; BID=Twice daily: Cmax=Maximum observed drug concentration; CV=Coefficient of variation; LLOQ=Lower limit of quantification; PK=Pharmacokinetic; PKS=Pharmacokinetic analysis set; taa=Time of the last plasma concentration above LLOQ; tmax=Time to maximum observed drug concentration a: Median [range]

b: n=11

c: n=12

Note: Units and values from the source data were transformed to g/mL and rounded to 3 significant diqits manually.

The PK parameters resulting from NCA evaluation of darolutamide, (S,R)-darolutamide, (S,S)darolutamide, and keto-darolutamide are presented in Table 5 . The corresponding concentration-time profiles are shown in Figure 1.

Table 5: Geometric mean (%CV) PK parameters of darolutamide, (S,S)-darolutamide, (S,R)darolutamide, and keto-darolutamide after repeated administration of 600 mg darolutamide BID on the first day of docetaxel administration of 75 mg/m 2 (PKS -Safety/PK lead-in)

| Parameter    | Unit   | Darolutamide (n=12)   | (S,R)-darolutamide (n=12)   | (S,S)-darolutamide (n=12)   | Keto-darolutamide (n=12)   |
|--------------|--------|-----------------------|-----------------------------|-----------------------------|----------------------------|
| AUC(0-12)a   | mg-h/L | 35.5 (75%)            | 4.65 (48%)                  | 30.3 (86%)                  | 80.5 (70%)                 |
| AUC(0-8)     | mg.h/L | 24.4 (79%)            | 3.52 (50%)                  | 20.6 (89%)                  | 57.7 (73%)                 |
| AUC(0-tiast) | mg.h/L | 35.3 (71%)            | 4.49 (47%)                  | 30.3 (81%)                  | 82.1 (67%)                 |
| Cmax         | mg/L   | 4.33 (50%)            | 0.781 (37%)                 | 3.51 (63%)                  | 10.2 (57%)                 |
| tmax b       | h      | 3.83 [0.00 - 8.13]    | 3.31 [1.00 - 8.13]          | 3.83 [0.00 - 8.13]          | 3.00 [1.50 - 8.13]         |
| tlast        | h      | 12.0 [8.00 - 12.0]    | 12.0 [8.00 - 12.0]          | 12.0 [8.00 - 12.0]          | 12.0 [8.00 - 12.0]         |

Abbreviations: AUC=Area under the plasma concentration-time curve; BID=Twice daily; Cmax=Maximum observed drug concentration; CV=Coefficient of variation; LLOQ=Lowerlimit of quantification;PK=Pharmacokinetic; PKS=Pharmacokinetic analysis set; tast=Time of the last plasma concentration above LLOQ; tmax=Time to maximum observeddrugconcentration a: n=11

b: Median [range]

Note:Units andvalues from thesource datawere transformed to ma/L and rounded to3 sianificant diaits manuallv.

<div style=\"page-break-after: always\"></div>

Figure 1: Geometric mean (+/ -geom. StD) of darolutamide, (S,S)-darolutamide, (S,R)darolutamide, and keto-darolutamide after multiple dose administration on the first day of docetaxel injection on linear scale (left) and semi-log scale (right), (PKS -Safety/PK leadin)

<!-- image -->

## China PK substudy

Among the 25 patients who met the PK population criterion in the China PK substudy, 14 patients were randomized into the darolutamide + docetaxel arm. PK parameters of darolutamide, (S,R)darolutamide, (S,S)- darolutamide, and keto-darolutamide following single and multiple administration

## Population PK modelling results for study 17777 ARASENS

Study number: CPMX50017 / report R-13408, report date 10 January 2022

## Objectives

A previously developed population PK model for nmCRCP patients was used to describe the PK of darolutamide in mHSPC patients. In addition, the PK of (S,S)-darolutamide, (S,R)- darolutamide and keto-darolutamide were investigated and covariates potentially influencing their PK were examined. Moreover, individual docetaxel clearance and exposure on the basis of established literature models were evaluated. The potential of drug-drug interaction between darolutamide and docetaxel was analysed (refer to section 'Pharmacokinetic interaction studies').  Furthermore, a meta -population PK analysis of study 17777 and study 17712 was done (presented below).

## Data

Among the 1305 patients included in study 17777 ARASENS, 645 contributed to the darolutamide final population PK model analysis with 2496 concentrations of both (S,S)-darolutamide and ketodarolutamide and 2485 concentrations of (S,R)-darolutamide above the LLOQ. In addition, a total of 190 observations of both (S,S)- darolutamide and keto-darolutamide and 201 concentrations of (S,R)darolutamide were below the LLOQ. In total, 1252 patients contributed to the PK assessment of docetaxel, with 2135 samples above the LLOQ and 225 concentration measures below the LLOQ, and 94 excluded.

A visualisation revealed non-normally distributed observed data. Box-Cox transformation were applied to evaluate if the transformed data more closely follow a normal distribution. Model building resumed with use of the Box-Cox transformed data. Re-estimation of parameter values could still not address bias in residuals on treatment day one. Attempts were made to include darolutamide concentrations below the LLOQ, but this constantly resulted in unstable parameter estimation. Therefore, it was

<div style=\"page-break-after: always\"></div>

decided to omit data below LLOQ during model development. For model development where observations &lt;LLOQ were included, the M3 method was used.

The median age of patients was 67 years (range 41 to 86 years) and the median body weight was 75.05 kg (range 39 to 144 kg). In total, 52.5 % of the patients were White, 35.9 % were Asian and 11.6% were categorized as other. Asian and 'other' were combined to create the ethnicity covariate 'white' vs 'non -white'. In total, 16.3 % of patients were from Mainland China, 9.9 % from Japan, 7.1 % from Korea and 2.5 % from Taiwan. Further to this, 16.5% patients were from the USA. The median baseline serum creatinine level was 0.88 mg/dL (range 0.4 to 2.39 mg/dL) and median estimated glomerular filtration rate at baseline was 92.75 mL/min (range 16.37 to 230.59 mL/min). The median baseline total bilirubin level was 0.53 mg/dL (range 0.04 to 1.95 mg/dL), median aspartate transaminase (AST) level was 24 U/L (range 7.95 to 79.8 U/L) and median alanine transaminase (ALT) was 24 U/L (range 1 to 161.6 U/L). In total, 92.2% of patients had normal hepatic function, 7.5% of patients had mild hepatic impairment and two patients had moderate hepatic impairment. The median baseline serum albumin level was 4.3 g/dL (range 2.4 to 6.15 g/dL) and the median baseline total protein level was 7.2 g/dL (range 5.2 to 9.11 g/dL).

## Model development and results

The previously developed population PK model for nmCRCP patients was used. Parameters were reestimated for study 17777 ARASENS data. Covariates were investigated using the forward inclusion (OFV 10.828, p &lt; 0.001, 1 degree of freedom) and backward elimination procedure (OFV &gt; +15.137, p &gt; 0.001, 1 degree of freedom). Model selection criteria included commonly used methods like goodness-of-fit (GOF) plots, precision and plausibility of parameter estimates. For model qualification prediction-corrected visual predictive checks (pcVPC) were carried out (1000 replicates).

For docetaxel, a literature model was used (please refer to section 'Pharmacokinetic interaction studies').

Parameter estimates of the final population PK model for darolutamide in study 17777 ARASENS are shown in Table 6 . Bootstrap results are given in Table 7 . VPCs are presented in Figure 2 , Figure 3 , and Figure 4 . The model structure remained the same as the previously model structure. The population typical CL was 4.88 L/h (IIV = 41.5 %CV) and the total volume of distribution for all three analyses was 32.7 L (IIV = 117 %CV). ETA shrinkages were below 10.2 %. The absorption of darolutamide was described by several (inter-connected) processes due to the interconversion of the diastereomers via keto-darolutamide. Keto-darolutamide was more rapidly absorbed (KA3=0.26 h -1 ) compared to ( S , R )-darolutamide (KA1 = 0.06 h -1 ) and R,S-darolutamide (KA2 = 0.006 h -1 ). Following absorption, keto-darolutamide was rapidly interconverted back to ( S , R )- and (mainly) ( S , S )-darolutamide. As a result, the model predicted a much faster occurrence of ( S , R )- and ( S , S )-darolutamide, as reflected by the Tmax (3.33 h (18.4%,1.35 -4.59)) estimates, in the plasma/central compartment as the estimated KA1 and KA2 values might suggest. Parameter KRET (estimate: 0.475) represented the ratio between the transformation rate of (S,S)- or (S,R)-darolutamide to ketodarolutamide and the transformation rate of keto-darolutamide back to (S,S)- or (S,R)-darolutamide. It informed about the net transformation of darolutamide to keto-darolutamide or vice versa. Age, Japanese, and Chinese were identified as statistically significantly covariates. As such, CL increased by approximately 26.3 % for patients under 65 versus patients  65 years, Japanese having a CL 32 % lower than patients from the rest of regions (excluding Mainland China) and patients in Mainland China having a CL 19.7% lower than patients from the rest of regions (excluding Japan). Residual variability varied between 14 -35 %. Relative standard error (RSE) was below 26 %.

<div style=\"page-break-after: always\"></div>

Table 6 : Parameter estimates of the final population PK model for darolutamide

| Parameter                                           | Unit                                                | Estimato                                            | RSE[%]                                              | LLCI                                                | ULCI                                                | Description                                                                        |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|------------------------------------------------------------------------------------|
| Fixed elledls (THETA)                               | Fixed elledls (THETA)                               | Fixed elledls (THETA)                               | Fixed elledls (THETA)                               | Fixed elledls (THETA)                               | Fixed elledls (THETA)                               | Fixed elledls (THETA)                                                              |
| KTR                                                 | hr!                                                 | 17.2                                                | 4.83                                                | 15.6                                                | 18.9                                                | Transit comparment rale                                                            |
| KA1                                                 | hr1                                                 | 0.0601                                              | 7.26                                                | 0.0515                                              | 0.0686                                              | Absorplion rale conslant for (S,R) darolulamide                                    |
| KA2                                                 | hrl                                                 | 0.00556                                             | 9.49                                                | 0.00452 0.00659                                     |                                                     | Absorplion rale conslant for (S. S)- darolulamide                                  |
| KA3                                                 | hr1                                                 | 0.262                                               | 5.28                                                | 0.235                                               | 0.289                                               | Absorplionraleconslantforkelo darolutamide                                         |
| CLpp                                                | Llh                                                 | 4.88                                                | 2.78                                                | 4.62                                                | 5.15                                                | Clearance for a typical palient wilh AGE 2 65 and not from Asia                    |
| V                                                   | L                                                   | 32.7                                                | 6.68                                                | 28.4                                                | 37.0                                                | Volume of distribution for all three analytes in a typical patient                 |
| KMETSR                                              | hr1                                                 | 0.763                                               | 18.3                                                | 0.489                                               | 1.04                                                | Rale conslant for conversion between (S,R) darolulamide and kelo- darolutamide     |
| KMETSS                                              | hr!                                                 | 6.76                                                | 25.5                                                | 3.38                                                | 10.1                                                | Rale constant for conversion belween (S,S)-darolulamide and kelo- darolulamide     |
| KRET                                                |                                                     | 0.475                                               | 0.970                                               | 0.466                                               | 0.484                                               | Scaling parameler for rale of conversion from kelo lo (S.R) and (S.S) darolulamide |
|                                                     |                                                     | -1.94                                               | 1.12                                                | -1.99                                               | -1.90                                               | RR                                                                                 |
|                                                     |                                                     | 0.263                                               | 18.4                                                | 0.168                                               | 0.358                                               | Parameler describingthe influenceofa palient being younger than B5 on CL           |
|                                                     |                                                     | -0.322                                              | 12.7                                                | -0.403                                              | -0.242                                              | Parameler describing the influence of Japan geographie region on CL                |
| DoINA                                               |                                                     | -0.197                                              | 23.1                                                | -0.287                                              | -0.108                                              | Parameler describing the influence of Mainland China geographic region on CL       |
| Random elfecis: Inler-individual variabiity (OMEGA) | Random elfecis: Inler-individual variabiity (OMEGA) | Random elfecis: Inler-individual variabiity (OMEGA) | Random elfecis: Inler-individual variabiity (OMEGA) | Random elfecis: Inler-individual variabiity (OMEGA) | Random elfecis: Inler-individual variabiity (OMEGA) | Random elfecis: Inler-individual variabiity (OMEGA)                                |
| CL (\")                                              |                                                     | 0.159                                               | 5.88                                                | 0.141                                               | 0.177                                               | Inter-individual variabiily on CL                                                  |
| CL (CV)P                                            | %                                                   | 41.5                                                |                                                     | 38.9                                                | 44.0                                                |                                                                                    |
| CL (ShP                                             | %                                                   | 12.5                                                |                                                     |                                                     |                                                     |                                                                                    |
| V(E\")                                               |                                                     | 0.868                                               | 7.33                                                | 0.742                                               | 0.991                                               | Inler-individual variabiily on V                                                   |
| V(CVF                                               | %                                                   | 117                                                 |                                                     | 105                                                 | 130                                                 |                                                                                    |
| V(Sh)                                               | %                                                   | 10.2                                                |                                                     |                                                     |                                                     |                                                                                    |
| Residual emror (SIGMA)                              | Residual emror (SIGMA)                              | Residual emror (SIGMA)                              | Residual emror (SIGMA)                              | Residual emror (SIGMA)                              | Residual emror (SIGMA)                              | Residual emror (SIGMA)                                                             |
| (S,R)(o')                                           |                                                     | 34.9                                                | 2.99                                                | 32.9                                                | 37.0                                                | Additive residual error on Box-Cox scale                                           |
| (S,R)(CV)                                           | %                                                   | 21.5                                                |                                                     | 20.8                                                | 22.1                                                | for (S,R) darolutamide                                                             |
| (S,S)(0\")                                           |                                                     | 49.5                                                | 3.09                                                | 46.5                                                | 52.5                                                | Additive residual eror on Box-Cox scale for (S, S) darolutamide                    |
| (S,S)(CV)                                           | %6                                                  | 14.1                                                |                                                     | 13.7                                                | 14.6                                                |                                                                                    |
| Kelo (o\")                                           |                                                     | 169                                                 | 3.62                                                | 167                                                 | 181                                                 | Additive residual error on Box-Cox scale for kelo-darolulamide                     |
| Kelo (CV)*                                          | %6                                                  | 17.8                                                |                                                     | 17.2                                                | 18.4                                                |                                                                                    |

LLCl =lower llmit of 95% confidence Interval (estimate - 1.96SE)

ULCl =upper llmit of 95% confldence Interval (esllmate + 1.96SE)

1 Apparent PK parameter, equlvalent to CLpopiF and Vpop/F

RSE =relative standard error (100-SE/estimate)

2 The coefflclent of varlatlon (CV) Is calculated as 100SQRT(EXP(OMEGA2)-1)

4 The coeflclent of varlatlon (CV) for SIGMA Is calculated as 100SQRT(SIGMA2)u for = 27.5, 49.8 and 73.0, whlch corresponds to a concentratlon of 500 g/L for (S,R)-darolutamlde, 2000 g/L for

3 Shrinkage (Sh) calculated as 100(1-standard deviatlon of Individual eta estlmates/w)

(S,S)-darolutamlde and 5oo0 g/L for keto-darolutamlde, respectively.

<div style=\"page-break-after: always\"></div>

Table 7 : Parameter estimates of the final population PK model including bootstrap results

| Parameter                                        | Unit                                             | Estimate                                         | LLCI                                             | LLCl-bootstrap                                   | ULCI                                             | ULcl-bootstrap                                   |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Fixedeffects(THETA)                              | Fixedeffects(THETA)                              | Fixedeffects(THETA)                              | Fixedeffects(THETA)                              | Fixedeffects(THETA)                              | Fixedeffects(THETA)                              | Fixedeffects(THETA)                              |
| KTR                                              | h1                                               | 17.2                                             | 15.6                                             | 14.5                                             | 18.9                                             | 20.0                                             |
| KA1                                              | h-1                                              | 0.0601                                           | 0.0515                                           | 0.0373                                           | 0.0686                                           | 0.0893                                           |
| KA2                                              | h1                                               | 0.00556                                          | 0.00452                                          | 0.00466                                          | 0.00659                                          | 0.00658                                          |
| KA3                                              | h-1                                              | 0.262                                            | 0.235                                            | 0.174                                            | 0.289                                            | 0.383                                            |
| CLpop'                                           | L/h                                              | 4.88                                             | 4.62                                             | 4.60                                             | 5.15                                             | 5.19                                             |
| Vpop?                                            | L                                                | 32.7                                             | 28.4                                             | 20.9                                             | 37.0                                             | 45.8                                             |
| KMETSR                                           | h-1                                              | 0.763                                            | 0.489                                            | 0.636                                            | 1.04                                             | 0.877                                            |
| KMETSS                                           | h-1                                              | 6.76                                             | 3.38                                             | 5.09                                             | 10.1                                             | 9.50                                             |
| KRET                                             |                                                  | 0.475                                            | 0.466                                            | 0.458                                            | 0.484                                            | 0.493                                            |
| ORR                                              |                                                  | -1.94                                            | -1.99                                            | -2.02                                            | -1.90                                            | -1.88                                            |
| OAGE                                             |                                                  | 0.263                                            | 0.168                                            | 0.185                                            | 0.358                                            | 0.366                                            |
| OJPN                                             |                                                  | -0.322                                           | -0.403                                           | -0.406                                           | -0.242                                           | -0.227                                           |
| OCHINA                                           |                                                  | -0.197                                           | -0.287                                           | -0.258                                           | -0.108                                           | -0.126                                           |
| Randomeffects:Inter-individualvariabilityOMEGA) | Randomeffects:Inter-individualvariabilityOMEGA) | Randomeffects:Inter-individualvariabilityOMEGA) | Randomeffects:Inter-individualvariabilityOMEGA) | Randomeffects:Inter-individualvariabilityOMEGA) | Randomeffects:Inter-individualvariabilityOMEGA) | Randomeffects:Inter-individualvariabilityOMEGA) |
| CL (W)                                          |                                                  | 0.159                                            | 0.141                                            | 0.130                                            | 0.177                                            | 0.190                                            |
| V(W)                                             |                                                  | 0.866                                            | 0.742                                            | 0.688                                            | 0.991                                            | 1.16                                             |
| Residualerror(SiGMA)                             | Residualerror(SiGMA)                             | Residualerror(SiGMA)                             | Residualerror(SiGMA)                             | Residualerror(SiGMA)                             | Residualerror(SiGMA)                             | Residualerror(SiGMA)                             |
| (S,R) (o)                                       |                                                  | 34.9                                             | 32.9                                             | 31.6                                             | 37.0                                             | 37.4                                             |
| (S,S) (0)                                       |                                                  | 49.5                                             | 46.5                                             | 44.2                                             | 52.5                                             | 55.4                                             |
| Keto (o)                                        |                                                  | 169                                              | 157                                              | 155                                              | 181                                              | 184                                              |

AbbreviationsaredescrbedinModule5.3.3.5,ReportR-13408,Table14-8

LLCl=lowerlimitof95%confidenceinterval(estimate-1.96SE)

ULCl=upperlimitof95%confidenceinterval(estimate+1.96SE)

LLCl-bootstrap:2.5percentileofparameterestimatefromabootstrapwith463successfuliterations.

ULCl-bootstrap:97.5percentileofparameterestimatefromabootstrapwith463successfuliterations.

<!-- image -->

Abbreviations:TAD=Time after dose;VPC=Visual predictive check

Abbreviations:TAD=Time after dose;VPC=Visual predictive check

Note: The shaded grey and white boxed areas are the 90% confidence intervals around the 5*, 50, and 95 percentiles (thin black dotted lines) of the prediction-corrected simulated values for each time afterdose bin.Thebold grey andblack lines are the5\"50and95ercentiles of the prediction-correctedobservations foreachtime afterdosebin. Source:CPMX50156(available uponrequest)

<!-- image -->

Note:The shaded grey and white boxed areas are the90%confidence intervals around the5th50,and95percentilesthin arethe5.5o,and95percentilesof theprediction-correctedobservationsforeachtime after dose bin. Source:CPMX50156(available uponrequest)

Figure 2: Prediction-corrected VPC for (S,R)-darolutamide for Day 1(left) and Day &gt; 1 (right)

<div style=\"page-break-after: always\"></div>

<!-- image -->

TAD (hours)

Abbreviations: TAD=Time after dose; VPC=Visual predictive check

TAD (hours)

Abbreviations: TAD=Time after dose; VPC=Visual predictive check Note:The shaded grey and white boxed areas are the 90% confidence intervals around the 5,50, and 95 percentiles (thin black dotted ines) of the prediclion-corrected simulated values for eachtime afterdose bin.The bold greyand black lines are the 5,50, and 95 percentiles of the prediction-corrected observations for each time after dose bin. Source:CPMX50156(available upon request)

Note: The shaded grey and white boxed areas are the 90% confidence intervals around the 5,50, and 95h percentiles (thin black dolted ines) of the prediction-corrected simulated values foreachtime afterdose bin.Thebold greyand black lines are the 5, 5o, and 95* percentiles of the prediction-corrected observations for each time after dose bin. Source:CPMX50156(available uponrequest)

Figure 3:  Prediction-corrected VPC for (S,S)-darolutamide for Day 1(left) and Day &gt; 1 (right)

<!-- image -->

Abbreviations: TAD=Time after dose; VPC=Visual predictive check

<!-- image -->

TAD(hours)

Abbreviations:TAD=Time afterdose;VPC=Visual predictive check Note:The shadedgreyand white boxedareas arethe90%confidenceintervals around the550and95*percentlesthin blackdotted lines)oftheprediction-corrected simulatedvaluesforeachtime afterdosebin.Theboldgreyandblack lines arethe550,and95*percentilesof theprediction-correctedobservationsforeachtimeafterdose bin. Source:CPMX50156(available uponrequest)

TAD (hours)

Note:The shaded grey and white boxed areas are the 90% confidence intervals around the 5h, 50, and 95h percentiles (thin black dottedines)of the prediction-corrected simulatedvaluesforeachtime afterdosebin.Thebold greyandblack lines are the 5, 50, and 95* percentiles of the prediction-corrected observations for each time after dose bin. Source:CPMX50156(available uponrequest)

Figure 4: Prediction-corrected VPC for keto-darolutamide for Day 1(left) and Day &gt; 1 (right)

Population PK model-derived exposure for all analytes are summarised in Table 8, and Cmin, Cmax, and AUC0-12 are provided in Table 9 and Table 10. The median model-based effective half-life for darolutamide, keto-darolutamide, (S,R)-darolutamide and (S,S)-darolutamide were 15.4 h (62 %CV), 16 h (63.2 %CV), 9.53 h (76.2 %CV), and 16.9 h (58.8 %CV), respectively. Geometric mean tmax ranged between 2.24 h and 3.81 h (11 -19.5 %CV).

<div style=\"page-break-after: always\"></div>

Table 8: Summary of geometric mean (%CV) PK parameters as steady-state in study 17777

|                  | Darolutamide (n=652)   | (S,R)-darolutamide (n=652)   | (S,S)-darolutamide (n=652)   | Keto-darolutamide (n=652)   |
|------------------|------------------------|------------------------------|------------------------------|-----------------------------|
| Cmax,mg/L        | 3.84 (35.6%)           | 0.711 (39.1)                 | 3.16 (36.3%)                 | 7.53(36.3%)                 |
| tmax,h           | 3.33(18.4%)            | 2.24 (11.2%)                 | 3.81 (19.5%)                 | 3.66 (20.3%)                |
| AUC(0-12).hmg/L | 38.2(39.1%)            | 5.85 (35.9%)                 | 32.3 (40.1%)                 | 76.0 (41.1%)                |
| Effectivet1/2,h  | 18.4 (62.0%)           | 10.9 (76.2%)                 | 20.5(58.8%)                  | 19.0(63.2%)                 |

AUC(0-12)=Areaundertheplasmaconcentration-timecurvefromtime0to12hours;Cmax=Peak concentration;CV=Coefficientofvariation;PK=Pharmacokinetic;PopPK=Population pharmacokinetics;tmax=Timetopeakconcentration;ti/2=Effectivehalf-life

Table 9: Population PK model-derived exposure of darolutamide and keto-darolutamide in study 17777 ARASENS

| Statistic        |   Cmina [7/6w] |   Darolutamide Darolutamide Cmaxb [mg/L] |   Darolutamide AUC(0-12)* [h-mg/L] |   Keto- Cmina [mg/L] |   Keto- Cmaxb [mg/L] |   Keto- AUC(0-12)* [h-mg/L] |
|------------------|----------------|------------------------------------------|------------------------------------|----------------------|----------------------|-----------------------------|
| N                |        652     |                                  652     |                             652    |              652     |               652    |                      652    |
| Minimum          |          0.295 |                                    0.749 |                               6.19 |                0.566 |                 1.38 |                       11.7  |
| 5 Percentile     |          1.09  |                                    2.17  |                              20.5  |                2.09  |                 4.27 |                       39.5  |
| Median           |          2.43  |                                    3.9   |                              38.1  |                4.93  |                 7.49 |                       76.8  |
| 95h Percentile   |          4.84  |                                    6.45  |                              67.9  |               10     |                12.8  |                      138    |
| Maximum          |         10.5   |                                   11.6   |                             135    |               22     |                24.1  |                      280    |
| Arithmetic Mean  |          2.61  |                                    4.06  |                              40.8  |                5.34  |                 7.98 |                       81.8  |
| Geometric Mean   |          2.35  |                                    3.84  |                              38.2  |                4.75  |                 7.53 |                       76    |
| Geometric SD     |          1.6   |                                    1.41  |                               1.46 |                1.65  |                 1.42 |                        1.48 |
| Geometric CV (%) |         49.8   |                                   35.6   |                              39.1  |               53.2   |                36.3  |                       41.1  |

<div style=\"page-break-after: always\"></div>

Table 10: Population PK model-derived exposure of (S,R)-darolutamide and (S,S)darolutamide in study 17777 ARASENS

| Statistic        |   (S,R) Gmina [mg/L] |   (S,R) Cmaxb [mg/L] |   (S,R) AUC(0-12)c [h-mg/L] |   (S,S) Cmina [mg/L] |   (S,S) Cmaxb [mg/L] |   (S,S) AUC(0-12)c [h-mg/L] |
|------------------|----------------------|----------------------|-----------------------------|----------------------|----------------------|-----------------------------|
| N                |             652      |              652     |                      652    |              652     |              652     |                      652    |
| Minimum          |               0.0291 |                0.141 |                        1.11 |                0.266 |                0.582 |                        5.08 |
| 5 Percentile     |               0.103  |                0.388 |                        3.35 |                0.973 |                1.8   |                       17    |
| Median           |               0.279  |                0.72  |                        5.87 |                2.14  |                3.14  |                       32.4  |
| g5hPercentile    |               0.585  |                1.26  |                        9.89 |                4.25  |                5.39  |                       58.3  |
| Maximum          |               1.3    |                1.91  |                       17.8  |                9.2   |               10.1   |                      117    |
| Arithmetic Mean  |               0.304  |                0.761 |                        6.2  |                2.31  |                3.35  |                       34.6  |
| Geometric Mean   |               0.266  |                0.711 |                        5.85 |                2.08  |                3.16  |                       32.3  |
| Geometric SD     |               1.72   |                1.46  |                        1.42 |                1.59  |                1.42  |                        1.47 |
| Geometric CV (%) |              58.4    |               39.1   |                       35.9  |               48.9   |               36.3   |                       40.1  |

## Population PK modelling meta-analysis of study ARASENS and study ARAMIS (17712)

Study 17712 ARAMIS was the pivotal phase 3 monotherapy Study for nmCRPC patients treated with darolutamide 600 mg BID (refer to the initial Marketing Authorisation Application (MAA).

Table 11 presents the geometric mean phase 3 model-predicted PK parameters for study 17712 as presented in the initial MAA. The population PK model-predicted exposure for (S,R)-darolutamide, (S,S)-darolutamide and keto-darolutamide was different in Study 17777 (Table 8) compared to that of Study 17712 (Table 11).

Table 11: Geometric mean (CV [%]), PK parameters at steady state in Study 17712 using the selected Phase 3 population PK model (Study 18651 )

|                   | Darolutamide (n=388)   | (S,R)-darolutamide (n=388)   | (S,S)-darolutamide (n=388)   | Keto-darolutamide (n=388)   |
|-------------------|------------------------|------------------------------|------------------------------|-----------------------------|
| Cmax,g/mL        | 4.786(30.9)            | 0.682(22)                    | 4.212(32.1)                  | 8.475(35.4)                 |
| tmax,h            | 3.64 (4.4)             | 1.84 (3.5)                   | 4.73 (3.5)                   | 2.06 (3.3)                  |
| AUC(0-12),gh/mL | 52.817(33.9)           | 5.499(33.2)                  | 47.238(34.5)                 | 87.640(42.1)                |
| Effective t1/2.h  | 19.6(29.7)             | 8.92(36.5)                   | 21.9 (29.6)                  | 20.0(37.9)                  |

Abbreviations:AUC(0-12)=areaundertheplasmaconcentrationtimecurvefromtime0to12hours:Cmax=peak concentration;CV%=coefficientofvariation;PK=pharmacokinetics;popPK=populationpharmacokinetics; tmax=timetopeakconcentration;ti/2=half-life.

This meta-analysis was done using pooled data from study 17777 ARASENS and study 17712 ARMAIS to (1) evaluate the contribution of pre-defined covariates to the variability in darolutamide PK in the combined data, and (2) to assess the extent to which differences in darolutamide exposure between both studies is accounted for by differences in population characteristics.

<div style=\"page-break-after: always\"></div>

The population PK base model for Study 17777 was used and inter-individual variability (IIV) and covariates were re-estimated. The ratio of the model-derived geometric mean AUC(0- 12)ss value for Study 17777 versus 17712 was calculated for each analyte (bootstrap analysis). Additional IIV were identified for the rate at which keto is transformed to (S,S)-darolutamide or (S,R)-darolutamide (KRET) and RR as well as the following covariates: Age, Asian, and Japanese on CL, China on V, serum creatinine at baseline, body weight on KRET (i.e. scaling parameter for rate of conversion from keto to (S,R) and (S,S) darolutamide), and age, and AST on RR (i.e. conversion ratio of keto-darolutamide to either (S,R)-darolutamide or (S,S)- darolutamide). Parameter estimates of the population PK metaanalysis are provided in Table 12.

Table 12: Parameter estimates of the population PK meta-analysis, studies 17777 and 17712

| Parameter             |                       | Unlt Estlmate         | RSE [%]               | LLCI                  | ULCI                  | Descrlptlon                                                                               |
|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-------------------------------------------------------------------------------------------|
| Fixed effects (THETA) | Fixed effects (THETA) | Fixed effects (THETA) | Fixed effects (THETA) | Fixed effects (THETA) | Fixed effects (THETA) | Fixed effects (THETA)                                                                     |
| KTR.                  | h-1                   | 18.2                  | 3.49                  | 17                    | 19.5                  | Transit compartment rate constant                                                         |
| KA1                   | h-1                   | 0.0571                | 4.51                  | 0.0521                | 0.0621                | Absorption rate constant for (S,R)- darolutamide                                          |
| KA2                   | h-1                   | 0.00791               | 4.08                  | 0.00728               | 0.00855               | Absorption rate constant for (S, S)- darolutamide                                         |
| KA3                   | h-1                   | 0.256                 | 4.39                  | 0.234                 | 0.279                 | Absorption rate constant for keto- darolutamide                                           |
| CLpop'                | L/h                   | 5.09                  | 1.75                  | 4.91                  | 5.26                  | Clearance for a typical patient                                                           |
| Vpop1                 | L                     | 37.4                  | 4.84                  | 33.8                  | 40.9                  | Volume of distribution for all three analytes in a typical patient                        |
| KMETSR                | h-1                   | 0.615                 | 11.9                  | 0.472                 | 0.758                 | Rate constant for conversion between (S,R)-darolutamide and keto- darolutamide            |
| KMETSS                | h-1                   | 4.39                  | 15.9                  | 3.02                  | 5.77                  | Rate constant for conversion between (S,S)-darolutamide and keto- darolutamide            |
| OKRET                 |                       | 0.52                  | 1.22                  | 0.508                 | 0.533                 | Scaling parameter for rate of conversion from keto to (S,R) and (S,S) darolutamide        |
| ORR                   |                       | -2.24                 | 1.27                  | -2.29                 | -2.18                 | Conversion ratio of keto-darolutamide to either (S,R)-darolutamide or (S,S)- darolutamide |
| OAGE.CL               |                       | -0.0182               | 8.98                  | -0.0214               | -0.015                | Age on clearance                                                                          |

<div style=\"page-break-after: always\"></div>

| OWGHT                                                |                                                      | 0.522                                                | 9.81                                                 | 0.422                                                | 0.622                                                | Weight on KRET                                                  |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------|
| OASIAN                                               |                                                      | -0.173                                               | 17.5                                                 | -0.232                                               | -0.114                                               | Asian on CL                                                     |
| OAGERR                                               |                                                      | -0.0146                                              | 16.6                                                 | -0.0193                                              | -0.00983                                             | Age on RR                                                       |
| OCHN                                                 |                                                      | -0.373                                               | 14.9                                                 | -0.483                                               | -0.264                                               | China on V                                                      |
| OAST                                                 |                                                      | 0.0106                                               | 23.4                                                 | 0.00574                                              | 0.0154                                               | AST on RR                                                       |
| OJPN                                                 |                                                      | -0.192                                               | 22.5                                                 | -0.277                                               | -0.107                                               | JPN on CL                                                       |
| OsCRE                                                |                                                      | 0.179                                                | 24.4                                                 | 0.0933                                               | 0.265                                                | SCRE on KRET                                                    |
| Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA)            |
| CL (w)                                              |                                                      | 0.156                                                | 4.60                                                 | 0.142                                                | 0.17                                                 | Inter-individual variability on CL                              |
| CL (CV)2                                             | %                                                    | 41                                                   |                                                      | 39.0                                                 | 43.0                                                 |                                                                 |
| CL (Sh)                                              | %                                                    | 8.63                                                 |                                                      |                                                      |                                                      |                                                                 |
| V(w)                                                 |                                                      | 0.722                                                | 5.60                                                 | 0.642                                                | 0.801                                                | Inter-individual variability on V                               |
| V(CV)2                                               | %                                                    | 103                                                  |                                                      | 94.9                                                 | 111                                                  |                                                                 |
| V (Sh)3                                              | %                                                    | 13.66                                                |                                                      |                                                      |                                                      |                                                                 |
| KRET (w)                                            |                                                      | 0.0569                                               | 7.32                                                 | 0.0488                                               | 0.0651                                               | Inter-individual variability on KRET                            |
| KRET (CV)2                                           | %                                                    | 24.2                                                 |                                                      | 22.4                                                 | 25.9                                                 |                                                                 |
| KRET (Sh)3                                           | %                                                    | 30.1                                                 |                                                      |                                                      |                                                      |                                                                 |
| RR (w)                                              |                                                      | 0.137                                                | 9.70                                                 | 0.111                                                | 0.164                                                | Inter-individual variability on RR                              |
| RR (CV)2                                             | %                                                    | 16.6                                                 |                                                      | 14.9                                                 | 18.1                                                 |                                                                 |
| RR (Sh)3                                             | %                                                    | 39.61                                                |                                                      |                                                      |                                                      |                                                                 |
| Residual error (SIGMA)                               | Residual error (SIGMA)                               | Residual error (SIGMA)                               | Residual error (SIGMA)                               | Residual error (SIGMA)                               | Residual error (SIGMA)                               | Residual error (SIGMA)                                          |
| (S,R) (o)                                           |                                                      | 27.0                                                 | 2.19                                                 | 25.8                                                 | 28.2                                                 | Additive residual error on Box-Cox scale for (S,R)-darolutamide |
| (S,R)(CV)4                                           | %                                                    | 18.9                                                 |                                                      | 18.5                                                 | 19.3                                                 |                                                                 |
| (S,S) (0\")                                           |                                                      | 42.0                                                 | 1.77                                                 | 40.5                                                 | 43.4                                                 | Additive residual error on Box-Cox scale for (S,S)-darolutamide |
| (S,S) (CV)4                                          | %                                                    | 13.0                                                 |                                                      | 12.8                                                 | 13.2                                                 |                                                                 |
| Keto (o)                                            |                                                      | 125                                                  | 2.33                                                 | 119                                                  | 131                                                  | Additive residual error on Box-Cox scale for keto-darolutamide  |
| Keto (CV)*                                           | %                                                    | 15.3                                                 |                                                      | 14.9                                                 | 15.7                                                 |                                                                 |

LLCI = lower limit of 95% confidence interval (estimate -1.96SE)

(3ss6'j + 6jewjss) jewisjuj ssuspjuos %s6 jo jjwlj jsaan = i51n

## 2.3.2.4. Special populations

Information on special populations were updated based on a submitted population PK analysis of study 17777 ARASENS in patients with mHSPC (Study number: CPMX50017 / report R-13408, report date 10 January 2022).

## Renal impairment

The population PK analysis using data from Study 17777 ARASENS in patients with mHSPC reported a mean 1.11-fold (90 % CI: 1.06 -1.17), 1.27-fold (90 % CI: 1.14 -1.41), and 2.6-fold (one patient) higher exposure (AUC) of darolutamide in patients with mild, moderate, and severe renal impairment

<div style=\"page-break-after: always\"></div>

compared to patients with normal renal function. These results are consistent with previous findings from study 17712 ARAMIS in patients with nmCRPC.

No new information was provided regarding patients with end-stage renal disease receiving dialysis.

## Hepatic impairment

The population PK analysis using data from Study 17777 ARASENS in patients with mHSPC reported a similar exposure in patients with mild hepatic impairment (mean geometric ratio 0.977 [90 % CI: 0.879 -1.08]) compared to patients with normal hepatic function. These results are consistent with previous findings from study 17712 ARAMIS in patients with nmCRPC.

## Gender

Not applicable.

## Race/Ethnicity

The population PK analysis using data from Study 17777 ARASENS in patients with mHSPC reported a higher increase in exposure (AUC(0 -12)ss) for Japanese patients (mean ratio compared to rest of regions = 1.56 (90%CI: 1.43 -1.70) as compared to the previous analysis of data from study 17712 ARAMIS (mean ratio compared to rest of regions =1.42 (90%CI: 1.33 - 1.53)).

## Body weight

Results for body weight effects on exposure of darolutamide from the population PK analysis using data from Study 17777 ARASENS in patients with mHSPC were consistent with previous findings from study 17712 ARAMIS in patients with nmCRPC.

## Elderly

The population PK analysis using data from Study 17777 ARASENS in patients with mHSPC reported that mean exposure (AUC(0-12)ss) for patients aged 65 - &lt;75 years was about 1.28-fold (90%CI: 1.22 -1.34) higher and for patients aged 75 - &lt; 85 about 1.34-fold (90% CI: 1.25 -to patients aged &lt; 65 years. The ratio was similar for patients aged 85 years compared to the age group 75 - &lt; 85. However only three patients were aged above 85 years of age.

1.49) higher compared Results for the age group 65 - &lt;75 years were slightly lower compared to those from study 17712

ARAMIS in patients with nmCRPC, but were generally comparable and consistent.

## 2.3.2.5. Pharmacokinetic interaction studies

## Docetaxel population PK model

Study number:  CPMX50017 / report R-13408, report date 10 January 2022

Individual docetaxel clearance and exposure were investigated using an established literature population PK model. Docetaxel clearance between the two treatment arms (with or without darolutamide) in study 17777 ARASENS were assessed and the correlation between darolutamide and docetaxel clearance on an individual level was evaluated.

<div style=\"page-break-after: always\"></div>

Overall, 1152 patients with 2135 plasma PK samples above and 225 samples below LLOQ contributed to the analysis. The final population PK model for docetaxel is a 3-compartment model with linear elimination. The parameters were re-estimated based on study 17777 PK data. Parameter estimates from the final model for study 17777 are listed in Table 13. All covariates in the docetaxel literature model were id entified for study 17777 data, with the exception of 1 -acid glycoprotein (AAG). AAG was fixed to the median value provided in the literature. The remaining covariates on CL were body surface area (BSA, calculated using the DuBois method), albumin, age and hepatic function (called HEP12).

Based on the GOF plots DV versus Population Predicted Value (PRED) and pc-VPC, the population PK model of docetaxel is biased on the structural (PRED) predictions. Taking into account that the objective of the docetaxel population PK modelling was to estimate individual clearance and exposure of docetaxel in Study 17777, the bias on the population level was considered acceptable. The GOF plots for the individual weighted residuals (IWRES) were considered to show a lack of bias in the individual predictions, and it was concluded that the literature model was fit-for-purpose to estimate individual clearance and exposure of docetaxel in Study 17777.

Summary statistics of individual estimates of docetaxel clearance stratified by treatment arm are presented in Table 14 and box plots showing docetaxel concentrations versus time after dose are stratified by treatment arm are presented in Figure 5.

Table 13: Parameter values for the docetaxel literature model

| Parameter                                            | Unit                                                 | Value                                                | Description                                                                                                                                                         |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                                                                                                                               |
| cL                                                  | Lm2/h                                               | 22.1                                                 |                                                                                                                                                                     |
| AAG                                                 |                                                      | -3.55                                                | parameter giving the value to be adjusted by covaraites for clearance                                                                                               |
| AGE                                                 |                                                      | -0.095                                               | parameter describing the influenceof AAG on clearance parameter describing the influence of AGE on clearance parameter describing the influence of ALB on clearance |
| OALB                                                 |                                                      | 0.0225                                               | parameter describing the influence of hepatic impairment on clearance                                                                                               |
| OHEP12                                               |                                                      | 0.334                                                | apparent volume of central compartment intercompartmentalrateconstant                                                                                               |
| Vipop                                                | L                                                    | 8.31                                                 | intercompartmentalrateconstant                                                                                                                                      |
| K12                                                  | h-1                                                  | 1.07                                                 | intercompartmental rate constant                                                                                                                                    |
| K21pop                                               | h-1                                                  | 1.74                                                 | intercompartmentalrateconstant                                                                                                                                      |
| K13pop                                               | h-1                                                  | 1.28                                                 |                                                                                                                                                                     |
| K31pop                                               | h-1                                                  | 0.0787                                               |                                                                                                                                                                     |
| Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA)                                                                                                                |
| CL (W2)                                              |                                                      | 0.335                                                | Inter-individual variability on CL                                                                                                                                  |
| Vi (w)                                               |                                                      | 0.561                                                | Inter-individual variability on V1                                                                                                                                  |
| K21 (w2)                                             |                                                      | 1.31                                                 | Inter-individual variability on K21                                                                                                                                 |
| K13 (W)                                             |                                                      | 0.477                                                | Inter-individual variability on K13                                                                                                                                 |
| K31 (W2)                                             |                                                      | 0.147                                                | Inter-individual variability onK31                                                                                                                                  |
| Residual error (SIGMA)                               | Residual error (SIGMA)                               | Residual error (SIGMA)                               | Residual error (SIGMA)                                                                                                                                              |
| g                                                   |                                                      | 0.205                                                | Additive residual error                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

Table 14: Summary statistics of individual estimates of docetaxel clearance by treatment arm, study 17777 ARASENS

| Statistic            | Control arm Docetaxelclearance [Lm/h]   | Darolutamidearm Docetaxelclearance [Lm/h]   |
|----------------------|-------------------------------------------|-----------------------------------------------|
| N                    | 637                                       | 642                                           |
| Minimum              | 9.58                                      | 7.86                                          |
| 5thPercentile        | 14.3                                      | 14.7                                          |
| Median               | 26.5                                      | 28                                            |
| 95thPercentile       | 49.2                                      | 52.1                                          |
| Maximum              | 79                                        | 76.3                                          |
| Arithmetic Mean      | 28.2                                      | 29.8                                          |
| GeometricMean        | 26.5                                      | 27.8                                          |
| GeometricSD          | 1.43                                      | 1.46                                          |
| GeometricCV(%)       | 36.6                                      | 38.9                                          |
| GeometricMean ratioa |                                           | 1.05 (1.01-1.08)                              |

Figure 5: Docetaxel concentration data stratified by treatment arm, study 17777 ARASENS

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.3.3. PK/PD modelling

## Population PK/PD modelling for efficacy (study 17777 ARASENS)

Study number: CPMX50018 / report R-13397, report date 31 December 2021

An exploratory population pharmacodynamic (PD) analysis of change in prostate specific antigen over time in patients with metastatic hormone-sensitive prostate cancer of study 17777.

## Objectives

This study aimed to describe the change in prostate specific antigen (PSA) over time by means of a semi-mechanistic model, investigate covariates, and evaluate the multivariate relationship between darolutamide and/or active metabolite exposure, docetaxel exposure and the change in PSA over time. In addition, the potential relationship between the change in testosterone over time and darolutamide exposure was investigated using exploratory analysis. Furthermore, the association between the timecourse of PSA and overall survival was visualised (means of Kaplan Meier curves per quartile of change in PSA and curves per quartile of darolutamide exposure).

## Data and methods

Data below LLOQ (BLQ) under treatment were included in the dataset. Measurements with no recorded sample time and vice versa were excluded. Missing continuous and categorical baseline covariate data were in general either filled with the population median value or most frequent category across study 17777. The dataset considered for this analysis contained all patients of study 17777 who received at least one dose of study drug, either darolutamide or control.

Nonlinear mixed-effects modelling using NONMEM software version 7.4.3 was used.

Exposure variables were calculated based on the population PK models described in report CPMX50017 / report R-13408, report date 10 January 2022. Different exposure variables were tested.

A previous developed model was used as a starting point to investigate the PKPD relationship with PSA: BAY 1841788 (darolutamide) / 19792. Exploratory population pharmacodynamic analysis of change in prostate specific antigen over time in studies 17712, 17829 and 17830. M&amp;S Report R12788, Version 1.0, dated 08 JAN 2019. The base model described the growth of prostate cancer cells by means of a tumour cell proliferation and kill rate. Furthermore, the model described the secretion of PSA in the blood by the tumour cells and the elimination of PSA from the blood. Covariates were investigated using the forward inclusion (OFV  6.67, p &lt; 0.01, 1 degree of freedom) and backward elimination procedure (OFV &gt; +10.828, p &gt; 0.001, 1 degree of freedom). Model evaluation and qualification was done using generally applied methods (e.g. GOF plots, precision of parameter estimates, VPCs). The final covariate model was used to calculate the predicted reduction in PSA from baseline at different time-points. It was assumed that PSA concentrations in blood were at steady state at the start of treatment.

Change of testosterone over time was investigated using exploratory plots (i.e. spaghetti plots).

The potential relationships between darolutamide exposure and overall survival was explored through different Kaplan Meier plots.

Instantaneous concentration of docetaxel was not tested due to only a single PSA data-point being available during the docetaxel phase for the majority of patients. Instead, four docetaxel covariates were tested: Total docetaxel dose, average docetaxel dose, total docetaxel AUC and average docetaxel AUC.

<div style=\"page-break-after: always\"></div>

## Results

The darolutamide exposure variables at steady state for the 647 patients of study 17777 (initial data) and docetaxel exposure variables for the 1280 patients of study 17777 (initial data) were predicted based on the population PK models as described in CPMX50017 / report R-13408, report date 10 January 2022.

- PSA

Data used in the inference of the selected covariate model onto the final data, resulting in the final covariate model, included 13994 PSA observations from 1302 patients who received at least one dose of study drug. Compared to the initial data, one patient was removed from the data due to a serious data breach. Overall, 12693 post-baseline PSA observations were used for model inference. Of these 12693 post-baseline PSA observations, 3726 (29.4%) were below the LLOQ.

Parameter estimates of the final PD model for PSA are listed in Table 15.

<div style=\"page-break-after: always\"></div>

Table 15: Parameter estimates of the final PD model for PSA

| Parameter           | Unlt                | Estlmate            | RSE [%]             | LLCIb               |                     | ULCI Descrlptlon                                                                        |
|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|-----------------------------------------------------------------------------------------|
| Fixedeffecls(THETA) | Fixedeffecls(THETA) | Fixedeffecls(THETA) | Fixedeffecls(THETA) | Fixedeffecls(THETA) | Fixedeffecls(THETA) | Fixedeffecls(THETA)                                                                     |
| kaut                | day-1               | 0.046               | FIX                 |                     |                     | Rate constant for elimination of prostate tumor cells                                   |
| dell                | day-1               | 0.23                | FIX                 |                     |                     | Rate constant for elimination of PSA from the blood                                     |
| Orpro               | day1                | 0.0533              | 0.938               | 0.0523              | 0.0543              | Rate of prostate tumor cell proliferation in a typical patient                          |
| BEM                 | log(g/L)           | 6.02                | 2.56                | 5.72                | 6.33                | Value of Eu for a typical patient In the control arm                                    |
| 1000-0ER            | day-1               | 7.89                | 3.79                | 7.31                | 8.48                | Decay rate constant for E in a typical patient                                          |
| TREAT,pro          |                     | -0.103              | 8.65                | -0.121              | -0.0857             | Fractional change in rpro for patients in the darolutamide arm                          |
| TREAT,EM           |                     | 0.281               | 12.8                | 0.21                | 0.352               | Fractlonal change in Eu for patients in the darolutamide arm                            |
| 1000-BHGB           | (g/mL)-1            | -24.8               | 11.2                | -30.2               | -19.3               | Parameter describing the Influence of hemoglobin on rpra                                |
| 1000-0PSABL         | (g/L)-1            | 0.16                | 5.89                | 0.142               | 0.179               | Parameter describing the Influence of baseline PSA on Eu                                |
| 0ALP2               |                     | 0.0515              | 20.2                | 0.0311              | 0.0719              | Parameter descrbing the Influence of 2nd quartile of ALP                                |
| 0ALP3               |                     | 0.069               | 16.7                | 0.0465              | 0.0916              | on Turo Parameter describing the Influence of 3rd quartile of ALP on Turo               |
| BALP4               |                     | 0.109               | 11.7                | 0.0839              | 0.134               | Parameter descrbing the Influence of 4th quarile of ALP on Turo                         |
| 0ALPGIMED           |                     | 0.247               | 20.2                | 0.149               | 0.344               | Parameter describing the Influence ALP > median ALP on ER                               |
| BCHINA              |                     | 0.299               | 25                  | 0.153               | 0.446               | Parameter describing the Influence of geographical region China on ER                   |
| Ndrg                |                     | -0.0669             | 18.6                |                     |                     | -0.0912 -0.0425 Parameter describing the Influence of geographical region Japan on Tpro |
| OKOR.               |                     | -0.0605             | 18.6                |                     |                     | -0.0826-0.0384 Parameter describing the Influence of geographical region                |

| Random elfecls:Inter-Indlividual varlablity(OMEGA)   | Random elfecls:Inter-Indlividual varlablity(OMEGA)   | Random elfecls:Inter-Indlividual varlablity(OMEGA)   | Random elfecls:Inter-Indlividual varlablity(OMEGA)   | Random elfecls:Inter-Indlividual varlablity(OMEGA)   | Random elfecls:Inter-Indlividual varlablity(OMEGA)   | Random elfecls:Inter-Indlividual varlablity(OMEGA)   |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Fpro (w)                                            |                                                      | 0.0325                                               | 6.30                                                 | 0.0285                                               | 0.0365 19.3                                          | IIV on Tpro                                         |
| Fpra (CVa)                                           | %                                                    | 18.2                                                 |                                                      | 17.0                                                 |                                                      |                                                      |
| [pro (Shg)                                           | %                                                    | 17.5                                                 |                                                      |                                                      |                                                      |                                                      |
| rpro and Em (w)                                     |                                                      | 0.0486                                               | 10.5                                                 | 0.0386                                               | 0.0586                                               | Off diagonal term of OMEGA block                     |
| EM (w)                                              |                                                      | 0.271                                                | 6.32                                                 | 0.237                                                | 0.304                                                | IIV on Eu.                                           |
| EM (CV*)                                             | %                                                    | 55.7                                                 |                                                      | 51.7                                                 | 59.6                                                 |                                                      |
| Em (Shg)                                             | %                                                    | 27.2                                                 |                                                      |                                                      |                                                      |                                                      |
| Toro and ER (w)                                     |                                                      | -0.0448                                              | 16.2                                                 | -0.0591                                              | -0.0305                                              | Off diagonal terms of OMEGA                          |
| Em and ER (w*)                                       |                                                      | -0.238                                               | 10.8                                                 | -0.288                                               | -0.188                                               | block                                                |
| ER (w*)                                              |                                                      | 0.640                                                | 7.54                                                 | 0.545                                                | 0.734                                                | IIV on ER-                                           |
| ER (CV)                                              | %                                                    | 94.6                                                 |                                                      | 85.1                                                 | 104                                                  |                                                      |
| ER (She)                                             | %                                                    | 24.2                                                 |                                                      |                                                      |                                                      |                                                      |
| Resldual error (SIGMA)                               | Resldual error (SIGMA)                               | Resldual error (SIGMA)                               | Resldual error (SIGMA)                               | Resldual error (SIGMA)                               | Resldual error (SIGMA)                               | Resldual error (SIGMA)                               |
| Resld (o\")                                           |                                                      | 0.315                                                | 0.625                                                | 0.312                                                | 0.319                                                | Additive residual error on log                       |
| Resid CV                                             | %                                                    | 24.4                                                 |                                                      | 24.3                                                 | 24.6                                                 | scale                                                |

Korea on Toro

<div style=\"page-break-after: always\"></div>

Darolutamide and docetaxel exposure did not result in a statistically significant covariate in the PD model. Baseline PSA, haemoglobin, alkaline phosphatase and three Asian geographic region China, Japan, and Korea, were found to influence PSA time course.

Darolutamide-treated patients were found to be associated with a greater and longer lasting PSA reduction compared to control patients. The difference in the fraction of patients with  90% reduction in PSA from baseline at week 24 between darolutamide-treated and control groups is consistent in subgroups defined by age, race, geographical region, renal function, hepatic function and bodyweight. Also, dose reductions or interruptions for darolutamide-treated patients are not expected to affect PSA response. The PSA time-course was consistent over the darolutamide exposure range after 600 mg BID. Differences in docetaxel exposure were not found to influence PSA time course.

Despite of some deficiencies in the model, overall, it is considered to support darolutamide efficacy in patients from study 17777 ARASENS.

- Testosterone

Data used in the exploratory model-free analysis of the time-course of total testosterone included 11240 observations from 1303 patients. Of these, 8792 (78.2%) were below the LLOQ. The data file also included 2246 free testosterone observations from 597 patients. Of these, 91 (4.05%) were below the LLOQ. Spaghetti plot of the time-course of total testosterone were carried out. No differences in the time-course of total testosterone between darolutamide-treated and control patients were observed.

- Kaplan Meier plots of overall survival

Exploratory Kaplan Meier plots of overall survival were carried out and indicated:

- -There was no indication of an association between overall survival and darolutamide exposure within darolutamide-treated patients

Figure 6: Overall survival stratified by quartiles of darolutamide AUC(0- 12)ss

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Population PK/PD modelling for safety (study 17777 ARASENS)

Study number: CPMX50020 / report R-14071, report date 12 January 2022

Exploratory exposure-response analysis of relevant safety events in patients with metastatic hormonesensitive prostate cancer of study 17777.

## Objectives

Evaluate the association between darolutamide and docetaxel exposure and the temporal changes in absolute neutrophil count, AST, ALT, total bilirubin, haemoglobin, and selected treatment emergent adverse events (TEAEs) with an overall event rate greater than 10% in the data of Study 17777.

## Data and methods

Nonlinear mixed-effects modelling using NONMEM software version 7.4.3 was used, following a visual inspection of the data. The starting point for the development of the base model for each PD safety variable was a turnover type model and different models were considered if deemed necessary. Covariates were investigated using the forward inclusion (OFV  6.67, p &lt; 0.01, 1 degree of freedom) and backward elimination procedure (OFV &gt; +10.828, p &gt; 0.001, 1 degree of freedom). Model evaluation and qualification was done using generally applied methods.

## Results

Different datasets were created. After updating the dataset with additional neutrophil count observations it contained a total of 100852 observations in 1303 patients who received at least one dose of study drug.

The median age of patients was 67 years (range 41-89). In total, 36.5% of patients were aged &lt; 65 years, 46.7% were aged 65-74, 16.3% were aged 7584 and 0.5% were aged 85 at the star t of the study. In order to meet the 15% frequency requirement for a covariate category to be investigated in models, the age categories 7584 and 85 were combined into a single 75 category. A total of 63.5 % of patients were aged 65.

Overall, 15.5% of patients were from mainland China, 11.3% were from Japan, 6.5% were from Korea. 2.8% were from Taiwan, 16.6% were from USA and 47.2% were from the rest of regions. All regions were tested independently despite Japan, Korea and Taiwan not reaching the 15% requirement.

In total, 54.1% of patients had a normal renal function, 36.8% mild, 9.1% moderate, and 0.2% severe renal impairment. To meet the 15% frequency requirement, the categories 'mild', 'moderate' and 'severe' were combined into a single 'mild or worse' category for covariate testing. In total, 92.2% of patients had a normal hepatic function, 7.6% mild and 0.2% moderate hepatic impairment.

Bone metastases were found in 79.7% of patients, 17.3% had visceral metastases and 3% had nonregional lymph node metastases only. To meet the 15% frequency requirement, the visceral metastases and non-regional lymph node metastases only categories were combined into a single category. Overall, 71.8% of patients had ECOG=0 and 28.2% had ECOG=1.

- Absolute neutrophil count

In total, 21208 absolute neutrophil counts from 1303 patients were analysed.The final model is a fivecompartment model with three transit compartments and contains the neutrophil production as well as a feedback loop from blood concentration. The effect of docetaxel on neutrophil production is also reflected in the model by each a zero- and first order constant. Neutrophil suppression was found to be different between patients depending on geographical regions (China, USA, Japan, and Korea).

<div style=\"page-break-after: always\"></div>

Table 16: Parameter estimates of the final PD for absolute neutrophil counts, study 17777 ARASENS

| Parameter                                            | Unlt                                                 | Estimate                                             | RSE [%]                                              | LLCI                                                 | ULCI                                                 | Descrlptlon                                                                                                                       |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                                                                                             |
| BLNpop                                               | GIGA/L                                               | 4.06                                                 | 0.213                                                | 4.04                                                 | 4.08                                                 | Population value for baseline neutrophil count value                                                                              |
| MTTpop                                               | day                                                  | 4.39                                                 | 0.0845                                               | 4.39                                                 | 4.40                                                 | Population value of mean transit time for patients not from mainland China                                                        |
| SLOPEpop                                             | Lug                                                  | 0.0118                                               | 1.84                                                 | 0.0114                                               | 0.0122                                               | Population value of constant describing drop in neutrophil count in relation to docetaxel concentration for patienis not from USA |
|                                                      |                                                      | 0.239                                                | 0.105                                                | 0.238                                                | 0.239                                                | Constant used in the feedback mechanism relating neutrophils in the blood stream to the proliferation rate                        |
| CMAX                                                 |                                                      | -0.202                                               | 6.72                                                 | -0.229                                               | -0.176                                               | Constant giving the maximal change in neutrophils baseline over time                                                              |
| OT50                                                 | day                                                  | 272                                                  | 10.5                                                 | 216                                                  | 328                                                  | Time at which half the maximal change in the baseline neutrophil level occurs                                                     |
| A                                                    |                                                      | -0.676                                               | 0.700                                                | -0.686                                               | -0.667                                               | Rate constant used for box-cox transformation of etas for individuals SLOPE                                                       |
| OcHN                                                 |                                                      | -0.187                                               | 7.11                                                 | -0.213                                               | -0.161                                               | Constant describing the change in MTTpop for patients from mainland China                                                         |
| QusA                                                 |                                                      | 0.360                                                | 26.7                                                 | 0.171                                                | 0.549                                                | Constant describing the change in SLOPEpop for patients from USA                                                                  |
| OJPN,MTT                                             |                                                      | -0.196                                               | 9.59                                                 | -0.233                                               | -0.159                                               | Constant describing the change in MTTpop for patients from Japan                                                                  |
| OKOR                                                 |                                                      | 0.420                                                | 29.1                                                 | 0.181                                                | 0.660                                                | Constant describing the change in SLOPEpop for patients from Korea                                                                |
| Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA)                                                                              |
| BLNpop (w)                                          |                                                      | 0.0857                                               | 6.57                                                 | 0.0747                                               | 0.0968                                               | Inter-individual variability on BLN                                                                                               |
| BLNpop (CV)2                                         | %                                                    | 29.9                                                 |                                                      | 27.8                                                 | 31.9                                                 |                                                                                                                                   |
| BLNpop (Sh)3                                         | %                                                    | 9.25                                                 |                                                      |                                                      |                                                      |                                                                                                                                   |
| MTTpop (w)                                          |                                                      | 0.0299                                               | 11.8                                                 | 0.0230                                               |                                                      | 0.0369 Inter-individual variability on MTT                                                                                        |
| MTTop (CV)2                                          | %                                                    | 17.4                                                 |                                                      | 15.2                                                 | 19.4                                                 |                                                                                                                                   |
| MTTeop (Sh)                                         | %                                                    | 20.9                                                 |                                                      |                                                      |                                                      |                                                                                                                                   |
| SLOPEpop (W)                                        |                                                      | 0.809                                                | 4.68                                                 | 0.734                                                | 0.883                                                | Inter-individual variability on SLOPE                                                                                             |
| SLOPEpp (CV)                                         | %                                                    | 112                                                  |                                                      | 104                                                  | 119                                                  |                                                                                                                                   |
| SLOPEpop (Sh)                                        | %                                                    | 22.8                                                 |                                                      |                                                      |                                                      |                                                                                                                                   |
| Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                                                                                                            |
|                                                      |                                                      | 0.251                                                | 0.814                                                | 0.211                                                | 0.218                                                | Proportional residual error                                                                                                       |
| CV4                                                  | %                                                    | 48.9                                                 |                                                      | 48.5                                                 | 49.4                                                 |                                                                                                                                   |

ULCl = upper limit of 95% confidence interval (estimate + 1.96-SE)

RSE = relative standard error (100-SE/estimate)

3 Shrinkage (Sh) calculated as 100-(1-standard deviation of individual eta estimates/w)

2 The coefficient of varialion (CV) is calculated as 100SQRT(EXP(OMEGA2)-1)

4 Both the observations and the model predictions were log-transfomed and an additive residual error model was used. This is equivalent to an exponential residual error model on untransformed data and the coefficient of varialion (CV) calculated as 100SQRT(EXP(o*)-1). The confidence intervals of CV are derived through Lransfomalion uf cunfidence intervals uf ua.

<!-- image -->

Abbreviations:Cl=Confidence interval;VPC=Visual predictive check Note:Theupperpaneldisplaysthe cumulative percentage ofobservationswithtime.The verticalgreenline(solidintheupper plotanddashedinthelowerplotshowsthe timeat which90%ofobservationshavebeenplotted.Thelowerplotshowsa rangeVPC.Internal lickmarksonthex-axisdenotelime binboundaries.

<!-- image -->

[s]

Abbreviations:Cl=Confidence interval;VPC=Visual predictive check Note:Theupperpanel displays thecumulativepercentageof observationswithtime.Thevertical greenlinesolid inthe upper rangeVPC.Internaltick marks on thex-axisdenote timebinboundaries. Source:CPMX50156(available uponrequest)

Source:CPMX50156(available uponrequest)

Figure 7: VPC of neutrophils final model for darolutamide (left) and placebo (right) treated patients of Study 17777

<div style=\"page-break-after: always\"></div>

Slight differences due to region or race were established. The proportion of patients with neutropenia grade 3 and grade 4 based on the region or race, stratified by treatment arm are shown in Table 17. Higher incidences were reported in patients from the Asia Pacific region compared with patients from North America and rest of the world (ROW) in both treatment arms. These observed differences in Grade 3 or 4 neutrophil count decreased among geographical regions were generally consistent with the assessment of the typical patient's profile of absolute neutrophil count predicted by the PK -PD model, and are generally consistent in both treatment arms.

Table 17: Grade 3 and 4 TEAEs of neutrophil count decreased and neutropenia by geographical region and treatment arm (SAF)

|                            |                            | Darolutamldetdocetaxelarm Geographlcal reglon   | Darolutamldetdocetaxelarm Geographlcal reglon   | Darolutamldetdocetaxelarm Geographlcal reglon   | Placebo+docetaxelarm Geographlcal reglon   | Placebo+docetaxelarm Geographlcal reglon   | Placebo+docetaxelarm Geographlcal reglon   |
|----------------------------|----------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| MedDRA (v.24.1) PT         | Worst CTCAE grade          | North America N=125 n (%)                       | Asla Paciflc N=230 n (%)                        | ROW N=297 n (%)                                 | North Amerlca N=117 n (%)                  | Asla Pacific N=242 n (%)                   | ROW N=291 n (%)                            |
| Neutrophil count Any-grade | Neutrophil count Any-grade | 23 (18.4)                                       | 126 (54.8)                                      | 21 (7.1)                                        | 16 (13.7)                                  | 126 (52.1)                                 | 13 (4.5)                                   |
| decreased                  | Grade 3                    | 7 (5.6)                                         | 26 (11.3)                                       | 6 (2.0)                                         | 8 (6.8)                                    | 28 (11.6)                                  | 5 (1.7)                                    |
| decreased                  | Grade 4                    | 14 (11.2)                                       | 89 (38.7)                                       | 9 (3.0)                                         | 4 (3.4)                                    | 90 (37.2)                                  | 5 (1.7)                                    |
| Neutropenia                | Any-grade                  | 13 (10.4)                                       | 16 (7.0)                                        | 39 (13.1)                                       | 17 (14.5)                                  | 22 (9.1)                                   | 37 (12.7)                                  |
| Neutropenia                | Grade 3                    | 2 (1.6)                                         | 2 (0.9)                                         | 14 (4.7)                                        | 4 (3.4)                                    | 2 (0.8)                                    | 12 (4.1)                                   |
| Neutropenia                | Grade 4                    | 8 (6.4)                                         | 12 (5.2)                                        | 18 (6.1)                                        | 11 (9.4)                                   | 19 (7.9)                                   | 20 (6.9)                                   |

Abbreviations: CTCAE=Common Terminology Criteria for Adverse Events; MedDRA=Medical Dictionary for Regulatory Aclivilies: N=Total number of palienls (10o%6): n=Number of patienls with event; PT=Preferred term; RoW=Rest of the World:SAF=Safely analysis set;v.=Version

Notoc: Any adverco ovento with miccing CTCAE grade are not inoluded in thic cummary tablo.

CTCAEversion 4.03.

- Aspartate aminotransferase (AST)

Overall, 19384 AST concentrations from 1303 patients were analysed. The final model structure was a turnover model.

Parameter of the final model estimates are listed in Table 18.The typical percentage change in AST across all patients is shown in Table 19. AST concentration was found to be reduced during docetaxel treatment in both study arms. No other patient characteristics were found to influence AST. Differences in docetaxel exposure were not found to AST. No differences between darolutamide and control patients were identified.

<div style=\"page-break-after: always\"></div>

Table 18: Parameter estimates of the final PD model for AST, study 17777 ARASENS

| ParameterUnit                                     |                                                   | Estimate                                          | RSE [%]                                           | LLCI                                              | ULCI                                              | Description                                                             |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------------------------------|
| Fixed effects (THETA)                             | Fixed effects (THETA)                             | Fixed effects (THETA)                             | Fixed effects (THETA)                             | Fixed effects (THETA)                             | Fixed effects (THETA)                             | Fixed effects (THETA)                                                   |
| a                                                 | U/L                                               | 24.9                                              | 1.32                                              | 24.2                                              | 25.5                                              | Factor ofproductionrate                                                 |
| Kout                                              | 1/day                                             | 0.00593                                           | 12.5                                              | 0.004480.00738                                    |                                                   | Elimination rate constant for patient not receiving docetaxel treatment |
| BLN                                               | U/L                                               | 24.2                                              | 1.01                                              | 23.8                                              | 24.7                                              | PopulationbaselinevalueofALT concentration                              |
| ODTX                                              |                                                   | 0.212                                             | 12.4                                              | 0.161                                             | 0.264                                             | Docetaxel treatment effect on Kout                                      |
| Randomeffects:Inter-individual variability(OMEGA) | Randomeffects:Inter-individual variability(OMEGA) | Randomeffects:Inter-individual variability(OMEGA) | Randomeffects:Inter-individual variability(OMEGA) | Randomeffects:Inter-individual variability(OMEGA) | Randomeffects:Inter-individual variability(OMEGA) | Randomeffects:Inter-individual variability(OMEGA)                       |
| Kout (w)                                         |                                                   | 0.159                                             | 8.52                                              | 0.132                                             | 0.185                                             | Inter-individual variability on Kout                                    |
| Kout (CV)1                                        | %                                                 | 41.5                                              |                                                   | 37.6                                              | 45.1                                              |                                                                         |
| Kout (Sh)2                                        | %                                                 | 8.19                                              |                                                   |                                                   |                                                   |                                                                         |
| BLN (w?)                                          |                                                   | 0.105                                             | 5.83                                              | 0.0926                                            | 0.117                                             | Inter-individual variability on BLN                                     |
| BLN (CV)1                                         | %                                                 | 33.2                                              |                                                   | 31.1                                              | 35.2                                              |                                                                         |
| BLN (Sh)2                                         | %                                                 | 10.26                                             |                                                   |                                                   |                                                   |                                                                         |
| Resldual error (SlGMA)                            | Resldual error (SlGMA)                            | Resldual error (SlGMA)                            | Resldual error (SlGMA)                            | Resldual error (SlGMA)                            | Resldual error (SlGMA)                            | Resldual error (SlGMA)                                                  |
| (0)                                              |                                                   | 0.0805                                            | 5.26                                              | 0.0722                                            | 0.0888                                            | Additiveresidualerroronlogscale                                         |
| (CV)3                                             | %                                                 | 8.87                                              |                                                   | 8.40                                              | 9.31                                              |                                                                         |

LLCl =lower limit of 95%confidence interval(estimate -1.96SE)

ULCl = upper limit of 95% confidence interval (estimate + 1.96SE)

RSE=relativestandarderror(100SE/estimate)

- 1 Coeficient of variation (CV) calculated as 100SQRT(EXP(w)-1). The confidence intervals of CV are derived through transformation of confidence intervals of w.
- 2 Shrinkage (Sh) calculated as 100(1-standard deviation of individual eta estimates/w)
- 3 The coefficient of variation (CV) is calculated as 100SQRT(o2)/3.2 which is the CV for an observationof 3.2onlogscale,whichcorrespondstoanASTconcentrationof25U/L.

<!-- image -->

Time[days]

Abbreviations:AST=Aspartate aminotransferase:Cl=Confidenceinterval;VPC=Visualpredictive check

Note:The upperpanel displays the cumulative percentage of observationswithtime.Theverticalgreen line(solid inthe upper plotand dashedinthelowerplot) shows the time atwhichyu%otobservationshave beenplotted.1he iowerplotshowsa rangeVPC.Internal tickmarksonthex-axisdenote timebinboundaries. Source:CPMX50156(available uponrequest)

Abbreviations:AST=Aspartate aminotransferase;Cl=Confidence interval;VPC=Visualpredictive check Note:The upperpanel displays the cumulative percentage ofobservations with time.The vertical green line(solid in the upper Source: CPMX50156 (available upon request)

Figure 8: VPC of AST final model for darolutamide (left) and placebo (right) treated patients of Study 17777

Table 19: Typical percentage change of AST concentration for all patients, study 17777 ARASENS

| Typical patient   | TreatmentarmWeek9               | %change            | Week18 Week52 %change %change   | Week104 %change    |
|-------------------|---------------------------------|--------------------|---------------------------------|--------------------|
| All patients      | Darolutamide -5.50(-6.71,-4.43) | -9.01(-10.9,-7.23) | -0.269(-2.55,2.02)              | 2.25(-0.381,4.86)  |
|                   | Control -5.47(-6.63,-4.38)      | -9.01 (-10.7,-7.2) | -0.184 (-2.48, 2.01)            | 2.39 (-0.151,4.95) |

- Alanine aminotransferase (ALT)

Overall, 19606 ALT concentrations from 1303 patients were analysed. The final model was a turnover model as also used for AST. Parameter estimates are listed in Table 20. Docetaxel, age, Chinese, and

<!-- image -->

<div style=\"page-break-after: always\"></div>

Japanese were identified as statistically significant covariates. The overall model performance showed its ability to describe the time course of ALT on each sub-group of population.

Table 20:  Parameter estimates of the final PD model for ALT, study 17777 ARASENS

| Parameter Unit      |                     | Estimate            | RSE[%]              | LLCI                | ULCI                | Description                                                                                                                             |
|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Fixedeffects(THETA) | Fixedeffects(THETA) | Fixedeffects(THETA) | Fixedeffects(THETA) | Fixedeffects(THETA) | Fixedeffects(THETA) | Fixedeffects(THETA)                                                                                                                     |
| a                   | U/L                 | 22.1                | 1.95                | 21.3                | 23.0                | Constant forproductionrate                                                                                                              |
| Kout,pop            | 1/day               | 0.00486             | 9.73                | 0.003930.00578      |                     | Populationremoval rateforatypical patient of age 67years,from neitherJapannormainland China andnotcurrentlyreceiving docetaxeltreatment |
| BLN                 | U/L                 | 26.2                | 1.53                | 25.5                | 27.0                | Populationbaselinevalue of ALT concentration                                                                                            |
| DTX                |                     | 0.288               | 15.8                | 199                 | 377                 | Proportionaleffectofdocetaxel treatmentonremovalrate                                                                                    |
| OAGE                |                     | 0.00864             | 23.6                | 0.00463             | 0.0126              | Effect of continuous age on removal rate                                                                                                |
| OJAPAN              |                     | 0.263               | 21.3                | 0.153               | 0.373               | Proportional effect of region=Japan onremovalrate                                                                                       |
| OCHINA              |                     | 0.217               | 23.5                | 0.117               | 0.316               | Proportional effect of region=mainlandChinaonremoval rate                                                                               |

## Residualerror(SIGMA)

(0)

0.136

(CV)3

%

12.3

11.8

0.146

12.7

LLCl =lower limit of 95%confidence interval(estimate -1.96SE)

ULCl=upperlimitof95%confidenceinterval(estimate+1.96SE)

RSE=relativestandarderror(100-SE/estimate)

2Shrinkage (Sh) calculated as 100(1-standard deviation of individual ETA estimates/w)

1 Coefficient of variation (CV) calculated as 100-SQRT(EXP(w)-1). The confidence intervals of CV are derived throughtransformationofconfidenceintervalsof w.

- 3 The coefficient of variation (CV) is calculated as 100SQRT(o2)/3.0 which is the CV for an

observationof3.0onlogscale,whichcorrespondstoanALTconcentrationof20U/L.

<!-- image -->

Source:CPMx50156(availableuponrequest)

Figure 9: VPC of ALT final model for darolutamide (left) and placebo (right) treated patients of Study 17777

The typical percentage change in ALT across all patients is shown in Table 21. ALT concentration was found to be reduced during docetaxel treatment in both study arms. Older patients and patients from Japan or mainland China were associated with decreasing ALT levels. Differences in docetaxel exposure were not found to ALT. No differences between darolutamide and control patients were identified.

3.93

0.125

Additiveresidualerror

<div style=\"page-break-after: always\"></div>

Table 21: Typical percentage change of ALT concentration, study 17777 ARASENS

| Typical patient          | Treatmentarm             | Week9 %change'       | Week18 %change1      | Week52 %change1      | Week104 %change1     |
|--------------------------|--------------------------|----------------------|----------------------|----------------------|----------------------|
| Allpatients              | Darolutamide             | -12.2 (-20.9, -7.72) | -20.2 (-33.1,-13.1)  | -18.7 (-36.1, -7.8)  | -18.2 (-36.9, -5.57) |
| Allpatients              | Control                  | -12.1 (-20.8, -7.47) | -20.2(-33.2,-12.7)   | -18.7 (-35.9,-7.94)  | -18.1 (-36.7, -5.9)  |
| Age65 years             | Darolutamide             | -13.1 (-21.7,-10.3)  | -21.7(-34.3,-17.2)   | -20.7(-37.7,-14.8)   | -20.5 (-38.7,-13.7)  |
| Age65 years             | Control                  | -13.1 (-21.7, -10.1) | -21.6(-34.3,-16.9)   | -20.8 (-37.4, -14.6) | -20.5 (-38.1, -13.5) |
| Age<65 years             | Darolutamide             | -9.60 (-17.8, -6.53) | -16.3 (-28.8, -11.2) | -12.7 (-30.4, -5.37) | -11.5 (-31.0,-2.51)  |
| Age<65 years             | Control                  | -9.70 (-17.4, -6.47) | -16.4 (-28.2, -11.1) | -13.0 (-29.7, -5.37) | -11.6 (-30.3, -2.45) |
| Region: mainland China   | Darolutamide             | -18.7 (-22.8, -14.1) | -30.1 (-35.8, -23.2) | -32.4 (-39.2, -23.6) | -33.0(-40.2,-23.7)   |
| Region: mainland China   | Control                  | -18.8 (-23.1, -13.6) | -30.3 (-36.1, -22.5) | -32.6 (-39.5, -22.7) | -33.2 (-40.1,-22.6)  |
| Region.JapanDarolutamide | Region.JapanDarolutamide | -19.0 (-22.8, -14.3) | -30.5 (-36.0, -23.6) | -33.0 (-39.3, -24.1) | -33.7 (-40.2,-24.1)  |
|                          | Control                  | -18.3 (-22.5, -13.9) | -29.6(-35.3,-23.0)   | -31.7(-38.7,-23.4)   | -32.3(-39.5,-23.4)   |

1Percentage change from baseline: median (lower bound of 90% Cl, upper bound of 90% Cl)

- Total bilirubin

Overall, 19337 bilirubin observations from 1303 patients were analysed. The final model was a turnover model.

Parameter estimates of the final model are listed in Table 22. Docetaxel, darolutamide, age, Chinese, Japanese, and Korean were identified as statistically significant covariates. The overall model performance demonstrates its ability to describe the time course of bilirubin on each sub-group of population.

<div style=\"page-break-after: always\"></div>

Table 22: Parameter estimates of the final PD model for total bilirubin, study 17777 ARASENS

| Parameter                                            | Unit                                                 |                                                      | Estimate RSE [%] LLCI                                |                                                      | ULCI                                                 | Description                                                                                          |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                                                                |
| BLNpop                                               | mg/dL                                                | 0.541                                                | 1.51                                                 | 0.525                                                | 0.557                                                | Population value for baseline concentration of bllirubin                                             |
| KoutND,pop                                           | day-1                                                | 0.00596                                              | 3.26                                                 | 0.00558                                              | 30.00634                                             | Populatlon value for the rate of decrease In bilirubin concentration without the effect of docetaxel |
| Kin                                                  | day-1                                                | 0.00282                                              | 2.68                                                 | 0.00267                                              | 0.00297                                              | Value for the rate of Increase In bilirubin concentration                                            |
| BDTx                                                 |                                                      | 0.825                                                | 3.37                                                 | 0.770                                                | 0.879                                                | Proportion of recorded docetaxel treatment period in which an effect in the value of Kout is seen    |
| DTXEFF                                              |                                                      | 0.368                                                | 4.22                                                 | 0.337                                                | 0.398                                                | Change in Kout due to the use of docelaxel                                                           |
|                                                      |                                                      | -0.800                                               | 7.82                                                 | -0.922                                               | -0.677                                               | Rate constant used for box-cox transformalion of etas for KouND                                      |
| BDARO                                                |                                                      | -0.143                                               | 12.1                                                 | -0.177                                               | -0.109                                               | Effect of taking darolutamide on KouND                                                               |
| BAGE                                                 |                                                      | -0.00505                                             | 26.0                                                 |                                                      | -0.00762-0.00247                                     | Effect of the patient's age at baseline on KouIND                                                    |
| BCHINA                                               |                                                      | -0.221                                               | 10.9                                                 | -0.269                                               | -0.174                                               | Effect of region=mainland China on KouIND                                                            |
| BKOREA                                               |                                                      | -0.257                                               | 15.0                                                 | -0.332                                               | -0.181                                               | Effect of region=Korea on KouND                                                                      |
| BJAPAN                                               |                                                      | -0.193                                               | 14.6                                                 | -0.248                                               | -0.138                                               | Effect of region=Japan on KouIND                                                                     |
| Random effects: Inter-individual variabllity (OMEGA) | Random effects: Inter-individual variabllity (OMEGA) | Random effects: Inter-individual variabllity (OMEGA) | Random effects: Inter-individual variabllity (OMEGA) | Random effects: Inter-individual variabllity (OMEGA) | Random effects: Inter-individual variabllity (OMEGA) | Random effects: Inter-individual variabllity (OMEGA)                                                 |
| BLNpop (w)                                          |                                                      | 0.170                                                | 302                                                  | 0.159                                                | 0.180                                                | Inter-individual variability on BLN                                                                  |
| BLNpop (CV)                                          | %                                                    | 43.0                                                 |                                                      | 41.5                                                 | 44.5                                                 |                                                                                                      |
| BLNpop (Sh)2                                         | %                                                    | 4.75                                                 |                                                      |                                                      |                                                      |                                                                                                      |
| KouIND,pop (W)                                      |                                                      | 0.146                                                | 5.21                                                 | 0.131                                                | 0.161                                                | Inter-individual variability on KouND                                                                |
| KouND.,pop (CV)1                                     | %                                                    | 39.7                                                 |                                                      | 37.5                                                 | 41.8                                                 |                                                                                                      |
| KouND.pop (Sh)2                                      | %                                                    | 8.01                                                 |                                                      |                                                      |                                                      |                                                                                                      |
| Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                                                                               |
|                                                      |                                                      | 0.0657                                               | 0.595                                                | 0.0650                                               | 0.0665                                               | Proportional residual error                                                                          |
| CV                                                   | %                                                    | 25.6                                                 |                                                      | 25.5                                                 | 25.8                                                 |                                                                                                      |

ULCl = upper limit of 95% confidence Interval (estimate + 1.96SE)

RSE = relative standard error (100-SE/estimate)

- 2 Shrinkage (Sh) calculated as 100-(1-standard deviation of individual eta estimates/w)

1 Coefficlent of variation (CV) calculated as 100-SQRT(EXP(w*)-1). The confidence Intervals of CV are derived through transformation of confidence intervals of w.

3 Coefficient of variation (CV) calculated as 100SQRT(o). The confidence intervals of CV are derived through transformation of confidence intervals of o.

<!-- image -->

Time [days]

Abbreviations:Cl=Confidence interval;VPC=Visualpredictive check

Note:Ine upperpanel displays the cumulative percentage ot observationswith time.Ihe vertical green line(solidin the upper plotanddashedinthe lowerplot) showsthe time atwhich9o%of observationshave beenplotted.The lowerplot showsa rangeVPC.Internal tickmarks onthe x-axisdenote timebinboundaries. Source:CPMx50156(availableuponrequest)

<!-- image -->

Abbreviatons:CI=Uonhidence interval;VPU=Visual predictive check Note:The upperpanel displays the cumulative percentage of observationswith time.The vertical green line(solid in the upper plotanddashed in thelower plot)shows thetime atwhich9o%ofobservationshavebeenplotted.The lowerplot showsa rangeVPC.Internal tick markson thex-axis denote time binboundaries. Source:CPMx50156(availableuponrequest)

Figure 10: VPC of bilirubin final model for darolutamide (left) and placebo (right) treated patients of Study 17777

<div style=\"page-break-after: always\"></div>

The typical percentage change in AST across all patients is shown in Table 23. Total bilirubin was found to be reduced during docetaxel treatment in both study arms. Older patients and patients from Japan, Korea or mainland China were associated with increased total bilirubin. Darolutamide treatment was found to be associated with increased bilirubin levels over control, with model-predicted 0.1% (90% CI -8.6 to 24.7) increase from baseline after one year of treatment for a typical darolutamide-treated patient versus -12.1% (90% CI - 19.9 to 10.3) reduction from baseline for a typical control patient. The association with darolutamide treatment was consistent across the darolutamide exposure range at 600 mg BID.

Table 23: Typical percentage change of total bilirubin, study 17777 ARASENS

<!-- image -->

| TypicalpatientTreatmentarmWeek9   | TypicalpatientTreatmentarmWeek9   | % change1                                | Week18 % change1     | Week52 % change1     | Week104 % change1    |
|-----------------------------------|-----------------------------------|------------------------------------------|----------------------|----------------------|----------------------|
| All patients                      | Darolutamide                      | -8.19 (-11.9, 0.563)                     | -10.1(-15.7,3.83)    | 0.0829 (-8.63, 24.7) | 3.84 (-6.39, 35.3)   |
| All patients                      | Control                           | -13.5 (-17.2, -4.17)                     | -18.1 (-23.7,-3.97) | -12.1 (-19.9, 10.3)  | -10.2 (-19.0, 16.7)  |
| Age65yearsDarolutamide           |                                   | -7.26 (-10.1, 0.922)-8.91 (-13.0, 4.54)  |                      | 2.38 (-4.55,25.9)    | 6.63 (-1.61, 37.2)   |
| Age65yearsDarolutamide           | Control                           | -12.5 (-15.5, -3.84)-16.7 (-21.0, -3.29) |                      | -9.93 (-16.5, 11.7)  | -7.78 (-15.3, 18.4)  |
| Age<65yearsDarolutamide           |                                   | -9.68 (-12.8,-0.611) -12.5 (-17.1,1.94)  |                      | -3.52 (-10.7, 21.2)  | -0.435 (-8.72, 31)   |
| Age<65yearsDarolutamide           | Control                           | -15.3 (-18.2, -5.70)                     | -20.7 (-25.0,-6.39)  | -15.8 (-22.0, 6.43)  | 14.4 (-21.2, 11.6)   |
| Region: mainland China            | Darolutamide                      | -1.36 (-3.68, 1.07)                      | 0.831 (-2.95, 4.77)  | 19.0 (12.3, 26.4)    | 27.8 (18.9, 37.7)    |
| Region: mainland China            | Control                           | -5.93 (-8.80, -2.92)                     | -6.63 (-11.1, -1.79) | 5.99 (-1.37, 14.2)   | 11.1 (2.12, 21.2)    |
| Region:Japan                      | Darolutamide                      | -1.53 (-4.42, 0.842)0.359 (-4.22, 4.41)  |                      | 18.3(9.98,25.8)      | 26.9 (16.1,36.9)     |
| Region:Japan                      | Control                           | -6.55 (-9.51, -3.94)-7.49 (-12.3, -3.45) |                      | 4.41 (-3.22, 11.5)   | 9.08 (-0.0622, 17.9) |
| Region:KoreaDarolutamide          |                                   | 0.0583 (-3.28,3.18)3.09 (-2.59,8.28)     |                      | 23.3 (13.0,33.4)     | 33.6 (19.9, 47.7)    |
| Region:KoreaDarolutamide          | Control                           | -4.34 (-8.17,-1.10)                      | -4.05 (-10.0, 1.09)  | 10.3 (0.376, 19.7)   | 16.5 (4.30, 28.9)    |

1 Percentage change from baseline: median (lower bound of 90% Cl, upper bound of 90% Cl)

- Haemoglobin

Overall, 21317 haemoglobin observations from 1303 patients were analysed. The final model was a turnover model.

Parameter estimates of the final model are listed in Table 22. Docetaxel, darolutamide, prednisolone, age, Chinese, Japanese, and Korean were identified as statistically significant covariates. The overall model performance showed its ability to describe the time course of haemoglobin on each sub-group of population.

<div style=\"page-break-after: always\"></div>

Table 24: Parameter estimates of the final PD model for haemoglobin, study 17777 ARASENS

| Parameter                                            | Unit                                                 | Estimate                                             | RSE [%]                                              | LLCI                                                 | ULCI                                                 | Description                                                                                                                                                                    |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                | Fixed effects (THETA)                                                                                                                                                          |
| BLNpop                                               | g/dL                                                 | 13.3                                                 | 0.405                                                | 13.2                                                 | 13.4                                                 | Population value for baseline concentration of hemoglobin                                                                                                                      |
| KoutIND                                              | day-1                                                | 0.0207                                               | 2.55                                                 | 0.0197                                               | 0.0222                                               | Populationvalue for the rate of decrease in hemoglobin concentration without the effect of docetaxel                                                                           |
| Kin,pop                                              |                                                      | 13.0                                                 | 0.445                                                | 12.9                                                 | 13.1                                                 | Multiplicative constant used to give the population value of Kin in terms of KouND                                                                                             |
| ODTx                                                 |                                                      | 0.933                                                | 0.438                                                | 0.925                                                | 0.941                                                | Proportion of docetaxel treatment period in which an effect in the value on the turnover parameters is seen                                                                    |
| KO                                                  |                                                      | 1.40                                                 | 3.66                                                 | 1.30                                                 | 1.50                                                 | Constant used in describing the change In Kout due to the use of docetaxel                                                                                                     |
|                                                      |                                                      | 0.892                                                | 0.575                                                | 0.882                                                | 0.902                                                | Constant used in describing the change In Kn due to the use of docetaxel                                                                                                       |
|                                                      |                                                      | -3.34                                                | 5.06                                                 | -3.67                                                | -3.01                                                | Rate constant used for box-cox transformation of etas for individuals baseline and KouIND                                                                                      |
| BAGE1                                                |                                                      | -0.00235                                             | 13.3                                                 | -0.00296                                             | -0.00174                                             | Parameter describing the influence of age on Kin,pop                                                                                                                           |
| BAGE2                                                |                                                      | 0.00156                                              | 26.2                                                 | 0.000759                                             | 0.00236                                              | Parameter describing the influence of age on Ko                                                                                                                               |
| PREDN                                               |                                                      | -0.0259                                              | 22.9                                                 | -0.0376                                              | -0.0143                                              | Parameter describing the influence of a                                                                                                                                        |
| BDARO                                                |                                                      | -0.0197                                              | 24.2                                                 | -0.0290                                              | -0.0103                                              | patient taking prednisone/prednisolone during the docetaxel treatment period on KO Parameter describing the Influence of a patient being treated with darolutamide on Kin,pop |
| ODTXA1                                               |                                                      | -0.278                                               | 12.4                                                 | -0.345                                               | -0.210                                               | Parameter describing the Influence of the pallents total docetaxel AuC on Oko                                                                                                  |
| ODTXA2                                               |                                                      | 1.03                                                 | 2.22                                                 | 0.981                                                | 1.07                                                 | Parameter describlng the Influence of the patient's total docetaxel AUC, along with DTXA1,On                                                                                  |
| OJAPAN                                               |                                                      | 0.0675                                               | 15.0                                                 | 0.0476                                               | 0.0874                                               | Parameter describing the influence of region=Japan on KoutC                                                                                                                    |
| CHINA                                               |                                                      | -0.0449                                              | 19.3                                                 | -0.0618                                              | -0.0279                                              | Parameter describing the Influence of region=mainland China on KinC                                                                                                            |
| OKOREA                                               |                                                      | -0.0431                                              | 27.2                                                 | -0.0660                                              | -0.0201                                              | Parameter describing the influence of region=Korea on KinND                                                                                                                    |
| Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA) | Random effects: Inter-individual variability (OMEGA)                                                                                                                           |
| BLNpop (w)                                          |                                                      | 0.0121                                               | 5.91                                                 | 0.0107                                               | 0.0135                                               | Inter-individual variability on BLN                                                                                                                                            |
| BLNpop (CV)1                                         | %                                                    | 11.0                                                 |                                                      | 10.4                                                 | 11.6                                                 |                                                                                                                                                                                |
| BLNpop (Sh)2                                         | %                                                    | 10.41                                                |                                                      |                                                      |                                                      |                                                                                                                                                                                |
| KinND (W)                                           |                                                      | 0.00874                                              | 4.84                                                 | 0.00791                                              | 0.00957                                              | Inter-individual variability on KinND                                                                                                                                          |
| KiND (CV)                                            | %                                                    | 9.37                                                 |                                                      | 8.91                                                 | 9.81                                                 |                                                                                                                                                                                |
| KinND (Sh)2                                          | %                                                    | 5.19                                                 |                                                      |                                                      |                                                      |                                                                                                                                                                                |
| Kouc (w)                                            |                                                      | 0.00801                                              | 4.55                                                 | 0.00730                                              | 000873                                               | Inter-individual variability on Koutc                                                                                                                                          |
| Kouc (CV)1                                           | %                                                    | 8.97                                                 |                                                      | 8.56                                                 | 9.36                                                 |                                                                                                                                                                                |
| Kouic (Sh)2                                          | %                                                    | 12.56                                                |                                                      |                                                      |                                                      |                                                                                                                                                                                |
| Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                               | Residual error (SlGMA)                                                                                                                                                         |
| (o)                                                 |                                                      | 0.00376                                              | 0.279                                                | 0.00374                                              |                                                      | 0.00378Proportionalresidual error                                                                                                                                              |
| CV3                                                  | %                                                    | 6.13                                                 |                                                      | 6.11                                                 | 6.15                                                 |                                                                                                                                                                                |

LLCl = lower limit of 95% confidence interval (estimate - 1.96SE)

ULCl = upper limit of 95% confidence interval (estimate + 1.96SE)

RSE=relative standard error(100-SE/estimate)

1 Coefficlent of variation (CV) calculated as 100-SQRT(EXP(w)-1). The confidence intervals of CV are derived through transformation of confidence intervals of w?

3 Coefficlent of variation (CV) calculated as 100SQRT(o).

2 Shrinkage (Sh) calculated as 100(1-standard deviation of individual eta estimates/w)

<div style=\"page-break-after: always\"></div>

Figure 11: VPC of hemoglobin final model for darolutamide (left) and placebo (right) treated patients of Study 17777

<!-- image -->

Haemoglobin was found to be reduced during docetaxel treatment in both study arms. The reduction in haemoglobin due to docetaxel treatment was more pronounced in those with higher docetaxel exposure, older patients, patients from Japan and patients from China. After haemoglobin levels recovered from docetaxel treatment, darolutamide treated patients continued to be associated with lower haemoglobin levels than control patients for the remainder of the study, although the modelpredicted difference is small with a -4.5% (90% CI - 8.1 to 1.0) reduction from baseline one year after treatment start for a typical darolutamide-treated patient versus -2.4% (90% CI -5.9 to 0.77) reduction from baseline for a typical control patient). The same applies for older versus younger patients and patients from Korea versus not from Korea.

For patients from Japan, on average, 1.56-fold higher exposure in these patients did not result in a different change in haemoglobin over time compared with patients from the rest of the regions. The predicted change in haemoglobin after 1 year in the darolutamide + docetaxel arm was -5.6% (90% CI: [-7.9%; -2.2%]) in a typical Japanese patient vs. -4.3% (90% CI: [-7.3%; -0.7%]) in a typical rest of the regions patient and a comparable difference between a Japanese vs. rest of the regions patient was observed in the placebo + docetaxel arm, i.e., -3.3% (90% CI: [-6%; -0.1%]) vs. -2.4% (90% CI: [-5.4%; +1.1%], respectively. Similarly, the 1.27 -fold higher exposure in patients from mainland China vs. rest of the regions was not associated with differences in haemoglobin decrease. While the predicted change in haemoglobin after 1 year was -4.4% (90% CI: [-6.8%, -1.6%) in a typical patient from mainland China vs. -4.3% (90% CI: [-7.3%; -0.7%]) in a typical rest of the regions patient, a comparable difference between a patient from mainland China vs. a rest of the regions patient was observed in the placebo + docetaxel arm, i.e., -2.4% (90% CI: [-5.1%, +1.2%]) vs. -2.4% (90% CI: [-5.4%; +1.1%], respectively.

<div style=\"page-break-after: always\"></div>

Table 25: Typical percentage change of haemoglobin, study 17777 ARASENS

| Typical patient                           | Treatment arm   | Week9 % change1                                            | Week18 Week52 %change1 % change1                                          | Week104 % change1     |
|-------------------------------------------|-----------------|------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------|
| All palients                              |                 |                                                            | Darolutamide -11.9 (-18.0,-7.17)-12.7 (-18.5,-7.57)-4.53 (-8.08,-0.991)   | -4.47 (-8.01,-0.948)  |
| All palients                              | Control         |                                                            | -10.6 (-16.5, -5.74)-11.0 (-17.1, -5.67) -2.43 (-5.87, 0.766)             | -2.37 (-5.80,0.827)   |
| Age  65 years                            | Darolutamide    |                                                            | e-13.3(-19.0,-9.81)-14.1(-19.4,-10.5)-5.29(-8.49,-3.56)                   | -5.23(-8.42,-3.49)    |
| Age  65 years                            | Control         |                                                            | -12.2 (-17.2, -8.27) -12.9 (-17.5, -8.7)-3.44 (-6.92, -1.54)              | -3.38 (-6.86,-1.47)   |
| Age<65 years                              |                 |                                                            | Darolutamide -9.47 (-14.2,-5.9)-9.89 (-14.5,-5.98)-2.67 (-6.12,0.114)     | -2.61 (-6.06, 0.177)  |
| Age<65 years                              | Control         |                                                            | -8.38 (-12.9, -4.73)-8.49 (-12.9, -4.72) -0.725 (-2.86, 1.72)             | -0.667 (-2.81, 1.77)  |
| Prednisone or prednisolone                |                 |                                                            | Darolutamide -10.9 (-16.6,-6.48)-11.7 (-17.5,-6.84)-4.43 (-7.42,-1.42)    | -4.37 (-7.37, -1.37)  |
| Prednisone or prednisolone                | Control         |                                                            | -9.53 (-15.2,-4.92)-9.98 (-15.6,-4.87)-2.48 (-5.68, 0.826)                | -2.43 (-5.62, 0.874)  |
| No Prednisone JO prednisolone             | Control         |                                                            | Darolutamide -12.8 (-19.1,-8.24)-13.6 (-19.5,-8.49)-4.77 (-8.84,-1.07)    | -4.70 (-8.79, -1.00)  |
| No Prednisone JO prednisolone             |                 |                                                            | -11.4 (-17.3,-6.40)-11.9 (-17.6,-6.36)-2.67 (-6.63, 1.16)                 | -2.59 (-6.56, 1.21)   |
| Docelaxel AUCTolal > 28381 h-g/L Control |                 |                                                            | Darolutamide -11.7 (-16.4,-6.97)-12.8 (-17.9,-7.43)-4.79 (-7.79,-1.06)    | -4.72 (-7.74, -1.01)  |
| Docelaxel AUCTolal > 28381 h-g/L Control |                 |                                                            | -10.2(-15.3,-5.20)-11.0 (-16.5,-5.34)-2.69 (-6.14, 1.23)                  | -2.61 (-6.07, 1.30)   |
| Docetaxel AUCTolal S 28381 h-g/L Control |                 |                                                            | Darolutamide -12.6 (-19.2,-6.83)-12.9 (-19.3,-6.88)-4.32 (-8.41,-0.906)   | -4.25 (-8.33,-0.854)  |
| Docetaxel AUCTolal S 28381 h-g/L Control |                 |                                                            | -11.4 (-17.7,-6.06)-11.4 (-17.6,-5.89)-2.38 (-5.95, 0.871)                | -2.32 (-5.87, 0.929)  |
| Region: Japan                             |                 |                                                            | Darolutamide -17.8(-21.4,-13.3)-18.1(-21.6,-13.7)-5.49 (8.22,-2.17)       | -5.40 (-8.11,-2.09)   |
| Region: Japan                             | Control         |                                                            | -15.6 (-19.2, -11.5)-15.7 (-19.1, -11.3)-3.12 (-5.56, -0.141)             | -3.03 (-5.48,-0.0545) |
| Region: mainland China                    |                 |                                                            | Darolutamide -14.0 (-17.2,-10.7)-14.5 (-18.1,-10.9)-4.34 (-6.86,-1.52)    | -4.26 (-6.79, -1.43)  |
| Region: mainland China                    | Control         |                                                            | -13.0 (-16.1,-8.70)-13.2 (-16.6,-8.49)-2.47 (-5.06, 0.899)                | -2.39 (-4.99, 0.951)  |
|                                           |                 |                                                            |                                                                           | -8.30 (-11.6, -4.66)  |
| Region:                                   |                 |                                                            | Darolutamide -14.7 (-18.5, -10.3)-15.8 (-19.8, -11.2)-8.36 (-11.6, -4.72) |                       |
| Korea                                     | Control         | -13.5 (-17.2,-9.16)-14.6 (-18.3, -9.66)-6.77 (-9.91,-2.95) |                                                                           | -6.71 (-9.84, -2.90)  |

## 2.3.4. Discussion on clinical pharmacology

- Population PK modelling darolutamide

Although some slight misspecifications in the pc-VPC were identified for (S,R)-darolutamide, overall, the population PK model is considered fit-for-purpose to inform on PK characteristics and exposureresponse relationships.

- Comparison of studies 17777 ARASENS and 17712 ARAMIS

Based on PK analyses systemic exposure was shown to be generally lower and the PK more variable in patients with mHSPC in study ARASENS compared to patients with nmCRPC in study ARAMIS. However, this difference does not appear to be attributed to the cancer type but to other patient characteristics (e.g. age, body weight). Therefore, the PK of darolutamide is considered to be generally comparable between mHSPC and nmCRPC patients. Available data from study 17777 ARASENS suggested a higher increase in exposure (AUC(0 -12)ss) for Japanese patients (mean ratio compared to rest of regions = 1.56 (90%CI: 1.43 -1.70) as compared to the previous analysis of data from study 17712 ARAMIS (mean ratio compared to rest of regions =1.42 (90%CI: 1.33 - 1.53)). See section 5.2 of the SmPC.

- Population PK modelling of docetaxel and effect of darolutamide on PK of docetaxel

Based on the presented results, darolutamide 600 mg BID orally administered resulted in no clinically relevant changes in the systemic exposure of docetaxel (75 mg/mg 2  as 1 hour IV infusion every 21 days) in mHSPC patients.

<div style=\"page-break-after: always\"></div>

- PK/PD modelling for efficacy and safety

## Modelling aspects

Several PK/PD models have been developed to characterise the time course of darolutamide, docetaxel, PSA, neutrophil count, ALT, ALT, bilirubin and haemoglobin.

Although adequate PK data were limited, the current analysis reveals the ability of the model to capture the time-course of PSA over time and relevant covariates to explain differences among groups. No clear relationship between darolutamide exposure and PSA response was identified.

Exploratory analysis suggested no differences in time-course of total testosterone between darolutamide-treated and control patients.

Regarding neutrophil count, ALT, AST, bilirubin, and haemoglobin, no relevant differences on model performance was observed across the different treatment arms (refer to VPCs), suggesting that the model adequately captures the pharmacodynamic endpoints (neutrophil count, ALT, AST, bilirubin, and haemoglobin) on each arm.

The justification of including an alpha parameter, which represents the fraction of the correlation between Kin or Kout in the AST and ALT model is not completely understood, although it seems to improve the prediction of the AST and ALT time-course data. The sparse data available and the identification of three parameters of the turn-over model may be explained by non-steady state conditions of patients before initiating treatment or no relevant information of baseline AST and ALT values collected. Therefore, the estimation of baseline of AST and ALT together with Kin and Kout is supported to address the non-steady-state conditions of patients.

The Applicant recognized the inability to incorporate longitudinal predicted concentrations of docetaxel to predict AST, ALT, and bilirubin profiles over time. Although the PK/PD model captures the observed data, no relevant information is incorporated to understand how changes in docetaxel exposure may affect the response time-course. Therefore, simulation-based analyses to support changes in docetaxel dose level or schedule are of limited information.

## Neutrophil count, ALT, ALT, bilirubin and haemoglobin

Differences in neutrophil suppression due to docetaxel treatment in both study arms were identified for patients in different geographical regions (China, USA, Japan, and Korea). A slightly higher incidence of neutropenia Grade 3 / 4 in the placebo + docetaxel arm was observed versus the darolutamide + docetaxel arm.

AST and ALT concentrations were reduced during docetaxel treatment in both study arms. Older patients and patients from Japan or mainland China were associated with decreasing ALT levels. Differences in docetaxel exposure were not associated with changes in ALT levels. Overall, no differences between darolutamide and control patients were identified for AST and ALT.

Total bilirubin was reduced during docetaxel treatment in both study arms. Older patients and patients from Japan, Korea or mainland China were associated with increased total bilirubin. Darolutamide treatment was associated with increased bilirubin levels consistent across the darolutamide exposure range at 600 mg BID.

The co-administration of darolutamide with docetaxel was shown to reduce the decrease on bilirubin (BIL) level compared to docetaxel only. Although no definitive conclusions could be established regarding the mechanism involved in bilirubin change after darolutamide, it has been hypothesized that the inhibition of OATP1B1 and OATP1B3 by darolutamide may play a role, leading to higher BIL levels.

<div style=\"page-break-after: always\"></div>

Haemoglobin was reduced during docetaxel treatment in both study arms. The reduction in haemoglobin due to docetaxel treatment was more pronounced in those with higher docetaxel exposure, older patients, patients from Japan and patients from China. Darolutamide treatment was also associated with reduced haemoglobin levels.

## 2.3.5. Conclusions on clinical pharmacology

The PK of darolutamide appear generally comparable between mHSPC and nmCRPC patients.

Overall, the adequacy of the current PK/PD model to describe the observed (response) data is supported. However, it should be highlighted that the current PK/PD models developed for each PD outcome did not take into account how changes in darolutamide or docetaxel exposure may affect the PD outcome. Therefore, although several covariates were statistically identified to explain differences in PD response over time, the PK/PD models were not suitable to support any dose schedule modification since it is not possible to estimate how differences in exposure may translate into the PD outcome.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

The selected dose of darolutamide in ARASENS study is 600 mg bd tablets which is the same as the selected dose for the currently approved indication in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

The 600 mg bd dose of tablet formulation for treatment of patients with mHSPC in combination with docetaxel was primarily supported by a popPK meta-analysis and data of Study 17777.

## 2.4.2. Main study(ies)

## Study ARASENS

Study ARASENS is a randomized, double -blind, placebo -controlled Phase III study of darolutamide (ODM -201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone -sensitive prostate cancer.

<div style=\"page-break-after: always\"></div>

## Methods

<!-- image -->

Clinical Practice;mHSPC=Metastatichormone-sensitive prostate cancer; ULN=Upperlimit of normal.

- a:1306patientswererandomized.1patientwasexcludedduetoGCPviolation.

Patients in both treatment arms received ADT throughout the study.

Figure 12: ARASENS Study Design

## Study participants

## Key inclusion criteria included:

- Written informed consent
- -Males 18 years of age
- Histologically or cytologically confirmed adenocarcinoma of prostate
- Metastatic disease documented either by a positive bone scan, or for soft tissue or visceral metastases, either by contrast -enhanced abdominal/pelvic/chest computed tomography (CT) or magnetic resonance imaging  (MRI)  scan  assessed  by  investigator  and  confirmed  by  central  radiology  review.  Metastatic disease is defined as either malignant lesions in bone scan or measurable lymph nodes above the aortic bifurcation  or  soft  tissue/visceral  lesions  according  to  Response  Evaluation  Criteria  In  Solid  Tumors (RECIST) 1.1. Lymph nodes are measurable if the short axis diameter is 15 mm, soft tis sue/visceral lesions  are  measurable  if  the  long  axis  diameter  is  10  mm.  Patients  with  regional  lymph  node metastases only (N1, below the aortic bifurcation) will not be eligible for the study. Only patients with non -regional  lymph  node  metastases  (M1a)  and/or  bone  metastases  (M1b)  and/or  other  sites  of metastases with or without bone disease (M1c) will be eligible.
- -Patients must be candidates for ADT and docetaxel therapy per investigator's judgment
- Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti -androgen, but no longer than 12 weeks before randomization. For patients receiving LHRH agonists, treatment in combination  with  a  first  generation  anti -androgen  for  at  least  4  weeks,  prior  to  randomization  is recommended. First generation anti -androgen had to be stopped prior to randomization.
- An Eastern Cooperative Oncology Group performance status of 0 or 1
- Blood counts at Screening: hemoglobin  9.0 g/dL, absolute neutrophil count  1.5x10 9  /L, platelet count  100x10 9  /L (patient must not have received any growth factor within 4 weeks or a blood transfusion within 7 days of the hematology laboratory sample obtained at Screening)

<div style=\"page-break-after: always\"></div>

- Screening values of serum alanine aminotransferase and/or aspartate transaminase  1.5 x upper limit of normal (ULN), total bilirubin ULN, creatinine  2.0 x ULN

- Sexually active male patients must agree to use condoms as an effective barrier method and refrain from sperm donation, and/or their female partners of reproductive potential to use a method of effective birth control, during the treatment with darolutamide+placebo and for 3 months after the end of the treatment with darolutamide+placebo and 6 months after treatment with docetaxel

## Key exclusion criteria included:

- Prior treatment with:

o LHRH agonist/antagonists started more than 12 weeks before randomization o  Second -generation  androgen  receptor  (AR)  inhibitors  such  as  enzalutamide,  ARN -509, darolutamide, other investigational AR inhibitors

o  Cytochrome  P  17  enzyme  inhibitor  such  as  abiraterone  acetate  or  oral  ketoconazole  as antineoplastic treatment for prostate cancer

- o Chemotherapy or immunotherapy for prostate cancer prior to randomization

- Treatment with radiotherapy (external beam radiation therapy, brachytherapy, or radiopharmaceuticals) within 2 weeks before randomization

- Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
- Contraindication to both CT and MRI contrast agent

- Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)

- Uncontrolled hypertension as indicated by a resting systolic blood pressure (BP)  160 mmHg or diastolic BP  100 mmHg despite medical management

- Had a prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (ie, pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed  5 years before randomization and from which the patient has been disease -free

- A gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study drug

- An active viral hepatitis, known human immunodeficiency virus infection with detectable viral load, or chronic liver disease with a need for treatment

- Previous (within 28 days before the start of study drug or 5 half -lives of the investigational treatment of the previous study, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s)

- Any other serious or unstable illness, or medical, social, or psychological condition, that could jeopardize the safety of the patient and/or his/her compliance with study procedures, or may interfere with the patient's participation in the study or eval uation of the study results

- Inability to swallow oral medications

<div style=\"page-break-after: always\"></div>

- Close affiliation with the investigational site (eg, a close relative of the investigator, dependent person [eg, employee or student of the investigational site])
- Previous assignment to treatment in this study Study design: Randomized, double -blind, placebo -controlled, multicente

## Treatments

Patients were randomised in a 1:1 ratio to the treatments as specified below:

- -Darolutamide tablets orally 600 mg [2 x 300 mg tablets] twice daily [bd], tablet formulation combined with docetaxel at a dose of 75 mg/m 2  as an IV infusion every 21 days for 6 cycles, starting within 6 weeks after the start of study drug.
- -Placebo tablets orally combined with docetaxel at a dose of 75 mg/m 2  as an IV infusion every 21 days for 6 cycles, starting within 6 weeks after the start of study drug.

Docetaxel could be administered in combination with prednisone/prednisolone at the discretion of the Investigator. To prevent hypersensitivity reactions and fluid retention, the recommended pre -medication regimen was oral dexamethasone 8 mg, 12 hours, 3 hours and 1 hour before the docetaxel infusion. Anti-emetic regimens are recommended as per local clinical practice.

Treatment was administered until disease progression (symptomatic progressive disease, change of antineoplastic therapy), unacceptable toxicity, consent withdrawal or withdrawal from the study at the discretion of the Investigator or his/her designated associate(s), death, or non -compliance.

## Objectives and endpoints

Table 26 : Objectives and endpoints

| Primary endpoint                              | Definition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Overall survival (OS)                         | Time from the date of randomization until death from any cause. OS of patients not known to have died was censored at their last date of being known to be alive or at the database cut-off date, whichever came first.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Secondary endpoints                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Time to castration- resistant prostate cancer | Time from randomization to the first occurrence of one of the following events:  PSA progression, according to PCWG3 criteria with serum testosterone being at castrate level <0.50 ng/mL; defined as the date that a 25% or greater increase and an absolute increase of 2 ng/mL or more from the nadir (lowest at or after baseline) was documented, both of which were confirmed by a second value obtained at least 3 weeks later, including all potential PSA values 2 ng/mL above nadir and 25% increase above nadir between the initial assessment date and the confirmation assessment date. This definition required serum testosterone at castrate levels <0.50 ng/mL and a first assessment date at least 12 weeks from randomization. The analysis was based on PSA and testosterone assessments from the central laboratory. However, due to the COVID-19 pandemic, some PSA assessments were performed at local laboratories.  Radiological progression by soft tissue and visceral lesions; defined according to |
|                                               | RECIST v1.1, based on MRI/CT scans of the chest, abdomen, and pelvis performed by the investigator, as recommended by PCWG3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                               |  Radiological progression by bone lesions; defined according to PCWG3 criteria based on whole body 99m Tc methylene diphosphonate bone scans performed by the investigator.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

## Time to pain progression

Symptomatic skeletal event-free survival (SSE-FS)

Time to first symptomatic skeletal event (SSE)

Time to initiation of subsequent systemic antineoplastic therapy

Time to worsening of disease-related physical symptoms

Time to initiation of opioid use for 7 consecutive days

## Exploratory endpoints

Time to PSA progression

Rates of absolute and relative PSA response

ECOG Performance status

Time from randomization to the first date a patient experienced pain progression. Pain progression was defined as:

- For asymptomatic patients (worst pain subscale [WPS] = 0 at baseline, as assessed using the BPI-SF questionnaire [ePRO device]):
- -An increase of 2 or more points in the 'worst pain in 24 hours' score (ie, 2 or more point increase in WPS score) from nadir (ie, zero) observed at 2 consecutive evaluations 4 weeks apart, or
- -Initiation of short- or long-acting opioid use for pain
- For symptomatic patients (WPS &gt;0 at baseline):
- -An increase of 2 or more points in the 'worst pain in 24 hours' score (ie, 2 or more point increase in WPS score) from nadir observed at 2 consecutive evaluations 4 weeks apart and a WPS of 4, or
- -Initiation of short- or long-acting opioid use for pain

Time from randomization to the first occurrence of an SSE or death from any cause, whichever came first.

An SSE was defined as the occurrence of one of the following:

- Administration of EBRT to relieve skeletal symptoms, or
- New symptomatic pathologic bone fracture, or
- Spinal cord compression, or
- Tumor-related orthopedic surgical intervention

Time from randomization to the first occurrence of an SSE. Death was not considered as an event.

Time from randomization to initiation of the first subsequent systemic antineoplastic therapy. Patients in the study may have received subsequent antineoplastic therapy for prostate cancer or for additional primary malignancies. Systemic antineoplastic therapy treatment was selected as described in the SAP.

Time from randomization to the first date a patient experienced an increase in diseaserelated physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire (ePRO device).

An increase in disease-related physical symptoms was defined as a 3-point decrease in the FPSI-DRS-P subscale from baseline (a lower score indicates a higher symptom burden), observed at 2 consecutive evaluations 4 weeks apart.

Time from randomization to the date of first opioid use for 7 consecutive days.

Opioid use related to prostate cancer pain was included in the analysis, while opioid use for non-malignant cause(s) was excluded.

Time from randomization to the date of first PSA progression (with testosterone at castrate level &lt;0.5 ng/mL).

The definition of PSA progression is the same as described above for the time to castration-resistant prostate cancer endpoint.

Rate of response was determined by the number of patients with PSA response divided by the total number of patients randomized.

- Absolute PSA response (evaluated at 6 and 12 months after randomization) was defined as a baseline PSA value above the detection limit and a post-baseline PSA level below 0.2 ng/mL, confirmed by a second subsequent PSA value below 0.2 ng/mL 3 or more weeks later, with all potential PSA values between the initial date and confirmation date below 0.2 ng/mL.
- Relative 30% PSA response (evaluated at 3, 6, and 12 months after randomization) was defined as a baseline PSA value above the detection limit and a post-baseline 30% reduction in PSA level compared with the baseline value, confirmed by a second subsequent PSA value with a 30% reduction from baseline 3 or more weeks later, with all potential PSA values between the initial date and confirmation date showing a 30% reduction from baseline. Relative 50% and 90% PSA response were defined in the same way.

In addition, descriptive statistics and frequency distribution (no decline, &lt;30%, 30% to &lt;50%, 50% to &lt;90%, 90%) are provided for PSA maximum percent decline from baseline at any time on study.

Summary group comparison of ECOG PS values by visit and changes from baseline

Quality of life (QoL):

ePRO data, as collected using the NCCN-FACT-FPSI-17 and BPI-SF questionnaires were analyzed to assess differences in QoL between the treatment arms.

NCCN-FACT-FPSI-17

Summary group comparison of total and subscore values by visit and changes from baseline

BPI-SF

Summary group comparison of total and subscore values by visit and changes from baseline; time-adjusted AUC

<div style=\"page-break-after: always\"></div>

AUC=Area under the curve; BPI-SF=Brief pain inventory - short form; COVID-19=Coronavirus disease 2019; CT=Computed tomography; DRS-P=Disease-Related Symptoms Subscale - Physical; EBRT=External beam radiation therapy; ECOG PS=Eastern Cooperative Oncology Group performance status; eCRF=electronic case report form; ePRO=Electronic patient-reported outcome; MRI=Magnetic resonance imaging; NCCN-FACT-FPSI17=National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Prostate Symptom Index 17-item questionnaire; OS =Overall survival; PCWG3=Prostate Cancer Working Group 3; PSA=Prostatespecific antigen; QoL=Quality of life; RECIST v1.1=Response evaluation criteria in solid tumor version 1.1; SAP=Statistical analysis plan; SSE=Symptomatic skeletal event; WPS=Worst pain subscale

## Sample size

The sample size of the study was based on the primary endpoint of OS. The study was designed to have 90% power to detect a 25% decrease in risk of death with darolutamide compared with placebo with a one-sided test with a type I error of 0.025 (equivalent to a two-sided test with a type I error 0.05). The OS data were considered mature when approximately 509 deaths are observed.

With  the  additional  assumptions  that  patients  were  enrolled  at  a  rate  of  50  patients  per  month, exponential distributions of the OS event times, median time of OS in the placebo group of 60 months, 5% dropout rate of patients, and a 6-months enrolment ramp-up period, it followed that approximately 1,300 patients were required to be randomized to observe 509 deaths after approximately 70 months.

## Interim analysis

A futility interim analysis was planned. For the futility interim and final analyses together, a one-sided overall  beta  of  0.1  was  used.  Stopping  boundaries  were  calculated  with  an  O'Brien -Fleming  betaspending function using the actual number of events observed up to the cut-off date. The interim futility analysis was planned when approximately 153 deaths were observed (information fraction=0.3). The critical boundary for the futility analysis was calculated separately from the efficacy boundary, in order to not interfere with the type I error of the efficacy analysis.

## Stopping boundaries for interim analysis

|               |         | Stopping Boundaries HazardRatioScale (darolutamide+docetaxel arm vs.placebo+docetaxel arm) (%Improvement)/ZScore   | Stopping Boundaries HazardRatioScale (darolutamide+docetaxel arm vs.placebo+docetaxel arm) (%Improvement)/ZScore   |                        |                      |
|---------------|---------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|------------------------|----------------------|
| Analysis Time | #Events | Crossing LowerBound (efficacy)                                                                                     | Crossing UpperBound (futility-lackofefficacy)                                                                      | Cumulative Alpha Spent | Cumulative BetaSpent |
| 1st Interima  | 153     |                                                                                                                    | 1.166 (-14.2 %) /0.952                                                                                             |                        | 0.003                |
| Final         | 509     | 0.841 (19.0%) / 1.96                                                                                               | 0.841 (19.0%) / 1.96                                                                                               | 0.025                  | 0.100                |

SoftwareADDPLANneoV10.0.4wasusedforthisdesign

A second interim analysis was initially planned, which included a stopping boundary for efficacy calculated based on an alpha-spending function. It was removed with protocol amendment 7 (26 May 2020) due to the implications of the COVID -19 pandemic on the conduct of study procedures and data collection at the study sites.

<div style=\"page-break-after: always\"></div>

The 1st interim analysis was completed and its stopping boundaries were calculated before the decision was made to remove the 2nd interim analysis.

## Randomisation

Patients were randomly assigned on a 1:1 basis in a blinded fashion to treatment with darolutamide or matching placebo plus ADT and docetaxel. In addition, randomisation was stratified by:

- Extent of disease
- o Non -regional lymph nodes metastases only
- o Bone metastases with or without lymph node metastases
- o Visceral metastases with or without lymph node metastases or with or without bone metastases
- Alkaline Phosphatase
- o ALP&lt;ULN
- o ALPULN

Note: Blood samples to measure ALP levels for stratification were analysed in a central laboratory.

## Blinding (masking)

Study  ARESENS  was  a  double-blind  study.  Both  investigators  and  patients  remained  blinded  to randomised treatment for the study duration.

## Data monitoring committee (DMC)

A DMC was instituted to monitor ongoing safety of study patients with respect to a risk/benefit assessment during periodic data review meetings, review results from planned interim analyses and provide a formal recommendation for continuation/termination of the study and monitor study conduct to ensure the overall integrity of study was maintained. The DMC was to operate independently of the MAH and Investigators.

## Statistical methods

## Analysis populations

The Full Analysis Set was used for the analysis of all efficacy endpoints and all other endpoints. The Safety Analysis Set was used for the analyses of all safety endpoints. The pharmacokinetic data was analysed in the pharmacokinetic analysis set (PKS).

## Full analysis set (FAS)

All patients who were randomized were included in the FAS, except for cases with critical GCP violations. Following the intent-to-treat principle, the patients in this set were grouped according to the planned treatment they were allocated to receive at randomization, irrespective of actual treatment.

## Safety analysis set (SAF)

All randomized patients who received at least 1 dose of darolutamide or placebo were included in the SAF, except for cases with critical GCP violations. This safety population was used in the analyses of all

<div style=\"page-break-after: always\"></div>

safety endpoints and was included in the analyses according to the treatment they actually received. Patients were included in the darolutamide + docetaxel + ADT arm if they had received any dose of darolutamide and were included in the placebo + docetaxel + ADT arm if they received only placebo.

## Pharmacokinetic Analysis Set (PKS)

At least the first 20 randomized patients who received at least 1 cycle of docetaxel and for whom mandatory dense PK sampling was performed were included in the PKS. These patients received at least 3 days of uninterrupted study drug treatment, as well as one cycle of docetaxel and had at least one post-dose PK measurement, except for cases with critical GCP violations.

## Multiplicity adjustment

If the primary endpoint OS was statistically significant at a 0.025 level (one-sided), the secondary endpoints were to be tested using a hierarchical test procedure in the order below at the same nominal significance level.

- 1) Time to castration-resistant prostate cancer
- 2) Time to pain progression
- 3) Symptomatic skeletal event free survival (SSE-FS)
- 4) Time to first symptomatic skeletal event (SSE)
- 5) Time to initiation of subsequent systemic antineoplastic therapy

6) Time to worsening of disease-related physical symptoms based on functional assessment of cancer therapy / National Comprehensive Cancer Network prostate cancer symptom index 17 item questionnaire (NCCN-FACT FPSI-17)

7) Time to initiation of opioid use for  7 consecutive days

If OS or a secondary endpoint was not statistically significant, the hierarchical procedure was stopped, and all subsequent analyses of the secondary endpoints were to be considered exploratory.

## Interim analysis considerations

As described in the sample size section, a futility IA (not impacting the study type I error) was planned when approximately 153 deaths were observed (information fraction=0.3).  This IA was completed.

A second interim analysis which included a stopping boundary for efficacy calculated based on an alpha-spending function was initially planned but was removed with protocol amendment 7 (26 May 2020) due to the implications of the COVID -19 pandemic on the conduct of study procedures and data collection at the study sites.

As a consequence, no alpha-spending function was used and the final analysis was performed using a one-sided test with a type I error of 0.025.

## Primary endpoint

The primary efficacy endpoint was OS, defined as the time from the date of randomization until death from any cause. The censoring rules for OS are provided below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Situation                                                                                 | End Date                                                                         | Censored   |
|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|------------|
| Documented death during study before or at data cut-off date                              | Death date                                                                       | No         |
| No documented deathwith no contacts afterrandomization and before or at data cut-off date | Date of randomization (Day 1)                                                    | Yes        |
| No documented deathbefore or at data cut-off date                                         | Last known alive date (LKAD) or at the data cut-off date, whichever comesearlier | Yes        |

The last known alive date (LKAD) was derived from the main data sources, i.e. visit dates, exposure information, laboratory measurements, tumor assessment dates, SSE dates, demographics, survival status date, vital signs and disposition events or follow up assessments were used to determine survival status.

The primary analysis of OS was a stratified log-rank test with the same IxRS stratification factors as were used for randomization. The HR (darolutamide or placebo) for OS and its 95% confidence interval (CI) were calculated using the Cox model, stratified by the same factors as were used for randomization. If the p-value from the one-sided log-rank test was less than 0.025 (corresponding to a two-sided log-rank test less than 0.05) with the HR (darolutamide + docetaxel + ADT arm vs. placebo + docetaxel + ADT arm) less than 1, the null hypothesis was rejected in favor of the alternative hypothesis.

Kaplan-Meier (KM) estimates for the median time of OS (including 95% CI) and 25% and 75% percentiles are presented for each treatment arm. KM estimates at time points such as 12 months, 24 months, etc., together with corresponding 95% CIs and the differences of these estimates between the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm were also presented.

## Sensitivity analyses

OS was evaluated with the unstratified log-rank test and Cox model for the FAS population (OS sensitivity analysis 1 -unstratified analysis).

OS was to be also evaluated with the stratified log-rank test and Cox model for the FAS population using stratification factors collected from the eCRF, in case there were more than 5% of patients with different values in any stratification variable between IxRS and eCRF (OS sensitivity analysis 2 -eCRFvariables stratified analysis).

In addition, OS was evaluated with the stratified log-rank test and Cox model for the FAS population using extent of disease stratification factors collected from the central imaging review (OS sensitivity analysis 3 -central imaging review extent of disease as stratification factor).

## Secondary endpoints

All secondary endpoints were time-to-event variables, which were analyzed using a stratified log-rank test with randomization stratification factors using IxRS data. Hazard ratios and 95% CIs were provided using the Cox model stratified by the same factors as were used for randomization.

Median time, 25th and 75th percentiles, and associated 95% CI of KM estimates are presented by treatment arm, as well as the number and percentage of censored observations. KM curves were generated for each treatment arm.

<div style=\"page-break-after: always\"></div>

## Subgroup analyses

Subgroup analyses were conducted for the primary efficacy endpoint OS, based on the FAS population. Descriptive statistics and HR estimates with 95% CI were to be provided for the subgroups listed below, provided that at least 10 total events are observed within the subgroup across the treatment arms. HRs were presented in forest plots. All subgroups analyses were performed using an unstratified Cox model.

- Stratification Factor based on eCRF: Extent of disease (non-regional lymph nodes metastases only, bone metastases with or without lymph node metastases, or visceral metastases with or without lymph node metastases or with or without bone metastases)
- Stratification Factor based on eCRF: ALP at baseline (&lt;ULN, ULN)
- Age category (&lt;65, 65-74, 7584, 85 years)
- Race (White, Asian, Black or African American, Other)
- Geographical region (North America, Asia Pacific, Rest of the World)
- PSA values (&lt;median of overall population, median of overall population) at baseline
- ECOG PS at baseline (0, 1)
- Gleason score (&lt;8, 8) at initial diagnosis
- Metastases at initial diagnosis (Yes: Stage IV-M1, No: Stage I, IIA, IIB, III, IV-M0)

## Subgroup analysis

Subgroup analyses were conducted for the primary efficacy endpoint OS, based on the FAS population. Descriptive statistics and HR estimates with 95% CI were provided for the subgroups, provided that at least 10 total events were observed within the subgroup across both treatment arms. HRs were presented in forest plots. All subgroup analyses were performed using an unstratified Cox model. The number of patients, the number of events, and KM estimates for the median per arm for all planned subgroups were presented in the forest plot.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

- a: 1306 patients were randomized. One patient was excluded from analysis due to a GCP violation (Section 8.2.3).
- C: Docetaxel treatment was administered for only 6 cycles.
- b: ADT was administered throughout the entire study.
- randomized to the placebo+docelaxel arm but received at least one dose of darolutamide. This palient was included in the darolutamide+docetaxel arm in the analysis of all safety variables (Seclion 8.3).
- e: In total, 3 palients were randomized but were never administered study drug. All of these patienls were in the placebo+docetaxel amm.

Figure 13 : ARASENS Study Flow Chart

<div style=\"page-break-after: always\"></div>

Table 27 : Patient disposition at the time of database cut-off (25 OCT 2021) in Study 17777

| Enrolled Discontinued screening                                | 1686  380                         | 1686  380                    |
|----------------------------------------------------------------|-----------------------------------|------------------------------|
|                                                                | Darolutamide+ docetaxel arm N=651 | Placebo+ docetaxel arm N=654 |
| Randomized * (N=1305) (included in FAS)                        | 651 (100.0%)                      | 654 (100.0%)                 |
| Study drug never administered                                  | 0                                 | 3 (0.5%)                     |
| Started study treatment (N=1302) (included in SAF *)           | 651 (100.0%)                      | 651 (99.5%)                  |
| Discontinued study treatment                                   | 352 (54.1%)                       | 526 (80.4%)                  |
| Primary reason:                                                |                                   |                              |
| Progressive disease - clinical progression                     | 127 (19.5%)                       | 272 (41.6%)                  |
| Progressive disease -radiological progression                  | 84 (12.9%)                        | 132 (20.2%)                  |
| Adverse event not associated with clinical disease progression | 48 (7.4%)                         | 27 (4.1%)                    |
| Withdrawal by patient                                          | 25 (3.8%)                         | 35 (5.4%)                    |
| Adverse event associated with clinical disease progression     | 24 (3.7%)                         | 26 (4.0%)                    |
| Non-compliance with study drug                                 | 14 (2.2%)                         | 12 (1.8%)                    |
| Additional primary malignancy                                  | 11 (1.7%)                         | 6 (0.9%)                     |
| Death                                                          | 8 (1.2%)                          | 5 (0.8%)                     |
| COVID-19 related death*                                        | 0                                 | 0                            |
| Lost to follow-up                                              | 4 (0.6%)                          | 1 (0.2%)                     |
| Other                                                          | 3 (0.5%)                          | 4 (0.6%)                     |
| COVID-19 pandemic-related other reason                         | 0                                 | 1 (0.2%)                     |
| Physician decision                                             | 3 (0.5%)                          | 6 (0.9%)                     |
| Prolocol violation                                             | 1 (0.2%)                          | 0                            |
| Ongoing with study treatment (as of the cut-off date)          | 299 (45.9%)                       | 125 (19.1%)                  |
| Entered Active follow-up                                       | 224 (34.4%)                       | 381 (58.3%)                  |
| Completed Active follow-up                                     | 76 (11.7%)                        | 167 (25.5%)                  |
| Discontinued Active follow-up                                  | 133 (20.4%)                       | 185 (28.3%)                  |
| Primary reason:                                                |                                   |                              |
| Death                                                          | 70 (10.8%)                        | 87 (13.3%)                   |
| COVID-19 related death                                         | 1 (0.2%)                          | 0                            |
| Other                                                          | 25 (3.8%)                         | 41 (6.3%)                    |
| COVID-19 pandemic-related other reason                         | 2 (0.3%)                          | 3 (0.5%)                     |
| Withdrawal by patient                                          | 25 (3.8%)                         | 44 (6.7%)                    |
| Progressive disease - clinical progression                     | 8 (1.2%)                          | 8 (1.2%)                     |
| Progressive disease - radiological progression                 | 3 (0.5%)                          | 3 (0.5%)                     |
| Lost to follow-up                                              | 2 (0.3%)                          | 2 (0.3%)                     |
| Ongoing with Active follow-up (as of the cut-off date)         | 15 (2.3%6)                        | 29 (4.4%)                    |
| Entered Survival follow-up                                     | 224 (34.4%)                       | 373 (57.0%)                  |
| Discontinued Survival follow-up                                | 145 (22.3%)                       | 207 (31.7%)                  |
| Primary reason:                                                |                                   |                              |
| Dealh                                                          | 134 (20.6%)                       | 196 (30.0%)                  |
| COVID-19 related dealh                                         | 1 (0.2%)                          | 0                            |
| Withdrawal by patient                                          | 8 (1.2%)                          | 8 (1.2%)                     |
| Lost to follow-up                                              | 3 (0.5%)                          | 3 (0.5%)                     |
| Ongoing with Survival follow-up (as of the cut-off date)       | 79 (12.1%)                        | 166 (25.4%)                  |

COVID-19=Coronavirus disease 2019; FAS=Full analysis set; GCP=Good Clinical Practice; N=Total number of patients; SAF=Safety analysis  set;  TEAEs=Treatment-emergent  adverse  events  a:  A  total  of  122  patients  were  re-screened,  of  which  only  95  were randomized to the study. Re-screened and then randomized patients were only counted once (last enrollment captured). b: Includes all patients who discontinued the screening period for any reason. c: A total of 1306 patients were randomized. One patient was excluded from all analyses due to a GCP violation (Module 5.3.5.1, Report PH-42024, Section 8.2.3)

d: The analysis sets in this table are presented based on the randomized treatment assignment. One patient was randomized to the placebo + docetaxel + ADT arm but received at least 1 dose of darolutamide. This patient was included in the darolutamide + docetaxel + ADT arm in the analysis of all safety variables.

e: Although there were 6 patients with fatal (Grade 5) TEAEs that were related to COVID-19 (Module 5.3.5.1, Report PH-42024, Section  10.3.7),  none  of  these  events  were  reported  by  the  investigator  as  being  the  primary  reason  for  discontinuation  of  the treatment period.

<div style=\"page-break-after: always\"></div>

## Recruitment

1306 patients were randomized (1 patient was excluded from all analyses due to a GCP violation) at 301 study centers in 23 countries/regions: Australia (5 centers), Belgium (7 centers), Brazil (9 centers), Bulgaria (7 centers), Canada (5 centers), China (36 centers), Czech Republic (7 centers), Finland (7 centers), France (17 centers), Germany (11 centers), Israel (8 centers), Italy (9 centers), Japan (45 centers), Mexico (6 centers), Netherlands (8 centers), Poland (6 centers), Russian Federation (10 centers), South Korea (12 centers), Spain (13 centers), Sweden (5 centers), Taiwan (5 centers), UK (8 centers), US (55 centers).

First patient enrolled: 30 November 2016

Last patient first visit: 05 June 2018

Data cut-off date: 25 October 2021

The analyses presented in this report are based on a data cut-off of 25 October 2021.

## Conduct of the study

Protocol amendments:

The global versions of protocol or protocol amendments are presented below:

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Substantial protocol changes:   | Protocol Amendment 1, dated 20 SEP 2016, was valid only for centers located in China. The main modification was: Addition of new China specific pharmacokinetic (PK) sub-study Protocol Amendment 2, dated 04 OCT 2016, was globally implemented. The main modifications were: New drug-drug interaction data added Clarification of PK analysis Patients participating to the detailed PK analysis (dense PK sampling) had received at least one cycle of docetaxel Clarified the timing of the sparse PK sampling Additional analysis of docetaxel in all the randomized patients Addition of non-protein-bound (free) testosterone analysis Protocol Amendment 3, dated 04 NOV 2016, was valid only for centers located in UK. The main modification was: List of acceptable effective contraception methods to be used was added by request of the Medicines and Healthcare Products Regulatory Agency (MHRA) Protocol Amendment 4, dated 31 JAN 2017, was valid only for centers located in Japan. The main modification was: Added reporting requirements for medical device failures for imported and non-approved third-party devices used in Bayer-sponsored clinical trials in Japan to the PMDA, IECs/IRBs and investigators Protocol Amendment 5, dated 12 FEB 2018, was globally implemented. The main modifications were: New drug-drug interaction data added Modification of the dosing language to align darolutamide dosing wording across the development program Clarification of docetaxel dosage and administration in accordance with the label and clarified that the first cycle of docetaxel should be administered within 6 weeks after start of study drug instead of 6 weeks after randomization Guidance on laboratory tests before each docetaxel cycle to be in line with docetaxel label requirements   |
|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Clarification added for the evaluation of soft tissue and visceral lesions; these were to be performed using the same radiological methods and assessed by RECIST criteria ADT switch to LHRH agonist was added to the list of prohibited concomitant medications and treatments and a clarification wasadded to allow an ADT' switch to an antagonist during study treatment Collection of whole blood sample for pharmacogenetics test allowed at other visits if missed at Visit 1 Clarification added for: Unblinding in non-emergency situations was 0 not permitted For PK sampling For laboratory safety assessments Protocol Amendment 6, dated 10 DEC 2019, was globally implemented. The main modifications were: Option to continue darolutamide treatment in a separate program was added for those patients who are ongoing on darolutamide treatment; patients assigned to placebo would discontinue treatment and complete the study Additional survival sweeps were added Detailed information on darolutamide drug-drug interactions was removed and information on the effect of darolutamide on the PK of docetaxel was updated Guidance and cautions for specific drug-drug interactions were removed based on new data on these interactions becoming available AE reporting was modified to clarify that disease progression should not be reported as an AE; only the associated signs and symptoms should be reported as AEs In a subset of patients, additional determination of total and free testosterone was added to be performed also at the EOT Visit Protocol Amendment 7, dated 26 MAY 2020,was globally implemented. The main modifications were: Planned second interim analysis was removed due to the implications of the COVID-19 pandemic on the conduct of study procedures and data collection at the study sites. The risk for not achieving the needed quality of data for a formal analysis at that point in time   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

## Protocol deviation

The number of patients with important protocol deviations in each treatment arm and overall is summarised below.

Table 28 : Important protocol deviations (FAS)

|                                                                      | Protocol Devlatlons Overall             | Protocol Devlatlons Overall        | Protocol Devlatlons Related to COVID-19   | Protocol Devlatlons Related to COVID-19   |
|----------------------------------------------------------------------|-----------------------------------------|------------------------------------|-------------------------------------------|-------------------------------------------|
| Protocol Devlatlon Category                                          | Darolutamlde+ docetaxel arm N=651 n (%) | Placebo+ docetaxel arm N=654 n (%) | Darolutamlde+ docetaxel arm N=651 n (%)   | Placebot docetaxel arm N=654 n (%)        |
| Patientswith any important deviation                                 | 477 (73.3%)                             | 483 (73.9%)                        | 103 (15.8%)                               | 79 (12.1%)                                |
| Procedure deviations                                                 | 370 (56.8%)                             | 373 (57.0%)                        | 103 (15.8%)                               | 78 (11.9%)                                |
| Treatment deviations                                                 | 237 (36.4%)                             | 232 (35.5%)                        | 0                                         | 1 (0.2%)                                  |
| Excluded concomitant medication treatment                            | 34 (5.2%)                               | 53 (8.1%)                          | 0                                         | 1 (0.2%)                                  |
| Withdrawal criteria during treatment phase present but not withdrawn | 47 (7.2%)                               | 26 (4.0%)                          | 0                                         | 1 (0.2%)                                  |
| Inclusion/exclusion criteria not met butsubject entered treatment    | 36 (5.5%)                               | 46 (7.0%)                          | Not applicable                            | Not applicable                            |
| Time schedule deviations                                             | 3 (0.5%)                                | 3 (0.5%)                           | Not applicable                            | Not applicable                            |
| Randomization errors                                                 | 0                                       | 1 (0.2%)                           | Not applicable                            | Not applicable                            |

Abbrevialions: COVID-19=Coronavirus disease 2019; FAS=Full analysis set; N=Total number of palients (100%); n=Number of patients with event

The CoviD-19 pandemic associated imporlant deviations are a subset of the overall important deviations and thus are included in the overall number of patients with imporlant prolocol devialions.

Patients may have had more than one protocol deviation but are only counted once within each devialion category.

## Changes to planned analyses

Several changes to planned analyses were implemented with protocol amendments or revisions to the statistical analysis plan (SAP).

A main update to the analysis plan was introduced with protocol amendment 7 (26 May 2020), which removed the second planned IA. The rationale provided for its removal was the implications of the COVID-19 pandemic for the conduct of study procedures and data collection at the study sites. In

## was considered to be too high

- Clarification added for biomarker analysis and reporting
- Added text regarding ranking of secondary endpoints
- Due to removal of interim analysis 2, the sentence regarding alpha-spending was removed and a statement about beta-spending was added for clarification

Protocol Amendment 8, dated 30 AUG 2021 was valid only for centers located in Japan. The main modifications were:

- To minimize the burden for subjects still enrolled after the study reached primary completion, the number of procedures will be reduced to a minimum, to guarantee patient treatment continuation and safety
- Japanese subjects will be provided the opportunity to continue treatment at the discretion of the investigator

<div style=\"page-break-after: always\"></div>

addition, the secondary endpoints were ranked in a gatekeeping procedure as part of this same amendment.

The removal of the second IA was reflected in the SAP in version 3.0 (26 May 2020). The hierarchical gatekeeping procedure was implemented in version 4.0 (dated 22 September 2021) of the SAP.

With SAP version 4.1 (11 November 2021), a change in the analysis populations was introduced. Patients were to be excluded from all FAS, SAF, and PKS if they were related to or associated with any critical GCP violations that result in fraudulent patient data. After detection of issues with investigator fraud at one site, it was decided to exclude one affected patient from all analysis sets as these data could not be trusted.

Post-hoc analyses were described in a SAP supplement (version 1.0, 4 February 2022), which included a set of additional sensitivity analyses for the primary and secondary endpoints: OS by 6 cycles versus 5 and less cycles, OS by 6 and 5 cycles versus 4 and less cycles, OS including one patient with violation of GCP (based on all randomized patients), time to pain progression based on unconfirmed pain progression as event, time to pain progression based on 4 or more points increase in WPS score.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 29 : Summary of Key Demographic and Baseline Characteristics (FAS)

|                                                           | Darolutamlde+ docetaxel arm N=651 (100%%)   | Placebo+ docetaxel arm N=654 (100%6)   |
|-----------------------------------------------------------|---------------------------------------------|----------------------------------------|
| Age (yeare)                                               |                                             |                                        |
| Mean (S10)                                                | 66.7 (7.9)                                  | 67.0 (7.8)                             |
| Madlan (Min, Man)                                         | 67.0 (41.89)                                | 67.0 (42.86)                           |
| Age group (yeare]. n (96)                                 |                                             |                                        |
| -65                                                       | 243 (37.396)                                | 234 (35.896)                           |
| 65-74                                                     | 303 (46.516)                                | 306 (46.896)                           |
| 75-84                                                     | 102 (15.796)                                | 110 (16.8%6)                           |
| 583                                                       | 3 (0.596)                                   | 4 (0.696)                              |
| Race, n (96)                                              |                                             |                                        |
| Whlle                                                     | 345 (53.096)                                | 333 (50.996)                           |
| Black or Aimlean Amerlcan                                 | 26 [4.0%8)                                  | 28 (4.396)                             |
| Aslan                                                     | 230 (35.396)                                | 245 (37.596)                           |
| Other.                                                    | 7 (1.156)                                   | 2 (0.396)                              |
| Not reported                                              | 43 (6.616)                                  | 46 (7.016)                             |
| Ethnlcity. n (9%)                                         |                                             |                                        |
| Hlepanlc or Latino                                        | 40 (6.1%6)                                  | 49 (7.5%6)                             |
| Not Hlspanle or Lalino                                    | 561 (86.2%6)                                | 557 (85.296)                           |
| Not reported                                              | 50 (7.796)                                  | 48 (7.356)                             |
| Geographlcal reglon, n (6)                                |                                             |                                        |
| North Amerca                                              | 125 (19.296)                                | 119 (18.2%)                            |
| Asla Paclile                                              | 229 (35.216)                                | 244 (37.396)                           |
| Rest ol the Word (Row)                                    | 297 (45.696)                                | 291 (44.596)                           |
| Body maea Index group (kgim]. n (%6)                     |                                             |                                        |
| -20                                                       | 45 (6.916)                                  | 34 (5.296)                             |
| 20--25                                                    | 254 (39.096)                                | 248 (37.996)                           |
| 25---30                                                   | 240 (36.996)                                | 254 (38.896)                           |
| 230                                                       | 108 (16.6%6)                                | 116 (17.79%)                           |
| Mlsslng                                                   | 4 (0.616)                                   | 2(0.356)                               |
| Renal functlon - eGFR at baaellne (mLimln)                |                                             |                                        |
| Nomal                                                     | 375 (57.696)                                | 365 (55.896)                           |
| Mlld Impalment                                            | 236 (36.396)                                | 235 (35.996)                           |
| Moderate Impslrment                                       | 39 (6.0%6)                                  | 53 (6.196)                             |
| Severe Impalment e                                        | 1 (0.296)                                   |                                        |
| Mlsslng                                                   | D                                           | 1 (0.2%6)                              |
| Hepatlc funcilon at baeellne d                            |                                             |                                        |
| Nomal                                                     | 597 (91.7%6)                                | 593 (90.796)                           |
| Mlld Impalrment                                           | 49 (7.516)                                  | 52 (8.016)                             |
| Moderate Impalrment                                       | 2 (0.396)                                   | D                                      |
| Mlsslng                                                   | 3 (0.516)                                   | 9(1.456)                               |
| Extent ot metastatlc dlaease at study entry               |                                             |                                        |
| (eCRF). n (%)                                             |                                             |                                        |
| Mia: Non-reglonal lymph nodes only                        | 23 (3.5%8)                                  | 16 (2.496)                             |
| Mib: Bone with or wlthout lymph nodes                     | 517 (79.496)                                | 520 (79.596)                           |
| Mie: Vlsceral wlth or wlthout lymph nodes or bone         | 111 (17.15%)                                | 118 (18.0%)                            |
| ALP at baaellne (central laboratory': eCRF) (uIL). n (%%) |                                             |                                        |
| ALP :ULN                                                  | 290 [44.596)                                | 291 (44.596)                           |
| ALP2ULN                                                   | 361 (55.516)                                | 363 (55.596)                           |
| Stage of proatate cancer at Inltlal dlagnoala             |                                             |                                        |
| TNM clagalmcatlonj. n (99)                                |                                             |                                        |
| siage1                                                    | 12 (1.8%:)                                  | 10 (1.596)                             |
| Sage IIA                                                  | 18 (2.8%)                                   | 10 (1.556)                             |
| Slage 11B                                                 | 15 (2.316)                                  | 10 (1.516)                             |
| stage Ill                                                 | 36 (5.516)                                  | 38 (5.816)                             |
| Stage IV                                                  | 563(86.596)                                 | 580 (08.796)                           |
| siage IV. MO                                              | 5 (0.896)                                   | 14 (2.196)                             |
| slage IV, M1 Mlesing                                      | 558 (85.796) 7 (1.15%)                      | 566 (86.596) 6 (0.996)                 |

<div style=\"page-break-after: always\"></div>

|                                                          | Darolutamide+ docetaxelarm N=651(100%)   | Placebo+ docetaxel arm N=654(100%)   |
|----------------------------------------------------------|------------------------------------------|--------------------------------------|
| Gleasonscore atinitial diagnosis ofprostate cancer,n (%) |                                          |                                      |
| 8                                                        | 122 (18.7%)                              | 118 (18.0%)                          |
|                                                          | 505 (77.6%)                              | 516 (78.9%)                          |
| Mssing                                                   | 24 (3.7%)                                | 20 (3.1%)                            |
| PSA at baseline (central laboratory) (ng/mL)             |                                          |                                      |
| n                                                        | 651                                      | 653                                  |
| Mean(SID)                                                | 248.47 (714.08)                          | 204.71 (742.54)                      |
| Median (Min,Max)                                         | 30.30(0.0,9219.0)                        | 24.20(0.0,11947.0)                   |
| Missing ECOG Performance Status,n (%)                    | 0                                        | 1                                    |
| 0                                                        | 466 (71.6%)                              | 482(70.8%)                           |
| 1                                                        | 185(28.4%)                               | 190 (29.1%)                          |
| Missing                                                  | 0                                        | 2(0.3%)                              |
| Testosterone atbaseline(central laboratory)(ng/mL)       |                                          |                                      |
| 0.5                                                      | 339(52.1%)                               | 353(54.0%)                           |
| 20.5                                                     | 309 (47.5%)                              | 296 (45.3%)                          |
| Missing                                                  | 3(0.5%)                                  | 5(0.8%)                              |

eCRF=Electroniccase report formeGFR=Estimated glomerular fitration rate,ECOG=Eastem Cooperative Oncology Group.FAS=Ful analyssset,Max=MaximumcMin=Minimum;N=Total numberofpatients(1oo%];n=Number of patients wi event; PSA=Prostate-speoiic anigen; SsD=Standard deviaton; TNM=Tumor, Node,Metastasis;U/L=Unit per lter, ULN=UpperHmit ofnommal a:Race'Othe IncludesAmenican Indan or Alaska Narive,Native Hawalan or other Pacific IsanderandMuliple

b:Renal function:nommal:eGFR90mLmin;mid impaiment 60seGFR90 mL/minmoderate impainment30seGFR60 mLimin,severeimpaiment15seGFR30mLimin

C1patent wih severe renal impament at baseline waseligiblebased on a serum creatinine level belows2.0xULN.

bliubin ULN and ASTsUUN,moderateimpament:Total binubin&gt;1.5 to3xULN,anyAST

e:For 2patients (1 in the darolutamide+docetac arm and the other in the placebo+dooetacl arm).cental laboratory ALP valueswere not avaiable at baseline and the ocal iaboratoryALPvaueswere selected as baseine nstead

Note: Data collection for race and ethnicity was not allowed in some countries (eg. France) due to local regulations.

Table 30 : Prior local treatment for prostate cancer at study entry in Study 17777 (FAS

| Number of patients (%)                     | Darolutamide+ docetaxelarm N=651 n (%)   | Placebo+ docetaxel arm N=654 n (%)   |
|--------------------------------------------|------------------------------------------|--------------------------------------|
| Status of primary tumor at study entry     |                                          |                                      |
| Primary tumor unresected                   | 572 (87.9%)                              | 582 (89.0%)                          |
| Prostatectomy                              | 44 (6.8%)                                | 42 (6.4%)                            |
| Surgery (not further specified)            | 31 (4.8%)                                | 21 (3.2%)                            |
| TURP                                       | 8 (1.2%)                                 | 7 (1.1%)                             |
| Other                                      | 4 (0.6%)                                 | 3 (0.5%)                             |
| Radiation                                  | 28 (4.3%)                                | 22 (3.4%)                            |
| No surgery (prostatectomy) and noradiation | 546 (83.9%)                              | 566 (86.5%)                          |

FAS=Full analysis set; N=Total number of patients; n=Number of patients with event; TURP=Transurethral resection of the prostate

<div style=\"page-break-after: always\"></div>

Table 31: Anti-hormonal therapy and orchiectomy at study entry in Study 17777 (FAS)

|                                              | Darolutamlde+ docetaxel arm N=651 n (%)   | Placebo+ docetaxel arm N=654 n (%)   |
|----------------------------------------------|-------------------------------------------|--------------------------------------|
| Number (%) of patlents with at least one ADT | 651 (100.0%)                              | 652 (99.7%)                          |
| LHRH agonist/antagonist only                 | 635 (97.5%)                               | 635 (97.1%)                          |
| Orchiectomy only                             | 11 (1.7%)                                 | 12 (1.8%)                            |
| LHRH agonist/antagonist and orchiectomy      | 5 (0.8%)                                  | 5(0.8%)                              |

analysis set; LHRH=Luteinizing hormone-releasing homone; N=Total number of patients (1oo%): n=Number of palientswithevent

Medications or procedures taken before the start of darolutamide/placebo are included in this table. ADT was defined by ATC c0des: L02BX, L02BB, H01CC, V98, G03HB, L02AE, H01CA.

a: Twopatients in theplacebo+docetaxel arm were not counted toward thepatientswithprior ADT treatment. One of these patients began ADT treatment on the same day of the first study drug administration and therefore, the ADT treatment was captured as a concomitant medication. The other patient had prior ADT incorrectly reported in the database as of the cut-off date, which was corrected and is captured in the

## Numbers analysed

The FAS included all patients randomized to receive darolutamide + docetaxel + ADT (651 patients) and placebo + docetaxel + ADT (654 patients).

## Outcomes and estimation

## Primary variables

At the time of the database cut-off date for the primary completion analysis (25 OCT 2021), a total of 533 OS events had occurred, with 229 deaths (35.2% of patients) in the darolutamide + docetaxel + ADT arm and 304 deaths (46.5% of patients) in the placebo + docetaxel + ADT arm.

The median follow-up time from randomisation to the last contact or death was 43.7 months in the darolutamide + docetaxel + ADT arm and 42.4 months in the placebo + docetaxel + ADT arm.

<div style=\"page-break-after: always\"></div>

Table 32 : ARASENS: Overall survival in Study 17777 (FAS)

|                                                    | Darolutamide+ docetaxel arm N=651   | Placebo+ docetaxel arm N=654   |
|----------------------------------------------------|-------------------------------------|--------------------------------|
| Number (%) of patients with event                  | 229 (35.2%)                         | 304 (46.5%)                    |
| Number (%) of patients censored                    | 422 (64.8%)                         | 350 (53.5%)                    |
| OS (months)                                        |                                     |                                |
| Median [95% Cl]                                    | A[A; A]                             | 48.9 [44.4; A]                 |
| Range (including censored values)                  | 0.6-56.5**                          | 0.1**-58.0**                   |
| 12-month survival rate [95% Cl]                    | 0.949 [0.932; 0.966]                | 0.903 [0.880; 0.925]           |
| 24-month survival rate [95% Cl]                    | 0.831 [0.802; 0.860]                | 0.768 [0.735; 0.801]           |
| 36-month survival rate [95% Cl]                    | 0.723 [0.688; 0.758]                | 0.638 [0.601; 0.676]           |
| 48-month survival rate [95% Cl]                    | 0.627 [0.587; 0.667]                | 0.504 [0.463; 0.546]           |
| Hazard ralio: (darolutamide vs. placebo) [95% Cl]* | 0.675 [0.568; 0.801]                | 0.675 [0.568; 0.801]           |
| One-sided p-value from stratified log-rank test    | <0.0001                             | <0.0001                        |

ALP=Alkaline phosphatase; Cl=Confidence interval; FAS=Full analysis set; M1a/M1b/M1c=classification of metastatic disease; N=Total number of patients (100%); OS=Overall survival; ULN=Upper limit of normal I* Censored observallon; A=Value cannot be estimated due to censored data.

- a: A hazard ratio &lt;1 Indicates superiorily of the darolutamide+docelaxel arm over the placebo+docetaxel arm. The hazard ratio and 95% Cl were based on a Cox regression model, stratified by extent of disease (M1a vs. M1b vs. M1c) and ALP (&lt;ULN vS. 2ULN).
- Medlan, percentile and other 95% Cls were computed using Kaplan-Meler estimates.

<!-- image -->

FAS=Full analysis set

At-risk patlent counts were calculated as at start of timepolnt.

Figure 14 : Kaplan-Meier curves of overall survival in Study 17777 (FAS)

<div style=\"page-break-after: always\"></div>

## Key secondary endpoint

##  Time to castration-resistant prostate cancer

Table 33 : Time to castration-resistant prostate cancer (FAS)

|                                                                | Darolutamide+ docetaxel arm N=651   | Placebo+ docetaxel arm N=654   |
|----------------------------------------------------------------|-------------------------------------|--------------------------------|
| Number (%) of patients with event                              | 225 (34.6%)                         | 391 (59.8%)                    |
| PSA progressiona                                               | 121/225(53.8%)                      | 289/391 (73.9%)                |
| Radiological progression by bone leslons a                     | 53/225 (23.6%)                      | 53/391 (13.6%)                 |
| Radlological progression by soft tissue and visceral leslons * | 51/225 (22.7%)                      | 49/391 (12.5%)                 |
| Number (%) of patients censored                                | 426 (65.4%)                         | 263 (40.2%)                    |
| Time to CRPC (months)                                          |                                     |                                |
| Median [95% Cl]                                                | A [A; A]                            | 19.1 [16.5; 21.8]              |
| Range (including censored values)                              | (0.03**56.2**)                      | (0.03**55.6**)                 |
| Hazard ratio: (darolutamide vs. placebo) [95% Cl] b            | 0.357 [0.302; 0.421]                | 0.357 [0.302; 0.421]           |
| One-sided p-valuefrom stratified log-rank test                 | 0.0001                              | 0.0001                         |

Abbreviations: ALP=Alkaline phosphatase; Cl=Confidence interval; CRPC=Castration-resistant prostate cancer; FAS=Full analysis set; M1a/M1b/M1c=classification of metastatic disease; N=Total number of patients (100%); PCWG3=Prostate Cancer Working Group 3; PSA=Prostate-specific antigen; RECIST v1.1=Response evaluation criteria in solid tumors version 1.1; ULN=Upper limit of nomal

** Censored observation. A=Value cannot be estimated due to censored data.

- a:Percentages by treatment arm are based on the number of patients with time to castration-resistant prostate cancer events. component events occurred on the same date for one patient, the patient was only counted in one category in the order of: radiological soft tissue/visceral lesion progression &gt; radiological bone progression &gt; PSA progression.
- b: A hazard ratio &lt;1 indicates superiority of the darolutamide+docetaxel arm over the placebo+docetaxel arm. The hazard ratio and 95% Cl were based on a Cox Regresslon Model, stratified by extent of disease (M1a vs. M1b vs. M1c) and ALP (&lt;ULN vS. ULN).

Median, percentile and other 95% Cls were computed using Kaplan-Meier estimates. Note: PSA progression and radiological progression by bone lesions were determined according to PCWG3 criteria.

<!-- image -->

Abbreviations:FAS=Fullanalysisset

At-riskpatientcountswerecalculatedasatstartoftimepoint.

Figure 15 : Kaplan-Meier curves of time to castration-resistant prostate cancer (FAS)

<div style=\"page-break-after: always\"></div>

##  Time to pain progression

Table 34 : Time to pain progression (FAS)

|                                               | Darolutamide+ docetaxelarm N=651   | Placebo+ docetaxelarm N=654   |
|-----------------------------------------------|------------------------------------|-------------------------------|
| Number(%)of patients with event               | 222 (34.1%)                        | 248 (37.9%)                   |
| Number(%)ofpatientscensored                   | 429 (65.9%)                        | 406 (62.1%)                   |
| Time to pain progression (months)             |                                    |                               |
| Median[95%CI]                                 | A [30.5; A]                        | 27.5 [22.0; 36.1]             |
| Range(includingcensoredvalues)                | (0.03-55.0**)                      | (0.03-52.4**)                 |
| Hazardratio:(darolutamide vs.placebo)[95%Cl]a | 0.792 [0.660; 0.950]               | 0.792 [0.660; 0.950]          |
| One-sidedp-valuefromstratifiedlog-ranktest    | 0.0058                             | 0.0058                        |

Median,percentileandother95%ClswerecomputedusingKaplan-Meierestimates.

Figure 16: Kaplan-Meier curves of time to pain progression (FAS)

<!-- image -->

<div style=\"page-break-after: always\"></div>

##  SSE-FS

Table 35 : Symptomatic skeletal event-free survival (FAS)

|                                                 | Darolutamide+ docetaxel arm N=651   | Placebo+ docetaxel arm N=654   |
|-------------------------------------------------|-------------------------------------|--------------------------------|
| Number(%) of patients with event                | 257 (39.5%)                         | 329 (50.3%)                    |
| Dealh*                                          | 162/257 (63.0%)                     | 221/329 (67.2%)                |
| EBRT to relieve skeletal symptoms a             | 60/257 (23.3%)                      | 89/329 (27.1%)                 |
| New symptomaticpathologicbone fracture ?        | 17/257 (6.6%)                       | 8/329 (2.4%)                   |
| Spinal cord compression                         | 14/257 (5.4%)                       | 9/329 (2.7%)                   |
| Tumor-related orthopedicsurgical interventiona  | 4/257 (1.6%)                        | 2/329 (0.6%)                   |
| Number(%) of patients censored                  | 394 (60.5%)                         | 325 (49.7%)                    |
| SSE-FS(months)                                  |                                     |                                |
| Median[95% Cl]                                  | 51.2 [47.2; A]                      | 39.7 [36.0; 42.3]              |
| Range (including censored values)               | (0.03**55.5**)                      | (0.03-55.6**)                  |
| Hazardratio:(darolutamide vs.placebo) [95% Cl]b | 0.609 [0.516; 0.718]                | 0.609 [0.516; 0.718]           |
| One-sided p-valuefromstratified log-ranktest    | <0.0001                             | <0.0001                        |

- Abbreviations:ALP=Alkalinephosphatase;CI=Confidenceinterval;EBRT=Extemalbeamradiationtherapy;FAS=Full analysisset;M1a/M1b/M1c=classificationofmetastaticdisease;N=Totalnumberofpatients(100%):SSEFS=Symptomaticskeletalevent-freesurvival;ULN=Upperlimitofnormal
- a:Percentages arebased on the total numberof patientswith anSSE-FSevent ineach treatment arm.Patientswith multipleeventswereonlycountedforthecategoryinwhichthefirsteventoccurred.IfmultipleSSEs(component events)occurredonthesamedateforonepatient,thepatientwasonlycountedinonecategoryintheorderof:spinal
- **Censored observation.A=Value cannot be estimated due to censored data.
- b:Ahazardratio&lt;1indicatessuperiorityofthedarolutamide+docetaxel armovertheplacebo+docetaxel am.Thehazard ratioand95%ClwerebasedonaCoxRegressionModel,stratifiedbyextentofdisease(M1avs.M1bvs.M1c)and ALP (&lt;ULN vS. ULN).

Median,percentileandother95%ClswerecomputedusingKaplan-Meierestimates.

<!-- image -->

Abbreviations:FAS=Full analysisset:SSE-FS=Symptomaticskeletal event-free survival At-riskpatientcountswerecalculatedasatstartof timepoint.

Figure 17 : Kaplan-Meier curves of SSE-FS (FAS)

<div style=\"page-break-after: always\"></div>

##  Time to first SSE

|                                                     | Darolutamide+ docetaxel arm N=651   | Placebo+ docetaxel arm N=654   |
|-----------------------------------------------------|-------------------------------------|--------------------------------|
| Number (%) of patients with event                   | 95 (14.6%)                          | 108 (16.5%)                    |
| Extermal beam radiation therapy *                   | 60/95 (63.2%)                       | 89/108 (82.4%)                 |
| Symptomatic pathologic bone fracture a              | 17/95 (17.9%)                       | 8/108 (7.4%)                   |
| Spinal cord compression a                           | 14/95 (14.7%)                       | 9/108 (8.3%)                   |
| Tumor-related orthopedic surgical intervention *    | 4/95 (4.2%)                         | 2/108 (1.9%)                   |
| Number (%) of patients censored                     | 556 (85.4%)                         | 546 (83.5%)                    |
| Time to first SSE (months)                          |                                     |                                |
| Median [95% Cl]                                     | A[A; A]                             | A[A; A]                        |
| Range (including censored values)                   | (0.03**55.5**)                      | (0.03-55.6**)                  |
| Hazard ralio: (darolutamlde vs. placebo) [95% Cl] b | 0.712 [0.539; 0.940]                | 0.712 [0.539; 0.940]           |
| One-sided p-value from stratified log-rank test     | 0.0081                              | 0.0081                         |

Abbreviations:ALP=Alkaline phosphatase; Cl=Confidence interval; EBRT=Extemal beam radiation therapy; FAS=Full analysis set; M1a/M1b/M1c=classification of metastatic disease; N=Total number of patients (100%); SSE=Symptomatic skeletal event; ULN=Upper limit of nomal

- ** Censored observation. A=Value cannot be estimated due to censored data.
- a: Percentages are from the number of patients with an SSE in each treatment arm. Patients with multiple events were only counted for the category in which the first event occurred. If multiple SSEs (component events) occurred on the same date for one patient, the patient was only counted in one category in the order of: spinal cord compression &gt; bone fracture &gt; orthopedic surgery &gt; EBRT.
- b: A hazard ratio &lt;1 indicates superiority of the darolutamide+docetaxel arm over the placebo+docetaxel arm. The hazard ratio and 95% Cl were based on a Cox Regression Model, stratified by extent of disease (M1a vs. M1b vs. M1c) and ALP (ULN vS. 2ULN).

Median, percentile and other 95% Cls were computed using Kaplan-Meier estimates.

Figure 18 : Time to first symptomatic skeletal event (FAS)

<!-- image -->

Abbreviations:FAS=Fullanalysis set;SSE=Symptomaticskeletal event At-riskpatientcountswerecalculatedasatstartof timepoint.

Figure 19 : Kaplan-Meier curves of time to first SSE (FAS)

<div style=\"page-break-after: always\"></div>

##  Time to initiation of subsequent systemic antineoplastic therapy

Table 36 : Time to initiation of subsequent systemic antineoplastic therapy (FAS)

|                                                                           | Darolutamide+ docetaxel arm N=651   | Placebo+ docetaxel arm N=654   |
|---------------------------------------------------------------------------|-------------------------------------|--------------------------------|
| Number (%) of patients with event                                         | 219 (33.6%)                         | 395 (60.4%)                    |
| Number (%) of patients censored                                           | 432 (66.4%)                         | 259 (39.6%)                    |
| Time to Initiation of subsequent systemic antineoplastic therapy (months) |                                     |                                |
| Median [95% Cl]                                                           | A [A; A]                            | 25.3 [23.1; 28.8]              |
| Range (Iincluding censored values)                                        | (0.256.5**)                         | (0.1**55.7**)                  |
| Hazard ratio: (darolutamide vs. placebo) [95% Cl]                         | 0.388 [0.328; 0.458]                | 0.388 [0.328; 0.458]           |
| One-slded p-value from stratified log-rank test                           | 0.0001                             | 0.0001                        |

Median, percentile and other 95% Cls were computed using Kaplan-Meier estimates.

<!-- image -->

FAS=Full analysis set

At-risk patient counts were calculated as at start of timepoint.

Figure 20 : Kaplan-Meier curves of time to initiation of subsequent systemic antineoplastic therapy in Study 17777 (FAS)

<div style=\"page-break-after: always\"></div>

Table 37 : Summary of first subsequent systemic antineoplastic therapy after randomization by preferred drug name based on WHO-DD drug record number (full analysis set)

| Prcferred drug name(s) WHO-DD Version 2021SEP                               | Darolutamide+docetaxelarm N=651 (100%)   | Placebo+docetaxel arm N=654 (100%)   | Total N=1305 (100%)   |
|-----------------------------------------------------------------------------|------------------------------------------|--------------------------------------|-----------------------|
| Number (%) of patient with first systemic subsequent antineoplastic therapy | 219 ( 33.6%)                             | 395 ( 60.4%)                         | 614 ( 47.0%)          |
| ABIRATERONE, ABIRATERONE ACETATE                                            | 77 ( 11.8%)                              | 178 ( 27.2%)                         | 255 ( 19.5%)          |
| ENZALUTAMIDE                                                                | 25( 3.8%)                                | 83 (12.7%)                           | 108( 8.3%)            |
| BICALUTAMIDE                                                                | 27( 4.1%)                                | 45 6.9%)                            | 72( 5.5%)             |
| DOCETAXEL                                                                   | 25 ( 3.8%)                               | 36 ( 5.5%)                           | 61( 4.7%)             |
| CABAZITAXEL,CABAZITAXELACETONE                                              | 24( 3.7%)                                | 26 ( 4.0%)                           | 50( 3.8%)             |
| CARBOPLATIN                                                                 | 17( 2.6%)                                | 5( 0.8%)                             | 22( 1.7%)             |
| ETOPOSIDE                                                                   | 12 ( 1.8%)                               | 2( 0.3%)                             | 14 ( 1.1%)            |
| RADIUM RA 223 DICHLORIDE                                                    | 8( 1.2%)                                 | 5( 0.8%)                             | 13 ( 1.0%)            |
| SIPULEUCEL-T                                                                | 4( 0.6%)                                 | 7 1.1%)                              | 11 ( 0.8%)            |
| CISPLATIN                                                                   | 6( 0.9%)                                 | 4( 0.6%)                             | 10( 0.8%)             |
| FLUTAMIDE                                                                   | 1 0.2%)                                  | 3 0.5%)                              | 4 0.3%)               |
| PEMBROLIZUMAB                                                               | 2 0.3%)                                  | 0.3%)                                | 4 0.3%)               |
| ATEZOLIZUMAB                                                                | 3 0.5%)                                  | 0                                    | 3( 0.2%)              |
| INVESTIGATIONAL DRUG                                                        | 0                                        | 3 0.5%)                              | 3( 0.2%)              |
| LUTETIUM (LU 177)                                                           | 1 0.2%)                                  | 0.3%)                                | 3( 0.2%)              |
| PACLITAXEL,PACLITAXEL ALBUMIN                                               | 2 0.3%)                                  | 1 0.2%)                              | 3( 0.2%)              |
| ANTINEOPLASTICAGENTS                                                        | 1 0.2%)                                  | 1 0.2%)                              | 2( 0.2%)              |
| ESTRAMUSTINE, ESTRAMUSTINE PHOSPHATE                                        | 0                                        | 2 0.3%)                              | 2( 0.2%)              |
| ETHINYLESTRADIOL                                                            | 0                                        | 2 0.3%)                              | 2( 0.2%)              |
| OLAPARIB                                                                    | 0.2%)                                    | 0.2%)                                | 2 0.2%)               |
| APALUTAMIDE                                                                 | 1 0.2%)                                  | 0                                    | <0.1%)                |
| BLINDEDTHERAPY                                                              | 0                                        | 0.2%)                                | <0.1%)                |
| CATEQUENTINIBHYDROCHLORIDE                                                  | 0                                        | 0.2%)                                | <0.1%)                |
| DIETHYLSTILBESTROL                                                          | 0                                        | 0.2%)                                | <0.1%)                |
| GEMCITABINE                                                                 | 0.2%)                                    | 0                                    | <0.1%)                |
| GIMERACIL;OTERACIL POTASSIUM;TEGAFUR                                        | 1 0.2%)                                  | 0                                    | 1 (<0.1%)            |
| METHOTREXATE                                                                | 0.2%)                                    | 0                                    | <0.1%)                |
| MITOXANTRONE                                                                | 0.2%)                                    | 0                                    | <0.1%)                |
| NIVOLUMAB                                                                   | 0                                        | 1 0.2%)                              | <0.1%)                |
| RITUXIMAB                                                                   | 0.2%)                                    | 0                                    | <0.1%)                |
| SORAFENIB TOSILATE                                                          | 0.2%)                                    | 0                                    | 1 ( <0.1%)            |
| TALAZOPARIB                                                                 | 0                                        | 1( 0.2%)                             | 1 (<0.1%)             |

Note: Multiple subsequent systemic antineoplastic therapies for prostate cancer could occur on the same date, so a patient may be counted in more than one therapy. The medicalions summarized in this table are all after randomization.

Different Preferred drug namcs listed under the same WHO-DD drug record number were combined.

Patients with additional primary malignancies that reccived as subsequent systemic antineoplastic therapy for the additional primary malignancy are included in this table. Preferred drug name is defined based on WHO-DD drug number, sequence #1 and sequence #2=001'

Note: 13 patients started systemic antineoplastic medications during the treatment period are included.

Bayer:/var/swan/root/bhc/1841788/17777/stat/main01/prod/analysis/pgms/t 14 2 2 s21 adcm\\_adtte\\_isat.sas 07JAN2022 11:25 End of table

##  Time to worsening of disease-related physical symptoms

Table 38 : Time to worsening of disease-related physical symptoms (FAS)

|                                                                 | Darolutamide+ docetaxel arm N=651   | Placebot docetaxel arm N=654   |
|-----------------------------------------------------------------|-------------------------------------|--------------------------------|
| Number (%) of patients with event                               | 351 (53.9%)                         | 308 (47.1%)                    |
| Number (%) of patlents censored                                 | 300 (46.1%)                         | 346 (52.9%)                    |
| Tlme to worsening of disease-related physical symptoms (months) |                                     |                                |
| Median [95% CI]                                                 | 19.3 [13.8; 24.8]                   | 19.4 [15.4; 27.6]              |
| Range (including censored values)                               | (0.03**52.8**)                      | (0.03**-52.5**)                |
| Hazard ratio: (darolutamide vs. placebo) [95% Cl]a              | 1.043 [0.894; 1.217]                | 1.043 [0.894; 1.217]           |
| One-sided p-value from stratified log-rank test                 | 0.7073                              | 0.7073                         |

Median, percentile and other 95% Cls were computed using Kaplan-Meier estimates.

<div style=\"page-break-after: always\"></div>

<!-- image -->

At-riskpatientcountswerecalculatedasatstartof timepoint.

Figure 21 : Kaplan-Meier curves of time to worsening of disease-related physical symptoms (FAS)

##  Time to initiation of opioid use for 7 consecutive days

Table 39 : Time to initiation of opioid use for 7 consecutive days (FAS)

|                                                                                   | Darolutamide+ docetaxel arm N=651   | Placebo+ docetaxel arm N=654   |
|-----------------------------------------------------------------------------------|-------------------------------------|--------------------------------|
| Number (%) of patients with event                                                 | 92 (14.1%)                          | 117 (17.9%)                    |
| Number (%) of patients censored                                                   | 559 (85.9%)                         | 537 (82.1%)                    |
| Time (months) to initiation of oplold use for 27 consecutive days Median [95% Cl] | A [A; A]                            | A[A; A]                        |
| Range (including censored values)                                                 | (0.03**55.5**)                      | (0.03-55.6**)                  |
| Hazard ratio: (darolutamide vs. placebo) [95% Cl]*                                | 0.688 [0.523; 0.906]                | 0.688 [0.523; 0.906]           |
| One-sided p-value from stratified log-rank test                                   | 0.0037                              | 0.0037                         |

Median, percentile and other 95% Cls were computed using Kaplan-Meier estimates.

<div style=\"page-break-after: always\"></div>

<!-- image -->

At-riskpatientcountswerecalculated asatstartof timepoint.

Figure 22 : KaplanMeier curves of time to initiation of opioid use for 7 consecutive days (FAS)

## Exploratory secondary endpoints

##  Time to PSA Progression

Table 40 : Time to PSA progression according to PCWG3 (FAS)

|                                                    | Darolutamide+ docetaxel arm N=651   | Placebo+ docetaxel arm N=654   |
|----------------------------------------------------|-------------------------------------|--------------------------------|
| Number (%) of patients with event                  | 136 (20.9%)                         | 310 (47.4%)                    |
| Number (%) of patients censored                    | 515 (79.1%)                         | 344 (52.6%)                    |
| Time to PSA progresslon (months)                   |                                     |                                |
| Median [95% Cl]                                    | A [A; A]                            | 22.4 [22.1; 27.6]              |
| Range (including censored values)                  | (0.03**55.5**)                      | (0.03**-55.6**)                |
| Hazard ratio: (darolutamide vs. placebo) [95% Cl]* | 0.255 [0.208; 0.313]                | 0.255 [0.208; 0.313]           |
| One-sided p-value from stratified log-rank test    | <0.0001                             | <0.0001                        |

Median, percentile and other 95% Cls were computed using Kaplan-Meier estimates.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations:FAS=FullanalysissetPCWG3=ProstateCancerClinical TrialsWorking Group3;PSA=Prostate-specificantigen At-riskpatientcountswerecalculatedasatstartoftimepoint.

Figure 23 : Kaplan-Meier curves of time to PSA progression according to PCWG3

##  PSA Response

Table 41: Maximum percent decline in PSA from baseline at any time on study (FAS)

| Maximum decline in PSAfrombaseline   | Darolutamide+ docetaxel arm N=651   | Placebo+ docetaxel arm N=654   |
|--------------------------------------|-------------------------------------|--------------------------------|
| No decline a                         | 8 (1.2%)                            | 22 (3.4%)                      |
| <30%                                 | 1 (0.2%)                            | 11 (1.7%)                      |
| 230%and50%                           | 5 (0.8%)                            | 19 (2.9%)                      |
| %06>pue %092                         | 44 (6.8%)                           | 135 (20.6%)                    |
| 290%                                 | 577 (88.6%)                         | 449 (68.7%)                    |
| Missing b                            | 16 (2.5%)                           | 17 (2.6%)                      |

Abbreviations: FAS=Full analysis set; N=Total number of patients (100%); PSA=Prostate-specific antigen

Note: Only patients with PSA not missing at baseline are included in this table.

a:A negative percent indicates a decline in PSA,whereas a positive percent indicates that the patients never had a decline in PSA.

b:Nopost baseline value.

Table 42 : PSA response rates (FAS)

|                                                                | Darolutamide+ docetaxel arm N=651   | Darolutamide+ docetaxel arm N=651   | Placebo+ docetaxel arm N=654   | Placebo+ docetaxel arm N=654   |
|----------------------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------------|--------------------------------|
| Absolute PSA response rate (PSA level 0.2 ng/mL)a             | n (%)                               | [95% CI]                            | n (%)                          | [95% CI]                       |
| At 6monthsfrom randomization                                   | 317 (48.7%)                         | [44.8%; 52.6%]                      | 156 (23.9%)                    | [20.6%; 27.3%]                 |
| At 12 months from randomlzation                                | 392 (60.2%)                         | [56.3%; 64.0%]                      | 171 (26.1%)                    | [22.8%; 29.7%]                 |
| Relative PSAresponse rate (290%reduction inPSA frombaseline) b |                                     |                                     |                                |                                |
| At 6 monthsfromrandomlzation                                   | 534 (82.0%)                         | [78.9%; 84.9%]                      | 356 (54.4%)                    | [50.5%; 58.3%]                 |
| At 12 mionths from randomization                               | 549 (84.3%)                         | [81.3%; 87.0%]                      | 376 (57.5%)                    | [53.6%; 61.3%]                 |

<div style=\"page-break-after: always\"></div>

##  ECOG PS

Table 43: ECOG Performance status - shift tables of change from baseline to worst score of post-baseline (full analysis set)

|                                  |          | Worstpost-baselineECOG-PSscoreduringtreatment   | Worstpost-baselineECOG-PSscoreduringtreatment   | Worstpost-baselineECOG-PSscoreduringtreatment   | Worstpost-baselineECOG-PSscoreduringtreatment   | Worstpost-baselineECOG-PSscoreduringtreatment   | Worstpost-baselineECOG-PSscoreduringtreatment   | Worstpost-baselineECOG-PSscoreduringtreatment   |
|----------------------------------|----------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Treatment                        | Baseline | 0                                               |                                                 | 2                                               | 3                                               | 4                                               | Missing                                         | Total                                           |
| Darolutamide+docetaxelam (N=651) | 0        | 230 (35.3%)                                     | 198 ( 30.4%)                                    | 21 (3.2%)                                       | 7( 1.1%)                                        | 0                                               | 10 (1.5%)                                       | 466 ( 71.6%)                                    |
|                                  |          | 15( 2.3%)                                       | 134 ( 20.6%)                                    | 28 4.3%)                                       | 7( 1.1%)                                        | 0                                               | 1( 0.2%)                                        | 185 ( 28.4%)                                    |
|                                  | Missing  | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               |
|                                  | Total    | 245 ( 37.6%)                                    | 332 ( 51.0%)                                    | 49 (7.5%)                                       | 14 (2.2%)                                       | 0                                               | 11 ( (1.7%)                                     | 651 (100.0%)                                    |
| Placebo+docetaxelarm (N=654)     | 0        | 241 ( 36.9%)                                    | 181 ( 27.7%)                                    | 25 (3.8%)                                       | 8 (1.2%)                                        | 2 (0.3%)                                        | 5(0.8%)                                         | 462 ( 70.6%)                                    |
|                                  |          | 15 (2.3%)                                       | 137 (20.9%)                                     | 24 (3.7%)                                       | 6( 0.9%) 0                                      | 0                                               | 8( 1.2%)                                        | 190 (29.1%)                                     |
|                                  | Missing  | 0                                               | 0                                               | 2 0.3%)                                        |                                                 | 0                                               | 0                                               | 2 (0.3%)                                        |
|                                  | Total    | 256 (39.1%)                                     | 318 (48.6%)                                     | 51 (7.8%)                                       | 14 (2.1%)                                       | 2 (0.3%)                                        | 13 (2.0%)                                       | 654 (100.0%)                                    |

Note:BasclineECOGvalue is thelast non-missingobservation on orbefore therandomizationdate.

##  Quality of life

QoL of patients during the study was evaluated with the NCCN-FACT-FPSI-17 and the BPI-SF questionnaires. The NCCN-FACT-FPSI-17 questionnaire was used to assess symptoms of prostate cancer, symptoms of treatment of prostate cancer, and HRQoL in prostate cancer patients. The BPI-SF questionnaire was used to assess clinical pain. Results of question 3 in the BPISF, 'worst pain in 24 hours,' were used for the analysis of time to pain progression, a secondary efficacy endpoint.

NCCN-FACT FPSI-17 questionnaire - total score and subscale scores

<!-- image -->

EOT (End of treatment) visits are included by +/- 6 weeks-time window for the corresponding timepoints in this plot.

Figure 24 a: NCCN-FACT FPSI 17 questionnaire during treatment period - means with 95% CI: FPSI-17 Total Score (FAS)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviation: EOT = End of treatment visit,FU = Follow-up.

Figure 25 b: NCCN-FACT FPSI 17 questionnaire during follow-up period - means with 95% CI: FPSI-17 Total Score (FAS)

<!-- image -->

Figure 26 a : NCCN-FACT FPSI 17 questionnaire during treatment period - means with 95% CI: Disease-related symptoms subscale - physical (DRS-P) Score (full analysis set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviation: EOT = End of treatment visit,FU = Follow-up.

Figure 27 b : NCCN-FACT FPSI 17 questionnaire during follow-up period - means with 95% CI: Disease-related symptoms subscale - physical (DRS-P) Score (full analysis set)

Figure 28 a: NCCN-FACT FPSI 17 questionnaire during treatment period - means with 95% CI: Disease-related symptoms subscale - emotional (DRS-E) Score (full analysis set)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviation: EOT = End of treatment visit, FU = Follow-up.

Figure 29 b: NCCN-FACT FPSI 17 questionnaire during follow-up period - means with 95% CI: Disease-related symptoms subscale - emotional (DRS-E) Score (full analysis set)

<!-- image -->

Figure 30 a: NCCN-FACT FPSI 17 questionnaire during treatment period - means with 95% CI: Treatment side effects subscale (TSE) Score (full analysis set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviation: EOT = End of treatment visit, FU = Follow-up.

Figure 31 b: NCCN-FACT FPSI 17 questionnaire during follow-up period - means with 95% CI: Treatment side effects subscale (TSE) Score (full analysis set)

<!-- image -->

EOT (End of treatment) visits are included by +/- 6 weeks-time window for the corresponding timepoints in this plot.

Figure 32a: NCCN-FACT FPSI 17 questionnaire during treatment period - means with 95% CI: Function and well-being subscale (FWB) Score (full analysis set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviation: EOT = End of treatment visit, FU = Follow-up.

Figure 33 b: NCCN-FACT FPSI 17 questionnaire during follow-up period - means with 95% CI: Function and well-being subscale (FWB) Score (full analysis set)

BPI-SF questionnaire -Pain assessment

<!-- image -->

Figure 34 a: BPI-SF questionnaire during treatment period - means with 95% CI: Pain Severity Score (full analysis set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviation: EOT = End of treatment visit, FU = Follow-up.

Figure 30 b: BPI-SF questionnaire during follow-up period - means with 95% CI: Pain Severity Score (full analysis set)

Figure 35 a: BPI-SF questionnaire during treatment period - means with 95% CI: Pain Interference Score (full analysis set)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviation: EOT = End of treatment visit, FU = Follow-up.

Figure 31 b: BPI-SF questionnaire during follow-up period - means with 95% CI: Pain Interference Score (full analysis set)

Table 44 : BPI-SF questionnaire - Time Adjusted AUC overall: summary statistics (full analysis set)

| BPI-SFParameter             | Treatmentgroup            |   n | Mean (SD)     |   Median | Min,Max   |
|-----------------------------|---------------------------|-----|---------------|----------|-----------|
| BPI-SFpain severityscore    | Darolutamide+docetaxelarm | 618 | 1.555 (1.506) |    1.134 | 0.00,8.37 |
|                             | Placebo+docetaxelam       | 617 | 1.636 (1.533) |    1.245 | 0.00,8.86 |
| BPI-SFpaininterferencescore | Darolutamide+docetaxelarm | 618 | 1.614 (1.617) |    1.106 | 0.00,8.24 |
|                             | Placebo+docetaxelam       | 617 | 1.727 (1.705) |    1.167 | 0.00,9.15 |

Table 45 : BPI-SF questionnaire - ANCOVA analysis of time adjusted AUC - descriptive Analysis: Mean difference (full analysis set)

| BPI-SFParameter       | Treatmentgroup            |   LS Mean | 95%confidenceinterval   |
|-----------------------|---------------------------|-----------|-------------------------|
| PainSeverityScore     | Darolutamide+docetaxelarm |      1.57 | [1.41;1.73]             |
|                       | Placcbo+docetaxelamm      |      1.65 | [1.49;1.81]             |
|                       | Difference                |     -0.08 | [-0.22;0.05]            |
| PainInterferenceScore | Darolutamide+docetaxelarm |      1.61 | [1.43;1.78]             |
|                       | Placebo+docetaxelam       |      1.76 | [1.59;1.93]             |
|                       | Difference                |     -0.15 | [-0.30:0.00]            |

Note:Patientlevclvariabilityisarandomeffect.Treatmentscoreatbaseline andIxRSstratificationfactors:extentof disease andALPare thefixedeffectsinthislinearmixed model.

<div style=\"page-break-after: always\"></div>

Table 46 : BPI-SF questionnaire - ANCOVA analysis of time adjusted AUC - inferential Analysis: Treatment effect (full analysis set)

|                       | Effect:Two-sidedp-value   | Effect:Two-sidedp-value   | Effect:Two-sidedp-value   | Effect:Two-sidedp-value   |
|-----------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                       |                           | Extentof disease*         | ALP(<ULNvs. >=ULN)        | Score atbaseline          |
| PainSeverityScore     | 0.2309                    | 0.9567                    | 0.3948                    | <.0001                    |
| PainInterferenceScore | 0.0436                    | 0.9753                    | 0.7796                    | <.0001                    |

Note:*Extent of disease: Non-regional lymph nodes metastases only,Bone metastases with or without lymph node metastases,Visceral metastases with or without lymph node metastasesorwithorwithoutbonemetastases.

Note:Two-sidedtypeIerrorof5%p-value.

AUCwasnotcalculatedifbaselinescorewasmissing

Note:Patientlevelvariability isarandom effect.Treatment,score at baseline and IxRSstratificationfactors:extent of disease andALPare thefixedeffectsin thislinearmixed model.

## Ancillary analyses

## Subgroup Analysis

## Primary efficacy endpoint - Overall survival

<!-- image -->

|                                  | Darolutamide+ docetaxel no.of events/no.of patients   | Placebo+ docetaxel   | Darolutamide+ docetaxel median   | Placebo+ docetaxel median   |              | HRD/P)[95%CI]       |
|----------------------------------|-------------------------------------------------------|----------------------|----------------------------------|-----------------------------|--------------|----------------------|
| Overall                          | 229/651                                               | 304/654              | NE                               | 48.9                        | KI           | 0.689[0580,0.818]    |
| Cxtent of Diseose (eCRr)         |                                                       |                      |                                  |                             |              |                      |
| Non-regional lymph nodes mets    | 5/23                                                  | 5/16                 | NE                               | NE                          |              | 0.651[0.188,2.249]   |
| Bone.mets                        | 171/517                                               | 237/520              | NE                               | NE                          |              | 0.658[0.548,0.813]   |
| Visceralmets                     | 53/111                                                | 62/118               | 49.0                             | 42.0                        |              | 0.792[0.549,1.143]   |
| ALP Stratification Factor (eCRF) |                                                       |                      |                                  |                             |              |                      |
| AIPCIIN                          | 62/290                                                | 47791                | NF                               | NF                          |              | 066[0461.0877]       |
| ALP>=ULN                         | 167/361                                               | 211/363              | NE                               | 38.1                        |              | 0.692[0564,0847]     |
| Age (years)                      |                                                       |                      |                                  |                             |              |                      |
| <65                              | 80/243                                                | 117/234              | NE                               | 43.9                        |              | 0.592[0.446,0.787]   |
| 65-74                            | 107/303                                               | 124/306              | NE                               | NE                          |              | 0.821[0.634,1.054]   |
| 75-84                            | 40/102                                                | 60/110               | NE                               | 43.3                        |              | 0.606[0.406.0.904]   |
| 58=<                             | 2/3                                                   |                      | 33.7                             | 27.8                        |              |                      |
| Race                             |                                                       |                      |                                  |                             |              |                      |
| White                            | 131/345                                               | 173/333              | NE                               | 43.3                        |              | 0.633[0.504,0.794]   |
| Asian                            | 74/230                                                | 93/245               | NE                               | NE                          |              | 0.838[0617.1.137]    |
| Black Or Alrican American        | 8/26                                                  | 16/28                | NE                               | 38.7                        |              | 0.460 [0.196,1.077]  |
| Uther or not reported            | 16/50                                                 | 22148                | NE                               | 45.7                        |              | 0.579[0.303,1.107]   |
| Geographical region              |                                                       |                      |                                  |                             |              |                      |
| North Amenica                    | 42/125                                                | 56/119               | NE                               | 43.9                        |              | 0.611[0.409,0.913]   |
| Asia Pacific                     | 74/229                                                | 92/244               | NE                               | NE                          |              | 0.849[0.625,1.153]   |
| Rest of the World                | 113/297                                               | 156/291              | NE                               | 43.2                        |              | 0.612 [0.480, 0.780] |
| PSAatDaseline PSA<median         | 110/315                                               | 142/337              | NE                               | NE                          |              | 0.765[0.596,0.981]   |
| PSA>=median                      | 119/336                                               | 162/316              | NE                               | 44.3                        |              | 0.618[0.488,0.783]   |
| ECOG at Baseline                 |                                                       |                      |                                  |                             |              |                      |
| 0                                | 150/456                                               | 188/462              | NE                               | NE                          | H            | 0.753[0608.0.934]    |
| 1                                | 79/185                                                | 115/190              | NE                               | 35:8                        |              | 0.575[0432.0766]     |
| Gleason score                    |                                                       |                      |                                  |                             |              |                      |
|                                  | 33/122                                                | 44/118               | NE                               | NE                          |              | 0.653[0.416,1.025]   |
| >=8                              | 187/505                                               | 248/516              | NE                               | 46.0                        |             | 0.708 [0.586, 0.856] |
| Metastasis at initial diagnosis  |                                                       |                      |                                  |                             |              |                      |
| Yes.                             | 206/558                                               | 271/566              | NE                               |                             |              | 0.707[0.590,0.848]   |
|                                  | 22/86                                                 | 30/82                |                                  |                             |              | 0.605[0.348,1.052]   |
|                                  |                                                       |                      |                                  | 46.7                        |              |                      |
| No                               |                                                       |                      | NE                               | NE                          |              |                      |
|                                  |                                                       |                      |                                  |                             | 0.1 1.0      |                      |
|                                  |                                                       |                      |                                  |                             | Hazard Ratio |                      |

Abbreviations: ALP=Alkaline phosphatase; Cl=Confidence interval; D/P=Darolutamide+docetaxel arm/ placebo+docetaxel arm; ECOG=Eastem Cooperative Oncology Group performance status; eCRF=Electronic case report form; FAS=Full analysis set; HR=Hazard ratio; mets=Metastases; NE=Notevaluable due to censored data; no.=number; PSA=Prostate-specific antigen; ULN=Upper limit of normal

A hazard ratio &lt;1 indicates superiority of the darolutamide+docetaxel arm over the placebo+docetaxel arm. Hazard ratios and Cls were obtained from univariate analysis using Cox regression (unstratified). Medians were computed using Kaplan-Meier estimates.

No HR was calculated if &lt;10 total events were observed within the subgroups across the treatment arms.

Figure 36: Subgroup analysis results of overall survival (FAS)

<div style=\"page-break-after: always\"></div>

## Sensitivity analyses

Table 47 : Sensitivity analyses of overall survival in Study 17777 (FAS)

| Sensitivity analysis   | Sensitivity analysis                                                            | Hazard ratio : Darolutamide+docetaxel vs.Placebo+docetaxel [95% CI]   | One-sided p-value from log-rank test   |
|------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------|
| Analysis 1             | Without Including stratification factors In the                                 | 0.689 [0.580; 0.818]                                                   | <0.0001                                |
| Analysis 2             | Using stratification data from the eCRF                                         | 0.678 [0.571; 0.806]                                                   | <0.0001                                |
| Analysis 3 b           | Using extent of disease stratificatlon data according to central imaging review | 0.678 [0.571; 0.805]                                                   | <0.0001                                |

a: A hazard ratio&lt;1 Indicatessuperiority of the darolutamlde+docetaxel arm over theplacebo+docetaxel arm. The hazard ratio and 95% Cl were based on Cox regresslon model.

b:The stratification process in the Imaging Charter was set up such that in case of disagreement on the stralification group between central review and the site, the site re-evaluated the assessment with additional information from central review. Only in case of agreement could the patient be randomized. Nevertheless, there were discrepancies in 4 patients' stratification groups. A sensitivity analysis using stratification data according to central imaging revlew was performed to address the discrepancy.

Sensitivity analysis of time to CRPC : A sensitivity analysis was performed based on both central and local laboratory PSA and testosterone assessments. With 147 (22.6%) events in the darolutamide+docetaxel arm and 217 (33.2%) in the placebo+docetaxel arm, positive results in time to CRPC excluding PSA progression were observed in favour of the darolutamide+docetaxel arm, supporting the primary analysis (HR 0.463; 95% CI: 0.375; 0.572)

<div style=\"page-break-after: always\"></div>

## Additional Analysis

Table 48: Summary of subsequent life-prolonging systemic antineoplastic therapy for prostate cancer, by preferred drug name based on WHO-DD drug record number (FAS)

| Preferred drug name(s) WHO-DDVersion 2021SEP                             | Darolutamide+ docetaxel arm N=651 n (%)   | Placebo+ docetaxel arm N=654 n (%)   |
|--------------------------------------------------------------------------|-------------------------------------------|--------------------------------------|
| Patients with subsequent life-prolonging systemic antineoplastic therapy | 179 (27.5%)                               | 374 (57.2%)                          |
| 1 regimen                                                                | 108/179 (60.3%)                           | 221/374 (59.1%)                      |
| >1 regimen                                                               | 71/179 (39.7%)                            | 153/374 (40.9%)                      |
| Patients who entered Active or Survival follow-up *                      | 315/651 (48.4%)                           | 495/654 (75.7%)                      |
| Patients with subsequent life-prolonging systemic antineoplastic therapy | 179/315 (56.8%)                           | 374/495 (75.6%)                      |
| Ablraterone, ablraterone acetate                                         | 112/315 (35.6%)                           | 232/495 (46.9%)                      |
| Enzalutamlde                                                             | 48/315 (15.2%)                            | 136/495 (27.5%)                      |
| Cabazitaxel, cabazitaxel acetone                                         | 57/315 (18.1%)                            | 89/495 (18.0%)                       |
| Docelaxel                                                                | 46/315 (14.6%)                            | 89/495 (18.0%)                       |
| Radlum ra 223 dlchloride                                                 | 19/315 (6.0%)                             | 34/495 (6.9%)                        |
| Sipuleucel-T                                                             | 4/315 (1.3%)                              | 10/495 (2.0%)                        |
| Lutetlum (LU 177)                                                        | 1/315 (0.3%)                              | 6/495 (1.2%)                         |
| Apalutamide                                                              | 2/315 (0.6%)                              | 2/495 (0.4%)                         |
| Lutetium (177LU) PSMA-617                                                | 1/315 (0.3%)                              | 1/495 (0.2%)                         |

FAS=Full analysis set; N=Total number of patients (100%);: n=Number of patients with event; WHO-DD=World Health Organization Drug Dictionary

A patient could receive more than one subsequent life-prolonging systemic antineoplastic medication. All medications

The 7 patients who started life-prolonging systemic antineoplastic medications during the treatment period are included.

Different preferred drug names listed under the same WHO-DD drug record number were combined.

Preferred drug name was defined based on WHO-DD drug number, sequence #1 and sequence #2='001'.

Subsequent life-prolonging therapies for prostate cancer were defined as: abiraterone, apalutamide, enzalutamide, docetaxel, cabazitaxel, radium-223, sipuleucel-T, and lutetium-177.

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 49 : Summary of Efficacy for ARASENS

| Title : ' A randomized, double-blind, placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone- sensitive prostate cancer'   | Title : ' A randomized, double-blind, placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone- sensitive prostate cancer'   | Title : ' A randomized, double-blind, placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone- sensitive prostate cancer'   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                       | Internal study number: 17777 Study name: ARASENS EudraCT number: 2015 - 002590 - 38 ClinicalTrials.gov identifier: NCT02799602                                                                                                                         | Internal study number: 17777 Study name: ARASENS EudraCT number: 2015 - 002590 - 38 ClinicalTrials.gov identifier: NCT02799602                                                                                                                         |
| Design                                                                                                                                                                                                                                                 | Multinational, randomized (1:1), double-blind, placebo-controlled, Phase 3 efficacy and safety study                                                                                                                                                   | Multinational, randomized (1:1), double-blind, placebo-controlled, Phase 3 efficacy and safety study                                                                                                                                                   |
| Hypothesis                                                                                                                                                                                                                                             | Superiority of darolutamide+docetaxel over placebo+docetaxel in overall survival                                                                                                                                                                       | Superiority of darolutamide+docetaxel over placebo+docetaxel in overall survival                                                                                                                                                                       |
| Treatment groups                                                                                                                                                                                                                                       | Darolutamide+docetaxel arm                                                                                                                                                                                                                             | Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg. Docetaxel (75 mg/m 2 as an IV infusion) every 21 days for 6 cycles                                                                            |

<div style=\"page-break-after: always\"></div>

|                           |                                                                             |                                     | Concurrently with ADT Duration (overall time under treatment) median (min - max): 40.982 months (0.13 - 56.50 months) Number randomized: 651 patients a                                                                                                                                            |
|---------------------------|-----------------------------------------------------------------------------|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                           | Placebo+docetaxel arm                                                       | Placebo+docetaxel arm               | Matching placebo twice daily with food. Docetaxel every 21 days for 6 cycles (75 mg/m 2 as an IV infusion) Concurrently with ADT Duration (overall time under treatment) median (min - max): 16.689 months (0.26 - 55.78 months) Number randomized: 654 patients a                                 |
| Endpoints and definitions | Primary: Overall survival                                                   | OS                                  | Time from randomization until death from any cause                                                                                                                                                                                                                                                 |
| Endpoints and definitions | Secondary: Time to castration- resistant prostate cancer                    | Time to CRPC                        | Time from randomization to the occurrence of PSA progression, radiological progression by soft tissue and visceral lesions, or radiological progression by bone lesions                                                                                                                            |
| Endpoints and definitions | Secondary: Time to pain progression                                         | Time to PP                          | Time from randomization to pain progression. Pain progression was assessed by the initiation of short- or long-acting opioid use for pain and the BPI-SF questionnaire.                                                                                                                            |
| Endpoints and definitions | Secondary: Symptomatic skeletal event-free survival                         | SSE-FS                              | Time from randomization to the first occurrence of an SSE or death from any cause, whichever came first. SSE was defined as EBRT to relieve skeletal symptoms, new symptomatic pathologic bone fracture, occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention. |
| Endpoints and definitions | Secondary: Time to first symptomatic skeletal event                         | Time to SSE                         | Time from randomization to the occurrence of the first SSE.                                                                                                                                                                                                                                        |
| Endpoints and definitions | Secondary: Time to initiation of subsequent systemic antineoplastic therapy | Time to 1 st subsequent therapy     | Time from randomization to start of the first subsequent systemic antineoplastic therapy for prostate cancer.                                                                                                                                                                                      |
| Endpoints and definitions | Secondary: Time to worsening of disease-related physical symptoms           | Time to worsening of symptoms       | Time from randomization to the first date a patient experienced an increase in disease-related physical symptoms based on the NCCN-FACT- FPSI-17 questionnaire.                                                                                                                                    |
| Endpoints and definitions | Secondary: Time to initiation of opioid use for 7 consecutive days         | Time to 1 st opioid use for 7 days | Time from randomization to the date of first opioid use (for prostate cancer pain) for 7 consecutive days.                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Results and Analysis                           | Results and Analysis                                                                              | Results and Analysis                                                                              | Results and Analysis                                                                              | Results and Analysis                                                                              |
|------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Analysis description                           | Primary Analysis                                                                                  | Primary Analysis                                                                                  | Primary Analysis                                                                                  | Primary Analysis                                                                                  |
| Analysis population and time point description | Full Analysis Set (all randomized patients) Primary completion database cut-off date: 25 OCT 2021 | Full Analysis Set (all randomized patients) Primary completion database cut-off date: 25 OCT 2021 | Full Analysis Set (all randomized patients) Primary completion database cut-off date: 25 OCT 2021 | Full Analysis Set (all randomized patients) Primary completion database cut-off date: 25 OCT 2021 |
|                                                | Treatment group                                                                                   | Treatment group                                                                                   | Darolutamide +docetaxel arm Placebo+ docetaxel arm                                                | Darolutamide +docetaxel arm Placebo+ docetaxel arm                                                |
|                                                | Number of subjects                                                                                | Number of subjects                                                                                | 654                                                                                               | 654                                                                                               |
|                                                | OS                                                                                                | Comparison groups                                                                                 | Comparison groups                                                                                 | Darolutamide+docetaxel vs Placebo+docetaxel                                                       |
|                                                | OS                                                                                                | Hazard ratio c                                                                                    | Hazard ratio c                                                                                    | 0.675                                                                                             |
|                                                | OS                                                                                                | [95% CI]                                                                                          | [95% CI]                                                                                          | [0.568; 0.801]                                                                                    |
|                                                | OS                                                                                                | p-value d                                                                                         | p-value d                                                                                         | <0.0001                                                                                           |
|                                                | Time to CRPC                                                                                      | Comparison groups                                                                                 | Comparison groups                                                                                 | Darolutamide+docetaxel vs Placebo+docetaxel                                                       |
|                                                | Time to CRPC                                                                                      | Hazard ratio c                                                                                    | Hazard ratio c                                                                                    | 0.357                                                                                             |
|                                                | Time to CRPC                                                                                      | [95% CI]                                                                                          | [95% CI]                                                                                          | [0.302; 0.421]                                                                                    |
|                                                | Time to CRPC                                                                                      | p-value d                                                                                         | p-value d                                                                                         | <0.0001                                                                                           |
|                                                | Time to PP                                                                                        | Comparison groups                                                                                 | Comparison groups                                                                                 | Darolutamide+docetaxel vs Placebo+docetaxel                                                       |
|                                                | Time to PP                                                                                        | Hazard ratio c                                                                                    | Hazard ratio c                                                                                    | 0.792                                                                                             |
|                                                | Time to PP                                                                                        | [95% CI]                                                                                          | [95% CI]                                                                                          | [0.660; 0.950]                                                                                    |
|                                                | Time to PP                                                                                        | p-value d                                                                                         | p-value d                                                                                         | 0.0058                                                                                            |
|                                                | SSE-FS                                                                                            | Comparison groups                                                                                 | Comparison groups                                                                                 | Darolutamide+docetaxel vs Placebo+docetaxel                                                       |
|                                                | SSE-FS                                                                                            | Hazard ratio c                                                                                    | Hazard ratio c                                                                                    | 0.609                                                                                             |
|                                                | SSE-FS                                                                                            | [95% CI]                                                                                          | [95% CI]                                                                                          | [0.516; 0.718]                                                                                    |
|                                                | SSE-FS                                                                                            | p-value d                                                                                         | p-value d                                                                                         | <0.0001                                                                                           |
|                                                | Time to SSE                                                                                       | Comparison groups                                                                                 | Comparison groups                                                                                 | Darolutamide+docetaxel vs Placebo+docetaxel                                                       |
|                                                | Time to SSE                                                                                       | Hazard ratio c                                                                                    | Hazard ratio c                                                                                    | 0.712                                                                                             |
|                                                | Time to SSE                                                                                       | [95% CI]                                                                                          | [95% CI]                                                                                          | [0.539; 0.940]                                                                                    |
|                                                | Time to SSE                                                                                       | p-value d                                                                                         | p-value d                                                                                         | 0.0081                                                                                            |
|                                                | Time to 1 st subsequent therapy                                                                   | Comparison groups                                                                                 | Comparison groups                                                                                 | Darolutamide+docetaxel vs Placebo+docetaxel                                                       |
|                                                | Time to 1 st subsequent therapy                                                                   | Hazard ratio c                                                                                    | Hazard ratio c                                                                                    | 0.388                                                                                             |
|                                                | Time to 1 st subsequent therapy                                                                   | [95% CI]                                                                                          | [95% CI]                                                                                          | [0.328; 0.458]                                                                                    |
|                                                | Time to 1 st subsequent therapy                                                                   | p-value d                                                                                         | p-value d                                                                                         | <0.0001                                                                                           |
|                                                | Time to worsening of symptoms                                                                     | Comparison groups                                                                                 | Comparison groups                                                                                 | Darolutamide+docetaxel vs Placebo+docetaxel                                                       |
|                                                | Time to worsening of symptoms                                                                     | Hazard ratio c                                                                                    | Hazard ratio c                                                                                    | 1.043                                                                                             |
|                                                | Time to worsening of symptoms                                                                     | [95% CI]                                                                                          | [95% CI]                                                                                          | [0.894; 1.217]                                                                                    |
|                                                | Time to worsening of symptoms                                                                     | p-value d                                                                                         | p-value d                                                                                         | 0.7073                                                                                            |
|                                                | Time to 1 st opioid use for 7 days e                                                             | Comparison groups                                                                                 | Comparison groups                                                                                 | Darolutamide+docetaxel vs Placebo+docetaxel                                                       |
|                                                | Time to 1 st opioid use for 7 days e                                                             | Hazard ratio c                                                                                    | Hazard ratio c                                                                                    | 0.688                                                                                             |
|                                                | Time to 1 st opioid use for 7 days e                                                             | [95% CI]                                                                                          | [95% CI]                                                                                          | [0.523; 0.906]                                                                                    |
|                                                | Time to 1 st opioid use for 7 days e                                                             | p-value d,e                                                                                       | p-value d,e                                                                                       | 0.0037 e                                                                                          |

<div style=\"page-break-after: always\"></div>

ADT=Androgen deprivation therapy; ALP=Alkaline phosphatase; BPI-SF=Brief pain inventory -short form; CI=Confidence interval; CRPC=Castration-resistant prostate cancer; EBRT=External beam radiation therapy; EudraCT=European Clinical Trials Database; FPFV=First patient's first visit; IV=Intravenous; M1a/M1b/M1c=classification of metastatic disease; max=Maximum; mHSPC=Metastatic hormone-sensitive prostate cancer; min=Minimum; NCCN-FACT-FPSI-17=National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy -Prostate Symptom Index 17-item questionnaire; OS =Overall survival; PP=Pain progression; PSA=Prostate-specific antigen; SSE=Symptomatic skeletal event; SSE-FS=Symptomatic skeletal event-free survival; ULN=Upper limit of normal

A=Value cannot be estimated due to censored data.

a: A total of 1306 patients were randomized. One patient was excluded from all analyses due to a Good Clinical Practice (GCP) violation. One patient randomized to and included in the placebo+docetaxel arm received darolutamide for 85 days.

b: Median and 95% CIs were computed using Kaplan-Meier estimates.

c: A hazard ratio &lt;1 indicates superiority of darolutamide+docetaxel over placebo+docetaxel. The hazard ratio and 95% CI were based on Cox regression model, stratified by extent of disease (M1a vs. M1b vs. M1c) and ALP (&lt;ULN vs.  ULN).

d: One-sided p-value from stratified log-rank test

e: The secondary endpoints were tested with a hierarchical gatekeeping procedure in the following order: Time to CRPC, Time to PP, SSEFS, Time to SSE, Time to 1 st  subsequent therapy, Time to worsening symptoms, and Time to 1 st  opioid use for  7 days. As Time to worsening symptoms did not reach the one-sided alpha significance threshold of 0.025 for this analysis, the secondary efficacy endpoint Time to 1 st  opioid use for  7 days was not tested for significance and was considered exploratory; p-value is for descriptive purposes only.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The current application is based on the results of the pivotal study ARASENS (Study 17777). This was a Phase III, multinational, randomized (1:1), double-blind, placebo-controlled study evaluating darolutamide 600 mg BID orally in combination with 6 cycles of docetaxel in combination with ADT. Patients were randomised in a 1:1 ratio to receive either darolutamide or placebo, each combined with docetaxel. The use of docetaxel in combination with ADT as comparator is acceptable as recommended by ESMO in the treatment of mHSPC (Cancer of the prostate: ESMO Clinical Practice, Guidelines for diagnosis, treatment and follow-up, volume 31, 25 June 2020).

Considering  the  study  design,  the  initially  claimed  indication  has  been  modified  to  reflect  that darolutamide is administered in combination not only with docetaxel but also with ADT.

Eligibility criteria are considered acceptable considering the claimed indication. It is noted that patients were included in the study regardless of disease volume. Patients were stratified at randomization by extent of disease (non-regional lymph node metastases only [M1a]; bones metastases with or without lymph node metastases [M1b]; visceral metastases with or without lymph node metastases or with or without bone me tastases [M1c]) and by alkaline phosphatase (ALP), &lt;ULN or ULN at baseline. The addition of radiotherapy may be recommended for some patients according to current guidelines (i.e. patients with low volume disease). However, patients receiving treatment with radiotherapy were excluded from the study, which is acknowledged taking into account the available evidence at the time of study start. According to the protocol, palliative radiation therapy or surgical intervention as needed were allowed during study treatment. Treatment with bisphosphonates and denosumab was also allowed.

The dose of darolutamide used in ARASENS study is the 600 mg bd tablet formulation in combination with  docetaxel  (75  mg/m 2   for  6  cycles).  This  dose  showed  a  statistically  significant  and  clinically meaningful  efficacy  benefit  for  mHSPC  patients.  The  data  indicate  that  darolutamide  (600  bd)  plus docetaxel  has  an  acceptable  tolerability  profile  when  administered  in  the  proposed  target  patient population.  This choice of dose was supported by safety and PK data, exposure-response analyses, and exposure-safety analysis.

The primary objective of this study was to demonstrate superiority of darolutamide in combination with docetaxel over placebo in combination with docetaxel in OS. The secondary objectives were to evaluate the  time  to  castration-resistant  prostate  cancer  (CRPC),  the  time  to  pain  progression,  symptomatic skeletal event-free survival (SSE-FS), the time to first symptomatic skeletal event (SSE), the time to

<div style=\"page-break-after: always\"></div>

initiation  of  subsequent  systemic  antineoplastic  therapy,  the  time  to  worsening  of  disease-related physical symptoms, the time to initiation of opioid use for 7 consecutive days, and to characterize the safety of darolutamide in combination with docetaxel in mHSPC patients. Overall, the study design is considered  acceptable.  The  Applicant  has  mostly  followed  the  CHMP  scientific  advice  except  for  the suggestion to add other primary endpoints (rPFS or Time to castrate resistance) considering OS could be confounded by further treatment lines given the disease stage. The sponsor did not add any further primary  endpoints  but  changed  the  hierarchy  of  secondary  endpoints  by  placing  Time  to  castrate resistance first which is acceptable.

The sample size calculations  were  acceptable.  The  targeted  treatment  effect  on  OS  (HR=0.75)  was considered 'meaningful and clinically  relevant'  (EMA/CHMP/SAWP/596563/2015). The randomisation process and associated stratification factors are appropriate.

Twenty-three patients (10 [1.5%] in the darolutamide arm and 13 patients [2.0%] in the placebo arm) never received docetaxel. According to the MAH, after randomization and start of study drug, they were no longer considered to be eligible to receive concomitant docetaxel within 6 weeks after start of study drug. Since numbers were low and balanced between treatment arms it is not considered that this may have impacted the results.

A relatively large proportion of patients had premature emergency unblinding performed at the study site  by  the  investigator  (89  patients  in  total,  26  darolutamide  +  docetaxel  +  ADT  and  63 placebo+docetaxel). Investigators were unblinding patients to inform the choice of subsequent therapy which was not allowed per protocol. The MAH clarified that premature unblinding was limited to the investigator and patient, and that study team members remained blinded to treatment allocation until the formal study unblinding at the time of analyses.  The impact and potential bias induced by premature unblinding on subsequent patient measurements have been discussed and post-hoc analyses have been provided for two endpoints considered to be most likely influenced by premature unblinding: time to pain progression and time to worsening of physical disease-related symptoms. The MAH also clarified that 18 patients (2.8%) in the darolutamide+docetaxel arm and 43 (6.6%) in the placebo+docetaxel arm  received  at  least  1  subsequent  systemic  antineoplastic  therapy  after  premature  unblinding.  In general, bias cannot be completely ruled out in the presence of premature unblinding. However, the additional information and post-hoc analyses performed (data not shown) provided some reassurance on the potential impact on study results.

For the secondary endpoint of time to castration-resistant prostate cancer, it is noted that data following two or more consecutive missing assessments or following the start of subsequent therapy are being censored at the last assessment date before these occurrences. The MAH was requested to perform a supplemental  analysis  of  time  to  castration-resistant  prostate  cancer  following  a  treatment  policy strategy for these intercurrent events (IEs) (start of subsequent therapy, and 2 consecutive missing assessment), i.e. without censoring data in these situations, and making use of following observations instead. The results (not shown) were consistent with the main analysis results.

The statistical methods for analysing primary and secondary endpoints (stratified log-rank test and Cox model) are standard and adequate for these time to event variables.

There  were  several  changes  to  the  planned  analyses,  including  the  removal  of  the  second  interim analysis, the introduction of gatekeeping procedure in the SAP, and the exclusion of the patient data with a critical GCP violation. Given the double-blind nature of the study, the review of the amendments is not thought to have affected the overall interpretation of the study results.

Regarding protocol deviations, frequency of important protocol deviations was similar between treatment arms  (73.3%  and  73.9%  in  the  darolutamide  and  placebo  arm,  respectively).  The  most  commonly

<div style=\"page-break-after: always\"></div>

reported were related to procedure deviations (56.8% vs 57.0%) and treatment deviations (36.4% vs 35.5%).  Of  the  total  number  of  protocol  deviations,  15.8%  and  12.1%,  in  each  treatment  arms, respectively, were related to COVID-19 pandemic. However, even if numbers were comparable between treatment arms, the rate was considered high. According to the MAH a bro ad definition of 'important protocol deviations' was used in the study, which somehow would explain the high rates of protocol deviations reported, in addition to those related to COVID-19 pandemic. Detailed information on the causes  of  procedure  and  treatment  deviations  was  also  submitted  and  no  major  differences  were observed between treatment arms.

## Efficacy data and additional analyses

## Baseline data

Overall, the baseline demographic and baseline patient and disease characteristics of FAS were generally well balanced between the 2 treatment arms. The majority of patients included in the study had high volume  disease  (77%),  applying  the  CHAARTED  criteria.  Further,  according  to  inclusion/exclusion criteria, patients with brain metastases were allowed to enter the study but there were no patients with (known) brain metastasis enrolled in the study.

Docetaxel could be given with prednisone/prednisolone. According to the information provided by the MAH,  18.6%  and  22%  of  patients  in  the  darolutamide  and  placebo  arms,  respectively,  received prednisolone while 23.2% and 18.5%, respectively, received prednisone. There were also around 7.5% of patients that received methylprednisolone. Further, around 80% of patients received dexamethasone. Dexamethasone was given as a premedication according to the above definition in 45.9% (299/651) of patients in the darolutamide+docetaxel arm and in 49.4% (323/654) in the placebo+docetaxel arm. Almost 235 patients in the darolutamide+docetaxel arm and 219 patients in the placebo+docetaxel arm received dexamethasone not used as premedication according to the predefined time window: a start date within 3 days prior to any docetaxel cycle treatment (Day-3), and a stop date within 5 days after each docetaxel cycle treatment date (Day+5). The reason why majority of the patients had the reason 'Other' was that there was no specific field in the eCRF to capture prophylactic use and the data was collected as free text.

The majority of patients (85%) had not received prior surgical or radiation treatment. Around 25% of patients received concomitant treatment with bisphosphonates or denosumab.

## Primary endpoint

The primary efficacy analysis in support of this application was performed at the data cut-off of 25-oct2021.

With a total of 553 OS events: 229 deaths (35.2% of patients) in the darolutamide + docetaxel + ADT arm; 304 deaths (46.5% of patients) in the placebo + docetaxel + ADT arm, ARASENS study met its primary endpoint with a statistically significant improvement of OS in the darolutamide + docetaxel + ADT arm compared to placebo + docetaxel + ADT. The addition of darolutamide to backbone docetaxel + ADT decreased the risk of death of 32.5% compared to the placebo arm (HR: 0.675; 95% CI: [0.568; 0.801], p&lt;0.0001) which is considered clinically relevant for the target population. Median OS was not reached in the darolutamide + docetaxel + ADT arm (95% CI: [A; A]) and was 48.9 months in the placebo + docetaxel + ADT arm (95% CI: [44.4; A]). However, median OS in the control arm was lower than expected at the time of the estimation of the sample size and lower than the reported in studies STAMPEDE and CHAARTED (62 months and 57.6 months, respectively).  Further, in the study PEACE-

<div style=\"page-break-after: always\"></div>

1 1 , in de novo metastatic prostate cancer patients, median OS in the docetaxel plus ADT arm was of around 53 months. In this study, radiotherapy was allowed. The MAH provided supporting evidence to justify the difference observed of median OS between studies (CHAARTED, STAMPEDE and PEACE-1). The most likely cause of this observed difference, was the difference in clinical prognostic factors between the patients. Indeed, it is well known that Gleason score &gt;8 as well as a diagnosis of de novo mHSPC or the presence of visceral metastases are factors of worse prognosis in prostate cancer.

A high number of censored patients was reported in both arms, representing almost 60% of the FAS population, with 64.8% in the darolutamide arm and 53.5% in the placebo arm.  The provided description of the reasons for censoring, provided reassurance that the censorships were balanced between both arms throughout the study conduct. Likewise, a sensitivity analysis of the primary endpoint imputing the use of prohibited medication as event was consistent with the primary analysis.

## Secondary endpoints

The  start  of  a new systemic antineoplastic  therapy was  reported  for  33.6%  of  patients  in  the darolutamide + docetaxel + ADT arm compared with 60.4% in the placebo + docetaxel + ADT arm. There  was  a  statistically  significant  and  clinically  meaningful  improvement  in  time  to  first  systemic therapy (TFST) associated with darolutamide + docetaxel + ADT vs the control arm (HR of 0.388, 95% CI: [0.328; 0.458]; p&lt;0.0001).

Given the stage of the disease, OS could be confounded by further treatment lines. The use of subsequent therapies known to have impact on patients survival was almost 1.33-fold higher in the placebo arm, which is in line with what can be expected based on primary results. However, the magnitude of the impact that subsequent therapies have in OS results cannot be complete elucidated.

Time to castrate resistance was considered the most relevant secondary endpoint and  was defined as the time to PSA progression (i.e.  25% increase and an absolute increase  2 ng/ml from the nadir) with serum testosterone being at castrate level &lt;0.50 ng/mL, or the time to radiological progression by soft tissue/visceral lesions or by bone lesions whichever occurs first. CRPC was documented for 225 (34.6%) patients in the darolutamide + docetaxel + ADT arm and 391 (59.8%) patients in the placebo + docetaxel + ADT arm. Of the patients who progressed to CRPC, the first progression event observed was mostly PSA progression for 121/225 patients (53.8%) in the darolutamide + docetaxel + ADT arm compared  with  289/391  patients  (73.9%)  in  the  placebo  +  docetaxel  +  ADT  arm.  A  statistically significant prolonged time to CRPC was observed for patients in the darolutamide + docetaxel + ADT arm compared with the placebo + docetaxel + ADT arm, with an HR of 0.357 (95% CI: [0.302; 0.421]); p&lt;0.0001. The median time to CRPC was not reached (95% CI: [A; A]) in the darolutamide + docetaxel + ADT arm and was 19.1 months (95% CI: [16.5; 21.8]) in the placebo + docetaxel + ADT arm.

This delay in the time to CRPC was mainly based on PSA progression, which was in fact the main (first) event  observed  in  both  treatment  arms.  However,  no  apparent  differences  were  observed  between treatment arms in terms of radiological progression by bone or visceral lesions. As mentioned, rPFS was not included as secondary endpoint in the study, which would have provided information about the effect of darolutamide in delaying radiological disease progression.

The assessment of PSA progression was questioned taking into account that only 53% of patients had testosterone castrate levels at baseline. At Visit 2 (Week 12) 93.7% of patients had castrate levels of testosterone. Considering at Visit 2 most patients were already on castrated levels it is presumed that no events of PSA progression had been reported for the vast majority of patients. Since testosterone at castrate levels was a necessary condition for a PSA progression event, the MAH clarified that patients

1  Fizazi K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2  2 factorial design. Lancet. 2022 Apr 30;399(10336):1695-1707.

<div style=\"page-break-after: always\"></div>

who did not have a testosterone castrate level did not qualify for a PSA progression event. Among the 76 (6.3%) remaining patients with non-castrate testosterone level at Visit 2, 22 patients fulfilled the criteria for PSA progression at a subsequent and confirmation visit. There were 54 patients who did not fulfil the criteria and therefore were not evaluable for PSA progression but were assessed for radiological progression. Of these 54 patients 13 had radiological progression. Thus, in total, of the 76 patients, 35 experienced an event.

As this variation proposes the use of darolutamide as an add-on to one of the standard of care, the quality  of  life  of  patients  is  important  in  the  evaluation  of  the  claimed  indication.  Main  secondary endpoints which indirectly reflect the quality of life of patients were: Time to pain progression; SSE-FS; Time to first SSE; Time to initiation of subsequent systemic antineoplastic therapy; Time to worsening of  disease-related  physical  symptoms  based  on  functional  assessment  of  cancer  therapy;  Time  to initiation of opioid use for 7 consecutive days.

The time to first symptomatic skeletal events in the study and the time to initiation of opioid use were considered clinically relevant in this context.

A statistically significant delay in time to pain progression was observed in favour of the experimental arm (HR 0.792; 95% CI: [0.660, 0.950]), with 34.1% events in the darolutamide arm and 37.9% in the placebo arm. Median time to pain progression was not reached in the darolutamide arm and was of 27.5 months in the placebo arm. Sensitivity analyses were consistent. Approximately 71.5% of patients in the  study  were  taking  concomitant  analgesics.  SSEs  were  reported  in  14.6%  of  patients  in  the darolutamide + docetaxel + ADT arm compared with 16.5% in the placebo + docetaxel + ADT arm with a numerical improvement (i.e. a delay) of time to first SSE for patients in the darolutamide + docetaxel + ADT arm, with an HR of 0.712 (95% CI: [0.539; 0.940]); p=0.0081. The median time to first SSE was not reached (95% CI: [A; A]) in either treatment arm. The majority of the first SSEs were External beam radiation therapy to relieve skeletal symptoms, reported for 63.2% of patients with an SSE in the darolutamide + docetaxel + ADT arm and 82.4% of patients with an SSE in the placebo + docetaxel + arm.

Worsening of disease-related physical symptoms was observed for 53.9% of patients in the darolutamide + docetaxel + ADT arm and 47.1% of patients in the placebo + docetaxel + ADT arm. There was no significant  difference  in time to worsening of disease-related physical symptoms between  the treatment arms (HR=1.043; 95% CI: [0.894, 1.217]; p=0.7073). The median time to worsening of disease-related  physical  symptoms was 19.3 months (95% CI: [13.8, 24.8]) in the darolutamide + docetaxel + ADT arm and 19.4 months (95% CI: [15.4, 27.6]) in the placebo + docetaxel + ADT arm.

Since time to worsening of disease-related physical symptoms was not statistically significant, the results of the secondary endpoint time to initiation of opioid use were considered exploratory. It is to be noted that 14.1% of patients in the darolutamide + docetaxel + ADT arm and 17.9% in the placebo + docetaxel + ADT arm had initiated opioid treatment for cancer pain for 7 consecutive days. The time to  first  opioid  use  for  7  consecutive  days showed  an  advantage  in  favour  of  the  darolutamide  + docetaxel + ADT arm, with an HR of 0.688 (95% CI: [0.523; 0.906]); p=0.0037.

Findings  from  secondary  efficacy  analyses  all  showed  statistically  significant  results  in  favour  of darolutamide  +  docetaxel  +  ADT  arm  except  for  the  Time  to  worsening  of  disease-related  physical symptoms based on the NCCN -FACT-FPSI-17 questionnaire.

## Exploratory endpoints

Additional exploratory endpoints also favoured darolutamide + docetaxel + ADT arm compared to placebo + docetaxel.

<div style=\"page-break-after: always\"></div>

Baseline  PSA  values  were  comparable  between  the  treatment  arms  (median  30.30  ng/mL  in  the darolutamide  +  docetaxel  +  ADT  arm  and  24.20  ng/mL  in  the  placebo  +  docetaxel  +  ADT  arm). Treatment with darolutamide in combination with docetaxel resulted in a longer time to PSA progression than placebo in combination with docetaxel, with an HR of 0.255 (95% CI: [0.208; 0.313]); p&lt;0.0001.

The majority of the patients in the darolutamide + docetaxel + ADT arm (88.6%) and in the placebo + docetaxel + ADT arm (68.7%) had a maximum PSA decline of 90% from baseline at any time on study treatment.

Patients in the darolutamide + docetaxel + ADT arm showed a significantly higher relative PSA response rate of 90% reduction from baseline at 12 months after randomization than patients in the placebo + docetaxel + ADT arm, 84.3% vs. 57.5%, respectively (difference=26.82%, 95% CI: [22.11; 31.53], p&lt;0.0001). Both absolute PSA response rates (PSA level &lt;0.2 ng/mL) and relative PSA response rates (90% reduction in PSA from baseline) were higher in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm at all evaluated time points.

Concerning quality of life (QoL), the results indicated that health-related QoL was maintained while on treatment in patients in both treatment arms. At baseline (i.e., Screening or Visit 1/Day 1), the BPI-SF pain interference and pain severity scores were similar between the treatment arms. Changes in mean values from baseline for the pain severity and pain interference scores were observed in both treatment arms, and there were no clinically meaningful differences (MID=2 points) between the treatment arms.

## Subgroups analysis

The different subgroup analyses according to tumour volume (high and low tumour volume) showed a favourable benefit in overall survival and other efficacy outcomes (time to castration-resistant prostate cancer, symptomatic skeletal event-free survival, time to initiation of subsequent systemic antineoplastic therapy) with no major differences were observed regarding burden of disease.

## 2.4.4. Conclusions on the clinical efficacy

Despite  therapeutic  advances  in  recent  years  in  the  treatment  of  prostate  cancer,  the  arsenal  of treatment in mHSPC setting remains limited.

ARASENS  study  met  its  primary  endpoint  with  a  statistically  significant  improvement  of  OS  in  the darolutamide + docetaxel + ADT arm compared to placebo + docetaxel. ARASENS study demonstrated a reduction of the risk of death of 32.5% in the darolutamide + docetaxel + ADT arm compared to the placebo  +  docetaxel  +  ADT  arm  (HR:  0.675;  95%  CI:  [0.568;  0.801]),  and  the  log-rank  test  was statistically significant with a one-sided p&lt;0.0001.

Findings  from  secondary  efficacy  analyses  all  showed  statistically  significant  results  in  favour  of darolutamide  +  docetaxel  +  ADT  arm  except  for  the  Time  to  worsening  of  disease-related  physical symptoms based on the NCCN -FACT-FPSI-17 questionnaire. The combination darolutamide + docetaxel, in the ARASENS study, significantly reduced the onset of castration-resistant disease, prolonged the time to the first SSE, and the time to subsequent systemic antineoplastic therapy.

## 2.5. Clinical safety

## Introduction

The evidence for the clinical safety of darolutamide in combination with docetaxel for the treatment of mHSPC is based on the data from the pivotal Study 17777 (ARASENS) in patients with mHSPC

<div style=\"page-break-after: always\"></div>

(n=1302) from start of the study (30 NOV 2016) until the database cut-off date for the primary completion analysis (25 OCT 2021).

Safety data were also derived from the following sources:

- Integrated analysis of safety from completed uncontrolled Phase 1/2 darolutamide studies in patients with mCRPC (mCRPC pool) comprising Study 17829 (ARADES) [including extension Study 18035 (ARADES-EXT)], Study 17830 (ARAFOR), and Study 17719 (n=173).
- Integrated analysis of safety from completed Phase 1 single dose darolutamide studies in noncancer subjects (non-cancer subject pool) comprising Studies 17721, 17726, 17831, and 18426. No new multiple dose darolutamide studies were conducted since the submission of the initial dossier, therefore, 'non -cancer subject pool' refers to the up dated integrated analysis of the single dose studies in this SCS (n=80).

In addition, the summaries of deaths and serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs) leading to treatment discontinuation were provided from the ongoing Phase 3 Study 21140 (ARANOTE) in mHSPC patients, and for the ongoing roll-over Study 20321.

## Analysis sets

All safety evaluations are presented for the safety analysis set (SAF), defined as:

- Phase 3 Study 17777 (ARASENS): all randomized patients who received at least one dose of study drug (darolutamide or placebo), except for cases with critical GCP violations. Patients were included in the analyses according to the treatment they actually received. Patients were included in the darolutamide + docetaxel + ADT arm if they had received any dose of darolutamide.
- Integrated safety analyses in mCRPC patients (mCRPC pool) and in non-cancer subjects (noncancer subject pool): all patients and subjects, respectively, who received at least one dose of study treatment.

## Table 50 Overview of clinical studies included in the summary of clinical safety

<!-- image -->

| Studyno. and Phase   | Number of study centers and locations                                                                                                                                                                                         | Study period and studyreports                                                          | Study design and type of control                     | Primary and secondary objectives                                                                                                                                                                                                                                                                                                                                               | Study population   | Treatedpatients /exposed subjects as of 25 OCT2021                                  | Treatmentand dose                                                                                                                                                                              | Demographics Gender Median age in years(range) Race                                                                                                                                                                                                                                                 | Safety evaluations included in the submission                                                                                                                                             | Deaths/SAEs/ AEsleadingtostudy discontinuation/Any treatment AE a                                                                                                                                                                                                                                                                                                   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17777 Phase3         | 301centers in ARASENSAustralia, Belgium, Brazil, Bulgaria, Netherlands, France,Gemany, sraeltaly,n, Federation,South Canada,Czech Republic,mainland Mexico, Poland,Russian Korea, Spain, China,Finland, Sweden,Taiwan, UK, US | FPFV 30 NOV 2016 ReportPH-42024 Primary completion 25OCT2021 analysis: Module 5.3.5.1, | Randomized (1:1), double- blind, placebo- controlled | Primary: Superiority in OSof darolutamide in combinationwith Secondary. combination with docetaxelover placeboin docetaxel. timetoCRPC,time topainprogression, SSE-FS,timetofirst subsequent systemic SSE,time to initiationof antineoplastic therapy, time to worsening of disease-related physical symptoms, the time toinitiation of opioid usefor 7consecutivedays, safety | mHSPC              | Patients withTotal:1302b Darolutamide+ 652 Placebo+ docetaxelarm: 650 docetaxel am: | Darolutamide 600mg(2tablets of300mg)BID orplaceboin 21days withfood,equal to a dailydoseof 1200mg, combinationwith 6 cyclesof 75 mg/m as an IV infusionevery docetaxelat Concurrentlywith ADT | Darolutamide+ docetaxelarm: 651male 67.0years White:53.0% BlackorAfrican American:4.0% Not reported:6.6% (41-89years) Asian:35.3% Other. 1.1% Placebo+docetaxelparameters arm:c 654male 67.0 years (42-86years) White:50.9% BlackorAfrican American:4.3% Asian: 37.5% Other.0.3% Not reported: 7.0% | Extentofexposure TEAEs TEAEsleading to groupedAEtems TEAEs leading to TESAES Special topicsof Subgroupanalysis ofTEAES discontinuation dosemodification Deaths Vital signs ECG Laboratory | Darolutamide+docetaxel armvs. placelbo+docetaxelam 27 patients (4.1%)vs. 304 deaths (46.8%) Deaths: Grade5 TEAEs: 26 patients (4.0%) Overall: 229 deaths (35.1%)vs. 39 patients (6.0%) TESAEs: 40 patients (6.1%)vs. TEAEsleadingto discontinuationof study drug: 88patients (13.5%)vs. 69 patients (10.6%) Any TEAE: 649 patients (99.5%) vs. 643 patients (98.9%) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Studyno. and Phase                 | Numberofstudy centers and locations                                                                                                                                                                                                                                                                    | Study period and study reports                                                                                                                    | Study design and typeof control                                                                                                                        | Primary and secondary objectives                                                                                                                                                                                                                                                                                                                                       | Study population                                                                      | Treatedpatients /exposed subjects as of 25OCT2021                                            | Treatmentand dose                                                                                                                                        | Demographics Gender Median age in years (range) Race                                                                                       | Safety evaluations included in the submission                              | Deaths/SAEs/ AEs leading to study discontinuation/Any treatment AE a                                                                                                                                                                                  |
|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17830 ARAFOR (3104003) Phase 1     | 9centersinFinland,FPFV France,Latvia                                                                                                                                                                                                                                                                   | 14MAR2013 30APR2017cut-off (6patients ongoing with treatment) ReportR-9789 LPLV Module 5.3.1.1, 18DEC2020 Module 5.3.1.1, Report Addendum R-13926 | Open-label, randomized, uncontrolled, multicenter, 2-component extension) (PK and                                                                      | Primary. PK Component: Relative bioavailabilityof2 tablet products compared tothe short-tem safety and tolerability Extension capsule;the effectof tablet products; foodonthePKof Component: Long- temsafetyand tolerability                                                                                                                                           | Patients with30 mCRPC                                                                 |                                                                                              | Darolutamide 600mg PK Component: singledoseorally with and wlofood Extension Component: multiple dose BID orally Concurrently with ADT (both components) | 30male 68.0years (54-86years) 30patients (100%) Caucasian:                                                                                 | Extentofexposure TEAES TESAES Deaths Laboratory Vital signs parameters ECG | R-9789 Deaths: Grade 5 TEAE: 1 patient (3.3%) Overall:3deaths 11 patients (36.7%) TEAEsleadingto TESAEs: discontinuation: 3 patients (10.0%)d Any TEAE: 23 patients (76.7%) AddendumR-13926 TESAEs: 2 patients                                        |
| Studyno. and Phase                 | Numberof study centersand locations                                                                                                                                                                                                                                                                    | Study period and study reports                                                                                                                    | Study design andtypeof control                                                                                                                         | Primary and secondary objectives                                                                                                                                                                                                                                                                                                                                       | Study population                                                                      | Treatedpatients /exposed subjects as of 25OCT 2021                                           | Treatment and dose                                                                                                                                       | Demographics Gender Median age in years (range) Race                                                                                       | Safety evaluations included in the submission                              | Deaths/SAEs / AEs leading to study discontinuation/Any treatment AE a                                                                                                                                                                                 |
| 17829 ARADES (3104001) Phase 1/2   | 23centersinCzech Republic,Estonia, Finland,France, UK, US                                                                                                                                                                                                                                              | FPFV 28MAR 2011 LPLV D9JUL2013 ReportR-9584 Module 5.3.3.2,                                                                                       | Phase1: Open-label, non- randomized, uncontrolled, multicenter,first inman,dose- Open-label, escalation Phase 2: randomized, uncontrolled, multicenter | Primary: Phase1:Safetyand tolerability, including  DLTs and MTD Phase 2: Efficacy andsafetyof 3doselevels darolutamide at Secondary: Phase 1:PK profile of darolutamideand itsmajormetabolite after single and multipledose administrations in fedcondition at differentdoselevels BothPhases: preliminary antitumor activity, the dose(s) forfurther clinical studies | Patients withTotal:134 mCRPC                                                          | Phase 1: 24 Phase 2: 110                                                                     | Phase 1: Darolutamide 100-900mg BID orally with food Darolutamide Phase 2: 100mg 700 mg 200mg BID orally with pooj Concurrentlywith ADT (both phases)    | 134male 69.0 years (Ph 1) 69.5 years (Ph 2) (53-89 years) 128 patients Caucasian: (95.5%) 5 patients (3.7%) Black: Asian: 1 patient (0.7%) | Extentofexposure TEAES TESAES Deaths Laboratory parameters Vital signs ECG | Deaths: Grade5TEAEin 2 patients (1.5%) during treatment period Grade5TEAEin 2 patients (1.5%) during post-treatment period Overall:5deaths 13 patients (9.7%) TESAES: TEAEsleadingto discontinuation: 5 patients (3.7%) AnyTEAE: 117 patients (87.3%) |
| 18035 ARADES. EXT (3104002) Phase2 | 17centersinCzechFPFV Republic,Estonia, Finland, France, UK, US                                                                                                                                                                                                                                         | 30JUN2011 LPLV 21OCT2015 Module5.3.5.2, ReportR-11102                                                                                             | Extensionstudy for study 17829                                                                                                                         | Primary: Long-temsafety andtolerability Secondary. Antitumoractivity                                                                                                                                                                                                                                                                                                   | mCRPC                                                                                 | Patientswith76patientsfrom study17829 continuedto extension from Phase 1:19 from Phase 2: 57 | Samedoseas given inWeek12 of study 17829 Onedose escalationattime ofdisease progressionwas allowed                                                       | 76male 68.0years (55-83years) Caucasian: 74 patients (97.4%) Black: 1 patient(1.3%) Asian: 1patient(1.3%)                                  | Extentofexposure TEAES TESAES Deaths Laboratory parameters Vital signs ECG | Deaths: Grade 5 TEAE in 1 patient (1.3%) TESAES: 19 patients (25.0%) TEAEsleadingto discontinuation: 3 patients (3.9%) Any TEAE: 76 patients (100%)                                                                                                   |
| 20321 (ROS) Phase3                 | Argentina,Australia,FPFv Austria,Belarus, Belgium, Brazil, Bulgaria,Canada, Colombia, Czech Republic, Estonia, Finland,France, Gemany,Hungary Italy,apan, Latvia, Lithuania,Peru, Poland,Portugal, Romania,Russian Federation,Serbia Slovakia,South Africa, SouthKorea; Spain,Sweden, Taiwan, Turkey, | 20OCT2020 Ongoing Primary completion notreached                                                                                                   | Open-label,                                                                                                                                            | Primary. singleam,RosContinuationof darolutamide treatment and evaluationofsafety                                                                                                                                                                                                                                                                                      | Patients withTotal 4101 nmCRPC (fromStudy 17712) Patientswith mCRPC (fromStudy 17830) | 409patients (from Study 17712) 1patient 17830) (fromStudy                                    | Darolutamide600 mg(2tablets of 300mg)BIDwith food, equal to a daily doseof Concurrently with 1200mg,or placebo ADT                                       | NA primary completion notreached                                                                                                           | Deaths SAES AEs leading to discontinuation                                 | Deaths:' 8deaths SAEs:1 38 patients discontinuation:t AEsleadingto 7 patients                                                                                                                                                                         |
| 21140 ARANOTE Phase3               | Ukraine,UK,US Australia, Brazil, Canada, Chile, mainland China, India, Latvia, Lithuania,New Zealand,Peru, RussianFederation, SouthAfrica,Spain Taiwan, Ukraine                                                                                                                                        | FPFV 23 FEB 2021 Ongoing Primary completion notreached                                                                                            | Open-label, randomized, double-blind, placebo- controlled, multicenter                                                                                 | Primary: Superiority of darolutamide+ADT overplacebo+ADT inrPFS                                                                                                                                                                                                                                                                                                        | Patients with119 mHSPC                                                                |                                                                                              | Darolutamide600 mg (2 tablets of 300mg)BIDwith food, equal to a daily dose of 1200mg,or placebo Concurrently with ADT                                    | NA (primary completion SAEs not reached)                                                                                                   | Deaths AEsleading to discontinuation                                       |                                                                                                                                                                                                                                                       |

Abbreviations: ADT=Androgen deprivation therapy; AE=Adverse event; BID=Twice daily; 14C=Carbon-14 (radiocarbon); CBF=Cerebral blood flow; CRPC=Castration-resistant prostate cancer;

CYP=Cytochrome P450; DLT=Dose limiting toxicity; ECG=Electrocardiogram; FPFV=First patient first visit; FSFV=First subject first visit; HI=Hepatic impairment; IV=Intravenous; LPLV=Last patient last visit; LSLV=Last subject last visit; mCRPC=Metastatic castration-resistant prostate cancer; mHSPC=Metastatic hormone-sensitive prostate cancer; MTD=Maximum tolerated dose;

<div style=\"page-break-after: always\"></div>

NA=Not available; nmCRPC=Non-metastatic castration-resistant prostate cancer; no.=Number; OS=Overall survival; Ph=Phase; PK=Pharmacokinetics, pharmacokinetic;

PV=Pharmacovigilance; RI=Renal impairment; ROS=Roll-over study; rPFS=Radiological progression-free survival; SAE=Serious adverse event; SSE=Symptomatic skeletal event; SSEFS=

Symptomatic skeletal event-free survival; TEAE=Treatment-emergent adverse event; TESAE=Treatment-emergent serious adverse event; UK=United Kingdom; US=United States of

America; w/o=Without

- a: Only AEs occurring during study treatment (from first to last dose of study treatment) are included for study 17829. AEs occurring from start of study treatment until end-of-study visit are included

for studies 18035, 17830 and 17831. For all other completed studies, AEs occurring after start of study treatment until 30 days after the last study drug intake are presented.

- b: There were 299 patients in the darolutamide+docetaxel arm and 125 in the placebo+docetaxel arm ongoing with treatment at the time of the database cut-off date for the primary completion analysis of Study 17777 (25 OCT 2021).
- c: Demographics data are for the full analysis set, including 651 patients in the darolutamide+docetaxel arm and 654 patients in the placebo+docetaxel arm.
- d: Excluding 1 death leading to discontinuation.
- e: In the integrated safety analysis, the data from study 18035 (long-term safety follow-up of 76 patients who continued treatment after the 12-week treatment period of study 17829) are pooled with the safety data from study 17829.

##  Patient exposure

## Darolutamide exposure

A summary of study drug exposure in Study 17777 until the database cut-off date for the primary completion analysis (25 OCT 2021) is presented in the table below.

Table 51 Study drug exposure in Study 17777 (SAF)

|                                       | Darolutamide+ docetaxel arm N=652   | Placebo+ docetaxelarm N=650   |
|---------------------------------------|-------------------------------------|-------------------------------|
| Overall time under treatment(months)3 |                                     |                               |
| Mean (StD)                            | 31.853 (16.758)                     | 22.188 (15.349)               |
| Min, Max                              | 0.13, 56.50                         | 0.26, 55.78                   |
| Median                                | 40.982                              | 16.689                        |
| Categories (months), n (%) a          |                                     |                               |
| 0-3                                   | 34 (5.2%)                           | 23 (3.5%)                     |
| >3-6                                 | 22 (3.4%)                           | 53 (8.2%)                     |
| >6-9                                 | 33 (5.1%)                           | 71 (10.9%)                    |
| >9-12                                | 26 (4.0%)                           | 82 (12.6%)                    |
| >12-18                               | 69 (10.6%)                          | 118 (18.2%)                   |
| >18-24                               | 57 (8.7%)                           | 60 (9.2%)                     |
| >24 -30                              | 34 (5.2%)                           | 44 (6.8%)                     |
| >30-36                               | 31 (4.8%)                           | 33 (5.1%)                     |
| >36-42                               | 35 (5.4%)                           | 34 (5.2%)                     |
| >42-48                               | 206 (31.6%)                         | 94 (14.5%)                    |
| >48                                   | 105 (16.1%)                         | 38 (5.8%)                     |
| Average daily dose (mg/day) b         |                                     |                               |
| Mean (StD)                            | 1176.712 (96.585)                   | 1187.563 (65.658)             |
| Min, Max                              | 605.61,1200.87                      | 615.75,1204.36                |
| Median                                | 1200.000                            | 1200.000                      |
| Percent of planned dose c             |                                     |                               |
| Mean (StD)                            | 97.239 (9.276)                      | 98.459 (6.119)                |
| Min, Max                              | 32.14, 100.07                       | 48.40, 100.36                 |
| Median                                | 100.000                             | 100.000                       |

After the last dose of docetaxel, patients continued on study drug treatment for a median time of 36.9 months in the darolutamide + docetaxel + ADT arm (n=642) and 13.1 months in the placebo + docetaxel + ADT arm (n=637).

<div style=\"page-break-after: always\"></div>

Two cases of darolutamide overdose were reported, both with an actual total daily dose of 2400 mg for 1 day only. Following the overdose, no TEAEs were reported for either patient.

## Docetaxel exposure

In Study 17777, docetaxel was administered at a dose of 75 mg/m 2  as an IV infusion every 21 days for 6 cycles, starting within 6 weeks after the start of study drug. A summary of docetaxel exposure in Study 17777 until the database cut-off date for the primary completion analysis is presented in the table below.

Table 52 Docetaxel exposure in Study 17777 (SAF)

|                                                       | Darolutamide+ docetaxel arm N=652   | Placebo+ docetaxel arm N=650   |
|-------------------------------------------------------|-------------------------------------|--------------------------------|
| Number of patients with total number of cycles, n (%) |                                     |                                |
| 0 (never received docetaxel)                          | 10 (1.5%)                           | 13 (2.0%)                      |
| 1                                                     | 20 (3.1%)                           | 16 (2.5%)                      |
| 2                                                     | 14 (2.1%)                           | 14 (2.2%)                      |
| 3                                                     | 14 (2.1%)                           | 7 (1.1%)                       |
| 4                                                     | 12 (1.8%)                           | 17 (2.6%)                      |
| 5                                                     | 11 (1.7%)                           | 27 (4.2%)                      |
| 6                                                     | 571 (87.6%)                         | 556 (85.5%)                    |
| Total number of cycles                                |                                     |                                |
| N                                                     | 642                                 | 637                            |
| Mean (StD)                                            | 5.637 (1.134)                       | 5.658 (1.055)                  |
| Min, Max                                              | 1.00, 6.00                          | 1.00, 6.00                     |
| Median                                                | 6.000                               | 6.000                          |
| Average cycle dose received (mg)                      |                                     |                                |
| N                                                     | 642                                 | 637                            |
| Mean (StD)                                            | 138.497 (18.604)                    | 139.055 (19.057)               |
| Min, Max                                              | 82.96,195.00                        | 65.76, 206.00                  |
| Median                                                | 140.000                             | 139.667                        |
| Percent of planned dose a                             |                                     |                                |
| N                                                     | 638                                 | 635                            |
| Mean (StD)                                            | 96.039 (6.312)                      | 95.843 (6.587)                 |
| Min, Max                                              | 72.78, 109.90                       | 51.78,105.39                   |
| Median                                                | 98.567                              | 98.485                         |
| Missing (n)                                           | 14                                  | 15                             |

Abbreviations: Max=Maximum; Min=Minimum; N=Total number of patients (100%); n=Number of patients within category; SAF=Safety analysis set; StD=Standard deviation

Most patients in both treatment arms received at least 1 dose of docetaxel within 6 weeks after the first dose of darolutamide or placebo. There were 10 patients (1.5%) in the darolutamide + docetaxel + ADT arm and 13 patients (2.0%) in the placebo + docetaxel + ADT arm who never received docetaxel. These patients were initially assessed by the investigator to be candidates for ADT and docetaxel. After randomization and start of study drug, they were no longer considered to be eligible to receive concomitant docetaxel within 6 weeks after start of study drug.

## Disposition

- Study 17777

A summary of patient disposition in Study 17777 as of the database cut-off date for the primary completion analysis (25 OCT 2021) is presented in Table 53 by treatment arm. Note: the end of treatment was defined as the day of the last dose of study drug (darolutamide or placebo).

<div style=\"page-break-after: always\"></div>

Table 53 Patient disposition at the time of database cut-off date in Study 17777 (FAS)

| Number of patients (%)                                   | Darolutamide+ docetaxel arm N=652 n (%)   | Placebo+ docetaxel arm N=650 n (%)   |
|----------------------------------------------------------|-------------------------------------------|--------------------------------------|
| Randomized(N=1305;includedinFAS)                        | 651 (100.0%) 0                            | 654 (100.0%)                         |
| Study drug never administered                            |                                           | 3 (0.5%)                             |
| Started treatment (N=1302;included in SAF b)             | 651 (100.0%)                              | 651 (99.5%)                          |
| Discontinuedstudytreatment                               | 352 (54.1%)                               | 526 (80.4%)                          |
| Primaryreason:                                           |                                           |                                      |
| Progressive disease-clinical progression                 | 127 (19.5%)                               | 272 (41.6%)                          |
| Progressive disease -radiological progression            | 84 (12.9%)                                | 132 (20.2%)                          |
| Adverseeventnotassociatedwithclinicaldisease progression | 48 (7.4%)                                 | 27 (4.1%)                            |
| Withdrawal by patient                                    | 25 (3.8%)                                 | 35 (5.4%)                            |
| Adverseeventassociatedwithclinicaldisease progression    | 24 (3.7%)                                 | 26 (4.0%)                            |
| Non-compliance with study drug                           | 14 (2.2%)                                 | 12 (1.8%)                            |
| Additionalprimarymalignancy                              | 11 (1.7%)                                 | 6 (0.9%)                             |
| Death                                                    | 8 (1.2%)                                  | 5 (0.8%)                             |
| COVID-19 related death c                                 | 0                                         | 0                                    |
| Lost to follow-up                                        | 4 (0.6%)                                  | 1 (0.2%)                             |
| Other                                                    | 3 (0.5%)                                  | 4 (0.6%)                             |
| COVID-19pandemicrelatedotherreason                       | 0                                         | 1 (0.2%)                             |
| Physician decision                                       | 3 (0.5%)                                  | 6 (0.9%)                             |
| Protocol violation                                       | 1 (0.2%)                                  | 0                                    |
| Ongoing with study treatment (as of the cut-off date)    | 299 (45.9%)                               | 125 (19.1%)                          |

Abbreviations:COVID-19=Coronavirus disease2019;FAS=Full analysisset;GCP=Good clinicalpractice;N=Totalnumberof patients;n=Numberof patientswithincategory;SAF=Safety analysisset;TEAE=Treatment-emergent adverseevent

a:1306patientswererandomized.Onepatient wasexcludedfrom analysisduetoaGCPviolation(Module5.3.5.1,ReportPH42024,Sections 8.2.3 and 8.3).

b:Theanalysissetsinthistablearepresentedbasedontherandomizedtreatmentassignment.Onepatientwasrandomizedto theplacebo+docetaxelarmbutreceived atleastonedoseofdarolutamide.Thispatientwasincluded inthe darolutamide+docetaxelarmintheanalysisofallsafetyvariables.

c:Although therewere in total 6patientswithfatal(Grade5) TEAEsreported that wererelated toCOVID-19(Section 2.1.11),

- mCRPC pool

## Table 54 Pooled Phase1/2 studies in mCRPC patients

| Study no                       | PhasePopulationFPFV            |                                | LPLVorlatest cut-off   | Reportno                    | Study status   | Dose (mg BID)                 | Treated patients in mCRPC pool (SAF)   |
|--------------------------------|--------------------------------|--------------------------------|------------------------|-----------------------------|----------------|-------------------------------|----------------------------------------|
| 17829 18035a                   | 1/2 mCRPC                      | 28 MAR 2011 30JUN2011          | 09JUL2013 21 OCT 2015  | R-9584, R-11102             | Completed      | 100 200 300 500 700 900 Total | 42 44 3 4 38 3 134                     |
| 17830                          | 1 mCRPC                        | 14MAR 2013 14 MAR 2013         | 30APR2017 18 DEC2020b  | R-9789, Addendum R-13926    | Completed      | 600                           | 30                                     |
| 17719                          | 1 mCRPC                        | 23 FEB 2015 23 FEB 2015        | 09MAY 2016 21 DEC 2017 | PH-39192, Addendum PH-40296 | Completed      | 300 600 Total                 | 3 6 9                                  |
| ToTALnumberofpatientsinthepool | ToTALnumberofpatientsinthepool | ToTALnumberofpatientsinthepool |                        |                             | Darolutamide   | Darolutamide                  | 173                                    |

Abbreviations:BID=Twice daily;FPFV=First patient first visit;LPLV=Last patient last visit;mCRPC=Metastatic castrationresistantprostatecancer;SAF=Safetyanalysisset a: In the integrated safety analysis, the data from Study 18035 (long-term safety follow-up of 76 patients who continued

b: Only the data collected between30 APR 2017 (cut-off for the mainreport) and 18DEC 2020(LPLV) for the 6 patients who continued on treatment after the report cut-off are included in the report addendum (Module 5.3.1.1, Report Addendum R-13926).

c:Onlythedatacollectedbetween09MAY2016(cut-offforthemainreport)and21DEC2017(LPLV)fortheonepatient Addendum PH-40296).

<div style=\"page-break-after: always\"></div>

Table 55 Treatment duration in mCRPC pool (SAF)

|                                                    | Total N=173   |
|----------------------------------------------------|---------------|
| Duration of treatment (months) a                   |               |
| Mean (StD)                                         | 10.49 (12.92) |
| Min, Max                                           | 0.0, 90.0     |
| Median                                             | 6.50          |
| Duration of treatment - categories (months), n (%) |               |
| 1                                                 | 8 (4.6%)      |
| >1 to 6                                           | 76 (43.9%)    |
| >6 to 12                                          | 40 (23.1%)    |
| >12 to18                                          | 23 (13.3%)    |
| >18 to 24                                         | 13 (7.5%)     |
| >24 to 30                                         | 4 (2.3%)      |
| >30 to 36                                         | 2 (1.2%)      |
| >36                                                | 7 (4.0%)      |

patients within category; Max=Maximum; Min=Minimum; SAF=Safety analysis set, StD=Standard deviation

a:Months:(dayoflast doseminusdayoffirstdose+1)/30.44.

- Non-cancer patients

The integrated analysis of safety in non-cancer subjects included single dose clinical studies in healthy volunteers and subjects with renal or hepatic impairment. All dose groups were pooled.

Table 56 Pooled Phase 1 single dose studies in non-cancer subjects

| Study no                             | Population                           | FSFV                                 | LSLV                                 |                                      | Report no Study status               | Exposed subjects(SAF) Non-cancer subject pool   |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-------------------------------------------------|
| 17721                                | Healthy Moderate HI Severe RI        | 13SEP2016                            | 10APR2017                            | PH-39976                             | Completed                            | 10 6 10                                         |
| 17726                                | Healthy                              | 15FEB2017                            | 04 MAY 2017                          | PH-40010                             | Completed                            | 15                                              |
| 17831                                | Healthy                              | 26MAR2015                            | 20MAY2015                            | R-11003                              | Completed                            | 12                                              |
| 18426                                | Healthy                              | 23OCT2018                            | 01 OCT2019                           | PH-41300                             | Completed                            | 24                                              |
| ToTAL number of subjects in the pool | ToTAL number of subjects in the pool | ToTAL number of subjects in the pool | ToTAL number of subjects in the pool | ToTAL number of subjects in the pool | ToTAL number of subjects in the pool | 80                                              |

## Adverse events

- Study 17777 (ARASENS)

An overview of TEAEs in mHSPC patients treated with darolutamide or placebo in combination with docetaxel in Study 17777 as of the database cut-off date for the primary completion analysis (25 OCT 2021) is presented in Table 57 .

<div style=\"page-break-after: always\"></div>

Table 57 Overview of TEAEs in Study 17777 (SAF)

| Number of patients (%) with:                              | Darolutamide+ docetaxel arm N=652 n (%)   | Placebo+ docetaxel arm N=650 n (%)   |
|-----------------------------------------------------------|-------------------------------------------|--------------------------------------|
| Any TEAE a                                                | 649 (99.5%)                               | 643 (98.9%)                          |
| Worst Grade 1                                             | 28 (4.3%)                                 | 35 (5.4%)                            |
| Grade 2                                                   | 162 (24.8%)                               | 169 (26.0%)                          |
| Grade 3                                                   | 248 (38.0%)                               | 232 (35.7%)                          |
| Grade 4                                                   | 183 (28.1%)                               | 181 (27.8%)                          |
| Grade 5                                                   | 27 (4.1%)                                 | 26 (4.0%)                            |
| Missing                                                   | 1 (0.2%)                                  | 0                                    |
| Grade 1 or 2                                              | 190 (29.1%)                               | 204 (31.4%)                          |
| Grade3or 4                                                | 431 (66.1%)                               | 413 (63.5%)                          |
| Grade 3,4 or 5                                            | 458 (70.2%)                               | 439 (67.5%)                          |
| TESAE                                                     | 292 (44.8%)                               | 275 (42.3%)                          |
| TEAE leading to study drug dose modification b            | 169 (25.9%)                               | 112 (17.2%)                          |
| TEAE leading to pemmanent discontinuation of study drug * | 88 (13.5%)                                | 69 (10.6%)                           |
| TEAE leading to docetaxel dose modification b             | 214 (32.8%)                               | 214 (32.9%)                          |
| TEAE leading to pemmanent discontinuation of docetaxel c  | 52 (8.0%)                                 | 67 (10.3%)                           |
| Related to protocol-required procedure                    | 66 (10.1%)                                | 63 (9.7%)                            |

<div style=\"page-break-after: always\"></div>

|                                                                            | Darolutamide+ docetaxel arm N=652   | Placebo+ docetaxel arm N=650   |
|----------------------------------------------------------------------------|-------------------------------------|--------------------------------|
| Number of patients (%) with:                                               | n (%)                               | n (%)                          |
| Any study drug-related TEAE a. d                                           | 340 (52.1%)                         | 308 (47.4%)                    |
| Worst Grade 1                                                              | 140 (21.5%)                         | 144 (22.2%)                    |
| Grade 2                                                                    | 138 (21.2%)                         | 123 (18.9%)                    |
| Grade 3                                                                    | 53 (8.1%)                           | 31 (4.8%)                      |
| Grade 4                                                                    | 9 (1.4%)                            | 7 (1.1%)                       |
| Grade 5                                                                    | 0                                   | 3 (0.5%)                       |
| Grade 1 or 2                                                               | 278 (42.6%)                         | 267 (41.1%)                    |
| Grade 3or 4                                                                | 62 (9.5%)                           | 38 (5.8%)                      |
| Grade 3,4 or5                                                              | 62 (9.5%)                           | 41 (6.3%)                      |
| Study drug-related TESAE                                                   | 29 (4.4%)                           | 23 (3.5%)                      |
| Study drug-related TEAE leading to study drug dose modification b          | 75 (11.5%)                          | 41 (6.3%)                      |
| Study drug-related TEAE leading to permanent discontinuation of study drug | 25 (3.8%)                           | 13 (2.0%)                      |
| Any docetaxel-related TEAEa. d                                             | 573 (87.9%)                         | 575 (88.5%)                    |
| Worst Grade 1                                                              | 111 (17.0%)                         | 115 (17.7%)                    |
| Grade 2                                                                    | 183 (28.1%)                         | 183 (28.2%)                    |
| Grade 3                                                                    | 117 (17.9%)                         | 112 (17.2%)                    |
| Grade 4                                                                    | 160 (24.5%)                         | 161 (24.8%)                    |
| Grade 5                                                                    | 1 (0.2%)                            | 4 (0.6%)                       |
| Missing                                                                    | 1 (0.2%)                            |                                |
| Grade 1or 2                                                                | 294 (45.1%)                         | 298 (45.8%)                    |
| Grade 3or 4                                                                | 277 (42.5%)                         | 273 (42.0%)                    |
| Grade 3,4or 5                                                              | 278 (42.6%)                         | 277 (42.6%)                    |
| Docetaxel-related TESAE                                                    | 110 (16.9%)                         | 105 (16.2%)                    |
| Docetaxel-relatedTEAEleading todocetaxel dose modification b               | 179 (27.5%)                         | 180 (27.7%)                    |
| Docetaxel-related TEAEleading to permanent discontinuation of docetaxel    | 45 (6.9%)                           | 57 (8.8%)                      |

Abbreviations: AE=Adverse event; CTCAE=Common Terminology Criteria for Adverse Events; N=Total number of patients (100%); n=Number of patients with event; SAF=Safety analysis set; TEAE=Treatment-emergent adverse event;

a: Any TEAE also includes patients with grade not available for all AEs.

TESAE=Treatment-emergent serious adverse event b: Modifications include dose interruptions/delays and reductions.

c: Discontinuation of study drug (darolutamide/placebo) and docetaxel due to an AE was calculated for AEs where action taken was checked as \"Drug Withdrawn\".

d: Based on investigator's assessment.

CTCAE version 4.03.

## Most common TEAEs

An overview of the TEAEs reported in 10% of patients in either treatment arm of Study 17777 is presented in Table 58 by MedDRA Preferred Term (PT). To adjust for potential differences in study drug treatment duration between the treatment arms, exposure-adjusted incidence rates (EAIRs) per 100 PYs are also summarized.

<div style=\"page-break-after: always\"></div>

Table 58 Incidences and exposure-adjusted incidence rates of the most common TEAEs by MedDRA PT occurring in 10% of patients in either treatment arm in Study 17777 (SAF)

|                                      | Darolutamide+ docetaxel am N=652   | Darolutamide+ docetaxel am N=652   | Darolutamide+ docetaxel am N=652   | Darolutamide+ docetaxel am N=652   | Darolutamide+ docetaxel am N=652   | Placebo+ docetaxel amm N=650   | Placebo+ docetaxel amm N=650   | Placebo+ docetaxel amm N=650   | Placebo+ docetaxel amm N=650   | Placebo+ docetaxel amm N=650   |
|--------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                      | Total n (%)                        | EAIR per 100 PY                    | Worst CTCAE grade                  | Worst CTCAE grade                  | Worst CTCAE grade                  | Total n (%)                    | EAIR per 100                   | Worst CTCAE grade              | Worst CTCAE grade              | Worst CTCAE grade              |
| MedDRA PT V. 24.1                    |                                    |                                    | Grade 3 n(%)                       | Grade 4 n(%)                       | Grade 5 n (%)                      |                                | PY                             | Grade 3 n (%)                  | Grade 4 n (%)                  | Grade 5 n (%)                  |
| Alopecia                             | 264 (40.5)                         | 15.3                               | 1 (0.2)                            | 0                                  | 0                                  | 264 (40.6)                     | 22.0                           | 2 (0.3)                        |                                | D                              |
| Fatigue                              | 216 (33.1)                         | 12.5                               | 11 (1.7)                           | 0                                  | D                                  | 214 (32.9)                     | 17.8                           | 12 (1.8)                       | D                              | D                              |
| Anaemia                              | 181 (27.8)                         | 10.5                               | 29 (4.4)                           | 2 (0.3)                            | D                                  | 163 (25.1)                     | 13.6                           | 32 (4.9)                       | 1 (0.2)                        | D                              |
| Arthralgia                           | 178 (27.3)                         | 10.3                               | 8 (1.2)                            | 0                                  | D                                  | 174 (26.8)                     | 14.5                           | 9 (1.4)                        |                                | D                              |
| Oedema peripheral                    | 173 (26.5)                         | 10.0                               | 2 (0.3)                            | 1 (0.2)                            | D                                  | 169 (26.0)                     | 14.1                           | 1 (0.2)                        |                                | D                              |
| Neutrophil count decreased           | 170 (26.1)                         | 9.8                                | 39 (6.0)                           | 12 (17.2)                          | D                                  | 155 (23.8)                     | 12.9                           | 41 (6.3)                       | 19 (15.2)                      | D                              |
| Diarhoea                             | 167 (25.6)                         | 9.6                                | 8 (1.2)                            | 0                                  | D                                  | 156 (24.0)                     | 13.0                           | 7 (1.1)                        | 0                              | D                              |
| White blood cell count decreased     | 155 (23.8)                         | 9.0                                | 86 (13.2)                          | 24 (3.7)                           | D                                  | 143 (22.0)                     | 11.9                           | 80 (12.3)                      | 17 (2.6)                       |                                |
| Constipation                         | 147 (22.5)                         | 8.5                                | 2 (0.3)                            | 0                                  |                                    | 130 (20.0)                     | 10.8                           | 2 (0.3)                        | D                              | D                              |
| Hot flush                            | 124 (19.0)                         | 7.2                                | D                                  | 0                                  | D                                  | 122 (18.8)                     | 10.2                           | 1 (0.2)                        | 0                              |                                |
| Back pain                            | 123 (18.9)                         | 7.1                                | 12 (1.8)                           | 0                                  | D                                  | 123 (18.9)                     | 10.2                           | 11 (1.7)                       |                                | D                              |
| Decreased appetite                   | 121 (18.6)                         | 7.0                                | 1 (0.2)                            | 0                                  | D                                  | 85 (13.1)                      | 7.1                            | 4 (0.6)                        | D                              | 0                              |
| Weight increased                     | 116 (17.8)                         | 6.7                                | 14 (2.1)                           | 0                                  | D                                  | 102 (15.7)                     | 8.5                            | 8 (1.2)                        |                                |                                |
| Nausea                               | 115 (17.6)                         | 6.6                                | 3 (0.5)                            | 0                                  | D                                  | 133 (20.5)                     | 11.1                           | 2 (0.3)                        | D                              | D                              |
| Alanine aminotransferase increased   | 102 (15.6)                         | 5.9                                | 17 (2.8)                           | 1 (0.2)                            | D                                  | 84 (12.9)                      | 7.0                            | 9 (1.4)                        | 2 (0.3)                        | D                              |
| Pain in extremity                    | 98 (15.0)                          | 5.7                                | 2 (0.3)                            | 0                                  | D                                  | 78 (12.0)                      | 6.5                            | 2 (0.3)                        |                                | D                              |
| Aspartate aminotransferase increased | 91 (14.0)                          | 5.3                                | 16 (2.5)                           | 1 (0.2)                            | D                                  | 68 (10.5)                      | 5.7                            | 6 (0.9)                        | 1 (0.2)                        | D                              |
| Pyrexia                              | 86 (13.2)                          | 5.0                                | 3 (0.5)                            | 0                                  | D                                  | 90 (13.8)                      | 7.5                            | 3 (0.5)                        | D                              | D                              |
| Hypertension                         | 85 (13.0)                          | 4.9                                | 42 (6.4)                           | 0                                  | 1 (0.2)                            | 59 (9.1)                       | 4.9                            | 21 (3.2)                       | D                              | D                              |
| Cough                                | 84 (12.9)                          | 4.9                                | D                                  | 0                                  | D                                  | 73 (11.2)                      | 6.1                            | D                              | D                              | D                              |
| Bone pain                            | 81 (12.4)                          | 4.7                                | 8 (1.2)                            | 0                                  | D                                  | 84 (12.9)                      | 7.0                            | 17 (2.6)                       | 2 (0.3)                        | D                              |
| Neuropathy peripheral                | 76 (11.7)                          | 4.4                                | 3 (0.5)                            | 0                                  | D                                  | 67 (10.3)                      | 5.6                            | D                              | D                              | D                              |
| Hyperglycaemia                       | 74 (11.3)                          | 4.3                                | 17 (2.6)                           | 1 (0.2)                            | D                                  | 61 (9.4)                       | 5.1                            | 20 (3.1)                       | 4 (0.6)                        | D                              |
| Insomnia                             | 74 (11.3)                          | 4.3                                | D                                  | 0                                  | D                                  | 81 (12.5)                      | 6.7                            | D                              |                                |                                |
| Myalgia                              | 73 (11.2)                          | 4.2                                | 2 (0.3)                            |                                    | D                                  | 63 (9.7)                       | 5.2                            | 2 (0.3)                        | D                              | D                              |
| Dysgeusia                            | 69 (10.6)                          | 4.0                                | D                                  | 0                                  | D                                  | 80 (12.3)                      | 6.7                            | D                              |                                | D                              |
| Asthenia                             | 68 (10.4)                          | 3.9                                | 1 (0.2)                            | 0                                  | D                                  | 65 (10.0)                      | 5.4                            | 3 (0.5)                        | 0                              | D                              |
| Neutropenia                          | 68 (10.4)                          | 3.9                                | 18 (2.8)                           | 38 (5.8)                           | D                                  | 76 (11.7)                      | 6.3                            | 18 (2.8)                       | 50 (7.7)                       |                                |
| Stomatitis                           | 66 (10.1)                          | 3.8                                | 4 (0.6)                            | 0                                  | D                                  | 57 (8.8)                       | 4.7                            | 4 (0.6)                        |                                |                                |
| Peripheral sensory neuropathy        | 65 (10.0)                          | 3.8                                | 2 (0.3)                            | 0                                  | D                                  | 67 (10.3)                      | 5.6                            | 2 (0.3)                        |                                | D D                            |
| Urinary tract infection              | 61 (9.4)                           | 3.5                                | 13 (2.0)                           | 0                                  | D                                  |                                |                                |                                |                                | D                              |
| Dyspnoea                             |                                    |                                    | 2 (0.3)                            | 0                                  |                                    | 67 (10.3)                      | 5.6                            | 12 (1.8)                       |                                |                                |
| Malaise                              | 59 (9.0) 57 (8.7)                  | 3.4 3.3                            | D                                  | 0                                  | D D                                | 71 (10.9) 66 (10.2)            | 5.9 5.5                        | 4 (0.6) D                      | D                              | 1 (0.2) D                      |

Abbreviations: CTCAE=Common Temminology Criteria for Adverse Events; EAlR=Exposure-adjusted incidence rate; MedDRA=Medical Dictionary for Regulatory Activities;: N=Total number of patients (100%6): n=Number of patients with event; PT=Preferred tem, PY=Patient year; SAF=Safety analysis set; TEAE=Treatment-emergent adverse event a: EAIR of TEAEs, defined as the number of patients with a given TEAE divided by the total study drug treatment duration of all patients in years. The rate is expressed in number of patients with events per 100 PYs.

The EAlR is less relevant for adverse events that are known to occur with docetaxel and occumed predominantly during the first 6 months of study treatment (Section 2.1.2.2).

## Note:

A patient may have more than one entry.

The total column also includes patients with a missing CTCAE grade (2 patients with white blood cell count decreased and 1 patient with edema peripheral in the darolutamide+docetaxel arm, and 1 patient with hypertension in the placebo+docetaxel

## TEAEs over time

The incidence (new or worsening TEAEs) and prevalence of the most commonly reported TEAEs were analyzed within pre-specified time intervals (3-month intervals for the first year and 6-month intervals from thereafter up to 24 months) in Study 17777.

Incidences of commonly reported TEAEs, including alopecia, fatigue, anaemia, arthralgia, oedema peripheral, neutrophil count decreased, diarrhoea, WBC count decreased, neuropathy peripheral, and peripheral sensory neuropathy, were highest during the first 3 months of treatment and started to decrease during Months 4 to 6 after the start of study treatment in both treatment arms. A further

<div style=\"page-break-after: always\"></div>

decrease was seen during Months 7 to 12, after completing the docetaxel treatment (data not shown) The incidences of these events then remained stable during continued treatment with study drug.

Prevalence followed a similar general trend for most of the TEAEs listed above; however, the prevalence of TEAEs decreased over a longer period of time. The prevalence of neuropathy peripheral and peripheral sensory neuropathy remained stable throughout the whole study in both treatment arms. A trend of increasing prevalence of arthralgia, hypertension, and hyperglycaemia was observed in both treatment arms.

## Analysis of AEs by system organ class ( SOC)

A summary of TEAEs by MedDRA SOC and worst CTCAE grade in Study 17777 is shown below.

Table 59 Incidence of TEAEs by MedDRA SOC and worst grade in Study 17777 (SAF)

|                                                                 | Darolutamide+ docetaxelarm N=652 n (%)   | Darolutamide+ docetaxelarm N=652 n (%)   | Darolutamide+ docetaxelarm N=652 n (%)   | Darolutamide+ docetaxelarm N=652 n (%)   | Darolutamide+ docetaxelarm N=652 n (%)   | Darolutamide+ docetaxelarm N=652 n (%)   | Placebo+ docetaxelarm N=650 n (%)   | Placebo+ docetaxelarm N=650 n (%)   | Placebo+ docetaxelarm N=650 n (%)   | Placebo+ docetaxelarm N=650 n (%)   | Placebo+ docetaxelarm N=650 n (%)   | Placebo+ docetaxelarm N=650 n (%)   |
|-----------------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| MedDRASOC V. 24.1                                               |                                          | Grade 1                                  |                                          | Worst CTCAE grade Grade3                 | Grade 4                                  | Grade 5                                  | Total                               | Grade 1                             | Worst CTCAE grade Grade 2           | Grade3                              | Grade 4                             | Grade 5                             |
| AIISOCs                                                         | Total 648 (99.4)                         | 28 (4.3)                                 | Grade 2 162 (24.8)                       | 248 (38.0)                               | 183 (28.1)                               | 27 (4.1)                                 | 643 (98.9)                          | 35 (5.4)                            | 169 (26.0)                          | 232 (35.7)                          | 181 (27.8)                          | 26 (4.0)                            |
| Generaldisordersandadministrationsiteconditions                 | 461 (70.7)                               | 250 (38.3)                               | 181 (27.8)                               | 25 (3.8)                                 | 1 (0.2)                                  | 4 (0.6)                                  | 458 (70.5)                          | 239 (36.8)                          | 188 (28.9)                          | 21 (3.2)                            | 1 (0.2)                             | 9 (1.4)                             |
| Musculoskeletalandconnectivetissuedisorders                     | 421 (64.6)                               | 191 (29.3)                               | 179 (27.5)                               | 51 (7.8)                                 | 0                                        | 0                                        | 406 (62.5)                          | 191 (29.4)                          | 160 (24.6)                          | 52 (8.0)                            | 3 (0.5)                             | 0                                   |
| Skinandsubcutaneoustissuedisorders                              | 418 (64.1)                               | 245 (37.6)                               | 153 (23.5)                               | 19 (2.9)                                 | 1 (0.2)                                  | 0                                        | 398 (61.2)                          | 245 (37.7)                          | 149 (22.9)                          | 4 (0.6)                             | 0                                   | 0                                   |
| Gastrointestinal disorders                                      | 405 (62.1)                               | 216 (33.1)                               | 155 (23.8)                               | 33 (5.1)                                 | 1 (0.2)                                  | 0                                        | 411 (63.2)                          | 221 (34.0)                          | 156 (24.0)                          | 30 (4.6)                            | 3 (0.5)                             | 1 (0.2)                             |
| Investigations                                                  | 375 (57.5)                               | 87 (13.3)                                | 79 (12.1)                                | 89 (13.7)                                | 120 (18.4)                               | 0                                        | 353 (54.3)                          | 74 (11.4)                           | 72 (11.1)                           | 96 (14.8)                           | 111 (17.1)                          | 0                                   |
| Nervoussystemdisorders                                          | 344 (52.8)                               | 206 (31.6)                               | 96 (14.7)                                | 36 (5.5)                                 | 3 (0.5)                                  | 3 (0.5)                                  | 342 (52.6)                          | 214 (32.9)                          | 95 (14.6)                           | 31 (4.8)                            | 1 (0.2)                             | 1 (0.2)                             |
| Infections and infestations                                     | 320 (49.1)                               | 71 (10.9)                                | 155 (23.8)                               | 73 (11.2)                                | 15 (2.3)                                 | 6 (0.9)                                  | 309 (47.5)                          | 66 (10.2)                           | 165 (25.4)                          | 62 (9.5)                            | 10 (1.5)                            | 6 (0.9)                             |
| Metabolism and nutritiondisorders                               | 273 (41.9)                               | 134 (20.6)                               | 83 (12.7)                                | 48 (7.4)                                 | 8 (1.2)                                  | 0                                        | 222 (34.2)                          | 76 (11.7)                           | 78 (12.0)                           | 56 (8.6)                            | 11 (1.7)                            | 1 (0.2)                             |
| Blood and lymphatic system disorders                            | 270 (41.4)                               | 60 (9.2)                                 | 69 (10.6)                                | 94 (14.4)                                | 47 (7.2)                                 | 0                                        | 266 (40.9)                          | 64 (9.8)                            | 58 (8.9)                            | 83 (12.8)                           | 61 (9.4)                            | 0                                   |
| Vasculardisorders                                               | 243 (37.3)                               | 100 (15.3)                               | 91 (14.0)                                | 50 (7.7)                                 | 1 (0.2)                                  | 1 (0.2)                                  | 233 (35.8)                          | 116 (17.8)                          | 89 (13.7)                           | 26 (4.0)                            | 2 (0.3)                             | 0                                   |
| Respiratory,thoracic andmediastinal disorders                   | 227 (34.8)                               | 131 (20.1)                               | 72 (11.0)                                | 17 (2.6)                                 | 3 (0.5)                                  | 4 (0.6)                                  | 229 (35.2)                          | 128 (19.7)                          | 70 (10.8)                           | 22 (3.4)                            | 5 (0.8)                             | 4 (0.6)                             |
| Renaland urinarydisorders                                       | 189 (29.0)                               | 100 (15.3)                               | 56 (8.6)                                 | 30 (4.6)                                 | 3 (0.5)                                  | 0                                        | 177 (27.2)                          | 91 (14.0)                           | 53 (8.2)                            | 30 (4.6)                            | 1 (0.2)                             | 2 (0.3)                             |
| Injury,poisoningandproceduralcomplications                      | 129 (19.8)                               | 53 (8.1)                                 | 58 (8.9)                                 | 17 (2.6)                                 | 0                                        | 1 (0.2)                                  | 102 (15.7)                          | 43 (6.6)                            | 39 (6.0)                            | 19 (2.9)                            | 1 (0.2)                             | 0                                   |
| Psychiatric disorders                                           | 114 (17.5)                               | 74 (11.3)                                | 37 (5.7)                                 | 2 (0.3)                                  | 1 (0.2)                                  | 0                                        | 126 (19.4)                          | 85 (13.1)                           | 41 (6.3)                            | 0                                   | 0                                   | 0                                   |
| Eye disorders                                                   | 100 (15.3)                               | 62 (9.5)                                 | 26 (4.0)                                 | 12 (1.8)                                 | 0                                        | 0                                        | 96 (14.8)                           | 64 (9.8)                            | 24 (3.7)                            | 8 (1.2)                             | 0                                   | 0                                   |
| Cardiacdisorders                                                | 83 (12.7)                                | 35 (5.4)                                 | 27 (4.1)                                 | 12 (1.8)                                 | 4 (0.6)                                  | 5 (0.8)                                  | 90 (13.8)                           | 39 (6.0)                            | 31 (4.8)                            | 16 (2.5)                            | 1 (0.2)                             | 3 (0.5)                             |
| Reproductivesystemandbreastdisorders                            | 67 (10.3)                                | 39 (6.0)                                 | 27 (4.1)                                 | 1 (0.2)                                  | 0                                        | 0                                        | 57 (8.8)                            | 21 (3.2)                            | 28 (4.3)                            | 8 (1.2)                             | 0                                   | 0                                   |
| Neoplasmsbenign,malignant andunspecified(incl cysts and polyps) | 50 (7.7)                                 | 12 (1.8)                                 | 11 (1.7)                                 | 21 (3.2)                                 | 2 (0.3)                                  | 4 (0.6)                                  | 39 (6.0)                            | 17 (2.6)                            | 11 (1.7)                            | 10 (1.5)                            | 1 (0.2)                             | 0                                   |
| Ear and labyrinth disorders                                     | 30 (4.6)                                 | 22 (3.4)                                 | 5 (0.8)                                  | 2 (0.3)                                  | 1 (0.2)                                  | 0                                        | 29 (4.5)                            | 21 (3.2)                            | 6 (0.9)                             | 2 (0.3)                             | 0                                   | 0                                   |
| Hepatobiliarydisorders                                          | 28 (4.3)                                 | 15 (2.3)                                 | 6 (0.9)                                  | 4 (0.6)                                  | 3 (0.5)                                  | 0                                        | 31 (4.8)                            | 12 (1.8)                            | 13 (2.0)                            | 5 (0.8)                             | 0                                   | 1 (0.2)                             |
| Immune systemdisorders                                          | 27 (4.1)                                 | 9 (1.4)                                  | 15 (2.3)                                 | 2 (0.3)                                  | 1 (0.2)                                  | 0                                        | 9 (1.4)                             | 4 (0.6)                             | 3 (0.5)                             | 2 (0.3)                             | 0                                   | 0                                   |
| Surgicalandmedicalprocedures                                    | 13 (2.0)                                 | 4 (0.6)                                  | 0                                        | 9 (1.4)                                  | 0                                        | 0                                        | 6 (0.9)                             | 2 (0.3)                             | 2 (0.3)                             | 2 (0.3)                             | 0                                   | 0                                   |
| Endocrine disorders                                             | 9 (1.4)                                  | 3 (0.5)                                  | 6 (0.9)                                  | 0                                        | 0                                        | 0                                        | 9 (1.4)                             | 6 (0.9)                             | 3 (0.5)                             | 0                                   | 0                                   | 0                                   |
| Congenital, familial and genetic disorders                      | 3 (0.5)                                  | 0                                        | 2 (0.3)                                  | 1 (0.2)                                  | 0                                        | 0                                        | 2 (0.3)                             | 1 (0.2)                             | 1 (0.2)                             | 0                                   | 0                                   | 0                                   |
| Productissues                                                   | 2 (0.3) 1 (0.2)                          | 0 0                                      | 2 (0.3) 1 (0.2)                          | 0 0                                      | 0 0                                      | 0 0                                      | 4 (0.6)                             | 0 0                                 | 2 (0.3) 0                           | 2 (0.3) 0                           | 0 0                                 | 0 0                                 |

Abbreviations: CTCAE=Common Terminology Criteria for Adverse Events; MedDRA=Medical Dictionary for Regulatory Activities; N=Total number of patients (100%); n=Number of patients with event;SAF=Safety analysisset;SOC=System organ class;TEAE=Treatment-emergent adverse event

CTCAE version 4.03.

## Grade 3 TEAEs

TEAEs of Grade 3 or 4 as the worst grade occurring in 1.5% of patients in either treatment arm in Study 17777 are presented by MedDRA PT in the table below.

<div style=\"page-break-after: always\"></div>

Table 60 Incidence of worst Grade 3 or 4 TEAEs by MedDRA PT occurring in 1.5% of patients in either treatment arm in Study 17777 (SAF)

| MedDRA PT V. 24.1                    | Darolutamide+ docetaxel arm N=652 n (%)   | Placebo+ docetaxel arm N=650 n (%)   |
|--------------------------------------|-------------------------------------------|--------------------------------------|
| Neutrophilcountdecreased             | 151 (23.2%)                               | 140 (21.5%)                          |
| Whitebloodcellcountdecreased         | 110 (16.9%)                               | 97 (14.9%)                           |
| Neutropenia                          | 56 (8.6%)                                 | 68 (10.5%)                           |
| Febrile neutropenia                  | 51 (7.8%)                                 | 48 (7.4%)                            |
| Hypertension                         | 42 (6.4%)                                 | 21 (3.2%)                            |
| Anaemia                              | 31 (4.8%)                                 | 33 (5.1%)                            |
| Pneumonia                            | 21 (3.2%)                                 | 20 (3.1%)                            |
| Hyperglycaemia                       | 18 (2.8%)                                 | 24 (3.7%)                            |
| Alanineaminotransferaseincreased     | 18 (2.8%)                                 | 11 (1.7%)                            |
| Aspartate aminotransferaseincreased  | 17 (2.6%)                                 | 7 (1.1%)                             |
| Leukopenia                           | 15 (2.3%)                                 | 19 (2.9%)                            |
| Weight increased                     | 14 (2.1%)                                 | 8 (1.2%)                             |
| Urinary tract infection              | 13 (2.0%)                                 | 12 (1.8%)                            |
| Back pain                            | 12 (1.8%)                                 | 11 (1.7%)                            |
| Syncope                              | 12 (1.8%)                                 | 11 (1.7%)                            |
| Hyponatraemia                        | 12 (1.8%)                                 | 9 (1.4%)                             |
| Fatigue                              | 11 (1.7%)                                 | 12 (1.8%)                            |
| Blood alkaline phosphatase increased | 10 (1.5%)                                 | 12 (1.8%)                            |
| Bone pain                            | 8 (1.2%)                                  | 19 (2.9%)                            |

Note:

Abbreviations:CTCAE=CommonTerminologyCriteriaforAdverseEvents;MedDRA=MedicalDictionaryforRegulatory Activities;N=Total numberofpatients(100%);n=Numberofpatients withevent;PT=Preferred term,SAF=Safety analysis set;TEAE=Treatment-emergentadverseevent

Apatientmayhavemorethanoneentry.

## TEAEs of special -topic

Special topics were defined as events/disorders representing potential or known risks associated with ADT or with anti-androgens.

The overall incidences and EAIRs of the TEAEs of special topics in Study 17777 are presented in the table below.

Table 61 Incidences and exposure-adjusted incidence rates of TEAEs of special interest associated with ADT or anti-androgens in Study 17777 (SAF)

|                                                | Darolutamide+ docetaxel arm   | Darolutamide+ docetaxel arm   | Placebo+ docetaxelarm   | Placebo+ docetaxelarm   |                              |
|------------------------------------------------|-------------------------------|-------------------------------|-------------------------|-------------------------|------------------------------|
| Grouped TEAE term a                            | N=652 n (%)                   | EAIR per 100PYb               | N=650 n (%)             | EAIR per 100PYb         | Incidence risk ratio forEAIR |
| Fatigue/asthenicconditions                     | 315 (48.3%)                   | 18.2                          | 319 (49.1%)             | 26.5                    | 0.69                         |
| Bonefractures(excluding pathologicalfractures) | 49 (7.5%)                     | 2.8                           | 33 (5.1%)               | 2.7                     | 1.03                         |
| Fall                                           | 43 (6.6%)                     | 2.5                           | 30 (4.6%)               | 2.5                     | 1.00                         |
| Vasodilatation and flushing                    | 133 (20.4%)                   | 7.7                           | 141 (21.7%)             | 11.7                    | 0.66                         |
| Breast disorders/gynecomastia                  | 21 (3.2%)                     | 1.2                           | 10 (1.5%)               | 0.8                     | 1.46                         |
| Rash                                           | 108 (16.6%)                   | 6.2                           | 88 (13.5%)              | 7.3                     | 0.85                         |
| Hypertension c                                 | 90 (13.8%)                    | 5.2                           | 61 (9.4%)               | 5.1                     | 1.02                         |
| Cardiac disorders                              | 71 (10.9%)                    | 4.1                           | 76 (11.7%)              | 6.3                     | 0.65                         |
| Cardiac arrhythmias                            | 52 (8.0%)                     | 3.0                           | 55 (8.5%)               | 4.6                     | 0.66                         |
| Coronary artery disorders                      | 19 (2.9%)                     | 1.1                           | 13 (2.0%)               | 1.1                     | 1.01                         |
| Heart failures                                 | 4 (0.6%)                      | 0.2                           | 13 (2.0%)               | 1.1                     | 0.21                         |
| Diabetes mellitus and hyperglycemia            | 99 (15.2%)                    | 5.7                           | 93 (14.3%)              | 7.7                     | 0.74                         |
| Mental impairment disorders                    | 23 (3.5%)                     | 1.3                           | 15 (2.3%)               | 1.2                     | 1.06                         |
| Depressed mood disorders                       | 21 (3.2%)                     | 1.2                           | 24 (3.7%)               | 2.0                     | 0.61                         |
| Cerebralischaemia                              | 8 (1.2%)                      | 0.5                           | 8 (1.2%)                | 0.7                     | 0.69                         |
| Cerebralandintracranialhemorrhage              | 6 (0.9%)                      | 0.3                           | 1 (0.2%)                | 0.1                     | 4.17                         |
| Seizure                                        | 4 (0.6%)                      | 0.2                           | 1 (0.2%)                | 0.1                     | 2.78                         |
| Weight decreased                               | 22 (3.4%)                     | 1.3                           | 35 (5.4%)               | 2.9                     | 0.44                         |

<div style=\"page-break-after: always\"></div>

## o Hypertension

Approximately half of the patients in both the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm (51.3% vs. 49.2%, respectively) had a medical history of hypertension (single PT) in the FAS.

Medical history of blood pressure increased was reported for 0.5% vs. 0.2% of patients, and essential hypertension for 1.4% of patients in both the darolutamide + docetaxel + ADT and placebo + docetaxel + ADT arms, respectively.

Pre-treatment AEs of hypertension (single PT) were reported with a slightly higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm (2.5% vs 1.7%, respectively).

Treatment-emergent events of hypertension (data-driven grouping) were more commonly reported in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm 13.8% vs. 9.4%, respectively). When adjusted for the difference in study drug treatment duration, the EAIRs of hypertension were similar between the arms (5.2 vs. 5.1 per 100 PY), with an incidence risk ratio of 1.02. The events within this group were mainly driven by a single PT hypertension (13.0% vs 9.1%).

Although the incidence of Grade 1 and 2 hypertension events (data-driven grouping) were similar between the treatment arms, hypertension events with Grade 3 as the worst grade were more commonly reported in the darolutamide + docetaxel + ADT arm (6.4%) than in the placebo + docetaxel + ADT arm (3.5%). There was 1 patient with a Grade 4 event of hypertension in both the darolutamide + docetaxel + ADT arm (hypertensive emergency) and the placebo + docetaxel + ADT arm (hypertensive crisis).

One patient in the darolutamide + docetaxel + ADT treatment arm was reported with two Grade 5 events (hypertension and arteriosclerosis). As per the patient's d eath certificate, the patient died due to hypertensive and atherosclerotic cardiovascular disease. The investigator and sponsor did not suspect a causal relationship to darolutamide. There were no Grade 5 events in the placebo + docetaxel + ADT arm.

Overall, TEAEs of hypertension were reported more commonly in patients with no medical history of hypertension in both treatment arms, and the incidences were higher in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm (16.4% vs. 10.3% of patients, respectively). Among the patients with medical history of hypertension, the incidence of TEAEs of hypertension with worst grade of 3 was higher in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm (7.2% vs. 3.9%, respectively). The incidence of hypertension with worst grade of 3 was also higher in patients without history of hypertension in the darolutamide +docetaxel arm compared with the placebo+docetaxel + ADT arm (5.6% vs 3.1%).

<div style=\"page-break-after: always\"></div>

Table 62 Incidence of TEAEs hypertension by present history of hypertension (MLG) and worst CTCAE grade in Study 17777 (SAF)

|                   |                  | Darolutamide+ docetaxel arm         | Darolutamide+ docetaxel arm           | Placebo+ docetaxel arm              | Placebo+ docetaxel arm                 |
|-------------------|------------------|-------------------------------------|---------------------------------------|-------------------------------------|----------------------------------------|
| MLG MedDRA v.24.1 | WorstCTCAE grade | History of hypertension N=347 n (%) | Nohistory of hypertension N=305 n (%) | History of hypertension N=330 n (%) | No history of hypertension N=320 n (%) |
| Hypertension a    | Total            | 39 (11.2%)                          | 50 (16.4%)                            | 27 (8.2%)                           | 33 (10.3%)                             |
|                   | Grade 1          | 3 (0.9%)                            | 12 (3.9%)                             | 2 (0.6%)                            | 6 (1.9%)                               |
|                   | Grade 2          | 10 (2.9%)                           | 21 (6.9%)                             | 11 (3.3%)                           | 17 (5.3%)                              |
|                   | Grade 3          | 25 (7.2%)                           | 17 (5.6%)                             | 13 (3.9%)                           | 10 (3.1%)                              |
|                   | Grade 5          | 1 (0.3%)                            | 0                                     | 0                                   | 0                                      |
|                   | Missing          | 0                                   | 0                                     | 1 (0.3%)                            | 0                                      |

Abbreviations:CTCAE=CommonTerminology CriteriaforAdverseEvents;MedDRA=Medical Dictionaryfor Regulatory Activities; MLG=MedDRA labeling grouping; N=Total number of patients (100%); n=Number of patients with event; PT=Preferredterm;SAF=Safetyanalysisset;TEAE=Treatment-emergentadverseevent;

CTCAEversion4.03

o Rash

Treatment-emergent events of rash were reported with a higher incidence in the darolutamide + docetaxel + ADT arm compared with the placebo + docetaxel + ADT arm (16.6% vs. 13.5%, respectively). When adjusted for the difference in study drug treatment duration, the EAIRs of rash were similar between the arms (6.2 vs. 7.3 per 100 PY), with an incidence risk ratio of 0.85. At the PT level, the most commonly reported TEAE within this group was an unspecific term rash in both treatment arms (7.8% vs. 6.9%).

Events of rash were reported with a worst grade of 1 or 2 in severity in most patients. Events with a worst grade of 3 were reported with a slightly higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm (1.2% vs. 0.2%), respectively. At the PT level, the difference was mainly driven by Grade 3 rash maculo-papular (0.6% vs. 0%), followed by Grade 3 drug eruption (0.3% vs. 0%) and Grade 3 rash (0.3% vs. 0.2%). Grade 4 rash (PT drug eruption) was reported in 1 patient (0.2%) in the darolutamide + docetaxel + ADT arm whereas no Grade 4 events of rash were observed in the placebo + docetaxel + ADT arm.

The events of rash were considered serious in 1 patient (0.2%) in both treatment arms. Study drug and docetaxel were permanently discontinued due to rash in 1.1% and 0.9% of patients in the darolutamide + docetaxel + ADT arm, respectively, with no permanent discontinuations being reported in the placebo + docetaxel + ADT arm. Study drug dose was interrupted in 1.4% vs. 0.2% of patients and reduced in 0.5% vs. 0% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. Docetaxel dose was interrupted in 0.6% vs. 0.5% of patients and reduced in 1.1% vs. 0.5% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively.

## o Cardiac disorders

The overall incidence (12.7% vs. 13.8%) of TEAEs within the SOC cardiac disorders was similar in the darolutamide + docetaxel + ADT arm and in the placebo + docetaxel + ADT arm, respectively. The events were mostly reported with Grade 1 or 2 as the worst grade in both treatment arms. Grade 5 events within the SOC cardiac disorders included 5 patients (0.8%) in the darolutamide + docetaxel + ADT arm and 3 patients (0.5%) in the placebo + docetaxel + ADT arm. The events were mostly reported with Grade 1 or 2 as the worst grade in both treatment arms. Grade 5 events within the SOC cardiac disorders included 5 patients (0.8%) in the darolutamide + docetaxel + ADT arm and 3 patients (0.5%) in the placebo + docetaxel + ADT arm.

<div style=\"page-break-after: always\"></div>

Altogether, 112 patients in the darolutamide + docetaxel + ADT arm and 128 patients in the placebo + docetaxel + ADT arm had a medical history of cardiac disorders before the start of study treatment. In both treatment arms, the incidence of TEAEs within the SOC cardiac disorders was higher in patients who had a history of cardiac disorders, and this difference was more evident in patients in the placebo + docetaxel + ADT arm:

- -Darolutamide + docetaxel + ADT arm
- -Placebo + docetaxel + ADT arm

o History of cardiac disorders: 20/112 patients (17.9%)

o No history of cardiac disorders: 63/540 patients (11.7%)

o History of cardiac disorders: 37/128 patients (28.9%)

o No history of cardiac disorders: 53/522 patients (10.2%)

TEAEs within the HLGT (High Level Group Term) cardiac arrhythmias were reported with a similar incidence (8.0% vs. 8.5%) in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. The most common PTs within this HLGT were sinus tachycardia (1.5% in both arms), tachycardia (1.4% vs. 1.5%), atrial fibrillation (1.4% vs. 1.2%) and sinus bradycardia (1.1% and 0.6%) in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively.

TEAEs within the HLGT coronary artery disorders were reported with a small difference between the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm (2.9% vs. 2.0%, respectively). When adjusted for the difference in study drug treatment duration, the EAIR was 1.1 per 100 PY in both treatment arms. The most common PTs within this HLGT were myocardial infarction (0.9% vs. 0.3%), acute myocardial infarction (0.5% vs. 0.5%), and angina pectoris (0.5% vs. 0.3%) in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. Two fatal events of myocardial infarction were reported in the darolutamide + docetaxel + ADT arm.

TEAEs within the HLGT heart failures were reported in 0.6% vs. 2.0% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. Of note, the most commonly reported TEAEs within this HLGT were less frequent in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm, respectively: cardiac failure (0.2% vs. 1.4%) and left ventricular failure (0% vs. 0.6%).

## o Diabetes mellitus and hyperglycaemia

TEAEs of diabetes mellitus and hyperglycaemia were reported with a similar incidence between the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm (15.2% vs. 14.3%, respectively). At the PT level, the most commonly reported TEAE within this group was hyperglycaemia in both treatment arms (11.3% vs. 9.4%). Events of diabetes mellitus and hyperglycaemia were reported with a worst grade of 3 in 3.5% vs. 4.5% of patients, and with a worst grade of 4 in 0.2% vs. 0.9% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. An analysis of diabetes mellitus and hyperglycaemia over time showed that both the incidence and prevalence of Grade 3 or 4 events were highest during the first 3 months of treatment and decreased thereafter in both treatment arms, whereas there was a consistent increase in the prevalence of Grade 1 or 2 events over time in both treatment arms.

The events of diabetes mellitus were considered serious in 0.5% vs. 1.1% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. No study

<div style=\"page-break-after: always\"></div>

drug or docetaxel discontinuations, dose interruptions or dose reductions were reported in the darolutamide + docetaxel + ADT arm.

## o Fatigue/asthenic conditions

TEAEs of special topics were most commonly reported within the grouped term of fatigue/asthenic conditions in both the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm (48.3% vs. 49.1%, respectively). At the PT level, the most commonly reported TEAE within this group was fatigue, which was also reported with a similar incidence in both treatment arms (33.1% vs. 32.9%). An analysis of fatigue/asthenic conditions events over time showed that the events were predominantly reported during the first months from the start of study treatment in both treatment arms. The events of fatigue/asthenic conditions were considered serious in 0.5% vs. 0.3% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. The events resulted in study drug dose interruption in 0.8% vs. 0.2% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively, and in dose reduction in 0.6% of patients in both treatment arms.

## o Bone fractures (excluding pathological fractures)

TEAEs of bone fracture were reported with a small difference between the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm (7.5% vs. 5.1%, respectively). When adjusted for the difference in study drug treatment duration, the EAIRs of bone fractures were similar between the treatment arms (2.8 vs. 2.7 per 100 PY), with an incidence risk ratio of 1.03. Of note, there were 1.1% of patients in the darolutamide + docetaxel + ADT arm and 0.5% of patients in the placebo + docetaxel + ADT arm who had pathological fracture (not part of the grouped term).

Bone fractures were reported with a worst grade of 1 or 2 in severity in most patients. Events with a worst grade of 3 were reported in 1.5% of patients in the darolutamide + docetaxel + ADT arm and in 2.3% in the placebo + docetaxel + ADT arm. The bone fracture events were considered serious in 1.4% vs. 1.5% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. Study drug was permanently discontinued due to bone fracture in 0.3% of patients in the placebo + docetaxel + ADT arm with no respective events reported in the darolutamide + docetaxel + ADT arm.

## o Fall

Treatment-emergent events of fall were reported with a small difference between the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm (6.6% vs. 4.6%, respectively). When adjusted for the difference in study drug treatment duration, the EAIRs of fall were 2.5 per 100 PY in both treatment arms, with an incidence risk ratio of 1.00. Almost all events within this group were due to a PT fall. The events of fall were reported with a worst grade of 1 or 2 in severity in most patients and thus were minor with no resultant injuries or were symptomatic with noninvasive intervention needed. The fall events were considered serious in 0.3% of patients in the darolutamide + docetaxel + ADT arm and no serious events were reported in the placebo + docetaxel + ADT arm.

## o Vasodilatation and flushing

Treatment-emergent events of vasodilatation and flushing were reported with a similar incidence in the darolutamide + docetaxel + ADT arm and in the placebo + docetaxel + ADT arm (20.4% vs. 21.7%, respectively).

## o Breast disorders/gynaecomastia

TEAEs of breast disorders/gynaecomastia were more commonly reported in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm (3.2% vs. 1.5%, respectively). When

<div style=\"page-break-after: always\"></div>

adjusted for the difference in study drug treatment duration, the EAIRs of breast disorders/gynaecomastia were 1.2 vs. 0.8 per 100 PY, with an incidence risk ratio of 1.46.

All events of breast disorders/gynaecomastia were either Grade 1 or 2 as the worst grade in both treatment arms. No TESAEs, study drug or docetaxel discontinuations, dose interruptions or dose reductions were reported due to breast disorders/gynaecomastia in the darolutamide + docetaxel + ADT arm.

## o Mental impairment disorders

TEAEs of mental impairment disorders were reported with a small difference between the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm (3.5% vs. 2.3%, respectively). When adjusted for the difference in study drug treatment duration, the EAIRs of mental impairment disorders were similar between the arms (1.3 vs. 1.2 per 100 PY), with an incidence risk ratio of 1.06. Grade 1 or 2 was the worst grade for all reported events. At the PT level, the most commonly reported TEAE within this group was memory impairment (1.2% vs. 0.9%), followed by cognitive disorder (0.9% vs. 0.5%) and disturbance in attention (0.8% vs. 0.5%) in both the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively.

## o Depressed mood disorders

TEAEs of depressed mood disorders were reported with a similar incidence in the darolutamide + docetaxel + ADT arm and in the placebo + docetaxel + ADT arm (3.2% vs. 3.7%, respectively).

## o Cerebrovascular disorders

TEAEs of cerebral ischemia were reported in 1.2% of patients in both treatment arms. Cerebral and intracranial hemorrhage were reported in 6 patients (0.9%) in the darolutamide + docetaxel + ADT arm and in 1 patient (0.2%) in the placebo + docetaxel + ADT arm. Confounding factors, such as preceding surgery, fall or underlying comorbidities (hypertension, aneurysma, thrombocytopenia), were identified for all 6 patients who had cerebral or intracranial hemorrhage in the darolutamide + docetaxel + ADT arm. None of the events were considered drug-related by the investigator.

## o Seizure

During the study, seizure was reported in 4 patients (0.6%) in the darolutamide + docetaxel + ADT arm and in 1 patient (0.2%) in the placebo + docetaxel + ADT arm (Table 2 -17). At the PT level, the events were seizure (3 patients) and focal dyscognitive seizures (1 patient) in the darolutamide + docetaxel + ADT arm, and epilepsy (1 patient) in the placebo + docetaxel + ADT arm.

All seizure events were of Grade 1 (0.2% vs. 0%) or Grade 2 (0.5% vs. 0.2%) in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. No study drug permanent discontinuations were reported due to seizure.

The 4 patients with a reported seizure in the darolutamide + docetaxel + ADT arm had no medical history of seizure. Two of these patients had confounding factors: CVA and movement disorders as medical history in one patient, and CVA as a co-reported event in another patient.

The third patient in the darolutamide + docetaxel + ADT arm had a history of anxiety and experienced focal dyscognitive seizures (reported term: complex partial epileptic crisis) 341 days after starting darolutamide treatment. Darolutamide dose was not changed as a result of this event.

The event was treated with valproic acid and levetiracetam. The fourth patient had a seizure between docetaxel cycles 1 and 2. The brain CT and electroencephalogram were without findings. Darolutamide dose was not changed, whereas docetaxel treatment was interrupted due to the event.

<div style=\"page-break-after: always\"></div>

Overall, 2 of the 4 seizure events in the darolutamide + docetaxel + ADT arm occurred during the docetaxel treatment. The seizure event led to docetaxel interruption in 1 of the patients but darolutamide dose was not changed in either of these 2 patients.

## o Weight decreased

TEAEs of weight decreased (single PT) were reported with a slightly lower incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm (3.4% vs. 5.4%, respectively).

## TEAEs commonly associated with docetaxel

The most common TEAEs in Study 17777 largely overlapped with the TEAEs commonly associated with docetaxel (alopecia, anaemia, neutrophil count decreased and neutropenia, diarrhoea, constipation, nausea, neuropathy peripheral and peripheral sensory neuropathy, myalgia, dysgeusia, asthenia, and dyspnoea).

- -Neutrophil count decreased was one of the most commonly reported TEAEs occurring in 26.1% of patients in the darolutamide + docetaxel + ADT arm and in 23.8% of patients in the placebo + docetaxel + ADT arm. Neutropenia was reported in 10.4% and 11.7% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. Most of the patients with neutrophil count decreased or neutropenia had an event with a worst grade of 3 or 4 in both treatment arms (these were the most common Grade 4 TEAEs). Neutrophil count decreased was assessed as study drug-related by the investigator in 1.4% vs. 0.6% of patients, and docetaxel-related in 24.8% vs. 22.8% of patients in the darolutamide + docetaxel + ADT and the placebo + docetaxel + ADT arm, respectively. Neutropenia was assessed as study drug-related in 0.6% vs. 0.3% of patients, and docetaxel-related in 9.2% vs. 10.6% of patients in the darolutamide + docetaxel + ADT and the placebo + docetaxel + ADT arm.
- -AST and ALT increased were reported as TEAEs with slightly higher incidences in the darolutamide + docetaxel + ADT arm (14.0% and 15.6% of patients, respectively) than in the placebo + docetaxel + ADT arm (10.5% and 12.9% of patients, respectively). AST increased and ALT increased were among the most commonly reported study drug-related TEAEs, TEAEs leading to permanent discontinuation of study drug or docetaxel, and TEAEs leading to study drug or docetaxel dose modifications.

## Additional primary malignancies

In Study 17777, additional primary malignancies were reported in 25 patients (3.8%) in the darolutamide + docetaxel + ADT arm and in 16 patients (2.5%) in the placebo + docetaxel + ADT arm.

Additional primary malignancies rep orted in 2 patients in either the darolutamide + docetaxel + ADT arm or the placebo + docetaxel + ADT arm, respectively, are summarized below.

- -Basal cell carcinoma: 3 patients (0.5%) vs. 1 patient (0.2%)
- -Squamous cell carcinoma of skin: 2 patients (0.3%) vs. 2 patients (0.3%)
- -Pancreatic carcinoma: 2 patients (0.3%) vs. 0 patients (0%)
- -Squamous cell carcinoma: 2 patients (0.3%) vs. 0 patients (0%)

<div style=\"page-break-after: always\"></div>

There was 1 patient in the darolutamide + docetaxel + ADT arm reported with a suspicion of laryngeal cancer that was never confirmed. For this patient, a laryngoscopy was performed, but there was no confirmation of cancer (data from the clinical database).

In 8 patients in the darolutamide + docetaxel + ADT arm and in 2 patients in the placebo + docetaxel + ADT arm subsequent systemic antineoplastic therapy was given for additional primary malignancies

- mCRPC pool

At least one TEAE was experienced by 94.2% of patients in the mCRPC pool.

TEAEs were of Grade 1 or Grade 2 as the worst grade in severity in the majority of the patients (64.2%). Grade 5 TEAEs were reported in 4.0% of patients.

TESAEs were reported in 28.3% of patients and TEAEs led to permanent discontinuation of the study drug in 7.5% of patients.

Similar to Study 17777, TEAEs of special topics were most commonly reported within the grouped term of fatigue/asthenic conditions in the mCRPC pool (32.4%). At the PT level, fatigue was also the most commonly reported TEAE in the mCRPC pool (26.0%)

Table 63 Incidences of TEAEs of special topics in mCRPC pool (SAF)

|                                                   | Darolutamide   |
|---------------------------------------------------|----------------|
| Grouped TEAE term                                 | N=173 n (%)    |
| Fatigue/asthenic conditions                       | 56 (32.4%)     |
| Bone fractures (excluding pathological fractures) | 9 (5.2%)       |
| Fall                                              | 11 (6.4%)      |
| Vasodilatation and flushing                       | 12 (6.9%)      |
| Breast disorders/gynecomastia                     | 10 (5.8%)      |
| Rash                                              | 12 (6.9%%)     |
| Hypertension                                      | 12 (6.9%)      |
| Cardiac disorders                                 | 18 (10.4%)     |
| Diabetes mellitus and hyperglycemia               | 3 (1.7%)       |
| Mental impaiment disorders                        | 0              |
| Depressed mood disorders                          | 4 (2.3%)       |
| Cerebral ischaemia                                | 1 (0.6%)       |
| Cerebral and intracranial hemomhage               | 0              |
| Seizure                                           | 1 (0.6%)       |
| Weight decreased                                  | 13 (7.5%%)     |

N-Total number of patlents (1oo%);: n=Number of patlents with event, PT-Preferred tem; SAF-Safety analysls set;

TEAE-Treatment-emergent adverseevent

Note: The lable contalns counts of paltlents. If a patlent experlenced more than one eplsode of a TEAE, the patlent Is counled only once wlthin a grouped tem.

a: The speciflc tems used for MedDRA searches and reported PTs for grouped TEAE tems are descrbed In Module 5.3.5.1, IA mCRPC pool, Table 3.1/44.

MedDRA verslon 24.0.

## Adverse drug reactions

For identification of ADRs of darolutamide in mHSPC indication, the clinical data from the Phase 3 Study 17777 (ARASENS) were analyzed.

The analysis of TEAEs and laboratory abnormalities for the identification of ADR was as follows:

- -Selection of the TEAE preferred or grouped terms by evidence of disproportionality between the treatment arms: Selection of the TEAE preferred or grouped terms by evidence of disproportionality be tween the treatment arms ( 2%),
- -Analysis of selected TEAE terms to identify further potential evidence: compatibility/consistency with the pharmacological properties of darolutamide such as mode of action, known pharmacological class effect, analysis of TEAEs over time, analysis of absolute and exposure-adjusted incidence rate,

<div style=\"page-break-after: always\"></div>

- -Assessment of relevance of the prioritized TEAE term/medical concept based on the frequency of ADR, proportion of SAEs, proportion of Grade 3 TEAEs, proportion of events leading t o permanent discontinuation of study treatment or dose adjustment, analysis of baseline patient characteristics.

In addition to the analysis of TEAE terms, hematological and biochemical laboratory-based abnormalities were also reviewed, focusing on a highe r incidence (5% difference) in the darolutamide + docetaxel + ADT arm compared to the placebo + docetaxel + ADT arm, central tendency (mean and median values), abnormal values distribution (categorized by severity grade) including shift-frombaseline analysis and laboratory-based abnormalities occurring with a difference in incidence between treatment arms of less than 5% were reviewed for clinical significance and considered in the context of the totality of safety data. (SmPC section 4.8)

Table 64 : Adverse reactions reported in mHSPC patients treated with darolutamide in combination with docetaxel in the ARASENS study a, b

| System organ class (MedDRA)                     | Very common                                                                      | Common        |
|-------------------------------------------------|----------------------------------------------------------------------------------|---------------|
| Vascular disorders                              | Hypertensionc                                                                    |               |
| Skin and subcutaneous tissue disorders          | Rashd, e                                                                         |               |
| Musculoskeletal and connective tissue disorders |                                                                                  | Fractures     |
| Reproductive system and breast disorders        |                                                                                  | Gynaecomastia |
| Investigationsf                                 | Neutrophil count decreased Blood bilirubin increased ALT increased AST increased |               |

a The median duration of exposure was 41.0 months (range: 0.1 to 56.5 months) in patients treated with darolutamide+docetaxel and 16.7 months (range: 0.3 to 55.8 months) in patients treated with placebo+docetaxel.

b Adverse reactions incidences may not be attributable to darolutamide alone but may contain contributions from other medicinal products used in combination.

c Includes hypertension, blood pressure increased, hypertensive emergency.

d Includes rash, drug eruption, rash erythematous, rash follicular, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, rash vesicular, erythema, dermatitis.

e The incidence was highest during the first 6 months of treatment.

f Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The incidence is based on values reported as laboratory abnormalities.

## Serious adverse event/deaths/other significant events

##  Deaths

Table 65 Overview of all deaths in Study 17777 (SAF)

| Deaths Cause of death                                          | Darolutamide+ docetaxel arm N=652 n (%)   | Placebo+ docetaxel am N=650 n (%)   |
|----------------------------------------------------------------|-------------------------------------------|-------------------------------------|
| All deaths                                                     | 229 (35.1%)                               | 304 (46.8%)                         |
| Progressive disease                                            | 170 (26.1%)                               | 234 (36.0%)                         |
| Adverse event not associated with cinical disease progression  | 22 (3.4%)                                 | 16 (2.5%)                           |
| Unknown                                                        | 22 (3.4%)                                 | 26 (4.0%)                           |
| Other                                                          | 13 (2.0%)                                 | 19 (2.9%)                           |
| Adverse event associated with clinical disease progression     | 2 (0.3%)                                  | 9 (1.4%)                            |
| Death from first to last dose of study drug                    | 1 (0.2%)                                  | 0                                   |
| Adverse event not associated with clinical disease progression | 1 (0.2%)                                  | 0                                   |
| Death within 30 days after last dose of study drug             | 29 (4.4%)                                 | 27 (4.2%)                           |
| Adverse event not associated with clinical disease progression | 19 (2.9%)                                 | 10 (1.5%)                           |
| Progressive disease                                            | 5 (0.8%)                                  | 4 (0.6%)                            |
| Unknown                                                        | 3 (0.5%)                                  | 5 (0.8%)                            |
| Adverse event associated with clinical disease progression     | 2 (0.3%)                                  | 7 (1.1%)                            |
| Other                                                          | 0                                         | 1 (0.2%)                            |
| Death later than 30 days after last dose of study drug         | 199 (30.5%)                               | 277 (42.6%)                         |
| Progressive disease                                            | 165 (25.3%)                               | 230 (35.4%)                         |
| Unknown                                                        | 19 (2.9%)                                 | 21 (3.2%)                           |
| Other                                                          | 13 (2.0%)                                 | 18 (2.8%)                           |
| Adverse event not associated with clinical disease progression | 2 (0.3%)                                  | 6 (0.9%)                            |
| Adverse event associated with clinical disease progression     | 0                                         | 2 (0.3%)                            |

<div style=\"page-break-after: always\"></div>

A total of 229 patients (35.1%) in the darolutamide + docetaxel + ADT arm and 304 patients (46.8%) in the placebo + docetaxel + ADT arm had died as of the database cut-off date. The most common cause of death was progressive disease in both the darolutamide + docetaxel + ADT arm (26.1% of patients) and placebo + docetaxel + ADT arm (36.0% of patients).

The majority of deaths in the study occurred more than 30 days after the last dose of study drug in both the darolutamide + docetaxel + ADT arm (30.5% of patients) and the placebo + docetaxel + ADT arm (42.6% of patients).

No patients died before the treatment start. One patient in the darolutamide + docetaxel + ADT arm died during the treatment period due to an AE not associated with disease progression (acute cardiac failure reported on the same day when study drug was stopped).

A death within 30 days after the last dose of study drug was reported in 4.4% vs. 4.2% of patients in the darolutamide + docetaxel + ADT arm and placebo + docetaxel + ADT arm, respectively, mostly due to AEs not associated with disease progression (2.9% vs. 1.5%) or progressive disease (0.8% vs. 0.6%).

The incidences of all TEAEs with fatal outcome (Grade 5) are displayed in the table below.

<div style=\"page-break-after: always\"></div>

Table 66 Incidence of all Grade 5 TEAEs by MedDRA PT in Study 17777 (SAF)

| MedDRA PT V. 24.1                     | Darolutamide+ docetaxel arm N=652 n (%)   | Placebo+ docetaxel arm N=650 n (%)   |
|---------------------------------------|-------------------------------------------|--------------------------------------|
| Any Grade 5 TEAE                      | 27 (4.1%)                                 | 26 (4.0%)                            |
| COVID-19 pneumonia                    | 4 (0.6%)                                  | 1 (0.2%)                             |
| Sudden death                          | 2 (0.3%)                                  | 3 (0.5%)                             |
| General physical health deterioration | 1 (0.2%)                                  | 4 (0.6%)                             |
| Cardiac arrest                        | 1 (0.2%)                                  | 2 (0.3%)                             |
| Death                                 | 1 (0.2%)                                  | 2 (0.3%)                             |
| Hypoxia                               | 1 (0.2%)                                  | 1 (0.2%)                             |
| Acute myocardial infarction           | 1 (0.2%)                                  | 0                                    |
| Anaesthetic complication cardiac      | 1 (0.2%)                                  | 0                                    |
| Arteriosclerosis                      | 1 (0.2%)                                  | 0                                    |
| COVID-19                              | 1 (0.2%)                                  | 0                                    |
| Cardiac disorder                      | 1 (0.2%)                                  | 0                                    |
| Cardiac failure acute                 | 1 (0.2%)                                  | 0                                    |
| Gastric cancer                        | 1 (0.2%)                                  | 0                                    |
| Haemoptysis                           | 1 (0.2%)                                  | 0                                    |
| Haemorrhagic stroke                   | 1 (0.2%)                                  | 0                                    |
| Hypertension                          | 1 (0.2%)                                  | 0                                    |
| Metastases to central nervous system  | 1 (0.2%)                                  | 0                                    |
| Myocardial infarction                 | 1 (0.2%)                                  | 0                                    |
| Oesophageal carcinoma                 | 1 (0.2%)                                  | 0                                    |
| Parkinson's disease                   | 1 (0.2%)                                  | 0                                    |
| Pneumonitis                           | 1 (0.2%)                                  | 0                                    |
| Respiratory distress                  | 1 (0.2%)                                  | 0                                    |
| Septic shock                          | 1 (0.2%)                                  | 0                                    |
| Subarachnoid haemorrhage              | 1 (0.2%)                                  | 0                                    |
| Transitional cell carcinoma           | 1 (0.2%)                                  | 0                                    |
| Pneumonia                             | 0                                         | 2 (0.3%)                             |
| Pulmonary sepsis                      | 0                                         | 2 (0.3%)                             |
| Acute kidney injury                   | D                                         | 1 (0.2%)                             |
| Cachexia                              | 0                                         | 1 (0.2%)                             |
| Cardiac failure                       | 0                                         | 1 (0.2%)                             |
| Cerebrovascular accident              |                                           | 1 (0.2%)                             |
| Dyspnoea                              | 0                                         | 1 (0.2%)                             |
| Gastric ulcer perforation             |                                           | 1 (0.2%)                             |
| Hypertransaminasaemia                 | 0                                         | 1 (0.2%)                             |
| Interstitial lung disease             | D                                         | 1 (0.2%)                             |
| Respiratory failure                   | D                                         | 1 (0.2%)                             |
| Sepsis                                | 0                                         | 1 (0.2%)                             |

Abbreviations: COVID-19=Coronavirus disease 2019; CTCAE=Common Terminology Criteria for Adverse Events;

MedDRA=Medical Dictionary for Regulatory Activities; N=Total number of patients (100%); n=Number of patients with event; PT=Preferred term; SAF=Safety analysis set; TEAE=Treatment-emergent adverse event

## Notes:

A patient may have more than one entry. Any adverse events with missing CTCAE grade are not included in this summary table. CTCAE version 4.03.

- Other serious adverse events (SAEs)

An overview of treatmentemergent SAEs (TESAEs) that occurred in 1% of patients in either treatment arm in Study 17777 is presented in the table below.

<div style=\"page-break-after: always\"></div>

Table 67 Incidence of TESAEs (any grade) by MedDRA PT occurring in 1% of patients in either treatment arm in Study 17777 (SAF)

|                                    | Darolutamide+ docetaxel arm N=652   | Darolutamide+ docetaxel arm N=652   | Placebo+ docetaxel arm N=650   | Placebo+ docetaxel arm N=650   |
|------------------------------------|-------------------------------------|-------------------------------------|--------------------------------|--------------------------------|
| MedDRA PT V. 24.1                  | Total n (%)                         | EAIR per 100PYa                     | Total n (%)                    | EAIR per 100PYa                |
| Febrile neutropenia                | 40 (6.1%)                           | 2.3                                 | 39 (6.0%)                      | 3.2                            |
| Neutrophilcountdecreased           | 18 (2.8%)                           | 1.0                                 | 10 (1.5%)                      | 0.8                            |
| Pneumonia                          | 16 (2.5%)                           | 0.9                                 | 21 (3.2%)                      | 1.7                            |
| Neutropenia                        | 12 (1.8%)                           | 0.7                                 | 14 (2.2%)                      | 1.2                            |
| Pyrexia                            | 9 (1.4%)                            | 0.5                                 | 15 (2.3%)                      | 1.2                            |
| COVID-19 pneumonia                 | 7 (1.1%)                            | 0.4                                 | 3 (0.5%)                       | 0.2                            |
| Alanine aminotransferase increased | 6 (0.9%)                            | 0.3                                 | 8 (1.2%)                       | 0.7                            |
| Urinary tract infection            | 6 (0.9%)                            | 0.3                                 | 7 (1.1%)                       | 0.6                            |
| Spinal cord compression            | 2 (0.3%)                            | 0.1                                 | 7 (1.1%)                       | 0.6                            |

Abbreviations: COVID-19=Coronavirus disease 2019; EAIR=Exposure-adjusted incidence rate; MedDRA=Medical Dictionary for Regulatory Activities; N=Total number of patients (100%); n=Number of patients with event; PT=Preferred term; PY=Patientyear;SAF=Safetyanalysisset;TEAE=Treatment-emergentadverseevent;TESAE=Treatment-emergent seriousadverseevent allpatientsinyears.Therateisexpressedinnumberofpatientswitheventsper1o0PYs.

Note: A patient may have more than one entry.

In the ongoing Study 21140 in mHSPC patients receiving darolutamide or placebo in addition to ADT (based on non-validated clinical database), SAE was reported during treatment or within 30 days after study treatment discontinuation as of the database cut-off date for the submission (25 OCT 2021).

In the ongoing roll-over Study 20321 in patients receiving treatment with darolutamide in addition to ADT (based on non-validated clinical database), at least one SAE was reported in 38 patients during treatment or within 30 days after study treatment discontinuation as of the database cut-off date for the submission (25 OCT 2021). SAEs were most frequently reported in SOCs infections and infestations (14 events), renal and urinary disorders (8 events) and cardiac disorders (6 events).

## Laboratory findings

##  Hematological and biochemical laboratory abnormalities

Laboratory abnormalities at baseline were reported with a worst grade of 1 or 2 for most patients in both treatment arms. There were only a few laboratory abnormalities with a worst grade of 4: ALP increased in 1.7% of patients in the darolutamide + docetaxel + ADT arm vs. 2.9% of patients in the placebo + docetaxel + ADT arm, lymphocyte count decreased (0.8% vs. 0.2%), neutrophil count decreased (0.8% vs. 0%), hyperglycaemia (0.4% vs. 0%), and hyperkalaemia (0% vs. 0.2%). Overall, pre-treatment laboratory abnormalities were reported at similar incidences in both treatment arms.

The incidences of hematological and biochemical laboratory abnormalities in Study 17777 after the start of treatment are presented by CTCAE term and worst CTCAE grade in the table below.

<div style=\"page-break-after: always\"></div>

Table 68 CTCAE grades for abnormal hematological and biochemical laboratory values in Study 17777: Worst grade after start of treatment (SAF)

|                                          | Darolutamide+ docetaxel arm n (%)   | Darolutamide+ docetaxel arm n (%)   | Darolutamide+ docetaxel arm n (%)   | Darolutamide+ docetaxel arm n (%)   | Darolutamide+ docetaxel arm n (%)   | Darolutamide+ docetaxel arm n (%)   | Placebo+ docetaxel arm n (%)   | Placebo+ docetaxel arm n (%)   | Placebo+ docetaxel arm n (%)   | Placebo+ docetaxel arm n (%)   | Placebo+ docetaxel arm n (%)   | Placebo+ docetaxel arm n (%)   |
|------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                          |                                     |                                     | Worst CTCAEgrade                    | Worst CTCAEgrade                    |                                     |                                     |                                |                                |                                |                                |                                |                                |
| Event category CTCAE term (version 4.03) | Na                                  | Grade 1-4                           | Grade 1                             | Grade 2                             | Grade 3                             | Grade 4                             | Na                             | Grade 1-4                      | Grade 1                        | Grade 2                        | Grade 3                        | Grade 4                        |
| Blood and lymphaticsystem disorders      |                                     |                                     |                                     |                                     |                                     |                                     |                                |                                |                                |                                |                                |                                |
| Anemia                                   | 649 (100.0)                         | 622 (95.8)                          | 413 (63.6)                          | 171 (26.3)                          | 38 (5.9)                            | 0                                   | 646 (100.0)                    | 605 (93.7)                     | 412 (63.8)                     | 149 (23.1)                     | 44 (6.8)                       | 0                              |
| Leukocytosis                             | 649 (100.0)                         | 1 (0.2)                             | 0                                   | 0                                   | 1 (0.2)                             | 0                                   | 647 (100.0)                    | 0                              | 0                              | 0                              | 0                              | 0                              |
| Investigations                           |                                     |                                     |                                     |                                     |                                     |                                     |                                |                                |                                |                                |                                |                                |
| Alkalinephosphataseincreased             | 646 (100.0)                         | 405 (62.7)                          | 264 (40.9)                          | 76 (11.8)                           | 62 (9.6)                            | 3 (0.5)                             | 644 (100.0)                    | 409 (63.5)                     | 235 (36.5)                     | 97 (15.1)                      | 66 (10.2)                      | 11 (1.7)                       |
| Whitebloodcelldecreased                  | 649 (100.0)                         | 362 (55.8)                          | 87 (13.4)                           | 100 (15.4)                          | 136 (21.0)                          | 39 (6.0)                            | 647 (100.0)                    | 339 (52.4)                     | 71 (11.0)                      | 97 (15.0)                      | 134 (20.7)                     | 37 (5.7)                       |
| Lymphocyte count decreased               | 526 (100.0)                         | 297 (56.5)                          | 99 (18.8)                           | 132 (25.1)                          | 55 (10.5)                           | 11 (2.1)                            | 495 (100.0)                    | 274 (55.4)                     | 94 (19.0)                      | 113 (22.8)                     | 63 (12.7)                      | 4 (0.8)                        |
| Aspartate aminotransferase increased     | 647 (100.0)                         | 284 (43.9)                          | 238 (36.8)                          | 23 (3.6)                            | 22 (3.4)                            | 1 (0.2)                             | 647 (100.0)                    | 254 (39.3)                     | 218 (33.7)                     | 21 (3.2)                       | 13 (2.0)                       | 2 (0.3)                        |
| Neutrophil countdecreased                | 543 (100.0)                         | 275 (50.6)                          | 42 (7.7)                            | 46 (8.5)                            | 67 (12.3)                           | 120 (22.1)                          | 516 (100.0)                    | 235 (45.5)                     | 32 (6.2)                       | 41 (7.9)                       | 62 (12.0)                      | 100 (19.4)                     |
| Alanineaminotransferaseincreased         | 647 (100.0)                         | 274 (42.3)                          | 221 (34.2)                          | 29 (4.5)                            | 22 (3.4)                            | 2 (0.3)                             | 647 (100.0)                    | 246 (38.0)                     | 204 (31.5)                     | 23 (3.6)                       | 16 (2.5)                       | 3 (0.5)                        |
| Plateletcountdecreased                   | 649 (100.0)                         | 170 (26.2)                          | 149 (23.0)                          | 11 (1.7)                            | 9 (1.4)                             | 1 (0.2)                             | 646 (100.0)                    | 161 (24.9)                     | 143 (22.1)                     | 7 (1.1)                        | 9 (1.4)                        | 2 (0.3)                        |
| Creatinineincreased                      | 647 (100.0)                         | 163 (25.2)                          | 130 (20.1)                          | 26 (4.0)                            | 3 (0.5)                             | 4 (0.6)                             | 645 (100.0)                    | 161 (25.0)                     | 127 (19.7)                     | 28 (4.3)                       | 5 (0.8)                        | 1 (0.2)                        |
| Bloodbilirubinincreased                  | 647 (100.0)                         | 127 (19.6)                          | 97 (15.0)                           | 27 (4.2)                            | 1 (0.2)                             | 2 (0.3)                             | 647 (100.0)                    | 65 (10.0)                      | 52 (8.0)                       | 11 (1.7)                       | 2 (0.3)                        | 0                              |
| INR increased                            | 214 (100.0)                         | 32 (15.0)                           | 20 (9.3)                            | 8 (3.7)                             | 4 (1.9)                             | 0                                   | 197 (100.0)                    | 39 (19.8)                      | 25 (12.7)                      | 9 (4.6)                        | 5 (2.5)                        | 0                              |
| Lymphocytecountincreased                 | 527 (100.0)                         | 29 (5.5)                            | 0                                   | 29 (5.5)                            | 0                                   | 0                                   | 495 (100.0)                    | 38 (7.7)                       | 0                              | 37 (7.5)                       | 1 (0.2)                        | 0                              |
| Hemoglobin increased                     | 649 (100.0)                         | 4 (0.6)                             | 3 (0.5)                             | 0                                   | 1 (0.2)                             | 0                                   | 646 (100.0)                    | 6 (0.9)                        | 5 (0.8)                        | 1 (0.2)                        | 0                              | 0                              |
| Metabolism and nutrition disorders       |                                     |                                     |                                     |                                     |                                     |                                     |                                |                                |                                |                                |                                |                                |
| Hyperglycemia                            | 638 (100.0)                         | 477 (74.8)                          | 317 (49.7)                          | 101 (15.8)                          | 56 (8.8)                            | 3 (0.5)                             | 636 (100.0)                    | 451 (70.9)                     | 265 (41.7)                     | 110 (17.3)                     | 68 (10.7)                      | 8 (1.3)                        |
| Hypoallbuminemia                         | 645 (100.0)                         | 259 (40.2)                          | 204 (31.6)                          | 51 (7.9)                            | 4 (0.6)                             | 0                                   | 642 (100.0)                    | 275 (42.8)                     | 215 (33.5)                     | 58 (9.0)                       | 2 (0.3)                        | 0                              |
| Hypocalcemia                             | 647 (100.0)                         | 225 (34.8)                          | 149 (23.0)                          | 57 (8.8)                            | 14 (2.2)                            | 5 (0.8)                             | 644 (100.0)                    | 199 (30.9)                     | 133 (20.7)                     | 51 (7.9)                       | 12 (1.9)                       | 3 (0.5)                        |
| Hyponatremia                             | 647 (100.0)                         | 195 (30.1)                          | 167 (25.8)                          | 0                                   | 25 (3.9)                            | 3 (0.5)                             | 645 (100.0)                    | 176 (27.3)                     | 152 (23.6)                     | 0                              | 24 (3.7)                       | 0                              |
| Hyperkalemia                             | 647 (100.0)                         | 168 (26.0)                          | 124 (19.2)                          | 34 (5.3)                            | 10 (1.5)                            | 0                                   | 645 (100.0)                    | 132 (20.5)                     | 106 (16.4)                     | 20 (3.1)                       | 5 (0.8)                        | 1 (0.2)                        |
| Hypercalcemia                            | 647 (100.0)                         | 128 (19.8)                          | 122 (18.9)                          | 3 (0.5)                             | 1 (0.2)                             | 2 (0.3)                             | 644 (100.0)                    | 108 (16.8)                     | 101 (15.7)                     | 5 (0.8)                        | 1 (0.2)                        | 1 (0.2)                        |
| Hypokalemia                              | 647 (100.0)                         | 116 (17.9)                          | 0                                   | 100 (15.5)                          | 14 (2.2)                            | 2 (0.3)                             | 645 (100.0)                    | 96 (14.9)                      | 0                              | 86 (13.3)                      | 7 (1.1)                        | 3 (0.5)                        |
| Hypematremia                             | 647 (100.0)                         | 87 (13.4)                           | 79 (12.2)                           | 6 (0.9)                             | 2 (0.3)                             | 0                                   | 645 (100.0)                    | 81 (12.6)                      | 69 (10.7)                      | 10 (1.6)                       | 1 (0.2)                        | 1 (0.2)                        |
| Hypoglycemia                             | 645 (100.0)                         | 46 (7.1)                            | 40 (6.2)                            | 5 (0.8)                             | 1 (0.2)                             | 0                                   | 644 (100.0)                    | 41 (6.4)                       | 35 (5.4)                       | 6 (0.9)                        | 0                              | 0                              |

Abbreviations:AE=Adverse event; CTCAE=Common Terminology Criteria forAdverseEvents; N=Total numberof patients; n=Number of patients with event; SAF=Safety analysis set.

a:Thenumberofpatientswithaspecificlaboratoryvalueavailable.Itdoesnot includenotgraded\".

Notes:

A patient wasconsidered at riskof the laboratory abnormality if thepatient had alaboratory measurement for theparticular laboratory abnormality.

Denominatorandratesforeachlaboratoryisthenumberofpatientswithspecificlaboratoryvalueavailable.

If the reference ranges or other information necessary to derive grades are unavailable or result has a special character (such as &gt; or &lt;) then the grade is set to 'not graded'. In the event of

Onlylaboratory values(noclinical assessments) were used forthe grading.Laboratory abnormalitiesreported asAEs that includeclinical assessments arepresented inAEtables.

CTCAFVersion 403

<div style=\"page-break-after: always\"></div>

Laboratory abnormalities that were reported with 5 percentage points higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm included blood bilirubin increased (19.6% vs. 10.0% of patients, respectively), neutrophil count decreased (50.6% vs. 45.5%), and hyperkalaemia (26.0% vs. 20.5%).

## Analysis of liver function tests

## o Alanine aminotransferase (ALT)

In Study 17777 at baseline, the median value was 24.00 U/L in both treatment arms. Before the start of study treatment, increased ALT (any grade) was reported as a laboratory abnormality in 11.4% of patients in the darolutamide + docetaxel + ADT arm and in 11.2% of patients in the placebo + docetaxel + ADT arm. No patients had pre-treatment abnormalities of Grade &gt;2.

ALT increased was reported as a laboratory abnormality with a slightly higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm, i.e. 42.3% vs 38.0%. Most of the events were reported with a worst grade of 1 in both treatment arms (34.2% and 31.5% in the darolutamide + docetaxel + ADT arm and placebo + docetaxel + ADT arm respectively). Treatment-emergent laboratory abnormality of ALT increased with a worst grade of 3 was observed in 22 patients (3.4%) in the darolutamide + docetaxel + ADT arm vs. 16 patients (2.5%) in the placebo + docetaxel + ADT arm, and with a worst grade of 4 in 2 patients (0.3%) vs. 3 patients (0.5%), respectively.

ALT increased of any grade was reported as a TEAE in 15.6% of patients in the darolutamide + docetaxel + ADT arm and in 12.9% of patients in the placebo + docetaxel + ADT arm. TEAEs of Grade 3/4 ALT increased occurred in 18 patients (2.8%) in the darolutamide + docetaxel + ADT arm compared with 11 patients (1.7%) in the placebo + docetaxel + ADT arm.

## o Aspartate aminotransferase (AST)

In Study 17777 at baseline, the median value was 24.00 U/L in both treatment arms. Before the start of study treatment, increased AST (any grade) was reported as a laboratory abnormality in 7.7% of patients in the darolutamide + docetaxel + ADT arm and in 8.6% of patients in the placebo + docetaxel + ADT arm. No patients had pre-treatment abnormalities of Grade &gt;2.

AST increased was reported as a laboratory abnormality with a slightly higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm, i.e. 43.9% vs 39.3%. Most of the events were reported with a worst grade of 1 in both treatment arms (36.8% and 33.7% in the darolutamide + docetaxel + ADT arm and placebo + docetaxel + ADT arm respectively).

Treatment-emergent laboratory abnormality of AST increased with a1 worst grade of 3 was observed in 22 patients (3.4%) in the darolutamide + docetaxel + ADT arm vs. 13 patients (2.0%) in the placebo + docetaxel + ADT arm, and with a worst grade of 4 in 1 patient (0.2%) vs. 2 patients (0.3%), respectively.

AST increased of any grade was reported as a TEAE in 14.0% of patients in the darolutamide + docetaxel + ADT arm and in 10.5% of patients in the placebo + docetaxel + ADT arm. TEAEs of Grade 3/4 AST increased occurred in 17 patients (2.6%) in the darolutamide + docetaxel + ADT arm compared with 7 patients (1.1%) in the placebo + docetaxel + ADT arm

## o Alkaline phosphatase (ALP)

ALP increased was reported as a laboratory abnormality with comparable incidences in both treatment arms (62.7% and 63.5% in darolutamide + docetaxel + ADT arm and in the placebo + docetaxel + ADT arm, respectively). Most of the events were reported with a worst grade of 1 or 2 in both

<div style=\"page-break-after: always\"></div>

treatment arms. Blood ALP increased was reported as a TEAE in 6.9% of patients in the darolutamide + docetaxel + ADT arm and in 6.6% of patients in the placebo + docetaxel + ADT arm.

- o Blood bilirubin

Before the start of study treatment, laboratory abnormality of blood bilirubin increased was observed at a similar incidence in the darolutamide + docetaxel + ADT arm (1.5%) and the placebo + docetaxel + ADT arm (1.1%).

Blood bilirubin increased was observed with a higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm. Most of the events were reported with a worst grade of 1 or 2 in both treatment arms, i.e. all grade 19.6% vs. 10.0% in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively; Grade 1: 15.0% vs. 8.0% and Grade 2: 4.2% vs. 1.7%. Overall, increases in worst grade from pre-treatment were observed at a higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm.

The difference in bilirubin between the treatment arms over time increased after the 6 months of docetaxel combination treatment period.

Blood bilirubin increased (part of SOC of investigations) was reported as a TEAE in 4.9% of patients in the darolutamide + docetaxel + ADT arm and in 2.9% of patients in the placebo + docetaxel + ADT arm. Almost all patients with TEAE blood bilirubin increased had events with a worst grade of 1 or 2, and there was 1 patient (0.2%) in the darolutamide + docetaxel + ADT arm with an event with a worst grade of 3 (no patients in the placebo + docetaxel + ADT arm). Hyperbilirubinemia (part of SOC of hepatobiliary disorders) was reported as a TEAE in 2 patients (0.3%) in the placebo + docetaxel + ADT arm (1 patient had an event with a worst grade of 1 and 1 patient with a worst grade of 3) (no patients in the darolutamide + docetaxel + ADT arm).

## Hy's Law and drug -induced liver injury (DILI)

## Potential Hy's Law cases

Possible Hy's Law cases were defined as patients with treatment -emergent abnormalities of liver function tests falling in the Hy's Law range (patients with elevated AST and/or ALT &gt;3xULN, and bilirubin 2xULN) with ALP &lt;2xULN. Two cases in darolutamide+docetaxel arm and two cases in the placebo+docetaxel arm. One case in the darolutamide+docetaxel arm experienced hepatocellular injury meeting Hy's Law criteria 37 days after commencing darolutamide treatment and 13 days after the first and only dose of docetaxel. Marked increases in ALT and AST occurred with evidence of hepatic functional impairment as indicated by concurrent elevated bilirubin and INR. Skin rash and pyrexia were also documented.

## Increase in transaminases

The incidence was 17.6% and 14.9%, respectively, in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm. Worst Grade 3 TEAEs occurred in 3.4% of patients in the darolutamide + docetaxel + ADT arm vs. 1.8% of patients in the placebo + docetaxel + ADT arm. TEAEs of increase in transaminases (MLG) with a worst grade of 4 occurred in 1 patient (0.2%) in the darolutamide + docetaxel + ADT arm and 2 patients (0.3%) in the placebo + docetaxel + ADT arm. This patient had reversible and clinically asymptomatic increases in ALT and AST of &gt;20xULN with concurrent normal bilirubin levels Docetaxel had been discontinued almost 5 months prior to the events. Dechallenge and rechallenge with darolutamide was positive.

Drug-induced liver injury (DILI), PT (part of SOC of hepatobiliary disorders): TEAEs occurred in 3 patients (0.5%) in the darolutamide + docetaxel + ADT arm and 4 patients (0.6%) in the placebo + docetaxel + ADT arm. In the darolutamide + docetaxel + ADT arm, 2 cases were Grade 2 and one

<div style=\"page-break-after: always\"></div>

case was Grade 4. In the place+docetaxel arm, one case was Grade 1, 2 cases were Grade 2 and one case was Grade 3.

Of the 7 patients, 3 patients in the placebo + docetaxel + ADT arm had non-serious TEAEs of DILI, all with isolated transaminase elevations and no meaningful increase in total bilirubin level.

The remaining 4 patients experienced TESAEs of DILI (3 patients in the darolutamide + docetaxel + ADT arm and 1 patient in the placebo + docetaxel + ADT arm). One of the patients in the darolutamide + docetaxel + ADT arm who had a DILI TESAE with a worst grade of 4 is discussed above as one of the potential Hy's Law cases.

## 12-lead ECG and QTc

At Screening, the 12-lead ECG was performed for 633/652 (97.1%) and 607/650 (93.4%) patients in the darolutamide + docetaxel + ADT and placebo + docetaxel + ADT arm, respectively, of which 43.4% and 41.7% of patients had central ECG reading interpreted as abnormal (of which 1.5% and 1.4%, respectively, were considered clinically significant by the investigator). The analysis of the ECG data by visit did not reveal any relevant imbalance between the treatment arms or changes from baseline.

A summary of QTcF values at baseline, at EOT, and at last visit is presented in the table below.

Table 69 Summary of QTcF values in Study 17777 (SAF)

|                                                                                                  | Darolutamide+ docetaxel arm N=652         | Darolutamide+ docetaxel arm N=652                    | Darolutamide+ docetaxel arm N=652              | Placebo+ docetaxel arm N=650             | Placebo+ docetaxel arm N=650                                   | Placebo+ docetaxel arm N=650                           |
|--------------------------------------------------------------------------------------------------|-------------------------------------------|------------------------------------------------------|------------------------------------------------|------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------|
| Numberofpatients(%)with:                                                                         | Baseline N=642                            | Endof treatment N=219                                | Last visit N=651                               | Baseline N=636                           | Endof treatment N=377                                          | Last visit N=647                                       |
| Value<=450msec Value 451-480 msec Value481-500msec Value>500msec Increase>30-60msecfrom baseline | 561 (87.4) 68 (10.6) 11 (1.7) 2 (0.3) 0 0 | 191 (87.2) 17 (7.8) 4 (1.8) 7 (3.2) 12 (5.5) 6 (2.7) | 563 (86.5) 71 (10.9) 7 (1.1) 10 (1.5) 36 (5.5) | 554 (87.1) 68 (10.7) 8 (1.3) 6 (0.9) 0 0 | 330 (87.5) 40 (10.6) 3 (0.8) 4 (1.1) 23 (6.1) 4 (1.1) Placebo+ | 559 (86.4) 73 (11.3) 8 (1.2) 7 (1.1) 39 (6.0) 10 (1.5) |
| Increase>60msecfrombaseline                                                                      |                                           |                                                      | 10 (1.5)                                       |                                          |                                                                |                                                        |
|                                                                                                  | Darolutamide+ docetaxelarm N=652          | Darolutamide+ docetaxelarm N=652                     | Darolutamide+ docetaxelarm N=652               | docetaxelarm N=650                       | docetaxelarm N=650                                             | docetaxelarm N=650                                     |
| Atanytimeduringstudy                                                                             | n (%)                                     | EAIR(per100patient years)                            | EAIR(per100patient years)                      | n (%)                                    | EAIR(per100patient years)                                      | EAIR(per100patient years)                              |
| QTcF>500msec                                                                                     | 50 (7.7)                                  | 2.9                                                  | 2.9                                            | 39 (6.0)                                 | 3.2                                                            | 3.2                                                    |

Abbreviations:EAIR=Exposure-adjusted incidencerate;N=Total numberofpatients(1oo%);n=Numberofpatientswith event;QTcF=CorrectedQT(Fridericia'sfommulae);SAF=Safetyanalysisset

Among the 7 patients with a post baseline QTcF value &gt;500 msec at the EOT visit in the darolutamide + docetaxel + ADT arm, most of them had this value only at the EOT visit and not in prior visits.

TEAE electrocardiogram QT prolonged was reported in 5 patients (0.8%) in the darolutamide + docetaxel + ADT arm and in 7 patients (1.1%) in the placebo + docetaxel + ADT arm. All these were reported as non-serious and the study drug doses were not modified due to the events in any of the patients.

Fridericia QTc results were in general similar between treatments arms, and within a treatment arm, at baseline, end of treatment, and last visit. Baseline ECG abnormalities were observed at a similar incidence in patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm. An analysis of ECG data over time did not reveal any relevant imbalance between the treatment arms.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Subgroup analyses for TEAEs were performed for age, geographical region, renal function at baseline, hepatic function at baseline and concomitant statin use.

## Age

An overview of TEAEs by age groups (&lt;65, 65 -74, 75 -84, and 85 years) is presented in the table below.

Table 70 Overview of TEAEs by age in Study 17777 (SAF)

|                                                                                       |                                  |                               |                             |           | Placebo+ docetaxelarm         | Placebo+ docetaxelarm            | Placebo+ docetaxelarm       | Placebo+ docetaxelarm   |
|---------------------------------------------------------------------------------------|----------------------------------|-------------------------------|-----------------------------|-----------|-------------------------------|----------------------------------|-----------------------------|-------------------------|
|                                                                                       | 65                              | Age (years)                   | Age (years)                 |           |                               | Age (years) 65-74                | Age (years) 65-74           |                         |
|                                                                                       |                                  | 65-74                         | 75-84                       | 85       | <65                           |                                  | 75-84                       | 85                     |
|                                                                                       | N=243                            | N=303                         | N=103                       | N=3       | N=232                         | N=305                            | N=109                       | N=4                     |
| Number of patients (%) with:                                                          | n (%)                            | n (%)                         | n (%)                       | n (%)     | n (%)                         | n (%)                            | n (%)                       | n (%)                   |
| Any TEAE                                                                              | 242 (99.6) 302 (99.7) 102 (99.0) |                               |                             | 3 (100.0) |                               | 230 (99.1) 301 (98.7) 108 (99.1) |                             | 4 (100.0)               |
| Worst grade: Grade 1                                                                  | 14 (5.8)                         | 10 (3.3)                      | 4 (3.9)                     | 0         | 20 (8.6)                      | 13 (4.3)                         | 2 (1.8)                     | 0                       |
| Grade 2                                                                               | 84 (34.6)                        | 60 (19.8)                     | 18 (17.5)                   | 0         | 62 (26.7)                     | 88 (28.9)                        | 19 (17.4)                   | 0                       |
| Grade 3                                                                               |                                  | 83 (34.2) 127 (41.9)37 (35.9) |                             | 1 (33.3)  |                               | 92 (39.7) 102 (33.4)             | 37 (33.9)                   | 1 (25.0)                |
| Grade 4                                                                               |                                  |                               | 51 (21.0)92 (30.4)38 (36.9) | 2 (66.7)  | 53 (22.8)                     | 87 (28.5)                        | 39 (35.8)                   | 2 (50.0)                |
| Grade 5                                                                               | 10 (4.1)                         |                               | 12 (4.0) 5 (4.9)            | 0         | 3 (1.3)                       | 11 (3.6)                         | 11 (10.1)                   | 1 (25.0)                |
| Missing                                                                               | 0                                | 1 (0.3)                       | 0                           | 0         | 0                             | 0                                | 0                           | 0                       |
| Serious TEAE                                                                          | 82 (33.7) 152 (50.2)             |                               | 55 (53.4)                   | 3 (100.0) |                               | 89 (38.4) 125 (41.0)             | 58 (53.2)                   | 3 (75.0)                |
| Fatal (Grade 5)                                                                       | 10 (4.1)                         | 12 (4.0)                      | 5 (4.9)                     | 0         | 3 (1.3)                       | 11 (3.6)                         | 11 (10.1)                   | 1 (25.0)                |
| Requires or prolongs hospitalization                                                  |                                  | 76 (31.3) 143 (47.2)          | 52 (50.5)                   | 3 (100.0) |                               | 82 (35.3) 118 (38.7)             | 56 (51.4)                   | 3 (75.0)                |
| Life-threatening                                                                      | 6 (2.5)                          | 13 (4.3)                      | 4 (3.9)                     | 1 (33.3)  | 3 (1.3)                       | 15 (4.9)                         | 7 (6.4)                     | 2 (50.0)                |
| Disability/incapacity                                                                 | 2 (0.8)                          | 1 (0.3)                       | 0                           | 0         | 4 (1.7)                       | 4 (1.3)                          | 0                           | 0                       |
| Other (medically significant)                                                         | 9 (3.7).                         | 17 (5.6)                      | 4 (3.9)                     | 1 (33.3)  | 8(3.4)                        | 10 (3.3)                         | 4 (3.7)                     | 0                       |
| TEAE leading to study drug dose modification a                                        |                                  |                               | 56 (23.0)87 (28.7)24 (23.3) | 2 (66.7)  | 25 (10.8)                     | )60 (19.7)26 (23.9)              |                             | 1 (25.0)                |
| TEAE leading to permanent discontinuation of study drug                               |                                  |                               | 31(12.8)41 (13.5)14 (13.6)  | 2 (66.7)  |                               | 17 (7.3)32 (10.5)19 (17.4)       |                             | 1 (25.0)                |
| TEAE leading to docetaxel dose modification a                                         |                                  | 68 (28.0) 108 (35.6)37 (35.9) |                             | 1 (33.3)  |                               | 64 (27.6) 101 (33.1)46 (42.2)    |                             | 3 (75.0)                |
| TEAE leading to permanent discontinuation of docetaxel                                |                                  |                               | 11 (4.5)28 (9.2)12(11.7)    | 1 (33.3)  |                               | 11 (4.7)33 (10.8)23 (21.1)       |                             | 0                       |
| Specific categories                                                                   |                                  |                               |                             |           |                               |                                  |                             |                         |
| Psychiatric disorders (SOC)                                                           |                                  | 45(18.5)55(18.2)12(11.7)      |                             | 2 (66.7)  |                               | 50 (21.6)54 (17.7)22 (20.2)      |                             | 0                       |
| Nervous system disorders (SOC)                                                        | 121 (49.8) 163 (53.8)58 (56.3)   |                               |                             | 2 (66.7)  | 113 (48.7) 172 (56.4)         |                                  | 55 (50.5)                   | 2 (50.0)                |
| Accidents and injuries (SMQ)                                                          |                                  | 38 (15.6)50 (16.5)22 (21.4)   |                             | 1 (33.3)  | 33 (14.2)                     | 47 (15.4)                        | 11 (10.1)                   | 1 (25.0)                |
| Cardiac disorders (SOC)                                                               | 25 (10.3)43 (14.2)14 (13.6)      |                               |                             | 1 (33.3)  |                               |                                  | 25 (10.8)47 (15.4)17 (15.6) | 1 (25.0)                |
| Vascular disorders (SOC)                                                              | 93 (38.3) 116 (38.3)33 (32.0)    |                               |                             | 1 (33.3)  |                               |                                  | 91 (39.2)99 (32.5)43 (39.4) | 0                       |
| Central nervous system vascular                                                       | 4 (1.6)                          | 17 (5.6)                      | 3 (2.9)                     | 0         | 6 (2.6)                       | 9 (3.0)                          | 4 (3.7)                     | 0                       |
| disorders (SMQ)                                                                       |                                  |                               |                             |           |                               |                                  |                             |                         |
| Infections and infestations (SOC)                                                     | 120 (49.4) 153 (50.5)            |                               | 45 (43.7)                   |           | 2 (66.7)101 (43.5) 150 (49.2) |                                  | 55 (50.5)                   | 3 (75.0)                |
| Anticholinergic syndrome (SMQ)                                                        | 2 (0.8)                          | 2 (0.7)                       | 1 (1.0)                     | 0         | 0                             | 0                                | 1 (0.9)                     | 0                       |
| Quality of life decreased (PT)                                                        | 0                                | 0                             | 0                           | 0         | 0                             | 0                                | 0                           | 0                       |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures |                                  |                               | 42 (17.3)70 (23.1)26 (25.2) | 2 (66.7)  | 36(15.5)52 (17.0)27 (24.8)    |                                  |                             | 0                       |

MedDRA=Medical Dictionary for Regulatory Activities; N=Total number of patients (100%); n=Number of patients with event; PT=Preferred term; SAF=Safety analysis set; SMQ=Standardized MedDRA Query; SOC=System organ class;

Abbreviations: CTCAE=Common Teminology Criteria for Adverse Events; EMA=European Medicines Agency;

TEAE=Treatment-emergent adverse event

a: Modifications include dose interruption/delay and reductions.

b: The algorithm approach is used per MedDRA guidance of the SMQ Anticholinergic syndrome.

Notes: 'Any TEAE' also includes patients with grade not available for all adverse events.

CTCAE version 4.03. MedDRA version 24.1.

<div style=\"page-break-after: always\"></div>

## Geographical region

## Table 71 Overview of TEAEs by geographical region in Study 17777 (SAF)

|                                                         |               | Darolutamide+ docetaxel arm Geographical region   |            |                     | Placebo+ docetaxel arm   |                     |
|---------------------------------------------------------|---------------|---------------------------------------------------|------------|---------------------|--------------------------|---------------------|
|                                                         |               |                                                   |            | Geographical region | Geographical region      | Geographical region |
|                                                         | North America | Asia Pacific                                      |            | North America       | Asia Pacific             | ROW                 |
|                                                         | N=125         | N=230                                             | ROW N=297  | N=117               | N=242                    | N=291               |
| Number of patients (%) with                             | n (%)         | n (%)                                             | n (%)      | n (%)               | n (%)                    | n (%)               |
| Any TEAE                                                | 125 (100.0)   | 229 (99.6)                                        | 295 (99.3) | 116 (99.1)          | 239 (98.8)               | 288 (99.0)          |
| Worst grade: Grade 1                                    | 5 (4.0)       | 4 (1.7)                                           | 19 (6.4)   | 4 (3.4)             | 8 (3.3)                  | 23 (7.9)            |
| Grade 2                                                 | 37 (29.6)     | 31 (13.5)                                         | 94 (31.6)  | 33 (28.2)           | 44 (18.2)                | 92 (31.6)           |
| Grade 3                                                 | 49 (39.2)     | 75 (32.6)                                         | 124 (41.8) | 55 (47.0)           | 69 (28.5)                | 108 (37.1)          |
| Grade 4                                                 | 27 (21.6)     | 110 (47.8)                                        | 46 (15.5)  | 23 (19.7)           | 113 (46.7)               | 45 (15.5)           |
| Grade 5                                                 | 7 (5.6)       | 8 (3.5)                                           | 12 (4.0)   | 1 (0.9)             | 5 (2.1)                  | 20 (6.9)            |
| Missing                                                 | 0             | 1 (0.4)                                           | 0          | 0                   | 0                        | 0                   |
| TESAE                                                   | 55 (44.0)     | 121 (52.6)                                        | 116 (39.1) | 44 (37.6)           | 110 (45.5)               | 121 (41.6)          |
| TEAEleading to study drug dose modification a           | 41 (32.8)     | 55 (23.9)                                         | 73 (24.6)  | 27 (23.1)           | 34 (14.0)                | 51 (17.5)           |
| TEAE leading to permanent discontinuation of study drug | 22 (17.6)     | 30 (13.0)                                         | 36 (12.1)  | 11 (9.4)            | 19 (7.9)                 | 39 (13.4)           |
| TEAEleading to docetaxel dose modification a            | 34 (27.2)     | 117 (50.9)                                        | 63 (21.2)  | 33 (28.2)           | 116 (47.9)               | 65 (22.3)           |
| TEAE leading to permanent discontinuationofdocetaxel    | 10 (8.0)      | 27 (11.7)                                         | 15 (5.1)   | 11 (9.4)            | 28 (11.6)                | 28 (9.6)            |

patients with event; ROW=Rest of the world; SAF=Safety analysis set; TEAE=Treatment-emergent adverse event TESAE=Treatment-emergent serious adverse event

Abbreviations:CTCAE=CommonTerminology Criteria forAdverseEvents; N=Total numberof patients(100%); n=Number of a:Modificationsincludedoseinterruption/delayandreductions.

CTCAE version 4.03.

Note: 'Any TEAE' also includes patients with grade not available for all adverse events.

## Renal function at baseline

## Table 72 Overview of TEAEs by renal function at baseline in Study 17777 (SAF)

|                                                  | Darolutamide+ docetaxelarm   | Darolutamide+ docetaxelarm   | Darolutamide+ docetaxelarm   | Darolutamide+ docetaxelarm   | Placebo+ docetaxel arm   | Placebo+ docetaxel arm   | Placebo+ docetaxel arm   | Placebo+ docetaxel arm   |
|--------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                  |                              | eGFRatbaseline               | eGFRatbaseline               | Severe                       |                          | eGFRatbaseline           | eGFRatbaseline           |                          |
|                                                  |                              | Mild                         | Moderate                     |                              |                          | Mild                     | Moderate                 | Severe                   |
|                                                  | Normal                       |                              |                              |                              | Normal                   |                          | impairment impaiment     |                          |
|                                                  |                              |                              |                              | impairment impairment        |                          | impairment               |                          |                          |
|                                                  |                              | impairment                   |                              |                              |                          |                          |                          |                          |
| Numberofpatients (%) with                        | N=376 n (%)                  | N=236 n (%)                  | N=39 n (%)                   | N=1 a n (%)                  | N=362 n (%)              | N=234 n (%)              | N=53 n (%)               | N=0 n (%)                |
| Any TEAE                                         | 374 (99.5)                   | 235 (99.6)                   | 39 (100.0)                   | 1 (100.0)                    | 357 (98.6)               | 232 (99.1)               | 53 (100.0)               | 0                        |
| Worst grade:                                     | 12 (3.2)                     | 15 (6.4)                     | 1 (2.6)                      | 0                            | 24 (6.6)                 | 10 (4.3)                 | 1 (1.9)                  | 0                        |
| Grade 1                                          |                              |                              |                              |                              |                          |                          |                          |                          |
| Grade 2                                          | 94 (25.0)                    | 57 (24.2)                    | 11 (28.2)                    | 0                            | 105 (29.0)               | 54 (23.1)                | 10 (18.9)                | 0                        |
| Grade 3                                          | 141 (37.5)                   | 89 (37.7)                    | 17 (43.6)                    | 1 (100.0)                    | 123 (34.0)               | 87 (37.2)                | 21 (39.6)                | 0                        |
| Grade 4                                          | 110 (29.3)                   | 66 (28.0)                    | 7 (17.9)                     | 0                            | 95 (26.2)                | 71 (30.3)                | 15 (28.3)                | 0                        |
| Grade5                                           | 16 (4.3)                     | 8 (3.4)                      | 3 (7.7)                      | 0                            | 10 (2.8)                 | 10 (4.3)                 | 6 (11.3)                 | 0                        |
| Missing                                          | 1 (0.3)                      | 0                            | 0                            | 0                            | 0                        | 0                        | 0                        | 0                        |
| TESAE                                            | 162 (43.1)                   | 111 (47.0)                   | 18 (46.2)                    | 1 (100.0)                    | 146 (40.3)               | 100 (42.7)               | 28 (52.8)                | 0                        |
| TEAE leading to study drug dose modification b   | 83 (22.1)                    | 72 (30.5)                    | 13 (33.3)                    | 1 (100.0)                    | 45 (12.4)                | 48 (20.5)                | 18 (34.0)                | 0                        |
| TEAE leading to permanent discontinuationofstudy | 47 (12.5)                    | 34 (14.4)                    |                              | 6 (15.4) 1(100.0)            | 33 (9.1)                 | 23 (9.8)                 | 12 (22.6)                | 0                        |
| drug TEAEleading to docetaxeldose modification b | 131 (34.8)                   | 70 (29.7)                    | 13 (33.3)                    | 0                            | 110 (30.4)               | 81 (34.6)                | 23 (43.4)                | 0                        |
| TEAE leading to permanent discontinuation of     | 30 (8.0)                     | 18 (7.6)                     | 4 (10.3)                     | 0                            | 36 (9.9)                 | 22 (9.4)                 | 9 (17.0)                 | 0                        |

numberofpatients(100%);n=Numberofpatientswithevent;SAF=Safety analysisset;TEAE=Treatment-emergent

Abbreviations:CTCAE=CommonTerminologyCriteriaforAdverseEvents;eGFR=Estimatedglomerularfiltrationrate;N=total adverse event; TESAE=Treatment-emergent serious adverse event; ULN=Upper limit of normal

a:OnepatienthadsevererenalimpairmentatbaselinebasedoneGFRbutwaseligiblebasedonaserumcreatininelevelbelow 2.0 x ULN (Module 5.3.5.1,Report PH-42024,Listing 16.2.4/5).

b:Modifications includedoseinterruption/delay and reductions.

Notes:Patientswithmissingrenalfunctioninformationatbaselinearenotincludedinthistable.

'AnyTEAE'alsoincludespatientswithgradenot availableforalladverseevents.

CTCAEversion4.03

<div style=\"page-break-after: always\"></div>

Hepatic function at baseline

## Table 73 Overview of TEAEs by hepatic function at baseline in Study 17777 (SAF)

|                                                       |                                                       | Darolutamide+ docetaxelarm   | Darolutamide+ docetaxelarm   | Darolutamide+ docetaxelarm                    | Placebo+ docetaxelarm   | Placebo+ docetaxelarm                     | Placebo+ docetaxelarm   |
|-------------------------------------------------------|-------------------------------------------------------|------------------------------|------------------------------|-----------------------------------------------|-------------------------|-------------------------------------------|-------------------------|
|                                                       |                                                       | Normal                       | Mild impairment              | Hepaticfunctionatbaseline Moderate impairment | Normal                  | Hepaticfunctionatbaseline Mild impairment | Moderate impaiment      |
|                                                       |                                                       | N=598                        | N=49                         | N=2                                           | N=589                   | N=52                                      | N=0                     |
| Number of patients (%) with                           | Number of patients (%) with                           | n (%)                        | n (%)                        | n (%)                                         | n (%)                   | n (%)                                     | n (%)                   |
|                                                       |                                                       | 595 (99.5)                   | 49 (100.0)                   | 2 (100.0)                                     | 583 (99.0)              | 51 (98.1)                                 | 0                       |
| Worst grade:                                          | Grade 1                                               | 26 (4.3)                     | 2 (4.1)                      | 0                                             | 33 (5.6)                | 2 (3.8)                                   | 0                       |
| Worst grade:                                          | Grade 2                                               | 146 (24.4)                   | 15 (30.6)                    | 0                                             | 155 (26.3)              | 14 (26.9)                                 | 0                       |
| Worst grade:                                          | Grade 3                                               | 230 (38.5)                   | 16 (32.7)                    | 1 (50.0)                                      | 204 (34.6)              | 21 (40.4)                                 | 0                       |
| Worst grade:                                          | Grade 4                                               | 167 (27.9)                   | 14 (28.6)                    | 1 (50.0)                                      | 169 (28.7)              | 10 (19.2)                                 | 0                       |
| Worst grade:                                          | Grade 5                                               | 25 (4.2)                     | 2 (4.1)                      | 0                                             | 22 (3.7)                | 4 (7.7)                                   | 0                       |
| Worst grade:                                          | Missing                                               | 1 (0.2)                      | 0                            | 0                                             | 0                       | 0                                         | 0                       |
| TESAE                                                 | TESAE                                                 | 270 (45.2)                   | 21 (42.9)                    | 1 (50.0)                                      | 240 (40.7)              | 28 (53.8)                                 | 0                       |
| TEAEleading tostudy drug dose modification 3          | TEAEleading tostudy drug dose modification 3          | 155 (25.9)                   | 12 (24.5)                    | 2 (100.0)                                     | 95 (16.1)               | 14 (26.9)                                 | 0                       |
| TEAEleading topermanent discontinuation of study drug | TEAEleading topermanent discontinuation of study drug | 82 (13.7)                    | 5 (10.2)                     | 1 (50.0)                                      | 61 (10.4)               | 7 (13.5)                                  | 0                       |
| TEAEleadingtodocetaxeldose modification a             | TEAEleadingtodocetaxeldose modification a             | 196 (32.8)                   | 18 (36.7)                    | 0                                             | 192 (32.6)              | 18 (34.6)                                 | 0                       |
| TEAEleadingtopermanent discontinuationofdocetaxel     | TEAEleadingtopermanent discontinuationofdocetaxel     | 47 (7.9)                     | 5 (10.2)                     | 0                                             | 63 (10.7)               | 4 (7.7)                                   | 0                       |

Abbreviations:CTCAE=CommonTerminology CriteriaforAdverseEvents;N=Totalnumberofpatients(100%);n=Numberof patientswithevent;SAF=Safetyanalysisset;TEAE=Treatment-emergent adverseeventTESAE=Treatment-emergent seriousadverseevent

Notes:Patientswithmissinghepaticfunctioninformation at baseline arenot included inthistable.

'AnyTEAE'alsoincludespatientswithgradenot availableforall adverseevents.

CTCAE version 4.03

## Concomitant statin use

Concomitant use of statins with darolutamide can increase the exposure to statins, with rosuvastatin increasing up to 5-fold (Zurth et al. 2019). Therefore, a subgroup analysis was performed to investigate whether the AE profile differs between users and non-users of statins. This analysis included all TEAEs that were reported in concomitant statin users compared with non-users regardless of the time when the event occurred (ie, not considering if the event occurred during concomitant darolutamide and statin administration). An overview of TEAEs by concomitant statin use in Study 17777 is presented below.

Table 74 Overview of TEAEs by concomitant statin use in Study 17777 (SAF)

|                                                      | Darolutamide+ docetaxelarm   | Darolutamide+ docetaxelarm   | Placebo+ docetaxel arm Concomitantstatin use   | Placebo+ docetaxel arm Concomitantstatin use   |
|------------------------------------------------------|------------------------------|------------------------------|------------------------------------------------|------------------------------------------------|
|                                                      | Concomitant statin use No    | Yes                          | No                                             | Yes                                            |
|                                                      | N=469                        | N=183                        | N=480                                          | N=170                                          |
| Number ofpatients (%) with                           | n (%)                        | n (%)                        | n (%)                                          | n (%)                                          |
| Any TEAE                                             | 467 (99.6%)                  | 182 (99.5%)                  | 473 (98.5%)                                    | 170 (100.0%)                                   |
| Worst grade: Grade 1                                 | 18 (3.8%)                    | 10 (5.5%)                    | 30 (6.3%)                                      | 5 (2.9%)                                       |
| Grade 2                                              | 120 (25.6%)                  | 42 (23.0%)                   | 126 (26.3%)                                    | 43 (25.3%)                                     |
| Grade 3                                              | 178 (38.0%)                  | 70 (38.3%)                   | 173 (36.0%)                                    | 59 (34.7%)                                     |
| Grade 4                                              | 131 (27.9%)                  | 52 (28.4%)                   | 121 (25.2%)                                    | 60 (35.3%)                                     |
| Grade 5                                              | 19 (4.1%)                    | 8 (4.4%)                     | 23 (4.8%)                                      | 3 (1.8%)                                       |
| Missing                                              | 1 (0.2%)                     | 0                            | 0                                              | 0                                              |
| TESAE                                                | 190 (40.5%)                  | 102 (55.7%)                  | 190 (39.6%)                                    | 85 (50.0%)                                     |
| TEAE leading to study drug dose modificationa        | 111 (23.7%)                  | 58 (31.7%)                   | 75 (15.6%)                                     | 37 (21.8%)                                     |
| TEAEleadingtopermanent discontinuation of study drug | 66 (14.1%)                   | 22 (12.0%)                   | 53 (11.0%)                                     | 16 (9.4%)                                      |
| TEAE leading to docetaxel dose modification a        | 147 (31.3%)                  | 67 (36.6%)                   | 146 (30.4%)                                    | 68 (40.0%)                                     |
| TEAEleadingtopermanent discontinuation ofdocetaxel   | 32 (6.8%)                    | 20 (10.9%)                   | 48 (10.0%)                                     | 19 (11.2%)                                     |

Abbreviations:CTCAE=CommonTerminologyCriteriaforAdverseEvents;N=Total numberofpatients(100%);n=Numberof patients with event; SAF=Safety analysis set; TEAE=Treatment-emergent adverse event TESAE=Treatment-emergent seriousadverseevent

a:Modificationsincludedoseinterruption/delayandreductions.

Note:'AnyTEAE'alsoincludespatientswithgradenotavailableforalladverseevents. CTC.AF versinn 4 3

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

- TEAEs leading to permanent discontinuation

Overall, TEAEs that resulted in permanent discontinuation of study drug occurred at a higher incidence in the darolutamide + docetaxel + ADT arm than the placebo + docetaxel + ADT arm (13.5% vs. 10.6%, respectively). The most common TEAEs leading to permanent discontinuation of study drug (in 5 patients in either treatment arm) were AST increased (0.9% vs. 0.3%), ALT increased (0.8% vs. 0.2%) and bone pain (0.3% vs. 1.4%).

The incidences of TEAEs that resulted in permanent discontinuation of docetaxel were slightly lower in the darolutamide + docetaxel + ADT arm compared to the placebo + docetaxel + ADT arm (8.0% vs. 10.3%, respectively). The most common TEAEs leading to permanent discontinuation of docetaxel (in 5 patients in either treatment arm) were neutrophil count decreased (0.8% vs. 0.5%), febrile neutropenia (0.5% vs. 0.8%), neutropenia (0.5% vs. 0.8%), and WBC count decreased (0.2% vs. 0.9%).

Table 75 Incidence of TEAEs leading to permanent discontinuation of study drug or docetaxel in Study 17777 (SAF)

|                                                                                                 | Darolutamide+ docetaxel arm N=652 n (%)                                                         | Placebo+ docetaxel arm N=650 n (%)                                                              |
|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| AnyTEAEleading todiscontinuationofstudy drug                                                    | 88 (13.5%)                                                                                      | 69 (10.6%)                                                                                      |
| Worst CTCAEgrade: Grade 1                                                                       | 8 (1.2%)                                                                                        | 4 (0.6%)                                                                                        |
|                                                                                                 | 16 (2.5%)                                                                                       | 20 (3.1%)                                                                                       |
| Grade 2 Grade 3                                                                                 | 38 (5.8%)                                                                                       | 22 (3.4%)                                                                                       |
| Grade 4                                                                                         | 7 (1.1%)                                                                                        | 7 (1.1%)                                                                                        |
| Grade 5                                                                                         | 19 (2.9%)                                                                                       | 16 (2.5%)                                                                                       |
| TEAEs (any grade) occurring in 20.5% of patients in either treatment arm by MedDRA PT (v. 24.1) | TEAEs (any grade) occurring in 20.5% of patients in either treatment arm by MedDRA PT (v. 24.1) | TEAEs (any grade) occurring in 20.5% of patients in either treatment arm by MedDRA PT (v. 24.1) |
| Aspartateaminotransferaseincreased                                                              | 6 (0.9%)                                                                                        | 2 (0.3%)                                                                                        |
| Alanineaminotransferaseincreased                                                                | 5 (0.8%)                                                                                        | 1 (0.2%)                                                                                        |
| COVID-19pneumonia                                                                               | 4 (0.6%)                                                                                        | 1 (0.2%)                                                                                        |
| Rash maculo-papular                                                                             | 3 (0.5%)                                                                                        | 0                                                                                               |
| Bone pain                                                                                       | 2 (0.3%)                                                                                        | 9 (1.4%)                                                                                        |
| Back pain                                                                                       | 2 (0.3%)                                                                                        | 3 (0.5%)                                                                                        |
| Interstitiallungdisease                                                                         | 1 (0.2%)                                                                                        | 3 (0.5%)                                                                                        |
| Pneumonia                                                                                       | 1 (0.2%)                                                                                        | 3 (0.5%)                                                                                        |
| AnyTEAEleadingtodiscontinuationofdocetaxel                                                      | 52 (8.0%)                                                                                       | 67 (10.3%)                                                                                      |
| Worst CTCAEgrade: Grade 1                                                                       | 8 (1.2%)                                                                                        | 6 (0.9%)                                                                                        |
| Grade 2                                                                                         | 18 (2.8%)                                                                                       | 21 (3.2%)                                                                                       |
| Grade 3                                                                                         | 17 (2.6%)                                                                                       | 27 (4.2%)                                                                                       |
| Grade 4                                                                                         | 7 (1.1%)                                                                                        | 8 (1.2%)                                                                                        |
| Grade 5                                                                                         | 2 (0.3%)                                                                                        | 5 (0.8%)                                                                                        |
| TEAEs (any grade) occurring in 20.5% of patients in either treatment arm by MedDRA PT (v. 24.1) | TEAEs (any grade) occurring in 20.5% of patients in either treatment arm by MedDRA PT (v. 24.1) | TEAEs (any grade) occurring in 20.5% of patients in either treatment arm by MedDRA PT (v. 24.1) |
| Neutrophilcount decreased                                                                       | 5 (0.8%)                                                                                        | 3 (0.5%)                                                                                        |
| Peripheral sensory neuropathy                                                                   | 4 (0.6%)                                                                                        | 1 (0.2%)                                                                                        |
| Febrile neutropenia                                                                             | 3 (0.5%)                                                                                        | 5 (0.8%)                                                                                        |
| Neutropenia                                                                                     | 3 (0.5%)                                                                                        | 5 (0.8%)                                                                                        |
| Malaise                                                                                         | 3 (0.5%)                                                                                        | 4 (0.6%)                                                                                        |
| Pneumonia                                                                                       | 3 (0.5%)                                                                                        | 4 (0.6%)                                                                                        |
| Alanine aminotransferase increased                                                              | 3 (0.5%)                                                                                        | 2 (0.3%)                                                                                        |
| Fatigue                                                                                         | 2 (0.3%)                                                                                        | 3 (0.5%)                                                                                        |
| Oedema peripheral                                                                               | 2 (0.3%)                                                                                        | 3 (0.5%)                                                                                        |
| Whitebloodcellcountdecreased                                                                    | 1 (0.2%)                                                                                        | 6 (0.9%)                                                                                        |
| Aspartate aminotransferase increased                                                            | 1 (0.2%)                                                                                        | 3 (0.5%)                                                                                        |
| Dyspnoea                                                                                        | 1 (0.2%)                                                                                        | 3 (0.5%)                                                                                        |
| Interstitiallungdisease                                                                         | 1 (0.2%)                                                                                        | 3 (0.5%)                                                                                        |
| Anaemia                                                                                         | 0                                                                                               | 3 (0.5%)                                                                                        |
| Pulmonary embolism                                                                              | 0                                                                                               | 3 (0.5%)                                                                                        |

Abbreviations:COVID-19=Coronavirus disease 2019; CTCAE=Common Teminology Criteria forAdverse Events;

MedDRA=Medical Dictionary for Regulatory Activities; N=Total number of patients (100%): n=Number of patients with event; PT=Preferred term; SAF=Safety analysis set; TEAE=Treatment-emergent adverse event; v.=Version Note: A patient may have more than one entry. CTCAE version 4.03.

<div style=\"page-break-after: always\"></div>

- TEAEs leading to dose interruption

TEAEs that resulted in interruption of study drug occurred at a higher incidence in the darolutamide + docetaxel + ADT arm (22.9%) than in the placebo + docetaxel + ADT+ ADT arm (15.7%). The most common TEAEs leading to interruption of study drug (in 2% of patients in either treatment arm) were ALT increased (3.2% vs. 1.5%), AST increased (3.1% vs. 1.1%), and febrile neutropenia (2.1% vs. 1.4%) in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. When adjusted for the difference in study drug treatment duration, the incidences of all TEAEs were comparable between the treatment arms, except for ALT increased (EAIRs of 1.2 vs. 0.8 per 100 PYs in the darolutamide + docetaxel + ADT and placebo + docetaxel + ADT arms, respectively), and AST increased (EAIRs of 1.2 vs. 0.6 per 100 PYs, respectively).

TEAEs that resulted in interruption of docetaxel occurred at a similar incidence between the treatment arms, in 21.9% of patients in the darolutamide + docetaxel + ADT arm and 20.6% of patients in the placebo + docetaxel + ADT arm. The most common TEAEs leading to interruption of docetaxel (in 2% of patients in either treatment arm) were ALT incr eased (4.0% vs. 3.4%), neutrophil count decreased (2.8% vs. 2.3%), and AST increased (2.8% vs. 1.7%) in the darolutamide + docetaxel + ADT arm and placebo + docetaxel + ADT arm, respectively.

Table 76 Incidence of TEAEs leading to interruption of study drug or docetaxel in Study 17777 (SAF)

|                                             |                                             | Darolutamide+ docetaxel arm N=652 n (%)   | Placebo+ docetaxel arm N=650 n (%)   |
|---------------------------------------------|---------------------------------------------|-------------------------------------------|--------------------------------------|
| AnyTEAE leading to interruptionofstudy drug | AnyTEAE leading to interruptionofstudy drug | 149 (22.9%)                               | 102 (15.7%)                          |
| Worst CTCAE grade:                          | Grade 1                                     | 6 (0.9%)                                  | 10 (1.5%)                            |
|                                             | Grade 2                                     | 34 (5.2%)                                 | 18 (2.8%)                            |
|                                             | Grade 3                                     | 92 (14.1%)                                | 53 (8.2%)                            |
|                                             | Grade 4                                     | 17 (2.6%)                                 | 21 (3.2%)                            |
|                                             | Grade 5                                     | 0                                         | 0                                    |
| Alanineaminotransferaseincreased            | Alanineaminotransferaseincreased            | 21 (3.2%)                                 | 10 (1.5%)                            |
| Aspartateaminotransferaseincreased          | Aspartateaminotransferaseincreased          | 20 (3.1%)                                 | 7 (1.1%)                             |
| Febrile neutropenia                         | Febrile neutropenia                         | 14 (2.1%)                                 | 9 (1.4%)                             |
| AnyTEAEleadingtointerruptionofdocetaxel     | AnyTEAEleadingtointerruptionofdocetaxel     | 143 (21.9%)                               | 134 (20.6%)                          |
| Worst CTCAEgrade:                           | Grade 1                                     | 28 (4.3%)                                 | 29 (4.5%)                            |
|                                             | Grade 2                                     | 58 (8.9%)                                 | 47 (7.2%)                            |
|                                             | Grade 3                                     | 41 (6.3%)                                 | 43 (6.6%)                            |
|                                             | Grade 4                                     | 16 (2.5%)                                 | 15 (2.3%)                            |
|                                             | Grade 5                                     | 0                                         | 0                                    |
| Alanineaminotransferaseincreased            | Alanineaminotransferaseincreased            | 26 (4.0%)                                 | 22 (3.4%)                            |
| Neutrophilcountdecreased                    | Neutrophilcountdecreased                    | 18 (2.8%)                                 | 15 (2.3%)                            |
| Aspartateaminotransferaseincreased          | Aspartateaminotransferaseincreased          | 18 (2.8%)                                 | 11 (1.7%)                            |
| Oedema peripheral                           | Oedema peripheral                           | 10 (1.5%)                                 | 5 (0.8%)                             |
| Neutropenia                                 | Neutropenia                                 | 8 (1.2%)                                  | 10 (1.5%)                            |
| Whitebloodcellcountdecreased                | Whitebloodcellcountdecreased                | 8 (1.2%)                                  | 6 (0.9%)                             |
| Febrile neutropenia                         | Febrile neutropenia                         | 7 (1.1%)                                  | 6 (0.9%)                             |
| Malaise                                     | Malaise                                     | 7 (1.1%)                                  | 3 (0.5%)                             |
| Bloodbilirubinincreased                     | Bloodbilirubinincreased                     | 5 (0.8%)                                  | 7 (1.1%)                             |

Activities; N=Total number of patients (100%); n=Number of patients with event; PT=Preferred term; SAF=Safety analysis set; TEAE=Treatment-emergent adverse event; v.=Version

Abbreviations: CTCAE=CommonTerminology Criteria forAdverse Events;MedDRA=Medical Dictionary for Regulatory

Note:Apatient mayhavemore thanoneentry.

CTCAE version 4.03.

- TEAEs leading to dose reduction

TEAEs that resulted in dose reduction of study drug occurred at a higher incidence in the darolutamide + docetaxel + ADT arm (8.7%) than in the placebo + docetaxel + ADT arm (4.3%). The most common TEAEs leading to dose reduction of study drug (in 2% of patients in either treatment

<div style=\"page-break-after: always\"></div>

arm) were ALT increased (2.8% vs. 1.2%) and AST increased (2.5% vs. 0.8%) in the darolutamide + docetaxel + ADT arm and placebo + docetaxel + ADT arm, respectively. All other TEAEs were reported in 4 patients each. When adjusted for the difference in treatment duration, the incidences of all TEAEs were comparable between the treatment arms, except for AST increased, for which the EAIRs were 0.9 vs. 0.4 per 100 PYs in the darolutamide + docetaxel + ADT and placebo + docetaxel + ADT arms, respectively.

TEAEs that resulted in dose reduction of docetaxel occurred at a similar incidence between the treatment arms, in 19.9% of patients in the darolutamide + docetaxel + ADT arm and 19.5% of patients in the placebo + docetaxel + ADT arm. The most common TEAEs leading to reduction of docetaxel (in 2% of patients in either treatment arm) were neutrophil co unt decreased (5.4% vs. 6.0%), febrile neutropenia (3.7% vs. 3.8%), WBC count decreased (3.2% vs. 3.4%), and neutropenia (1.8% vs. 2.2%) in the darolutamide + docetaxel + ADT arm and placebo + docetaxel + ADT arm, respectively. The incidences of these TEAEs were comparable between the treatment arms.

Table 77 Incidence of TEAEs leading to dose reduction of study drug or docetaxel in Study 17777 (SAF)

|                                                                                               |                                                                                               | Darolutamide+ docetaxel arm N=652 n (%)                                                       | Placebo+ docetaxel arm N=650 n (%)                                                            |
|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| AnyTEAE leading to study drug dosereduction                                                   | AnyTEAE leading to study drug dosereduction                                                   | 57 (8.7%)                                                                                     | 28 (4.3%)                                                                                     |
| Worst CTCAE grade:                                                                            | Grade 1                                                                                       | 18 (2.8%)                                                                                     | 9 (1.4%)                                                                                      |
| Worst CTCAE grade:                                                                            | Grade 2                                                                                       | 22 (3.4%)                                                                                     | 13 (2.0%)                                                                                     |
| Worst CTCAE grade:                                                                            | Grade 3                                                                                       | 15 (2.3%)                                                                                     | 6 (0.9%)                                                                                      |
| Worst CTCAE grade:                                                                            | Grade 4                                                                                       | 2 (0.3%)                                                                                      | 0                                                                                             |
| Worst CTCAE grade:                                                                            | Grade5                                                                                        | 0                                                                                             | 0                                                                                             |
| TEAEs (any grade) occurring in 1% of patients in either treatment am by MedDRA PT (v. 24.1)  | TEAEs (any grade) occurring in 1% of patients in either treatment am by MedDRA PT (v. 24.1)  | TEAEs (any grade) occurring in 1% of patients in either treatment am by MedDRA PT (v. 24.1)  | TEAEs (any grade) occurring in 1% of patients in either treatment am by MedDRA PT (v. 24.1)  |
| Alanineaminotransferaseincreased                                                              | Alanineaminotransferaseincreased                                                              | 18 (2.8%)                                                                                     | 8 (1.2%)                                                                                      |
| Aspartateaminotransferaseincreased                                                            | Aspartateaminotransferaseincreased                                                            | 16 (2.5%)                                                                                     | 5 (0.8%)                                                                                      |
| AnyTEAEleadingtodocetaxeldosereduction                                                        | AnyTEAEleadingtodocetaxeldosereduction                                                        | 130 (19.9%)                                                                                   | 127 (19.5%)                                                                                   |
| Worst CTCAE grade:                                                                            | Grade 1                                                                                       | 16 (2.5%)                                                                                     | 15 (2.3%)                                                                                     |
| Worst CTCAE grade:                                                                            | Grade 2                                                                                       | 29 (4.4%)                                                                                     | 28 (4.3%)                                                                                     |
| Worst CTCAE grade:                                                                            | Grade 3                                                                                       | 54 (8.3%)                                                                                     | 41 (6.3%)                                                                                     |
|                                                                                               | Grade 4                                                                                       | 31 (4.8%)                                                                                     | 43 (6.6%)                                                                                     |
|                                                                                               | Grade5                                                                                        | 0                                                                                             | 0                                                                                             |
| TEAEs (any grade) occurring in 1% of patients in either treatment arm by MedDRA PT (v. 24.1) | TEAEs (any grade) occurring in 1% of patients in either treatment arm by MedDRA PT (v. 24.1) | TEAEs (any grade) occurring in 1% of patients in either treatment arm by MedDRA PT (v. 24.1) | TEAEs (any grade) occurring in 1% of patients in either treatment arm by MedDRA PT (v. 24.1) |
| Neutrophil countdecreased                                                                     | Neutrophil countdecreased                                                                     | 35 (5.4%)                                                                                     | 39 (6.0%)                                                                                     |
| Febrile neutropenia                                                                           | Febrile neutropenia                                                                           | 24 (3.7%)                                                                                     | 25 (3.8%)                                                                                     |
| Whitebloodcellcountdecreased                                                                  | Whitebloodcellcountdecreased                                                                  | 21 (3.2%)                                                                                     | 22 (3.4%)                                                                                     |
| Neutropenia                                                                                   | Neutropenia                                                                                   | 12 (1.8%)                                                                                     | 14 (2.2%)                                                                                     |
| Myalgia                                                                                       | Myalgia                                                                                       | 8 (1.2%)                                                                                      | 4 (0.6%)                                                                                      |

Activities;N=Totalnumberofpatients(100%);n=Numberofpatientswithevent;PT=Preferred term;SAF=Safetyanalysis

Abbreviations:CTCAE=CommonTerminology CriteriaforAdverseEvents;MedDRA=Medical Dictionary forRegulatory set;TEAE=Treatment-emergentadverseevent;v.=Version

Note:Apatientmay havemore thanoneentry.

CTCAE version 4.03.

## Post marketing experience

No new safety concerns were identified from darolutamide post-marketing surveillance between the first marketing authorization (30 JUL 2019) and the cut-off date for the latest Periodic Benefit-Risk Evaluation Report (PBRER) (30 JUL 2021).

From 30 JUL 2019 until 30 JUL 2021, the distributed volume of darolutamide (NUBEQA) 300 mg filmcoated tablets was 6700440 tablets, and the estimated patient exposure to the marketed product worldwide was 4590 patient years.

The estimated patient exposure to the marketed product worldwide was 4,590 patient years. A total of 966 events were reported cumulatively from post-marketing data sources. Of these 966 events, 790

<div style=\"page-break-after: always\"></div>

events (81.8%) were derived from spontaneous reports, including regulatory authority and literature. Of these 790 events, 161 events were serious (20.4%) and 629 events were non-serious (79.6%). The remaining 176 events (18.2%) were derived from non-interventional post-marketing studies and other solicited sources.

## 2.5.1. Discussion on clinical safety

The safety profile of darolutamide in combination with docetaxel in the intended indication mHSPC was mainly based on data from the pivotal study 17777 (DCO date: 25 Oct 2021) including 652 patients with mHSPC treated with darolutamide + docetaxel + ADT and standard ADT and 650 patients with mHSPC treated with placebo+ docetaxel and standard ADT. Supportive safety data were provided by the mCRPC pool including Phase 1/2 darolutamide studies in patients with mCRPC (n=173) and the non-cancer subject pool including Phase 1 single dose darolutamide studies (n=80).

In Study 17777, docetaxel was administered at a dose of 75 mg/m 2  as an IV infusion every 21 days for 6 cycles, starting within 6 weeks after the start of study drug, ADT (LHRH agonist/ antagonist concurrently or bilateral orchiectomy) was started 12 weeks b efore randomization and continued throughout the study and darolutamide and its matching placebo were administered at a dose of 600 mg BID.

## Extent of exposure

The median treatment duration was longer in the darolutamide + docetaxel + ADT arm than the placebo + docetaxel + ADT arm, i.e. 41.0 months and 16.7 months, respectively. Difference between the 2 arms might be partly explained by the percentage of discontinuation of study treatment due to disease progression, i.e. 54.1% of treatment discontinuation in the darolutamide + docetaxel + ADT arm vs 80.4% in the placebo + docetaxel + ADT arm of the FAS. The average daily dose of study drug was comparable across the two treatments arms. The median percent of study drug planned dose was 100% and the mean was above 97% in both treatment arms, reflecting a good treatment compliance. The exposure to docetaxel was well balanced among the 2 treatment arms with 87.6% of subjects in the darolutamide + docetaxel + ADT arm and 85.5% in the placebo + docetaxel + ADT arm who received 6 cycles of docetaxel treatment. The average docetaxel cycle dose received was similar across the two treatment arms.

At the DCO there were 424 patients (32.5%) still on treatment, 299 (45.9%) receiving darolutamide and 125 (19.1%) receiving placebo. There were 105 (16.1%) patients in the darolutamide arm and 38 (5.8%) in the placebo arm that received treatment for &gt;48 months.

The fact that patients remained significantly longer time in the darolutamide arm reflects that the tolerability of darolutamide was acceptable, unmanageable side effects did not occur frequently and these patients had not progressed.

Importantly, the addition of darolutamide did not translate into a lower number of docetaxel cycles administered: 87.6% of patients in the darolutamide arm received 6 cycles of docetaxel, in comparison with 85.5% patients in the placebo arm. In the context of a combination therapy with chemotherapy, this observation is reassuring. The number of dose modifications for the study drug was higher in the darolutamide arm than in the placebo arm (670 vs. 463), as expected. However, the proportion of patients with dose modifications was overall comparable between treatment arms. The percentage of events with TEAE as primary reason for study drug dose modification was 37.0% for darolutamide and 32.0% for placebo. No differences were observed between treatment arms in dose modification of docetaxel due to TEAEs (46.5% and 43.2%). There were more patients with  10 dose modifications per patient in the darolutamide arm than in the placebo arm (7.9% vs. 4.4%).

<div style=\"page-break-after: always\"></div>

Overall, the patient exposure is considered to be sufficient to characterize the safety profile of darolutamide in combination with docetaxel in the proposed indication.

## Adverse events

The overview of TEAEs is comparable across the treatment arms. Almost all the patients experienced a TEAE, i.e. 99.5% in the darolutamide + docetaxel + ADT arm and 98.9% in the placebo + docetaxel + ADT arm. Slightly more TEAEs leading to study drug dose modification were reported in darolutamide + docetaxel + ADT arm than placebo + docetaxel + ADT arm, i.e. 25.9% vs 17.2%, while the TEAEs leading to docetaxel dose modification were similar across the treatment arms, i.e. 32.8% and 32.9%. The majority of the TE AEs reported were severe with 70.2% of Grade 3 TEAEs in darolutamide + docetaxel + ADT arm and 67.5% in placebo + docetaxel + ADT arm, with a greater rate of docetaxelrelated Grade 3 TEAEs (42.6% in both arms) compared to study drug -related Grade 3 TEA Es (9.5% in darolutamide + docetaxel + ADT arm and 6.3% in placebo + docetaxel + ADT arm).

The most commonly reported TEAEs were generally similar between the treatment arms. The most common events (25% of patients in either treatment arm) included alopec ia, fatigue, anaemia, arthralgia, oedema peripheral, neutrophil count decreased, and diarrhoea. Those observed TEAEs were consistent with the known safety profile of docetaxel and darolutamide.

The most common TEAEs reported with 3 percentage points highe r incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm were decreased appetite (18.6% vs 13.1%), hypertension (13.0% vs 9.1%), AST increased (14.0% vs 10.5%), and pain in extremity (15.0% vs 12.0%). When adjusted for the difference in study drug treatment duration, the EAIRs of these events were comparable between the treatment arms.

Overall, events with a worst grade of 3, 4, or 5 were reported with low incidences within the most common TEAEs, with the exception of the following Grade 3 or 4 TEAEs that occurred in 5% of patients in either treatment arm: neutrophil count decreased, febrile neutropenia, white blood count (WBC) count decreased, hypertension, anaemia and neutropenia.

Overall, these most common TEAEs occurred with similar incidences between the treatment arms, except for hypertension and ALT and AST increased, that occurred more frequently in darolutamide + docetaxel + ADT arm than placebo + docetaxel + ADT arm.

Concerning TEAEs over time, the incidence of commonly reported TEAEs, including alopecia, fatigue, anaemia, arthralgia, oedema peripheral, neutrophil count decreased, diarrhoea, WBC count decreased, neuropathy peripheral, and peripheral sensory neuropathy, were similar between the treatment arms. Prevalence followed a similar general decreasing trend for most of the TEAEs listed above. The trend of increasing prevalence of arthralgia, hypertension, and hyperglycaemia, observed in both treatment arms, could be explained due to the underlying comorbidities of the elderly patient population along with metastatic disease.

## Adverse events of special topics

Among the TEAEs of special topic identified as potential or known risks associated with ADT or with anti-androgens, comparable incidence across the two treatment arms were observed except for the following events (by grouped TEAE term) reported at a higher rate in darolutamide + docetaxel + ADT arm than placebo + docetaxel + ADT arm: rash (16.6% vs 13.5%), diabetes (15.2% vs 14.3%), hypertension (13.8% vs 9.4%), bone fractures (7.5% vs 5.1%), fall (6.6% vs 4.6%), breast disorders (3.2% vs 1.5%) and mental impairment disorders (3.5% vs 2.3%). It is noted that the incidence of the TEAEs of special interest was greater in the study 17777 compared to the ARAMIS study that supported the approval of darolutamide in nmCRPC.

<div style=\"page-break-after: always\"></div>

Since patients in the darolutamide arm remained significantly longer time on treatment than patients in the placebo arm, the incidences of AEs could be impacted by this difference. For this reason, the incidences adjusted by time and over time were provided. The results suggested that most AEs occurred within the first 6 months of treatment, and that afterwards the incidences decreased notably. It shou ld be noted that 'hypertension' did not seem to follow this pattern since it was less clear that incidences decreased over time. AEs prevalence also decreased over time with a similar trend among PTs.

Hypertension was newly identified as an ADR, with the grouped term hypertension (data-driven: PTs hypertension, blood pressure increased, hypertensive crisis, hypertensive emergency) reported at a higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm (51.3% vs 49.2%). Hypertension was reported in 13.8% of patients treated with darolutamide+docetaxel and 9.4% of patients treated with placebo+docetaxel.Grade 3 hypertension was reported in 6.4% of patients treated with darolutamide+docetaxel compared to 3.5% of patients treated with placebo+docetaxel. One patient had grade 4 hypertension in each treatment arm. One case was reported as grade 5 hypertension with grade 5 arteriosclerosis in the darolutamide+docetaxel arm. This patient had a long standing history of hypertension and smoking and the case occurred more than 3 years after starting darolutamide treatment. Events of hypertension were reported more commonly in patients with no medical history of hypertension in both treatment arms.

The section 4.8 of the SmPC has been updated to include relevant information about cases of hypertension reported in mHSPC.

Overall, no major differences were observed between treatment arms regarding AEOSIs, but there was a higher incidence of breast disorders/gynaecomastia, which was double in the darolutamide arm compared with the placebo arm (3.2% vs 1.5%). All these events were of Grade 1/2. After adjusting for treatment exposure, the exposure-adjusted incidence rate (EAIR) remained higher in the darolutamide arm (1.2 vs 0.8). In Study 17712 (ARAMIS) the profile of events of breast disorders/gynaecomastia was similar: 2.3% vs. 1.6%, further suggesting that there might be an increased risk of occurrence of these events with darolutamide, which has been somehow replicated in Study 17777 (ARASENS). Considering the replication of results in two different studies, the double frequency reported between arms in Study 17777 (ARASENS), and the fact that gynaecomastia is a known ADR for another second-generation androgen receptor inhibitor (i.e. enzalutamide), it is considered that there is a reasonable likelihood of a potential causal link that justifies the inclusion of this AE in section 4.8 of the SmPC. Therefore, 'gyn a ecomastia' has been included in section 4.8, with frequency 'common' .

Six (0.9%) patients in the darolutamide and only 1 (0.2%) in the placebo arm reported an event of cerebral and intracranial haemorrhage. After adjusting for treatment exposure differences appeared lower, but still higher in the darolutamide arm (0.3 vs 0.1 per 100 PY, respectively). A pooled analysis from ARASENS and ARAMIS studies including 1606 patients in the darolutamide arm and 1204 in the placebo arm showed cerebral and intracranial haemorrhage events of any-grade in 8 patients (0.5%) in the darolutamide arm vs. 3 patients (0.2%) in the placebo arm, being the RR 2.11 (95% CI: 0.61; 7.36). Although the evidence so far available does not clearly indicate a causal role for darolutamide, the fact that these events are of high-grade severity and that potentially they can lead to death or cause long-term damage is worrisome. Therefore, the MAH will continue to closely monitor these events in the PSURs.

Additional primary malignancies were reported in 25 patients (3.8%) in the darolutamide arm vs. 16 patients (2.5%) in the placebo arm. Besides, more SAEs and deaths due to secondary malignancies were reported in the darolutamide arm than in the placebo arm. Although the difference between arms observed in Study 17777 (ARASENS) is small, a carcinogenicity risk has been associated with other

<div style=\"page-break-after: always\"></div>

drugs from the same pharmacological class, and the non-clinical studies performed with darolutamide could not rule out this carcinogenicity risk. Therefore, based on the evidence so far available, the causal relationship with darolutamide could not be excluded and further monitoring should be warranted. As such, 'carcinogenicity potential' has been reclassified from 'missing information' to 'important potential risk' in the RMP.

An increased incidence for new symptomatic pathological fractures (6.6% vs 2.4%) and spinal cord compression (5.4% vs 2.7%) was observed in the SSE-FS and Time to SSE tables. It is recognized that the cumulative incidence might have been affected by the different median time on treatment between arms. In study 17777, there was a higher rate of TEAEs of bone fractures including pathological fractures in darolutamide+docetaxel arm than placebo+docetaxel arm (8.3% vs 5.5%, respectively) but when adjusted for the difference in study drug treatment duration, the EAIRs of bone fractures were similar between the treatment arms (2.8 vs. 2.7 per 100 PY). Nevertheless bone fracture is a known ADR of darolutamide (see SmPC section 4.8), there was an imbalance of TEAEs of bone fractures across the treatment arms and the effect of additional androgen depletion additive to ADT is likely to have increased negative effects on bone mineral density over time and likely increased the risk for fracture with longer duration of darolutamide+docetaxel+ADT above placebo+docetaxel+ADT. Therefore, bone fracture has been added to the list of ADRs reported in combination with docetaxel in the mHSPC patients in section 4.8 of the SmPC.

## Adverse drug reactions

The list of ADRs as reflected in the SmPC was elaborated based on the identification of a causal relationship between a TEAE and darolutamide.  As a result, ALT increased, hypertension and gynaecomastia were identified as new ADRs of darolutamide.

Less ADRs were identified for the combination of darolutamide+docetaxel in mHSPC compared to darolutamide alone for the treatment of nmCRPC while the safety profile is more unfavourable in mHSPC than in nmCRPC. Since darolutamide was administered in combination with docetaxel, adverse reactions from both darolutamide and docetaxel can be confounded and prevent the identification of a clear association between TEAE and one of the active substances.

## Serious adverse events / deaths

In terms of deaths causes, overall there is no evidence of any trend, suggesting that the causes of death were similar in nature between arms. The only cause of death by PT reported with a higher incidence in the darolutamide arm than in the placebo arm was 'COVID -19 pneumonia': 0.6% vs. 0.2%; although an additional death coded as 'COVID -19' was also reported in the darolutamide arm. The clinical relevance of this observation is uncertain taking into account that the rate of infections was not higher in the darolutamide arm in comparison with the placebo arm, and considering the small number of events.

Special attention should be given to deaths related to cardiac and vascular disorders: in the darolutamide arm there were 7 deaths during treatment and within 30 days post permanent treatment discontinuation caused by cardiac and vascular disorders (PTs: 'arteriosclerosis'+'hypertension'; 'anaesthetic complication cardiac'; 'cardiac failure acute'; 'myocardial infarction'; 'cardiac disorder'; 'acute myocardial infarction'; 'cardiac arrest'), and 2 additional deaths caused by 'haemorrhagic stroke' and 'subarachnoid haemorrhage'. Of note, only 3 deaths related to cardiac and vascular disorders were reported in th e placebo arm (2 due to 'cardiac arrest' and 1 due to 'cardiac failure'), together with an additional death caused by 'cerebrovascular accident'. Although none of the deaths of the darolutamide arm was considered as related by the investigator because patients had several underlying confounding factors. Further, in the darolutamide arm of study ARASENS there were 2

<div style=\"page-break-after: always\"></div>

deaths due to a secondary malignancy in contrast to no reported deaths in the placebo arm. The 2 deaths were considered a second primary malignancy (urothelial cell carcinoma and gastric cancer, respectively) and unrelated to darolutamide. Subjects died 3 and 2 years after receiving the first dose of darolutamide, respectively.

SAE rates, although considerably high (probably impacted by the concomitant administration of docetaxel), were similar between treatment arms, i.e. 44.8% vs 42.3%, respectively. Febrile neutropenia was the most common SAE and was reported in 6.1% vs. 6.0% of patients in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively. Neutrophil count decreased was the only SAE that occurred in 1% of patients at a higher incidence in darolutamide + docetaxel + ADT arm compared to placebo + docetaxel + ADT arm (2.8% vs 1.5%). Overall, no SOC was particularly higher in the darolutamide arm in comparison with the placebo arm, except for 'neoplasms benign, malignant and unspecified (including cysts and polyps)', which was reported in 4.1% in the darolutamide arm vs. 2.3% in the placebo arm and considered study drug related in 0.2% in darolutamide group (one case of myelofibrosis) and 0 in placebo group.

## Laboratory findings

The most commonly reported (50% of patients in either arm) laboratory abnormalities (any grade) were anaemia, hyperglycaemia, ALP increased, lymphocyte count decreased, WBC decreased, and neutrophil count decreased. Hematotoxicity is characterized with the use of docetaxel and anaemia and neutropenia are known risk associated with docetaxel. The incidence of anaemia, lymphocyte count decreased and WBC decreased was similar across the two treatment arms.  Laboratory abnormalities that were reported with 5 percentage points higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm included blood bilirubin increased (19.6% vs. 10.0% of patients, respectively), neutrophil count decreased (50.6% vs. 45.5%), and hyperkalaemia (26.0% vs. 20.5%).

'Neutrophil count decreased' was reported with a high incidence in both arms, but the incidence of G14 events and the incidence of G4 events were similar between arms: 50.6% vs. 45.5% and 22.1% vs. 19.4% respectively. Neutrophil count decreased is a known ADR of darolutamide and docetaxel. Therefore, it has been included in section 4.8 of the SmPC.

'AST/ALT increased' were reported with a high incidence, but the incidence of G1 -4 events was quite similar between arms (around 40%). Furthermore the incidence of G4 events was low in both arms. Section 4.8 of the SmPC includes ALT/AST increased as ADRs.

With regards to blood bilirubin, it can be concluded that there is a causal role of darolutamide in combination with docetaxel in triggering the laboratory abnormality of blood bilirubin increased. These results are in line with the exposure-response analysis which showed that the change in total blood bilirubin over time in mHSPC patients was statistically different in the darolutamide + docetaxel + ADT than in the placebo + docetaxel + ADT arm. Therefore it has been included in section 4.8 of the SmPC.

## Hepatotoxicity

Overall, the elevations of ALT, AST and blood bilirubin were more reported in patients treated with darolutamide + docetaxel + ADT than those treated with placebo+docetaxel, and liver functions increased were mostly of low grade of severity.

Cases of DILI were reported in Study 17777 and their occurrence was balanced across the 2 arms. However more serious cases were observed with darolutamide + docetaxel + ADT compared to

<div style=\"page-break-after: always\"></div>

placebo+docetaxel. There were 2 possible Hy's Law cases in darolutamide + docetaxel + ADT arm and one case in placebo + docetaxel + ADT arm, and both cases were reversible.

In addition, the MAH provided in the document on signal evaluation for Drug-Induced Liver Injury (DILI) across all darolutamide clinical trials and 5 cases were considered to provide strong evidence for a causal association between darolutamide and idiosyncratic hepatocellular liver injury and both 5 were serious cases: 2 cases from ARASENS (Study 17777), 2 from ARAMIS (Study 17712), and 1 case that met Hy's La w from an investigator sponsored research study (ODENZA).

Section 4.8 of the SmPC has been updated to reflect the cases of hepatic transaminase elevations suggestive of a DILI related to darolutamide.  In addition, a warning has been added in section 4.4 to reflect that in case of hepatic transaminase elevations suggestive of idiosyncratic drug-induced liver injury related to darolutamide, the treatment should be permanently discontinued.

## Vital signs

Overall, no meaningful differences in the changes of mean or median values for blood pressure measurements, body weight, body mass index (BMI), and heart rate were observed across the two treatment arms.

## Safety in special population

In both arms, the incidence of Grade 4-5 TEAEs, SAEs and TEAEs leading to docetaxel dose modification and permanent discontinuation increased with increasing age. While comparing the two treatment arms, the overview of TEAEs was comparable in the age groups &lt;65 and 75-84 except for TEAEs leading to study drug dose modification and permanent discontinuation of study drug for these 2 age groups. An imbalance was however observed in the age group 65-74 that included the majority of the subjects in study 17777 (n=303 in darolutamide + docetaxel + ADT arm and n=305 in placebo + docetaxel + ADT arm) with a higher proportion of Grade 3-4 TEAEs, SAE and TEAEs leading to study drug dose modification and permanent discontinuation of study drug in darolutamide + docetaxel + ADT arm compared to the placebo + docetaxel + ADT arm.

In both treatment arms, the number of patients with moderately impaired renal function at baseline was smaller than the number of patients with mildly impaired or normal renal function. Comparable overview of TEAEs by renal function was observed across the treatment arms except TEAEs leading to study drug modification in mild RI that were more reported in darolutamide + docetaxel + ADT arm than placebo + docetaxel + ADT arm (30.5% vs 20.5%).

There were 2 patients in the darolutamide + docetaxel + ADT arm with moderately impaired hepatic function, and the number of patients with mildly impaired hepatic function was small in both treatment arms; therefore, comparisons across hepatic function groups should be made with caution. Overall, the incidences of any TEAEs, TESAEs, and TEAEs leading to permanent discontinuation or dose modification were generally similar between the hepatic function groups in both treatment arms.

Regarding subgroups by geographical region, it should be noted that Asian patients had an increased rate of TESAEs and grade 4 events in both arms in comparison with patients from other regions. Notably, an increase in the TEAEs leading to docetaxel dose modification and docetaxel permanent discontinuation was observed in both arms, suggesting that the worse toxicity profile observed in this subgroup of patients was driven by the docetaxel administration and not by the darolutamide administration. Specifically, by PT this increase seemed to be associated with an increase rate of 'neutrophil count decreased', 'white blood cell count decreased' and 'anaemia'. The incidence of these TEAES was higher in the first 6 months, and afterwards it decreased over time. Apart from this apparent link between a worse tolerability in Asian patients and the administration of docetaxel, it should be noted that patients in the Asian Pacific region presented at study entry with a more

<div style=\"page-break-after: always\"></div>

advanced disease stage, which could also play a role in the worse tolerability observed in this subgroup of patients. Other PTs were also significantly increased in Asian patients, such as 'malaise', which was reported in 21.3% and 24.0% in the darolutamide and placebo arm, respectively; whereas in the other subgroups it was reported with an incidence lower than 5% in either arm. The clinical relevance of this observation remains unknown, although it does not seem to have an important impact on the safety profile of darolutamide.

The MAH also presented subgroups analysis by concomitant statin use. Overall, no clinically meaningful differences were observed among subgroups, although the incidence of TESAEs and TEAEs leading to study drug or docetaxel dose modification were higher in the subgroup of patients taking statins concomitantly. However, this observation should be interpreted with caution due to the smaller size of the subgroup of patients taking statins (N=183) than the subgroup of patients not taking statins (N=480). The incidence of pre-defined TEAEs reflecting frequent undesirable effects of statins (ALT/AST/transaminases increased, muscular weakness, renal failure/impairment, etc) were also assessed in those subsets and the results did not show any significant imbalance which could be explained by drug-drug interactions between darolutamide and statins.

## Discontinuation due to adverse events

Overall TEAEs leading to permanent discontinuation of study drug were more reported in darolutamide + docetaxel + ADT arm than placebo + docetaxel + ADT arm (13.5% vs 10.6%, respectively) while those leading to permanent docetaxel discontinuation occurred more frequently in the placebo + docetaxel + ADT arm than the darolutamide + docetaxel + ADT arm (10.3% vs 8.0%, respectively). All TEAEs leading to discontinuation of study drug and docetaxel occurred at low rate &lt;1% except bone pain in placebo + docetaxel + ADT arm. The most common TEAEs leading to permanent discontinuation of study drug (in 5 patients in either treatment arm) were AST increased (0.9% vs. 0.3%), ALT increased (0.8% vs. 0.2%) and bone pain (0.3% vs. 1.4%).

Regarding the incidence of TEAEs leading to interruption of the study drug, it should be highlighted that the incidence was markedly higher in the darolutamide arm (22.9%) vs. the placebo arm (15.7%), mainly due to Grade 3 TEAEs. The higher rate of interruptions seems to be driven mainly by the imbalance in some PTs, such as 'ALT and AST increased', as well as 'febrile neutropenia'; which were reported with approximately double frequency in the darolutamide compared with the placebo arm. TEAEs leading to interruption of docetaxel were reported with a similar incidence in both arms. The incidence of TEAEs leading to dose reduction of the study drug was overall low, although in the darolutamide arm it was twice as high as the incidence in the placebo arm (8.7% vs 4.3%), also apparently driven mainly by 'ALT and AST increased' PTs. The incidence of TEAEs leading to docetaxel dose reduction was similar between arms, suggesting that darolutamide addition did not have a detrimental effect on the planned administration of docetaxel.

## Post marketing experience

No new safety concerns were identified from darolutamide post-marketing surveillance.

## 2.5.2. Conclusions on clinical safety

Overall, the safety profile of darolutamide + docetaxel + ADT in mHSPC was comparable to placebo+docetaxel but worsened compared to the known safety profile of darolutamide in nmCRPC with a toxicity mainly driven by the combination with docetaxel. The majority of the reported adverse events were severe (Grade 3) in both treatment arms , with 70.2% of Grade 3 TEAEs in darolutamide + docetaxel + ADT arm and 67.5% in placebo + docetaxel + ADT arm. The incidence of

<div style=\"page-break-after: always\"></div>

serious adverse events was comparable across the treatment arms but greater in study 17777 (ARASENS) than in ARAMIS study in mCRPC patients for both treatment groups. Hypertension, ALT increased and gynaecomastia were newly identified as ADRs of darolutamide. Hepatotoxicity arised from the safety data of clinical trials in which 5 cases were considered to provide strong evidence for a causal association between darolutamide and idiosyncratic hepatocellular liver injury. In both cases the hepatotoxicity events were manageable. Concerning the carcinogenicity risk, which has been previously associated with other drugs from the same pharmacological class, based on the available evidence presented so far, the causal relationship with darolutamide could not be excluded. Therefore, 'carcinogenicity potential' has been reclassified from 'missing information' to 'important potential risk' in the RMP and additional pharmacovigilance activities have been proposed to further assess this risk.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 4.1 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 4.1 with the following content:

## Safety concerns

Table 78: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                      |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   |  None                                                                                                                                                                          |
| Important potential risks    |  ADRs resulting from increased exposure in patients with severe hepatic impairment  Cardiovascular events in patients with significant CV history  Carcinogenicity potential |
| Missing information          |  Use in patients with severe renal impairment                                                                                                                                  |

Abbreviations: ADR = Adverse drug reaction; CV = Cardiovascular.

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

Table 79: Ongoing and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |

## Risk minimisation measures

Table 80:  Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                                                                    | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                  | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                   |
|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks                                                         | Important potential risks                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                |
| ADRs resulting from increased exposure in patients with severe hepatic impairment | Routine risk communication SmPC section 4.2 Posology and method of administration SmPC section 4.8 Undesirable effects SmPC section 5.2 Pharmacokinetic properties Routine risk minimisation activities recommending specific clinical measures to address the risk SmPC section 4.2 Posology and method of administration SmPC section 4.4 Special warning and precautions for use Other routine risk minimisation measures beyond the Product Information | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Updates on important potential risks will be provided in each PBRER/PSUR, if new safety relevant information is received during the period of the report. Follow-up questionnaire in patients with history of hepatic impairment. |

<div style=\"page-break-after: always\"></div>

Table 80:  Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                                                | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                                                                                                                                                                                                                                         |
|---------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cardiovascular events in patients with significant CV history | Nubeqa is a prescription-only medicine Additional risk minimisation measures None Routine risk communication SmPC section 5.1 Pharmacodynamic properties Routine risk minimisation activities recommending specific clinical measures to address the risk SmPC section 4.2 Posology and method of administration SmPC section 4.4 Special warning and precautions for use Other routine risk minimisation measures beyond the Product Information Nubeqa is a prescription-only medicine Additional risk minimisation measures | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Updates on important potential risks will be provided in each PBRER/PSUR, if new safety relevant information is received during the period of the report. Follow-up questionnaire on cardiac disorders. |
| Carcinogenicity potential                                     | None Routine risk communication SmPC section 5.3 Preclinical safety data Routine risk minimisation activities recommending specific clinical measures to address the risk None proposed Other routine risk minimisation measures beyond the Product Information Nubeqa is a prescription-only medicine Additional risk minimisation measures                                                                                                                                                                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Updates will be provided in each PBRER/PSUR, if new safety relevant information is received during the period of the report. Follow-up questionnaire on second primary malignancies                     |

<div style=\"page-break-after: always\"></div>

Table 80:  Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                               | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                                                                                                                                                                                                                                                           |
|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing information                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                        |
| Use in patients with severe renal impairment | Routine risk communication SmPC section 4.2 Posology and method of administration SmPC section 4.4: Special warnings and precautions for use SmPC section 5.2 Pharmacokinetic properties Routine risk minimisation activities recommending specific clinical measures to address the risk SmPC section 4.2 Posology and method of administration SmPC section 4.4 Special warning and precautions for use Other routine risk minimisation measures beyond the Product Information Nubeqa is a prescription-only medicine Additional risk minimisation measures | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection Updates on missing information will be provided in each PBRER/PSUR, if new safety relevant information is received during the period of the report. Follow-up questionnaire in patients with history of renal impairment. |

Abbreviations: ADRs = Adverse Drug Reactions; CV = Cardiovascular; PBRER = Periodic Benefit-Risk Evaluation Report; PSUR = Periodic Safety Update Report; SmPC = Summary of Product Characteristics.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8 ,5.1, 5.2 and 5.3 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Please refer to Attachment 1 which includes all changes to the Product Information.

## 2.7.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to NUBEQA 300 mg film-coated tablets package leaflet. The bridging report submitted by the MAH has been found acceptable.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

This application was to extend the indication of Nubeqa (darolutamide) to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.

The recommended indication is: NUBEQA is indicated for the treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy.

## 3.1.2. Available therapies and unmet medical need

Metastatic HSPC, also known as metastatic castration-sensitive prostate cancer (mCSPC), is defined as metastatic prostate cancer in patients who have not yet received or are continuing to respond to antihormonal therapy. Depriving prostate cancer cells of androgen is the primary form of therapy since prostate cancer depends on androgen for growth and survival. ADT is defined as surgical castration by bilateral orchiectomy or medical castration with LHRH agonist/antagonists.

Although almost all men with mHSPC initially respond to ADT, most will progress to mCRPC within 1 to 3 years of their initial diagnosis.

According to ESMO guideline on cancer of the prostate (2020), the recommended treatment of hormone nave setting is ADT (luteinizing hormone-releasing hormone [LHRH] agonist or surgical castration) in combination with one of the following approved treatments of mHSPC: abiraterone, a CYP17 inhibitor (with prednisone or prednisolone), an ARI (apalutamide or enzalutamide), docetaxel with or without prednisone or prednisolone.

## 3.1.3. Main clinical studies

The  pivotal  study  for  this  application  is  trial  ARASENS  (study  17777):  a  Phase  III,  multinational, randomized (1:1), double-blind, placebo-controlled study evaluating darolutamide 600 mg BID orally in combination  with  6  cycles  of  docetaxel.  Patients  were  randomised  in  a  1:1  ratio  to  receive  either darolutamide or placebo, each combined with docetaxel and ADT.

The primary endpoint was OS. The secondary endpoints were the time to castration-resistant prostate cancer (CRPC), the time to pain progression, symptomatic skeletal event-free survival (SSE-FS), the time  to  first  symptomatic  skeletal  event  (SSE),  the  time  to  initiation  of  subsequent  systemic antineoplastic therapy, the time to worsening of disease-related physical symptoms, the time to initiation of opioid use for 7 consecutive days .

## 3.1.4. Favourable effects

The primary endpoint of the pivotal study was met, with a statistically significant improvement of OS in the darolutamide + docetaxel + ADT arm compared to placebo + docetaxel. ARASENS study showed a reduction of the risk of death of 32.5% in the darolutamide + docetaxel + ADT arm compared to the

<div style=\"page-break-after: always\"></div>

placebo  +  docetaxel  +  ADT  arm  (HR:  0.675;  95%  CI:  [0.568;  0.801]),  and  the  log-rank  test  was statistically significant with a one-sided p&lt;0.0001.

The  start  of  a  new  systemic  antineoplastic  therapy  was  reported  for  33.6%  of  patients  in  the darolutamide + docetaxel + ADT arm compared with 60.4% in the placebo + docetaxel + ADT arm which represents a statistically significant and clinically meaningful improvement with an HR of 0.388, 95% (CI: [0.328; 0.458]; p&lt;0.0001.

CRPC was documented for 225 (34.6%) patients in the darolutamide + docetaxel + ADT arm and 391 (59.8%) patients in the placebo + docetaxel + ADT arm. A statistically significant prolonged time to CRPC was observed for patients in the darolutamide + docetaxel + ADT arm compared with the placebo + docetaxel + ADT arm, with an HR of 0.357 (95% CI: [0.302; 0.421]); p&lt;0.0001.

SSEs were reported in 14.6% of patients in the darolutamide + docetaxel + ADT arm compared with 16.5% in the placebo + docetaxel + ADT arm with a numerical improvement (ie, a delay) of time to first SSE for patients in the darolutamide + docetaxel + ADT arm, with an HR of 0.712 (95% CI: [0.539; 0.940]); p=0.0081. The median time to first SSE was not reached (95% CI: [A; A]) in either treatment arm. The majority of the first SSEs were External beam radiation therapy to relieve skeletal symptoms, reported for 63.2% of patients with an SSE in the darolutamide + docetaxel + ADT arm and 82.4% of patients with an SSE in the placebo + docetaxel + ADT arm.

Findings  from  secondary  efficacy  analyses  all  showed  statistically  significant  results  in  favour  of darolutamide  +  docetaxel  +  ADT  arm  except  for  the  Time  to  worsening  of  disease-related  physical symptoms based on the NCCN -FACT-FPSI-17 questionnaire.

## 3.2. Uncertainties and limitations about favourable effects

A relatively large proportion of patients had premature emergency unblinding performed at the study site by the investigator to inform the choice of subsequent therapy. The premature unblinding was limited to the investigator and patient, and study team members remained blinded to treatment allocation until the formal study unblinding at the time of analyses. The impact and potential bias induced by premature unblinding on subsequent patient measurements were discussed and post-hoc analyses were provided for the endpoints that were considered to be most likely influenced by premature unblinding: time to pain progression and time to worsening of physical disease-related symptoms. Although bias cannot be completely ruled out in the presence of premature unblinding, the additional information and post-hoc analyses performed by the MAH provided some reassurance that the study conclusions were not affected.

## 3.3. Unfavourable effects

The majority of the patients in study 17777 experienced a TEAE, and the TEAEs observed were mostly severe (Grade 3) in both treatment arms. The incidence o f TEAEs, Grade 1-2 TEAEs and Grade 3-4 TEAEs was comparable between the darolutamide + docetaxel + ADT and the placebo + docetaxel + ADT arms in study 177777. The majority of the TEAEs reported were severe with 70.2% of Grade 3 TEAEs in darolutamide + docetaxel + ADT arm and 67.5% in placebo + docetaxel + ADT arm. The most common  events  (25%  of  patients  in  either  treatment  arm)  included  alopecia,  fatigue,  an aemia, arthralgia,  oedema  peripheral,  neutrophil  count  decreased  and  diarrhoea.  The  most  common  TEAEs reported with 3 percentage points higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm were decreased appetite, hypertension, AST increased and pain in extremity.

<div style=\"page-break-after: always\"></div>

The SAEs were reported at comparable rates in darolutamide + docetaxel + ADT and placebo + docetaxel + ADT arms, i.e. 44.8% vs 42.3%, respectively. Febrile neutropenia was the most common SAE across the two treatment arms and neutrophil count decreased was the only SAE that occurred in 1% of patients at a higher incidence in darolutamide + docetaxel + ADT arm compared to placebo + docetaxel + ADT arm (2.8% vs 1.5%). The Grade 5 TEAEs were reported at similar rate across the treatment arms (4.1% and 4.0% in the darolutamide + docetaxel + ADT arm and the placebo + docetaxel + ADT arm, respectively).

Hypertension and ALT increased were newly identified as ADRs

The grouped term hypertension (data-driven: PTs hypertension, blood pressure increased, hypertensive crisis, hypertensive emergency) was reported at a higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm (51.3% vs 49.2%). Also Grade 3 hypertension was higher in darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm (6.4% vs 3.5%  of  patients,  respectively).  One  case  of  Grade  5  Atherosclerotic  Cardiovascular  Disease  and Hypertensive was reported in darolutamide + docetaxel + ADT arm.

ALT increased was reported with a slightly higher incidence in the darolutamide + docetaxel + ADT arm than in the placebo + docetaxel + ADT arm. In addition, an increased frequency of AST elevations and blood bilirubin increased, already identified as adverse drug reactions of darolutamide in nmCRPC patients, were observed in patients treated with darolutamide in combination with docetaxel in comparison with patients who received placebo in combination with docetaxel.

Hepatotoxicity cases were reported in ARASENS study. Cases of DILI were reported in Study 17777 and their occurrence was balanced across the 2 arms. In addition, the MAH provided a document on signal evaluation for DILI across all darolutamide clinical trials and 5 cases were considered to provide strong evidence for a causal association between darolutamide and idiosyncratic hepatocellular liver injury and both 5 were serious cases: 2 cases from ARASENS (Study 17777), 2 from ARAMIS (Study 17712), and 1 case that met Hy's La w from an investigator sponsored research study (ODENZA).

Therefore, section 4.8 of the SmPC has been updated to reflect the cases of hepatic transaminase elevations suggestive of a DILI related to darolutamide.  In addition, a warning has been added in section 4.4 to reflect that in case of hepatic transaminase elevations suggestive of idiosyncratic drug-induced liver injury related to darolutamide, the treatment should be permanently discontinued.

## 3.4. Uncertainties and limitations about unfavourable effects

The characterization of the safety profile of darolutamide in mHSPC based on data from study 17777 remains challenging due to the combination with docetaxel. Reported adverse reactions incidences may not be attributable to darolutamide alone but may contain contributions from other medicinal products used in combination. This has been reflected in section 4.8 of the SmPC in where the adverse reactions observed in patients with mHSPC treated with darolutamide in combination with docetaxel have been listed  (see  Section  4.8,  Table 2  of  the  SmPC).  Additional  safety  information  when  darolutamide  is administered in combination can be found in  the product information of the individual medicinal products

Despite numbers were low, a higher incidence of cerebral and intracranial haemorrhage was reported in the  darolutamide  arm  compared  with  the  placebo  arm.  While  confounding  factors  were  present  a potential relationship with darolutamide (+docetaxel) could not be ruled out at this stage and will be further monitored in the PSURs.

With regards to the carcinogenicity risk , a causal association with darolutamide couldn't be ruled out based  on  the  available  evidence  presented  so  far.  As  a  result,  'carcinogenicity  potential'  has  been

<div style=\"page-break-after: always\"></div>

reclassified  from  'missing  information'  to  'important  potential  risk'  in  the  RMP  and  two  addi tional pharmacovigilance activities have been proposed to further assess this risk.

## 3.5. Effects Table

Table 81: Effects Table for Darolutamide in combination with docetaxel for the treatment of mHSPC (data cut-off: 25 Oct 2021)

| Effect               | Short description                                                                                 | Unit   | Darolutami de + docetaxel + ADT (N=651)   | Placebo + docetaxe l + ADT (N=654)    | Uncertaintie s / Strength of evidence                                                                                                                                         | References            |
|----------------------|---------------------------------------------------------------------------------------------------|--------|-------------------------------------------|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Favourable Effects   | Favourable Effects                                                                                |        |                                           |                                       |                                                                                                                                                                               |                       |
| OS                   | Overall Survival                                                                                  | N (%)  | 229 (35.2%)                               | 304 (46.5%)                           |                                                                                                                                                                               | Study 17777           |
| OS                   | Overall Survival                                                                                  | HR a   | 0.675; CI 95% (0.568; 0.801) p<0.0001     | 0.675; CI 95% (0.568; 0.801) p<0.0001 |                                                                                                                                                                               | (ARASENS)             |
| Unfavourable Effects | Unfavourable Effects                                                                              |        |                                           |                                       |                                                                                                                                                                               |                       |
| Grade 3 TEAEs       |                                                                                                   | %      | 70.2                                      | 67.5                                  | The toxicity is likely driven by the combination with docetaxel                                                                                                               | Study 17777 (ARASENS) |
| SAEs                 |                                                                                                   | %      | 44.8                                      | 42.3                                  |                                                                                                                                                                               |                       |
| Hypertension         | Including PTs hypertension, blood pressure increased, hypertensive crisis, hypertensive emergency | %      | 13.0                                      | 9.1                                   | Grade 3 hypertension highly reported in darolutamide + docetaxel + ADTarm than in the placebo + docetaxel + ADT arm, one Grade 5 event in darolutamide + docetaxel + ADT arm. |                       |
| ALT increased        | TEAE frequency                                                                                    | %      | 15.6                                      | 12.9                                  | TEAEs of Grade 3/4 ALT increased occurred more frequently in the darolutamide + docetaxel + ADT arm compared to the placebo + docetaxel + ADT arm                             |                       |
|                      | Grade 3/4 ALT increased                                                                           | %      | 2.8                                       | 1.7                                   |                                                                                                                                                                               |                       |

Abbreviations: ALT: Alanine liver transaminases, PTs: Preferred terms, SAEs: serious adverse events, TEAEs: treatment-emerging adverse event; a: Hazard ratio &lt; 1 favours darolutamide

The following secondary efficacy endpoints showed a statistically significant advantage in favour of the patients in the darolutamide+docetaxel arm compared to patients in the placebo+docetaxel arm: time to castration-resistant prostate cancer (median NR vs 19.1 months; HR=0.357, p&lt;0.0001); time to first symptomatic skeletal event (median NR vs NR months; HR=0.712, p=0.0081); time to initiation of subsequent antineoplastic chemotherapy (median NR vs 25.3 months; HR=0.388, p&lt;0.0001); time to pain progression (median NR vs 27.5 months; HR=0.792, p=0.0058); symptomatic skeletal event free survival time (median 51.2 vs 39.7 months; HR=0.609, p&lt;0.0001).

<div style=\"page-break-after: always\"></div>

## 3.6. Benefit-risk assessment and discussion

## 3.6.1. Importance of favourable and unfavourable effects

Darolutamide + docetaxel as add-on therapy to standard ADT showed a clinically relevant improvement in terms of OS and a delay in the onset of mCRPC. These results were consistently supported by most secondary  endpoints  which  are  considered  to  indirectly  reflect  the  quality  of  life  of  patients.  The combination darolutamide + docetaxel + ADT in the ARASENS study, significantly reduced the onset of castration-resistant disease, prolonged the time to the first SSE, and the time to subsequent systemic antineoplastic therapy.

The overall safety profile of darolutamide in the treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT) and docetaxel was consistent with the known safety profile of darolutamide and there were no unexpected findings. The majority of adverse events reported with darolutamide + docetaxel + ADT combination in mHSPC patients were severe and the frequency of serious adverse events was not negligible but comparable to the one reported with placebo+docetaxel+ADT. Although the combination with docetaxel makes the characterization of the safety profile of darolutamide in mHSPC challenging, ALT increased, hypertension and gynaecomastia were identified as new ADR of darolutamide. Furthermore, cases of hepatic transaminase elevations suggestive of idiosyncratic drug-induced liver injury related to darolutamide were reported with darolutamide and managed with darolutamide discontinuation. Overall, the safety profile is considered manageable and well tolerated, based on the frequencies of SAEs, AE leading to treatment discontinuation and AES leading to death, with no major differences over placebo.

## 3.6.2. Balance of benefits and risks

In study ARASENS darolutamide + docetaxel + ADR showed a clinically relevant and statistically significant benefit in terms of OS versus docetaxel + ADT for patients with mHSPC while the safety profile of darolutamide with docetaxel was consistent with the known safety profile of the two products and manageable with adequate risk minimisation measures.

## 3.6.3. Additional considerations on the benefit-risk balance

None

## 3.7. Conclusions

The overall B/R of Nubeqa is positive in the following indication:

NUBEQA is indicated for the treatment of adult men with metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the

<div style=\"page-break-after: always\"></div>

following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy, based on final results from Study 17777 (ARASENS); this is a randomized, double-blind, placebo-controlled Phase 3 study designed to demonstrate the superiority of darolutamide in combination with docetaxel over placebo in combination with docetaxel in OS in patients with mHSPC. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC have been updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Additional market protection

The request for one year of market protection for a new indication was withdrawn by the MAH during the current procedure.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion ' EMEA/H/C/004790/II/0009 ' .